

- A**
- Aaronson NK, *see* Fosså SD
- Aass N, *see* Christian JA
see Oldenburg J
- Abali H, *see* Kilickap S
- Abanour R, *see* Shafqat A
- Abbott DW, *see* Crum CP
- Abbruzzese J, *see* Cohen SJ
see Tempero M
- Abdel-Rahman WM, *see* Renkonen E
- Abdel-Wanis M, *see* Tsuchiya H
- Abell T, *see* Chao C
- Abe O, *see* Tominaga T
- Aboagye EO, *see* Propper DJ
- Abonour R, *see* Vaena DA
- Abraham J, Agrawal M, Bakke S, Rutt A, Edgerly M, Balis FM, Widemann B, Davis L, Damle B, Sonnichsen D, Lebowitz D, Bates S, Kotz H, Fojo T. Phase I Trial and Pharmacokinetic Study of BMS-247550, an Epothilone B Analog, Administered Intravenously on a Daily Schedule for Five Days, 1866
- Abrams J, *see* Citron ML
see Parnes HL
- Abrams R, *see* Brown PD
see Chakravarti A
see Movsas B
- Abrams RA, *see* Pollack A
- Abratt RP. A "Good Death" Revisited in the Context of Doctor-Patient Relationships (correspondence), 97s
- Abratt RP. When the Tumor Is Not the Target: A Title Whose Time Is Up (correspondence), 4463
- Abrey LE, Moskowitz CH, Mason WP, Crump M, Stewart D, Forsyth P, Paleologos N, Correa DD, Anderson ND, Caron D, Zelenetz A, Nimer SD, DeAngelis LM. Intensive Methotrexate and Cytarabine Followed by High-Dose Chemotherapy With Autologous Stem-Cell Rescue in Patients With Newly Diagnosed Primary CNS Lymphoma: An Intent-to-Treat Analysis, 4151
- Abrey LE, *see* Ferreri AJM
- Abruzzese E, Cantonetti M, Morino L, Orlandi G, Tendas A, Del Principe MI, Masi M, Amadori S, Orlandi A, Anemona L, Campione E. CNS and Cutaneous Involvement in Patients With Chronic Myeloid Leukemia Treated With Imatinib in Hematologic Complete Remission: Two Case Reports, 4256
- Achille E, *see* André T
- Acholonu S, *see* Khouri IF
- Achten R, *see* Verburgh E
- Adamo A, *see* Stemmer SM
- Adams GL, *see* Adelstein DJ
- Adams J, *see* Spencer BA
- Adams MT, *see* Wells RJ
- Adamson P, *see* Blaney SM
- Addeo A, *see* Ladetto M
- Addo F, *see* Hurt RD
- Adeleine P, *see* Gérard J-P
- Adelstein DJ. In Reply (correspondence), 3887
- Adelstein DJ, Li Y, Adams GL, Wagner H Jr, Kish JA, Ensley JF, Schuller DE, Forastiere AA. An Intergroup Phase III Comparison of Standard Radiation Therapy and Two Schedules of Concurrent Chemoradiotherapy in Patients With Unresectable Squamous Cell Head and Neck Cancer, 92
- Adinin R, *see* Rivera E
- Adjei A, *see* Shanafelt T
- Adjei AA, Mauer A, Bruzek L, Marks RS, Hillman S, Geyer S, Hanson LJ, Wright JJ, Erlichman C, Kaufmann SH, Vokes EE. Phase II Study of the Farnesyl Transferase Inhibitor R115777 in Patients With Advanced Non-Small-Cell Lung Cancer, 1760
- Adjei AA, *see* Goetz MP
- Adsay V, *see* El-Rayes BF
- Aebi S, *see* Mengis C
- Afessa B, *see* Haluska P
- Affronti ML, *see* Quinn JA
- Agliano AM, *see* Gradilone A
- Agnelli G, *see* Verso M
- Agrawal AR, *see* Agrawal RS
- Agrawal BL, Nath AR, Glynn TP Jr, Velazco D, Garnett RF Jr. Unusual Problems in Breast Cancer and a Rare Lung Cancer Case: Simultaneous and Synchronous Bilateral Inflammatory Breast Cancer, 2215
- Agrawal BL, *see* Agrawal RS
- Agrawal JR, *see* Agrawal RS
- Agrawal M, *see* Abraham J
- Agrawal RS, Agrawal JR, Agrawal BL, Nath AR, Agrawal AR, Gaddipati JC, Garnett RF Jr. Some Unusual Paraneoplastic Syndromes: Metastatic Pulmonary Calcification Causing Hypoxemia in Male Breast Cancer, 2620
- A'Hern R, *see* Kolomainen DF
- Ahmedzai SH, *see* Bottomley A
- Ahn YS, *see* Rosado MF
- Ahtinen H, *see* Hernberg M
- Ainslie J, *see* Poulsen M
- Aish LS, *see* Oo TH
- Aisner J, *see* Parnes HL
see Strair RK
- Aittomäki K, *see* Renkonen E
- Ajani JA. It's the Poison That Killed Him, You Say! (correspondence), 3885
- Ajani JA, *see* Vauthey J-N
- Ajchenbaum-Cymbalista F, *see* Vasconcelos Y
- Akechi T, *see* Uchitomi Y
- Akhurst T, *see* Downey RJ
- Aladjidi N, Auvrignon A, Leblanc T, Perel Y, Bénard A, Bordignon P, Gandemer V, Thuret I, Dalle JH, Pigué C, Pautard B, Baruchel A, Leverger G. Outcome in Children With Relapsed Acute Myeloid Leukemia After Initial Treatment With the French Leucémie Aiguë Myéloïde Enfant (LAME) 89/91 Protocol of the French Society of Pediatric Hematology and Immunology, 4377
- Alaoui-Jamali M, *see* Panasci L
- Alavi J, *see* Batchelor T
- Albain KS, *see* Gandara DR
see Hillner BE
- Albani JM, *see* Majhail NS
- Alberola V, Camps C, Provencio M, Isla D, Rosell R, Vadell C, Bover I, Ruiz-Casado A, Azagra P, Jiménez U, González-Larriba JL, Diz P, Cardenal F, Artal A, Carrato A, Morales S, Sánchez JJ, de las Peñas R, Felip E, López-Vivanco G. Cisplatin Plus Gemcitabine Versus a Cisplatin-Based Triplet Versus Nonplatinum Sequential Doublets in Advanced Non-Small-Cell Lung Cancer: A Spanish Lung Cancer Group Phase III Randomized Trial, 3207
- Albers P, Siener R, Kliesch S, Weissbach L, Kregge S, Sparwasser C, Schulze

- H, Heidenreich A, de Riese W, Loy V, Bierhoff E, Wittekind C, Fimmers R, Hartmann M. Risk Factors for Relapse in Clinical Stage I Nonseminomatous Testicular Germ Cell Tumors: Results of the German Testicular Cancer Study Group Trial, 1505
- Albers P, *see* Palmedo H
see Vergouwe Y
- Alberti D, *see* Thomas JP
- Alberts D, *see* Markman M
- Alberts DS, *see* Rothenberg ML
see Young RC
- Alberts DS. In Reply (correspondence), 957
- Albertsen PC, *see* Penson DF
- Albrand G, *see* Extermann M
- Aldape K, *see* Lang FF
- Alderfer MA, *see* Kazak AE
- Aldigé CR, *see* Comis RL
- Aleman BMP, van den Belt-Dusebout AW, Klokman WJ, van't Veer MB, Bartelink H, van Leeuwen FE. Long-Term Cause-Specific Mortality of Patients Treated for Hodgkin's Disease, 3431
- Aleman BMP, *see* Haas RLM
- Alexander A, Samlowski WE, Grossman D, Bruggers CS, Harris RM, Zone JJ, Noyes RD, Bowen GM, Leachman SA. Metastatic Melanoma in Pregnancy: Risk of Transplacental Metastases in the Infant, 2179
- Alexander HR, *see* Feldman AL
- Alexanian R, *see* Weber D
- Alfsen GC, *see* Oldenburg J
- Ali SM, *see* Lipton A
- Alibhai SMH, Naglie G, Nam R, Trachtenberg J, Krahn MD. Do Older Men Benefit From Curative Therapy of Localized Prostate Cancer?, 3318
- Aliff TB, *see* Weiss MA
- Ali Khan M, *see* Kohli M
- Alimi D, Rubino C, Pichard-Léandri E, Femand-Brulé S, Dubreuil-Lemaire M-L, Hill C. Analgesic Effect of Auricular Acupuncture for Cancer Pain: A Randomized, Blinded, Controlled Trial, 4120
- Alimonti A, Ferretti G, Di Cosimo S, Cognetti F, Vecchione A. Can Colorectal Cancer Patients With Thymidylate Synthase-Overexpressing Liver Metastases Have an Overall Survival Advantage With Hepatic Arterial Infusion Alone? (correspondence), 3543
- Allan SJ, *see* Olivotto IA
- Allegra C, Sargent D. Molecular Diagnostics: Assays, Tissues, Progress, and Pitfalls (editorial), 395
- Allegra CJ, Paik S, Colangelo LH, Parr AL, Kirsch I, Kim G, Klein P, Johnston PG, Wolmark N, Wieand HS. Prognostic Value of Thymidylate Synthase, Ki-67, and p53 in Patients With Dukes' B and C Colon Cancer: A National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study, 241
- Allegra CJ, *see* Johnston PG
- Allen ME, *see* Ayanian JZ
- Allen SL, *see* Parnes HL
- Allgeier A, *see* van den Bent MJ
- Alli P, *see* Olnes M
- Allione B, *see* Re A
- Alliot C. Fludarabine Versus Cyclophosphamide, Vincristine, and Prednisone in Recurrent Low-Grade Lymphomas (correspondence), 2626
- Allison PJ, Guichard C, Fung K, Gilain L. Dispositional Optimism Predicts Survival Status 1 Year After Diagnosis in Head and Neck Cancer Patients, 543
- Allouache J, *see* Culine S
- Allred DC, *see* Love RR
- Alum WH, *see* Ring A
- Almadrones L, *see* Moore DH
- Alonzo TA, *see* Gamis AS
see Wells RJ
- Alpaugh RK, *see* Cohen SJ
- Al-Sarraf M, *see* Unger JM
- Altman A, *see* Heath JA
- Altorki NK, Keresztes RS, Port JL, Libby DM, Korst RJ, Flieder DB, Ferrara CA, Yankelevitz DF, Subbaramaiah K, Pasmantier MW, Dannenberg AJ. Celecoxib, a Selective Cyclo-Oxygenase-2 Inhibitor, Enhances the Response to Preoperative Paclitaxel and Carboplatin in Early-Stage Non-Small-Cell Lung Cancer, 2645
- Altundag K, Altundag O. Superiority of Letrozole Over Tamoxifen in the First-Line Treatment of Metastatic Breast Cancer Patients With Normal Serum *HER-2/neu* Levels: Question of Tamoxifen Resistance (correspondence), 4656
- Altundag O, *see* Altundag K
- Alvarez I, *see* Andrés R
- Alvarez RD, *see* Markman M
see Varia MA
- Alvord WG, *see* Smith JW II
- Amadori D, *see* Volpi A
- Amadori S, *see* Abruzzese E
- Amann G, *see* Ambros IM
- Ambrosetti A, *see* Ferreri AJM
see Zucca E
- Ambros IM, Benard J, Boavida M, Bown N, Caron H, Combaret V, Couturier J, Darnfors C, Delattre O, Freeman-Edward J, Gambini C, Gross N, Hattinger CM, Luegmayr A, Lunec J, Martinsson T, Mazzocco K, Navarro S, Noguera R, O'Neill S, Pötschger U, Rumpler S, Speleman F, Tonini GP, Valent A, Van Roy N, Amann G, De Bernardi B, Kogner P, Ladenstein R, Michon J, Pearson ADJ, Ambros PF. Quality Assessment of Genetic Markers Used for Therapy Stratification, 2077
- Ambros IM, *see* Kerbl R
- Ambros PF, *see* Ambros IM
see Kerbl R
- Ames MM, *see* Goetz MP
- Amess J, *see* Last KW
- Amess JAL, *see* Taussig DC
- Amici S, *see* Longo R
- Amir M, Kalemkerian GP. Run for Your Life: The Reaction of Some Professionals to a Person With Cancer, 3696
- Amling C, *see* Carter CA
- Amyotte G, *see* Bruera E
- Anagnostopoulos A, *see* Dimopoulos MA
- Andersen W, *see* Gallion HH
- Anderson H, *see* Rustin GJS
- Anderson HL, Yap JT, Miller MP, Robbins A, Jones T, Price PM. Assessment of Pharmacodynamic Vascular Response in a Phase I Trial of Combretastatin A4 Phosphate, 2823
- Anderson J, *see* Powles T
- Anderson JR, *see* Breneman JC
- Anderson ND, *see* Abrey LE
- Anderson PM. Editorial Commentary, 39s
- Anderson S, *see* Bear HD
- Anderson WF, Chu KC, Chang S. Inflammatory Breast Carcinoma and Noninflammatory Locally Advanced Breast Carcinoma: Distinct Clinicopathologic Entities?, 2254
- Ando N, Iizuka T, Ide H, Ishida K, Shinoda M, Nishimaki T, Takiyama W, Watanabe H, Isono K, Aoyama N, Makuuchi H, Tanaka O, Yamana H, Ikeuchi S, Kabuto T, Nagai K, Shimada Y, Kinjo Y, Fukuda H. Surgery Plus Chemotherapy Compared With Surgery Alone for Localized Squamous Cell Carcinoma of the Thoracic Esophagus: A Japan Clinical Oncology Group Study—JCOG9204, 4592
- André T, Colin P, Louvet C, Gamelin E, Bouche O, Achille E, Colbert N, Boaziz C, Piedbois P, Tubiana-Mathieu N, Boutan-Laroze A, Flesch M, Buyse M, de Gramont A. Semimonthly Versus Monthly Regimen of Fluorouracil and Leucovorin Administered for 24 or 36 Weeks as Adjuvant Therapy in Stage II and III Colon Cancer: Results of a Randomized Trial, 2896

AUTHOR INDEX

- Andre T, *see* Tourani J-M
- Andreesen R, *see* Schmoll H-J
- Andrés R, Saenz A, Mayordomo JI, Zaballos P, Isla D, Escudero P, Alvarez I, Polo E, Lara R, Tres A. Unusual Abdominal and Pelvic Tumors: Hypertrophic Osteoarthropathy Associated With Pulmonary Metastasis of Uterine Leiomyosarcoma, 3535
- Andrews B, *see* Kattan MW
- Andrews PLR, *see* Morrow GR
- Anemona L, *see* Abruzzese E
- Ang P, *see* Leong SS
- Ang PT, *see* Leong SS
- Antimi M, *see* Papaldo P
- Antinori A, *see* Nasti G
- Antonescu CR, *see* Segal NH
see Weitz J
- Aoyama N, *see* Ando N
- Aozasa K, *see* Yamamoto S
- Apffelstaedt J, *see* Mouridsen H
- Apolone G, Cavuto S, Torri V, la Vecchia C. Effectiveness of Adjuvant Fluorouracil in Elderly Colon Cancer Patients: The Internal and External Validity of Nonrandomized Research Design (correspondence), 1892
- Aquino-Parsons C, *see* Hoskins PJ
- Arance A, *see* Danson S
- Arango MdC, *see* Carr A
- Arber DA, *see* Stein AS
- Arbuck SG, *see* Omura GA
- Arceci RJ, *see* Wells RJ
- Archer VR, *see* Darnton SJ
- Ardizzoni A. In Reply (correspondence), 1648
- Argenta PA, *see* Levine DA
- Aricò M, Conter V, Valsecchi MG, Masera G. Importance of Minimal Residual Disease Testing During the Second Year of Disease: Still No Answer? (correspondence), 4463
- Armand JP, *see* Morice P
- Armitage J, *see* Ferreri AJM
- Armitage JO, Carbone PP, Connors JM, Levine A, Bennett JM, Kroll S. Treatment-Related Myelodysplasia and Acute Leukemia in Non-Hodgkin's Lymphoma Patients, 897
- Armstrong K, *see* Randall TC
- Arndt V, Stürmer T, Stegmaier C, Ziegler H, Becker A, Brenner H. Provider Delay Among Patients With Breast Cancer in Germany: A Population-Based Study, 1440
- Arnold A, *see* Bordeleau L
see Leyland-Jones B
- Arnold RM, *see* Back AL
- Arpino G, *see* Bardou V-J
- Arquette MA, *see* Fisch MJ
- Arranz EE, *see* Belda-Iniesta C
- Artal A, *see* Alberola V
- Arteaga CL. EGF Receptor As a Therapeutic Target: Patient Selection and Mechanisms of Resistance to Receptor Targeted Drugs, 2899
- Arteaga CL, *see* Johnson DH
see Osborne CK
- Arts NJW, *see* Berends MJW
- Arun B, *see* Puzstai L
see Rivera E
- Arusell RM, *see* Brown PD
- Arzoomanian RZ, *see* Thomas JP
- Asaishi K, *see* Tominaga T
- Asbell SO, *see* Roach M III
- Asbury P, *see* Varterasian M
- Ascierto PA, *see* Palmieri G
- Ashcroft L, *see* Danson S
- Ashida S, *see* Sweet KM
- Ashley D, *see* Ekert H
- Ashley S, *see* Ring A
see Shannon C
- Asselain B, *see* Matthay KK
- Asselin BL, *see* Dalton VK
see Goldberg JM
- Astolfi A, *see* Scotlandi K
- Astolfi M, *see* Ladetto M
- Astrow AB. Fludarabine-Related Myeloid Leukemia (correspondence), 3709
- Atallah D, Chahine G, Voutsadakis IA. Uncommon Presentations of Malignancies: Brain Metastasis from Ovarian Cancer, 2993
- Atallah D, *see* Morice P
- Atasoy A, *see* Pels H
- Atherton P, *see* Goetz MP
- Atkins CD. Intraperitoneal Chemotherapy for Stage III Ovarian Cancer (correspondence), 957
- Atkins MB, *see* Clark JJ
see Gollob JA
- Atlan D, *see* Gérard J-P
- Au WY, Hung KN, Loong F, Ma SK. Patients Presenting With CNS Lesions: Sequential Myeloproliferative Disease and Glioblastoma Multiforme in a Renal Transplant Recipient, 4058
- Au WY, Wong WM, Khoo US, Liang R. Challenging and Unusual Cases: Concurrent Gastrointestinal Stromal Tumor and Burkitt's Lymphoma, 1416
- Au WY, *see* Hon C
- Auclerc M-F, *see* Boissel N
- Audette C, *see* Tolcher AW
- Auerbach AR, *see* Ladewski LA
- Augustin H, Graefen M, Palisaar J, Blonski J, Erbersdobler A, Daghofer F, Huland H, Hammerer PG. Prognostic Significance of Visible Lesions on Transrectal Ultrasound in Impalpable Prostate Cancers: Implications for Staging, 2860
- Aul C, *see* Büchner T
see Haferlach T
- Aung LL, Gorlick R, Healey JH, Shi W, Thaler HT, Shorter NA, Huvos AG, Meyers PA. Metachronous Skeletal Osteosarcoma in Patients Treated With Adjuvant and Neoadjuvant Chemotherapy for Nonmetastatic Osteosarcoma, 342
- Auster M, *see* Olnes M
- Austin JS. Calcitriol and Alopecia—Is it the *Hair* Apparent? (correspondence), 2044
- Autier P, Willem J, Mathieu C, Jean-François B, de Vries DE, Eggermont AMM. Management of Melanoma Patients: Benefit of Intense Follow-Up Schedule Is Not Demonstrated (correspondence), 3707
- Auvrignon A, *see* Aladjidi N
- Averbuch S, *see* Fukuoka M
- Averette HE, *see* Omura GA
- Avgeropoulos N, *see* Quinn JA
- Avigad S, *see* Ohali A
- Avorn J, *see* Partridge AH
- Avvisati G, *see* Tonini G
- Ayala A, *see* Seymour JF
- Ayala AG, *see* Goorin AM
- Ayanian JZ, Zaslavsky AM, Fuchs CS, Guadagnoli E, Creech CM, Cress RD, O'Connor LC, West DW, Allen ME, Wolf RE, Wright WE. Use of Adjuvant Chemotherapy and Radiation Therapy for Colorectal Cancer in a Population-Based Cohort, 1293
- Ayanian JZ, *see* Earle CC
see Keating NL
- Ayers M, *see* Puzstai L
- Ayoub J-P, *see* Leyland-Jones B
- Azagra P, *see* Alberola V
- Azli N, *see* Nabholz J-M

- B**
- Baak JPA, Snijders W, van Diermen B, van Diest PJ, Diepenhorst FW, Benraad J. Prospective Multicenter Validation Confirms the Prognostic Superiority of the Endometrial Carcinoma Prognostic Index in International Federation of Gynecology and Obstetrics Stage 1 and 2 Endometrial Carcinoma, 4214
- Baalbergen A, *see* Meijers-Heijboer H
- Baars JP, *see* Pronk WG
- Baars JW, *see* Haas RLM
- Babin-Boilletot A, *see* Laithier V
see Pellegrino B
- Babineau T, *see* Rayson D
- Bacci G, Ferrari S, Longhi A, Forni C, Ruggieri P, Briccoli A, De Paolis M, Setola E. Preoperative Therapy Versus Immediate Surgery in Nonmetastatic Osteosarcoma (correspondence), 4662
- Bacci G, *see* Ferrari S
see Serra M
- Bachleitner-Hofmann T, *see* Stift A
- Bach PB, *see* Bennett CL
- Bacik J, *see* Mazumdar M
- Back AL, Arnold RM, Tulsy JA, Baile WF, Fryer-Edwards KA. Teaching Communication Skills to Medical Oncology Fellows, 2433
- Back MF, *see* Shakespeare TP
- Baergen R, *see* Ozols RF
- Baidas S, *see* Esteva FJ
- Baile WF, *see* Back AL
- Baile WF, Beale EA. Giving Bad News to Cancer Patients: Matching Process and Content, 49s
- Bailey CC, *see* Taylor RE
- Bains M, *see* Ilson DH
- Bains MS, *see* Downey RJ
- Bajorin D, *see* Mazumdar M
- Bajorin DF, *see* Donadio AC
- Baker C, *see* Strair RK
- Baker KS, DeFor TE, Burns LJ, Ramsay NKC, Neglia JP, Robison LL. New Malignancies After Blood or Marrow Stem-Cell Transplantation in Children and Adults: Incidence and Risk Factors, 1352
- Baker KS, *see* Breneman JC
see Serna DS
- Baker LH, *see* Dhaini HR
- Bakke S, *see* Abraham J
- Balcerzak SP, *see* Ganz PA
see Velasquez WS
- Balda B-R, *see* Hauschild A
- Baldi A, *see* Tonini G
- Baldini L, Brugiattelli M, Luminari S, Lombardo M, Merli F, Sacchi S, Gobbi P, Liberati M, Cavanna L, Colombi M, Stelitano C, Goldaniga M, Morabito F, Federico M, Silingardi V. Treatment of Indolent B-Cell Nonfollicular Lymphomas: Final Results of the LL01 Randomized Trial of the Gruppo Italiano per lo Studio dei Linfomi, 1459
- Balis FM, *see* Abraham J
see Blaney SM
- Balk SP, Ko Y-J, Bublely GJ. Biology of Prostate-Specific Antigen, 383
- Ball DL, *see* Mac Manus MP
- Ball HA, *see* Morgan B
- Balla-Mekias S, *see* Delanian S
- Ballard-Barbash R, *see* Kerlikowske K
see McTiernan A
- Ballardini G, *see* Nasti G
- Balleisen L, *see* Haferlach T
- Ballo MT, *see* Pisters PWT
- Balsari A, *see* Moliterni A
- Balshem A, *see* Meropol NJ
- Balzarotti M, *see* Bernardi D
see Zucca E
- Bamberg M, *see* Classen J
- Banerjee D, *see* Gonen M
- Banerjee TK, *see* Morrow GR
- Bangash N, *see* Panasci L
- Baniel J, *see* Colombo R
- Bannerji R, Kitada S, Flinn IW, Pearson M, Young D, Reed JC, Byrd JC. Apoptotic-Regulatory and Complement-Protecting Protein Expression in Chronic Lymphocytic Leukemia: Relationship to In Vivo Rituximab Resistance, 1466
- Bapsy PP, *see* Mouridsen H
- Baracos V, *see* Bruera E
- Barakat RR, *see* Levine DA
- Baram J, *see* Mardor Y
- Barany F, *see* Nash GM
- Barassi F, *see* Buttitta F
- Barbera L, *see* Huang J
- Barbera S, *see* Gridelli C
- Barbera V, *see* Quintini G
- Barbet N, *see* Gérard J-P
- Barbey JT, Pezzullo JC, Soignet SL. Effect of Arsenic Trioxide on QT Interval in Patients With Advanced Malignancies, 3609
- Barcos M, *see* Peterson BA
- Bardou V-J, Arpino G, Elledge RM, Osborne CK, Clark GM. Progesterone Receptor Status Significantly Improves Outcome Prediction Over Estrogen Receptor Status Alone for Adjuvant Endocrine Therapy in Two Large Breast Cancer Databases, 1973
- Barge RMY, *see* Lokhorst HM
- Barker F, *see* Olivi A
- Barkhof F, *see* Vos MJ
- Barlogie B, *see* Lee C-K
- Barlow WE, *see* Kerlikowske K
- Barnard DR, *see* Gamis AS
- Barnd DL, *see* Slingluff CL Jr
- Barnes EA, *see* Bruera E
- Barnett MJ, *see* Taussig DC
- Barón AE, *see* Hirsch FR
- Baron B, *see* Hoang-Xuan K
see Köhne C-H
- Barone C, *see* Papaldo P
- Baron MG, *see* Belda-Iniesta C
- Barr RD, *see* Dalton VK
- Barreau-Pouhaer L, *see* Khanfir K
- Barry J, *see* Hennessy BT
- Barstis J, *see* Belani CP
- Bartelink H, *see* Aleman BMP
see Haas RLM
- Barthélemy P, *see* Fizazi K
- Bartlett DL, *see* Feldman AL
- Bartlett N, *see* Kemeny MM
- Bartolini S, *see* Cappuzzo F
- Barton DPJ, *see* Kolomainen DF
- Barton JH, *see* Hainsworth JD
- Baruchel A, *see* Aladjidi N
see Boissel N
- Baselga J, *see* Fukuoka M
see Mendelsohn J
- Bast RC Jr. Status of Tumor Markers in Ovarian Cancer Screening, 200s
- Bast RC Jr, *see* Cannistra SA
- Batchelor T, Carson K, O'Neill A, Grossman SA, Alavi J, New P, Hochberg F, Priet R. Treatment of Primary CNS Lymphoma With Methotrexate and Deferred Radiotherapy: A Report of NABTT 96-07, 1044
- Batchelor T, *see* Ferreri AJM
see Fine HA
- Bates S, *see* Abraham J
- Batist G, *see* Panasci L

AUTHOR INDEX

- Battle JF, *see* Belda-Iniesta C
- Bauer BA, *see* Gertz MA
- Bauer TL, *see* Panasuk DB
- Baumgartner R, *see* McTiernan A
- Bayle C, *see* Le Deley M-C
- Beale EA, *see* Baile WF
- Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B, Margolese R, Theoret H, Soran A, Wickerham DL, Wolmark N. The Effect on Tumor Response of Adding Sequential Preoperative Docetaxel to Preoperative Doxorubicin and Cyclophosphamide: Preliminary Results From National Surgical Adjuvant Breast and Bowel Project Protocol B-27, 4165
- Beard C, *see* Pellegrino B
- Beard CJ, *see* Talcott JA
- Beard M, *see* Cohen SJ
- Bearden JD III, *see* Gandara DR
- Bearman SI, *see* Blayney DW
- Beaujard AC, *see* Glehen O
- Beaumont M, Sanz M, Carli PM, Maloisel F, Thomas X, Detourmignies L, Guerci A, Gratecos N, Rayon C, San Miguel J, Odriozola J, Cahn JY, Huguet F, Vekhof A, Stamatoulas A, Dombret H, Capote F, Esteve J, Stoppa AM, Fenaux P. Therapy-Related Acute Promyelocytic Leukemia, 2123
- Bebelagua Y, *see* Carr A
- Beck K, *see* Hesketh PJ
- Becker A, *see* Arndt V
- Becker JC, *see* Hauschild A
- Becker K, *see* Ott K
- Beckwith JB, *see* Breslow NE
- Becquart D, *see* Mouridsen H
- Bedrosian I, Mick R, Xu S, Nisenbaum H, Faries M, Zhang P, Cohen PA, Koski G, Czerniecki BJ. Intranodal Administration of Peptide-Pulsed Mature Dendritic Cell Vaccines Results in Superior CD8⁺ T-Cell Function in Melanoma Patients, 3826
- Beele D, *see* Kazak AE
- Beer TM, Eilers KM, Garzotto M, Egorin MJ, Lowe BA, Henner WD. Weekly High-Dose Calcitriol and Docetaxel in Metastatic Androgen-Independent Prostate Cancer, 123
- Beer TM. In Reply (correspondence), 2044
- Beex LV, *see* Hoogerbrugge N
- Begg CB, Scardino PT. Taking Stock of Volume-Outcome Studies (editorial), 393
- Belanger K, *see* Townsley CA
- Belani CP, Barstis J, Perry MC, La Rocca RV, Nattam SR, Rinaldi D, Clark R, Mills GM. Multicenter, Randomized Trial for Stage IIIB or IV Non-Small-Cell Lung Cancer Using Weekly Paclitaxel and Carboplatin Followed by Maintenance Weekly Paclitaxel or Observation, 2933
- Belani CP, *see* Fossella F
- Belch A, *see* Kouroukis CT
- Belda-Iniesta C, Carpeno JdC, Vara JAF, Guerrero PC, Saenz EC, Arranz EE, Sanchez AR, Battle JF, Baron MG. Eicosapentaenoic Acid As a Targeted Therapy for Cancer Cachexia (correspondence), 4657
- Belfiglio M, *see* Sacco M
- Belhadj K, *see* Bouabdallah R
see Coiffier B
- Belinson J, *see* Markman M
- Belknap SM, *see* Ladewski LA
- Bell GJ, *see* Courneya KS
- Bell J, *see* Havrilesky L
- Bell JA, *see* Gonzalez MA
- Bellei M, *see* Federico M
- Bellomi M, *see* Sozzi G
- Beluffi G, *see* Rossi G
- Bénard A, *see* Aladjidi N
- Benard J, *see* Ambros IM
- Benda J, *see* Randall ME
- Benda JA, *see* Varia MA
- Benini S, *see* Scotlandi K
see Serra M
- Benjamin EM, *see* Mertens WC
- Benjamin RS, *see* Pisters PWT
see Vadhan-Raj S
- Benkoe T, *see* Stift A
- Bennett CL, Somerfield MR, Pfister DG, Tomori C, Yakren S, Bach PB. Perspectives on the Value of American Society of Clinical Oncology Guidelines as Reported by Oncologists and Health Maintenance Organizations, 937
- Bennett CL, *see* Ladewski LA
- Bennett JM. Morphologic Dysplasia in Acute Myeloid Leukemia: Importance of Granulocytic Dysplasia (correspondence), 3004
- Bennett JM, *see* Armitage JO
see Cheson BD
- Benraadt J, *see* Baak JPA
- Bensing JM, *see* Mellink WAM
- Benson A III, *see* Hamid O
- Benson AB III, *see* Johnston PG
see Meropol NJ
see Meyerhardt JA
- Berchuck A, *see* Havrilesky L
- Berdel WE, *see* Büchner T
see Ozaki T
see Schmoll H-J
- Berek JS, Schultes BC, Nicodemus CF. Biologic and Immunologic Therapies for Ovarian Cancer, 168s
- Berek JS, *see* Cannistra SA
- Berends MJW, Wu Y, Sijmons RH, van der Sluis T, Ek WB, Ligtenberg MJL, Arts NJW, ten Hoor KA, Kleibeuker JH, de Vries EGE, Mourits MJE, Hollema H, Buys CHCM, Hofstra RMW, van der Zee AGJ. Toward New Strategies to Select Young Endometrial Cancer Patients for Mismatch Repair Gene Mutation Analysis, 4364
- Berens ME, *see* Giese A
- Berenson JR, *see* Unger JM
see Yang HH
- Beresnev TH, *see* Feldman AL
- Berg S, *see* Blaney SM
- Berger F, *see* Ferreri AJM
- Berger MS, *see* Lang FF
- Berger R, *see* Mardor Y
- Berger S, *see* Rau B
- Bergh J, *see* Brandberg Y
- Berglund G, *see* Nystedt M
- Bergsland E, *see* Kabbinnar F
- Berkhof J, *see* Kuenen BC
see Vos MJ
- Berlin JD, *see* Rothenberg ML
- Bernardi D, Milan I, Balzarotti M, Spina M, Santoro A, Tirelli U. Comprehensive Geriatric Evaluation in Elderly Patients With Lymphoma: Feasibility of a Patient-Tailored Treatment Plan (correspondence), 754
- Bernard O, *see* Tourani J-M
- Bernardo P, *see* Sledge GW
- Bernheim A, *see* Le Deley M-C
- Bernstein L, *see* McTiernan A
- Berry DA, *see* Citron ML
see Giles FJ
see Henderson IC
see Parnes HL
see Weiss RB
- Bertario L, Russo A, Sala P, Varesco L, Giarola M, Mondini P, Pierotti M, Spinelli P, Radice P. Multiple Approach to the Exploration of Genotype-Phenotype Correlations in Familial Adenomatous Polyposis, 1698

- Bertetto O, *see* Ladetto M
- Berthold F, *see* Krams M
- Berthou C, *see* Boissel N
- Bertini M, *see* Cilloni D
- Bertino J, *see* Gonen M
- Bertolone SJ, *see* Hutchinsonson RJ
- Bertoni F, *see* Ferrari S
see Scotlandi K
see Serra M
- Bertrand Y, *see* Pellegrino B
- Bertucci D, *see* Sawyer MB
- Bertulli R, *see* Gronchi A
- Bertz H, *see* Finke J
- Bertz H, Potthoff K, Finke J. Allogeneic Stem-Cell Transplantation From Related and Unrelated Donors in Older Patients With Myeloid Leukemia, 1480
- Bessman D, *see* Raja V
- Betticher DC, Schmitz S-FH, Tötsch M, Hansen E, Joss C, von Briel C, Schmid RA, Pless M, Habicht J, Roth AD, Spiliopoulos A, Stahel R, Weder W, Stupp R, Egli F, Furrer M, Honegger H, Wernli M, Cerny T, Ris H-B. Mediastinal Lymph Node Clearance After Docetaxel-Cisplatin Neoadjuvant Chemotherapy Is Prognostic of Survival in Patients With Stage IIIA pN2 Non-Small-Cell Lung Cancer: A Multicenter Phase II Trial, 1752
- Betticher DC, *see* Ratschiller D
- Bettini AC, *see* Formenti SC
- Beuzeboc P, *see* Kaufmann M
- Beyer J, *see* Schetelig J
see Schmoll H-J
- Beyer JR, *see* Blaney SM
- Bezjak A, *see* Bordeleau L
see Gridelli C
see Mehta MP
- Bhatia S, Yasui Y, Robison LL, Birch JM, Bogue MK, Diller L, DeLaat C, Fossati-Bellani F, Morgan E, Oberlin O, Reaman G, Ruymann FB, Tersak J, Meadows AT. High Risk of Subsequent Neoplasms Continues With Extended Follow-Up of Childhood Hodgkin's Disease: Report From the Late Effects Study Group, 4386
- Bhatnagar A, *see* Mouridsen H
- Bian Y, *see* Kaklamani VG
- Bicker B, *see* Womer RB
- Biegel JA, *see* Nichols KE
- Bielack SS, *see* Kager L
see Ozaki T
- Bierhoff E, *see* Albers P
- Biermann JS, *see* Dhaini HR
- Bierman PJ, Sweetenham JW, Loberiza FR Jr, Taghipour G, Lazarus HM, Rizzo JD, Schmitz N, van Besien K, Vose JM, Horowitz M, Goldstone A. Syngeneic Hematopoietic Stem-Cell Transplantation for Non-Hodgkin's Lymphoma: A Comparison With Allogeneic and Autologous Transplantation—The Lymphoma Working Committee of the International Bone Marrow Transplantation Registry and the European Group for Blood and Marrow Transplantation, 3744
- Biersack H-J, *see* Palmedo H
- Biesma B, *see* Smit EF
- Biganzoli E, *see* Menard S
see Moliterni A
- Bigelow RH, *see* Rothenberg ML
- Bigner DD, *see* Quinn JA
- Bilchik AJ, Nora DT, Sobin LH, Turner RR, Trocha S, Krasne D, Morton DL. Effect of Lymphatic Mapping on the New Tumor-Node-Metastasis Classification for Colorectal Cancer, 668
- Billett A, *see* Smith RS
- Billups CA, *see* Rodriguez-Galindo C
- Biondi A, *see* Cheson BD
- Birch JM, *see* Bhatia S
- Bird BR, Daly PA. Uncommon Hematologic Malignancies: Parotid Swelling During Treatment for Transformed Mycosis Fungoides, 4248
- Bird K, *see* Gonzalez MA
- Biroccio A, *see* Pace A
- Bishop MR. The Graft-Versus-Lymphoma Effect: Fact, Fiction, or Opportunity? (editorial), 3713
- Bisogno G, *see* Indolfi P
- Bissett RJ, *see* Groome PA
- Bjarnason GA, *see* Townsley CA
- Bjerkhagen B, *see* Skotheim RI
- Bjerkvig R, *see* Giese A
- Björk O, *see* Schmiegelow K
- Blackwood A, *see* Domchek SM
- Blaheta H-J, *see* Garbe C
- Blake PR, *see* Kolomainen DF
- Blaney SM, Heideman R, Berg S, Adamson P, Gillespie A, Beyer JR, Packer R, Matthay K, Jaeckle K, Cole D, Kuttesch N, Poplack DG, Balis FM. Phase I Clinical Trial of Intrathecal Topotecan in Patients With Neoplastic Meningitis, 143
- Blanke C, *see* Masters GA
- Blanke CD, *see* Heinrich MC
- Blatter J, *see* Scagliotti GV
- Blay JY, *see* Marec-Berard P
- Blay J-Y, *see* Ferreri AJM
- Blayne DW, LeBlanc ML, Grogan T, Gaynor ER, Chapman RA, Spiridonidis CH, Taylor SA, Bearman SI, Miller TP, Fisher RI. Dose-Intense Chemotherapy Every 2 Weeks With Dose-Intense Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone May Improve Survival in Intermediate- and High-Grade Lymphoma: A Phase II Study of the Southwest Oncology Group (SWOG 9349), 2466
- Bleiberg H, *see* Di Leo A
- Bleicher RJ, Essner R, Foshag LJ, Wanek LA, Morton DL. Role of Sentinel Lymphadenectomy in Thin Invasive Cutaneous Melanomas, 1326
- Blessing JA, *see* Fracasso PM
- Block S, *see* Earle CC
- Blohmer J-U, *see* Kaufmann M
- Blonski J, *see* Augustin H
- Bloomfield CD, *see* Cheson BD
see Peterson BA
- Blot E, Staub E. Chemoradiotherapy in Unresectable Squamous Cell Head and Neck Cancer (correspondence), 3887
- Blum A, *see* Garbe C
- Blumenstein BA, *see* Halabi S
see Hillner BE
- Blumgart L, *see* Kemeny N
- Boavida M, *see* Ambros IM
- Boaziz C, *see* André T
- Boccardo M, *see* Ladetto M
- Bode U, *see* Pels H
- Bodenizza C, *see* Musto P
- Bodurka DC, Levenback C, Wolf JK, Giano J, Wharton JT, Kavanagh JJ, Gershenson DM. Phase II Trial of Irinotecan in Patients With Metastatic Epithelial Ovarian Cancer or Peritoneal Cancer, 291
- Bodurka DC, *see* Strasser F
- Boetes C, *see* Hoogerbrugge N
see Kriege M
- Boevé ER, *see* van Rhijn BWG
- Bogdhan U, *see* Hoang-Xuan K
- Bogner JR, *see* Jung CP
- Bogomolny F, *see* Levine DA
- Bogue MK, *see* Bhatia S
- Böhmig M, *see* Faiss S
- Boiron J-M, *see* Boissel N

AUTHOR INDEX

- Boissel N, Auclerc M-F, Lhéritier V, Perel Y, Thomas X, Leblanc T, Rouselot P, Cayuela J-M, Gabert J, Fegueux N, Piguët C, Huguët-Rigal F, Berthou C, Boiron J-M, Pautas C, Michel G, Fièrè D, Leverger G, Dombret H, Baruchel A. Should Adolescents With Acute Lymphoblastic Leukemia Be Treated as Old Children or Young Adults? Comparison of the French FRALLE-93 and LALA-94 Trials, 774
- Boissevain F, *see* Engert A
see Sieber M
- Bok R, *see* Rini BI
- Bokemeyer C, *see* Köhne C-H
see Schmoll H-J
- Bokhour BG, *see* Clark JA
- Bökkérink JPM, *see* Calaminus G
- Boku N, *see* Ishikura S
see Ohtsu A
- Bologna S, *see* Coiffier B
- Boltze C, *see* Schneider-Stock R
- Bolund C, *see* Brandberg Y
see Nystedt M
- Bonadonna G, *see* Licitra L
see Moliterni A
- Bonetti F, *see* De Bernardi B
- Bonetti M, *see* Wallgren A
- Boni C, *see* Mouridsen H
- Boni L, *see* De Bernardi B
- Boniver J, *see* Razavi D
- Bonnefoi H, *see* Therasse P
- Bonner JA, *see* Schild SE
- Bonnetterre J, *see* Fumoleau P
- Bono P, *see* Hernberg M
- Bonomi P, *see* Eton DT
- Bonomini S, *see* Giuliani S
- Bontenbal M, *see* Smorenburg CH
- Bonvalot S, *see* Khanfir K
- Boogaerts M, *see* Verburgh E
- Bookman MA, *see* Cannistra SA
- Bookman MA. Developmental Chemotherapy and Management of Recurrent Ovarian Cancer, 149s
- Bookman MA, Darcy KM, Clarke-Pearson D, Boothby RA, Horowitz IR. Evaluation of Monoclonal Humanized Anti-HER2 Antibody, Trastuzumab, in Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Carcinoma With Overexpression of HER2: A Phase II Trial of the Gynecologic Oncology Group, 283
- Booser D, *see* Puzsai L
- Booser DJ, *see* Buzdar A
- Boot H, *see* Verwaal VJ
- Boothby RA, *see* Bookman MA
- Boque C, *see* Roman-Gomez J
- Boracchi P, *see* Menard S
see Moliterni A
- Bordeleau L, Szalai JP, Ennis M, Leszcz M, Specá M, Sela R, Doll R, Chochinov HM, Navarro M, Arnold A, Pritchard KI, Bezjak A, Llewellyn-Thomas HA, Sawka CA, Goodwin PJ. Quality of Life in a Randomized Trial of Group Psychosocial Support in Metastatic Breast Cancer: Overall Effects of the Intervention and an Exploration of Missing Data, 1944
- Bordigoni P, *see* Aladjidi N
- Borgen E, *see* Wiedswang G
- Borges VF, *see* Burstein HJ
- Borgono C, *see* Yousef GM
- Borisch B, *see* Ferreri AJM
- Borkowf CB, *see* Fine HA
- Borner M, *see* Hess V
- Borner MM, *see* Ratschiller D
- Bornhäuser M, *see* Schetelig J
- Bosari S, *see* Buttitta F
- Bosco O, *see* Cruciani M
- Bosio A, *see* De Micheli C
- Bosl GJ, *see* Donadio AC
see Mazumdar M
- Bothun S, *see* Weiss RB
- Botti C, *see* Papaldo P
- Bottomley A, Efficace F, Thomas R, Vanvoorden V, Ahmedzai SH. Health-Related Quality of Life in Non-Small-Cell Lung Cancer: Methodologic Issues in Randomized Trials, 2982
- Bottomley A, Thomas R, Van Steen K, Flechtner H, de Graeff A. Guidelines for the Use of Epoetin: Have Quality-of-Life Benefits Been Proven? (correspondence), 2223
- Bottomley A, *see* Efficace F
see Fossá SD
- Bottoni U, *see* Gradilone A
- Bouabdallah R, Mounier N, Guettier C, Molina T, Ribrag V, Thieblemont C, Sonet A, Delmer A, Belhadj K, Gaulard P, Gisselbrecht C, Xerri L. T-Cell/Histiocyte-Rich Large B-Cell Lymphomas and Classical Diffuse Large B-Cell Lymphomas Have Similar Outcome After Chemotherapy: A Matched-Control Analysis, 1271
- Bouchardy C, Rapiti E, Fioretta G, Laissue P, Neyroud-Caspar I, Schäfer P, Kurtz J, Sappino A-P, Vlastos G. Undertreatment Strongly Decreases Prognosis of Breast Cancer in Elderly Women, 3580
- Bouche O, *see* André T
- Boue F, *see* Herida M
- Bougnoux P, *see* Freyer G
- Bours D, *see* Schleiermacher G
- Boutan-Laroze A, *see* André T
- Bouvet N, *see* Stewart RJ
- Bouzy J, *see* Culine S
- Bove L, *see* Pace A
- Bover I, *see* Alberola V
- Bowen GM, *see* Alexander A
- Bower JE, *see* Ganz PA
- Bower M, *see* Powles T
- Bowers DC, Gargan L, Kapur P, Reisch JS, Mulne AF, Shapiro KN, Elterman RD, Winick NJ, Margraf LR. Study of the MIB-1 Labeling Index as a Predictor of Tumor Progression in Pilocytic Astrocytomas in Children and Adolescents, 2968
- Bown N, *see* Ambros IM
- Boyd J, *see* Levine DA
- Boyer M, *see* Vogelzang NJ
- Boyett JM, *see* Edick MJ
- Boyle FM, Dunn SM, Heinrich P. More Than One Way to Foster Communication Skills for Medical Oncology Fellows: A National Program in Australia (correspondence), 4255
- Bozcuk HS, *see* Samur M
- Bradof JE, *see* Hainsworth JD
- Bradshaw PT, *see* Thomas CT
- Brady C, *see* Lipton A
- Brady MF, *see* Omura GA
see Young RC
- Braitman LE, *see* Phipps E
- Braly PS, *see* Rothenberg ML
- Brames MJ, *see* Fisch MJ
- Bramwell V, *see* Crump M
- Brandberg Y, Michelson H, Nilsson B, Bolund C, Erikstein B, Hietanen P, Kaasa S, Nilsson J, Wiklund T, Wilking N, Bergh J. Quality of Life in Women With Breast Cancer During the First Year After Random Assignment to Adjuvant Treatment With Marrow-Supported High-Dose Chemotherapy With Cyclophosphamide, Thiotepa, and Carboplatin or Tailored Therapy With Fluorouracil, Epirubicin, and Cyclophosphamide: Scandinavian Breast Group Study 9401, 3659
- Brandes AA, *see* van den Bent MJ

- Branscheid D, *see* Kager L
 Braun MS, *see* Chester JD
 Braun S, *see* Lugo TG
 see Winer EP
 Braun TM, *see* Chang AE
 Breathnach O, *see* Hennessy BT
 Breidenfeld H, *see* Sieber M
 Brekelmans CTM, *see* Kriege M
 see Meijers-Heijboer H
 Brekke HR, *see* Skotheim RI
 Bremnes RM, *see* Hirsch FR
 Brémond A, *see* Fumoleau P
 Breneman JC, Lyden E, Pappo AS, Link MP, Anderson JR, Parham DM, Qualman SJ, Wharam MD, Donaldson SS, Maurer HM, Meyer WH, Baker KS, Paidas CN, Crist WM. Prognostic Factors and Clinical Outcomes in Children and Adolescents With Metastatic Rhabdomyosarcoma—A Report From the Intergroup Rhabdomyosarcoma Study IV, 78
 Brennan MF, *see* Kattan MW
 see Segal NH
 see Weitz J
 Brenner H, *see* Arndt V
 Brenner HJ, *see* Stemmer SM
 Brereton H, *see* Hanks GE
 Breslow NE, Norris R, Norkool PA, Kang T, Beckwith JB, Perlman EJ, Ritchey ML, Green DM, Nichols KE. Characteristics and Outcomes of Children With the Wilms Tumor-Aniridia Syndrome: A Report From the National Wilms Tumor Study Group, 4579
 Breslow NE, *see* Green DM
 Bretscher M. Caring for Dying Patients: What Is Right?, 3s
 Breul J, *see* Carducci MA
 Briccoli A, Rocca M. Prognostic Value of Timing of Pulmonary Metastases Identification of Osteosarcoma Patients (correspondence), 177
 Briccoli A, *see* Bacci G
 see Ferrari S
 see Serra M
 Brice P, *see* Federico M
 Briggs T, *see* Strauss SJ
 Brindle J, *see* Schild SE
 Brisco MJ, *see* Marshall GM
 Bristow RG, *see* Ma BBY
 Brockmüller J, *see* Tremblay P-B
 Brockstein BE, *see* Vokes EE
 Broemeling L, *see* Erasmus JJ
 Broemeling LD, *see* Vadhan-Raj S
 Brostjan C, *see* Stift A
 Brouwers M, *see* Huang J
 Browman G, *see* Huang J
 Browman GP, *see* Winer EP
 Brown A, *see* Bear HD
 Brown CA, *see* Brown PD
 Brown D, *see* Mertens WC
 Brown JR, Wiczorek TJ, Shaffer K, Salgia R. Small-Cell Cancers, and an Unusual Reaction to Chemotherapy: Extrapulmonary Small-Cell Carcinoma Arising in the Prostate, 2437
 Brown PD, Buckner JC. Temozolomide: Too Early for Definitive Conclusions (correspondence), 3710
 Brown PD, Buckner JC, O’Fallon JR, Iturria NL, Brown CA, O’Neill BP, Scheithauer BW, Dinapoli RP, Arusell RM, Curran WJ, Abrams R, Shaw EG. Effects of Radiotherapy on Cognitive Function in Patients With Low-Grade Glioma Measured by the Folstein Mini-Mental State Examination, 2519
 Brown PD, *see* Buckner JC
 Brown S, *see* Hillner BE
 Brown TD, *see* Patt YZ
 Browne L, *see* Graham PH
 Broxmeyer HE, *see* Vadhan-Raj S
 Bruce J, *see* Olivi A
 Bruera E, Driver L, Barnes EA, Willey J, Shen L, Palmer JL, Escalante C. Patient-Controlled Methylphenidate for the Management of Fatigue in Patients With Advanced Cancer: A Preliminary Report, 4439
 Bruera E, MacDonald N. To Hydrate or Not to Hydrate: How Should It Be?, 84s
 Bruera E, Strasser F, Palmer JL, Willey J, Calder K, Amyotte G, Baracos V. Effect of Fish Oil on Appetite and Other Symptoms in Patients With Advanced Cancer and Anorexia/Cachexia: A Double-Blind, Placebo-Controlled Study, 129
 Bruera E. In Reply (correspondence), 3546
 Bruera E. In Reply (correspondence), 4658
 Bruera E, *see* Strasser F
 Bruggers CS, *see* Alexander A
 Brugiattelli M, *see* Baldini L; Federico M
 Brümmer J, *see* Jantschke P
 Brunelli C, *see* Ripamonti C
 Bruner JM, *see* Lang FF
 Brunetto G, *see* Randall ME
 Brunetto VL, *see* Gallion HH
 Bruning P, *see* Therasse P
 Brunner HG, *see* Hoogerbrugge N
 Bruzek L, *see* Adjei AA
 Bruzzi P, *see* De Bernardi B
 Bryant J, Fisher B. In Reply (correspondence), 1893
 Bryant J, *see* Smith RE
 see Winer EP
 Bryce C, Kennecke H, Chia S, Ragaz J. Benefit of Paclitaxel in Estrogen Receptor-Negative Versus Estrogen Receptor-Positive Early Breast Cancer (correspondence), 4465
 Bublely GJ, *see* Balk SP
 Bucaloiu ID, Dubagunta S, Pachipala KK, Kamal N, Fata F. Small-Cell Cancers, and an Unusual Reaction to Chemotherapy: Fluorouracil-Related Small Bowel Vasculitis, 2442
 Buchert M, *see* Morgan B
 Buchholz TA, *see* Woodward WA
 Büchner T, Hiddemann W, Berdel WE, Wörmann B, Schoch C, Fonatsch C, Löffler H, Haferlach T, Ludwig W-D, Maschmeyer G, Staib P, Aul C, Grüneisen A, Lengfelder E, Frickhofen N, Kern W, Serve HL, Mesters RM, Sauerland MC, Heinecke A. 6-Thioguanine, Cytarabine, and Daunorubicin (TAD) and High-Dose Cytarabine and Mitoxantrone (HAM) for Induction, TAD for Consolidation, and Either Prolonged Maintenance by Reduced Monthly TAD or TAD-HAM-TAD and One Course on Intensive Consolidation by Sequential Trial of the German AML Cooperative Group, 4496
 Büchner T, *see* Cheson BD
 see Haferlach T
 Buckley J, *see* Wells RJ
 Buckner JC, Gesme D Jr, O’Fallon JR, Hammack JE, Stafford S, Brown PD, Hawkins R, Scheithauer BW, Erickson BJ, Levitt R, Shaw EG, Jenkins R. Phase II Trial of Procarbazine, Lomustine, and Vincristine as Initial Therapy for Patients With Low-Grade Oligodendroglioma or Oligoastrocytoma: Efficacy and Associations With Chromosomal Abnormalities, 251
 Buckner JC, *see* Brown PD
 Buclon M, *see* Marec-Berard P
 Bueno R, *see* Salgia R
 see Soiffer R
 Bueso-Ramos C, *see* Vadhan-Raj S
 Bugat R, *see* Culine S
 Buijt I, *see* Doorduijn JK
 Buist DSM, *see* Kerlikowske K

AUTHOR INDEX

- Bujanda DA, Sarmiento UB, Morales JA. Some Unusual Paraneoplastic Syndromes: Metastatic Squamous Cell Esophageal Cancer to the Thumb, 2620
- Bukowski RM, *see* Majhail NS
- Bult P, *see* Hoogerbrugge N
- Bultz BD, *see* Hack TF
- Bundy BN, *see* Ozols RF
see Varia MA
- Bunn PA Jr. Early Detection of Lung Cancer Using Serum RNA or DNA Markers: Ready for "Prime Time" or for Validation? (editorial), 3891
- Bunn PA Jr. Implementing ASCO's Strategic Plan 2003: Diverse Membership Needs, Prevention, and Patient Partnerships, 231s
- Bunn PA Jr, *see* Hirsch FR
- Bunnell CA, *see* Burstein HJ
- Burd L, *see* Kobrinsky NL
- Burdach S, Meyer-Bahlburg A, Laws HJ, Haase R, van Kaik B, Metzner B, Wawer A, Finke R, Göbel U, Haerting J, Pape H, Gadner H, Dunst J, Juergens H. High-Dose Therapy for Patients With Primary Multifocal and Early Relapsed Ewing's Tumors: Results of Two Consecutive Regimens Assessing the Role of Total-Body Irradiation, 3072
- Burg G, *see* Hauschild A
- Bürger B, Zimmermann M, Mann G, Köhl J, Löning L, Riehm H, Reiter A, Schrappe M. Diagnostic Cerebrospinal Fluid Examination in Children With Acute Lymphoblastic Leukemia: Significance of Low Leukocyte Counts With Blasts or Traumatic Lumbar Puncture, 184
- Burger BG, *see* Rothenberg ML
- Burger C, *see* Meijers-Heijboer H
- Burger CW, *see* van Oostrom I
- Burger RA, *see* Gallion HH
see Ozols RF
- Burgess A, *see* Vadhan-Raj S
- Burgess MA, *see* Pisters PWT
- Burian C, *see* Goodman GR
- Burkhard F, *see* Madersbacher S
- Burkhard O, *see* Köhne C-H
- Burnett CB, *see* Meropol NJ
- Burns LJ, *see* Baker KS
- Burns RB, *see* McCarthy EP
- Burris H, *see* Gandara DR
see Scagliotti GV
- Burstein HJ, Harris LN, Gelman R, Lester SC, Nunes RA, Kaelin CM, Parker LM, Ellis LW, Kuter I, Gadd MA, Christian RL, Kennedy PR, Borges VF, Bunnell CA, Younger J, Smith BL, Winer EP. Preoperative Therapy With Trastuzumab and Paclitaxel Followed by Sequential Adjuvant Doxorubicin/Cyclophosphamide for HER2 Overexpressing Stage II or III Breast Cancer: A Pilot Study, 46
- Burstein HJ, Harris LN, Marcom PK, Lambert-Falls R, Havlin K, Overmoyer B, Friedlander RJ Jr, Gargiulo J, Strenger R, Vogel CL, Ryan PD, Ellis MJ, Nunes RA, Bunnell CA, Campos SM, Hallor M, Gelman R, Winer EP. Trastuzumab and Vinorelbine as First-Line Therapy for HER2-Overexpressing Metastatic Breast Cancer: Multicenter Phase II Trial With Clinical Outcomes, Analysis of Serum Tumor Markers as Predictive Factors, and Cardiac Surveillance Algorithm, 2889
- Burstein HJ, *see* Earle CC
see Winer EP
- Burzykowski T, *see* Buyse M
- Busam K, *see* Segal NH
- Busam KJ. Advances in Molecular Staging of Melanoma Patients: Multi-marker Analysis of Archival Lymph Node Tissue (editorial), 3550
- Busch R, *see* Ott K
- Butman J, *see* Leonard GD
- Buttafoco P, *see* Villa E
- Butterfield LH, *see* Ribas A
- Butterfield RM, *see* Emmons KM
- Buttitta F, Pellegrini C, Marchetti A, Gadducci A, Cosio S, Felicioni L, Barassi F, Salvatore S, Martella C, Coggi G, Bosari S. Human Telomerase Reverse Transcriptase mRNA Expression Assessed by Real-Time Reverse Transcription Polymerase Chain Reaction Predicts Chemosensitivity in Patients With Ovarian Carcinoma, 1320
- Button CJ, *see* Chester JD
- Buxton A, *see* Gamis AS
- Buxton AG, *see* Wells RJ
- Buyse CHCM, *see* Berends MJW
- Buyse M, Burzykowski T, Parmar M, Torri V, Omura G, Colombo N, Williams C, Conte P, Vermorken J. Using the Expected Survival to Explain Differences Between the Results of Randomized Trials: A Case in Advanced Ovarian Cancer, 1682
- Buyse M, *see* André T
see Di Leo A
- Buzdar A, O'Shaughnessy JA, Booser DJ, Pippen JE Jr, Jones SE, Munster PN, Peterson P, Melemed AS, Winer E, Hudis C. Phase II, Randomized, Double-Blind Study of Two Dose Levels of Arzoxifene in Patients With Locally Advanced or Metastatic Breast Cancer, 1007
- Buzyn A, *see* Raffoux E
- Bycott P, *see* Hamid O
- Byhardt R, *see* Movsas B
- Byrd JC, *see* Bannerji R
- Byrne J, *see* Glover DA

C

- Caballero M, *see* Maïllo A
- Cabanillas F, *see* Seymour JF
- Cackett P, Stebbing J, Dhillon B. Complications of Therapy and a Diagnostic Dilemma Case: Radiation Maculopathy Following Treatment of Nasopharyngeal Carcinoma, 4650
- Cadranel J, *see* Herida M
- Cahn JY, *see* Beaumont M
- Cain A, *see* Okcu MF
see Rodriguez-Galindo C
- Cairncross JG, *see* Perry JR
- Calaminus G, Schneider DT, Bökkerink JPM, Gadner H, Harms D, Willers R, Göbel U. Prognostic Value of Tumor Size, Metastases, Extension into Bone, and Increased Tumor Marker in Children With Malignant Sacrococcygeal Germ Cell Tumors: A Prospective Evaluation of 71 Patients Treated in the German Cooperative Protocols Maligne Keimzell-tumoren (MAKEI) 83/86 and MAKEI 89, 781
- Calaminus G, *see* Schneider DT
- Calandri C, *see* Cappuzzo F
- Caldarera E, *see* Colombo R
- Calder K, *see* Bruera E
- Calderoni A, *see* Ferreri AJM
- Callea V, *see* Zucca E
- Calvieri S, *see* Gradilone A
- Calzone K, *see* Domchek SM
- Camacho R, *see* Carr A
- Camatte S, *see* Morice P
- Cammà C, *see* Villa E
- Cammilluzzi E, *see* Papaldo P
- Camp RL, *see* Garcia-Rostan G
- Campbell GA, *see* Raja V
- Campione E, *see* Abruzzese E
- Campleman SL, *see* Cress RD
- Campos D, *see* Nabholz J-M
- Campos SM, *see* Burstein HJ
- Camps C, *see* Alberola V
- Cancellieri A, *see* Cappuzzo F
- Canellos GP, *see* Duggan DB
see Loprinzi CL

AUTHOR INDEX

- Cannistra SA, Bast RC Jr, Berek JS, Bookman MA, Crum CP, DePriest PD, Garber JE, Koh W-J, Markman M, McGuire WP III, Rose PG, Rowinsky EK, Rustin GJS, Skates SJ, Vasey PA, King L. Progress in the Management of Gynecologic Cancer: Consensus Summary Statement, 129s
- Cannistra SA, *see* Schumer ST
- Cannon MW, *see* Millikan R
- Cannon S, *see* Strauss SJ
- Cant MC, *see* Kazak AE
- Canto E, *see* Kattan MW
- Cantonetti M, *see* Abruzzese E
see Martelli M
- Cantor A, *see* Extermann M
- Cantù G, *see* Licitra L
- Capobianco A, *see* Tartarone A
- Capote F, *see* Beaumont M
- Cappuzzo F, Gregorc V, Rossi E, Cancellieri A, Magrini E, Paties CT, Ceresoli G, Lombardo L, Bartolini S, Calandri C, De Rosa M, Villa E, Crinò L. Gefitinib in Pretreated Non-Small-Cell Lung Cancer (NSCLC): Analysis of Efficacy and Correlation With HER2 and Epidermal Growth Factor Receptor Expression in Locally Advanced or Metastatic NSCLC, 2658
- Caracò C, *see* Palmieri G
- Caramatti C, *see* Giuliani N
- Carbone A, *see* Simonelli C
- Carbone D, *see* Miller VA
- Carbone DP. Epidermal Growth Factor Receptor Overexpression: The Importance of Context (editorial), 4268
- Carbone PP, *see* Armitage JO
- Carcangiu ML, *see* Garcia-Rostan G
- Cardenal F, *see* Alberola V
- Carducci MA, Padley RJ, Breul J, Vogelzang NJ, Zonnenberg BA, Daliani DD, Schulman CC, Nabulsi AA, Humerickhouse RA, Weinberg MA, Schmitt JL, Nelson JB. Effect of Endothelin-A Receptor Blockade With Atrasentan On Tumor Progression in Men With Hormone-Refractory Prostate Cancer: A Randomized, Phase II, Placebo-Controlled Trial, 679
- Carella AM, *see* Federico M
see Musto P
- Carides AD, *see* de Wit R
see Hesketh PJ
- Carides G, *see* de Wit R
- Carillio G, *see* Longo R
- Carli M, *see* De Bernardi B
see Indolfi P
- Carli PM, *see* Beaumont M
- Carlini P, *see* Papaldo P
- Carnaghi C, *see* Masci G
- Carney PA, *see* Kerlikowske K
- Carney W, *see* Lipton A
- Caron D, *see* Abrey LE
- Caron H, *see* Ambros IM
- Caron HN, *see* van Dalen EC
- Carosi G, *see* Re A
- Carpeno JdC, *see* Belda-Iniesta C
- Carpenter J, *see* Citron ML
- Carpenter JT, *see* Henderson IC
- Carr A, Rodríguez E, Arango MdC, Camacho R, Osorio M, Gabri M, Carrillo G, Valdés Z, Bebelagua Y, Pérez R, Fernández LE. Immunotherapy of Advanced Breast Cancer With a Heterophilic Ganglioside (NeuGcGM3) Cancer Vaccine, 1015
- Carrato A, *see* Alberola V
- Carrillo G, *see* Carr A
- Carroll PR, *see* D'Amico AV
- Carson K, *see* Batchelor T
- Carstensen H, *see* Sønderkær S
- Carter CA, Donahue T, Sun L, Wu H, McLeod DG, Amling C, Lance R, Foley J, Sexton W, Kusuda L, Chung A, Soderdahl D, Jackman S, Moul JW. Temporarily Deferred Therapy (watchful waiting) for Men Younger Than 70 Years and With Low-Risk Localized Prostate Cancer in the Prostate-Specific Antigen Era, 4001
- Casale F, *see* Indolfi P
- Casalini P, *see* Moliterni A
- Casali PG, *see* Gronchi A
- Casanova M, *see* Okcu MF
- Casari S, *see* Re A
- Casasnovas O, *see* Coiffier B
- Cascinu S, *see* Kilickap S
- Cashen A, DiPersio JF, Khoury H. Does Early Imatinib-Induced Myelosuppression Predict Hematologic Responses in Patients With Advanced-Phase Chronic Myeloid Leukemia? (correspondence), 4255
- Cassem NH, *see* Rauch PK
- Cassileth BR. Clinical Trials: Time for Action (editorial), 765
- Cassinat B, *see* Raffoux E
- Casson AG, *see* Darnton SJ
- Cassoni AM, *see* Strauss SJ
- Castagna L, *see* Masci G
- Castaigne D, *see* Morice P
- Castel L, *see* Meropol NJ
- Castello G, *see* Palmieri G
- Castiglione-Gertsch M, *see* Crivellari D
see Wallgren A
- Castillejo JA, *see* Roman-Gomez J
- Castro M. Thymidine Rescue: An Antidote for Pemetrexed-Related Toxicity in the Setting of Acute Renal Failure (correspondence), 4066
- Castro M. Timing Is Everything, or Could Be (correspondence), 755
- Catalano PJ, *see* Johnston PG
see Le Voyer TE
see Meyerhardt JA
- Cattanco C, *see* Re A
- Cauley JA, *see* Hillner BE
- Cavalli F, *see* Ferreri AJM
see Zucca E
- Cavallo F, *see* Ladetto M
- Cavanna L, *see* Baldini L
- Cavenagh JD, *see* Taussig DC
- Cavuto S, *see* Apolone G
- Cayuela J-M, *see* Boissel N
see Le Deley M-C
- Cecchetto G, *see* Indolfi P
- Celik I, *see* Kilickap S
- Cella D. What Do Global Quality-of-Life Questions Really Measure? Insights From Hobday et al and the “Do Something” Rule (correspondence), 3179
- Cella D, Zagari MJ, Vandoros C, Gagnon DD, Hurtz H-J, Nortier JWR. Epoetin Alfa Treatment Results in Clinically Significant Improvements in Quality of Life in Anemic Cancer Patients When Referenced to the General Population, 366
- Cella D, *see* Coyne CA
see Eton DT
see Hahn EA
see Rizzo JD
- Cella DF, *see* Moore DH
- Cerati M, *see* Ferreri AJM
- Ceresoli G, *see* Cappuzzo F
- Cerhan JR, *see* Ebbert JO
- Cerny T, *see* Betticher DC
- Cervantes F, *see* Roman-Gomez J
- Cesano A, *see* Leonard JP
- Chabner BA, *see* Roberts TG Jr
- Chachoua A, *see* Hochster H
- Chadburn A, *see* Leonard JP

- Chaganti RSK, *see* Donadio AC
- Chahine G, *see* Atallah D
- Chakravarti A, Heydon K, Wu CL, Hammond E, Pollack A, Roach M, Wolkov H, Okunieff P, Cox J, Fontanesi J, Abrams R, Pilepich M, Shipley W. Loss of p16 Expression Is of Prognostic Significance in Locally Advanced Prostate Cancer: An Analysis From the Radiation Therapy Oncology Group Protocol 86–10, 3328
- Champlin RE, *see* Khouri IF
- Chan AO-O, Chu K-M, Lam S-K, Wong BC-Y, Kwok K-F, Law S, Ko S, Hui W-M, Yueng Y-H, Wong J. Soluble E-Cadherin is an Independent Pretherapeutic Factor for Long-Term Survival in Gastric Cancer, 2288
- Chan S, *see* Nabholz J-M
- Chandler W, *see* Lang FF
- Chang AE, Li Q, Jiang G, Sayre DM, Braun TM, Redman BG. Phase II Trial of Autologous Tumor Vaccination, Anti-CD3-Activated Vaccine-Primed Lymphocytes, and Interleukin-2 in Stage IV Renal Cell Cancer, 884
- Chang S, *see* Anderson WF
see Jaeckle KA
see Lang FF
- Chang T-C, *see* Yen T-C
- Chansky K, *see* Gandara DR
- Chao C, Studts JL, Abell T, Hadley T, Roetzer L, Dineen S, Lorenz D, YoussefAgha A, McMasters KM. Adjuvant Chemotherapy for Breast Cancer: How Presentation of Recurrence Risk Influences Decision Making, 4299
- Chapet O, *see* Gérard J-P
- Chaplin D, *see* Stevenson JP
- Chapman C, *see* Nanduri VR
- Chapman PB, *see* Hwu W-J
see Wolchok JD
- Chapman RA, *see* Blayney DW
see Velasquez WS
- Chari RVJ, *see* Tolcher AW
- Charles CA, Whelan T, Gafni A, Willan A, Farrell S. Shared Treatment Decision Making: What Does It Mean to Physicians?, 932
- Chastagner P, *see* Laithier V
- Chau I, Cunningham D. Oxaliplatin for Colorectal Cancer in the United States: Better Late Than Never (editorial), 2049
- Chaudhary UB, Taksey JD, Johnson RD, Lewin DN. Small-Cell Cancers, and an Unusual Reaction to Chemotherapy: Small-Cell Carcinoma of the Stomach, 2441
- Chaudri-Ross H, *see* Mouridsen H
- Chaudri-Ross HA, *see* Lipton A
- Chavin SI, *see* Phipps E
- Chawla SP, *see* Hesketh PJ
- Cheeseman SL, *see* Chester JD
- Chemerynsky I, *see* Tchen N
- Chen C-J, *see* Heinrich MC
- Chen H, *see* Extermann M
- Chen J-T, *see* Yen T-C
- Chen M-H, *see* D'Amico AV
- Chen Q, *see* Smith RS
- Chen RC, *see* Talcott JA
- Chenal M, Molina H, Mendez V, Poole J, Parellada C. Uncommon Presentations of Non-Hodgkin's Lymphoma: Non-Hodgkin's Lymphoma of the Ileocecal Region, 564
- Cheng C, *see* Kishi S
- Cheong K, *see* Ward RL
- Chernoff M, *see* Sekeres MA
- Cherryman GR, *see* Morgan B
- Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH, Schiffer CA, Doehner H, Tallman MS, Lister TA, Lo-Coco F, Willemze R, Biondi A, Hiddemann W, Larson RA, Löwenberg B, Sanz MA, Head DR, Ohno R, Bloomfield CD. Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia, 4642
- Cheson BD, *see* Mavromatis B
- Chester JD, Joel SP, Cheeseman SL, Hall GD, Braun MS, Perry J, Davis T, Button CJ, Seymour MT. Phase I and Pharmacokinetic Study of Intravenous Irinotecan Plus Oral Cyclosporin in Patients With Fluorouracil-Refractory Metastatic Colon Cancer, 1125
- Cheung IY, Lo Piccolo MS, Kushner BH, Cheung N-KV. Early Molecular Response of Marrow Disease to Biologic Therapy Is Highly Prognostic in Neuroblastoma, 3853
- Cheung IY, Lo Piccolo MS, Kushner BH, Kramer K, Cheung N-KV. Quantitation of GD2 Synthase mRNA by Real-Time Reverse Transcriptase Polymerase Chain Reaction: Clinical Utility in Evaluating Adjuvant Therapy in Neuroblastoma, 1087
- Cheung N-KV, *see* Cheung IY
see Kushner BH
- Chevreau C, *see* Ferreri AJM
- Chew L, *see* Leong SS
- Chi K, *see* Ernst DS
see Townsley CA
- Chia S, *see* Bryce C
see Olivotto IA
- Chianese-Bullock KA, *see* Slingluff CL Jr
- Chim CS, Loong F, Yau T, Ooi GC, Liang R. Common Malignancies With Uncommon Sites of Presentation: Mantle-Cell Lymphoma of the Prostate Gland, 4455
- Chim CS, Shek TWH, Chung LP, Liang R. Unusual Abdominal Tumors: Multiple Lymphomatous Polyposis in Lymphoma of Colon, 950
- Chinot O, *see* Hoang-Xuan K
see van den Bent MJ
- Chiodo F, *see* Nasti G
- Chirala M, *see* Yorke R
- Chlebowski RT, *see* Hillner BE
see Winer EP
- Cho D, *see* Kattan MW
- Chochinov HM, *see* Bordeleau L
- Chodak GW, *see* Wilkinson S
- Chomienne C, *see* Raffoux E
- Chompret A, *see* Le Deley M-C
- Chong U, *see* Phipps E
- Chopin DK, *see* van Rhijn BWG
- Chou H-H, *see* Yen T-C
- Chow J, *see* Lam KC
- Choy H, *see* Movsas B
- Chrastek J, *see* Hilden JM
- Christian B, *see* Coiffier B
- Christian JA, Huddart RA, Norman A, Mason M, Fossa S, Aass N, Nicholl EJ, Dearnaley DP, Horwich A. Intensive Induction Chemotherapy With CBOP/BEP in Patients With Poor Prognosis Germ Cell Tumors, 871
- Christian RL, *see* Burstein HJ
- Chu KC, *see* Anderson WF
- Chu K-M, *see* Chan AO-O
- Chua B, *see* Olivotto IA
- Chuang E, *see* Parnes HL
- Chung A, *see* Carter CA
- Chung LP, *see* Chim CS
- Chung MH, Gupta RK, Hsueh E, Essner R, Ye W, Yee R, Morton DL. Humoral Immune Response to a Therapeutic Polyvalent Cancer Vaccine After Complete Resection of Thick Primary Melanoma and Sentinel Lymphadenectomy, 313
- Ciardella M, *see* Strair RK
- Cibull M, *see* Gallion HH
- Cigna E, *see* Gradilone A
- Cigolari S, *see* Gridelli C

- Cilloni D, Gottardi E, Messa F, Fava M, Scaravaglio P, Bertini M, Girotto M, Marinone C, Ferrero D, Gallamini A, Levis A, Saglio G. Significant Correlation Between the Degree of *WT1* Expression and the International Prognostic Scoring System Score in Patients With Myelodysplastic Syndromes, 1988
- Cimerman P, *see* Raffoux E
- Cinelli R, *see* Simonelli C
- Cirenei N, *see* Sozzi G
- Cirincione R, *see* Sozzi G
- Cirincione C, *see* Citron ML
see Parnes HL
- Cirincione CT, *see* Henderson IC
see Weiss RB
- Citron ML, Berry DA, Cirincione C, Hudis C, Winer EP, Gradishar WJ, Davidson NE, Martino S, Livingston R, Ingel JN, Perez EA, Carpenter J, Hurd D, Holland JF, Smith BL, Sartor CI, Leung EH, Abrams J, Schilsky RL, Muss HB, Norton L. Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/ Cancer and Leukemia Group B Trial 9741, 1431
- Clamp A, *see* Danson S
- Clancy D, *see* Gollob JA
- Clark E, *see* Pusztai L
- Clark GM, *see* Bardou V-J
- Clark JA, *see* Talcott JA
- Clark JA, Inui TS, Silliman RA, Bokhour BG, Krasnow SH, Robinson RA, Spaulding M, Talcott JA. Patients' Perceptions of Quality of Life After Treatment for Early Prostate Cancer, 3777
- Clark JI, Atkins MB, Urba WJ, Creech S, Figlin RA, Dutcher JP, Flaherty L, Sosman JA, Logan TF, White R, Weiss GR, Redman BG, Tretter CPG, McDermott D, Smith JW, Gordon MS, Margolin KA. Adjuvant High-Dose Bolus Interleukin-2 for Patients With High-Risk Renal Cell Carcinoma: A Cytokine Working Group Randomized Trial, 3133
- Clark JW, *see* Ramanathan RK
- Clark MM, *see* Koczwara B
- Clark R, *see* Belani CP
- Clarke M, Gaynon P, Hann I, Harrison G, Masera G, Peto R, Richards S. CNS-Directed Therapy for Childhood Acute Lymphoblastic Leukemia: Childhood ALL Collaborative Group Overview of 43 Randomized Trials, 1798
- Clarke-Pearson D, *see* Bookman MA
see Ozols RF
- Clarke-Pearson DL, *see* Varia MA
- Classen J, Schmidberger H, Meisner C, Souchon R, Sautter-Bihl M-L, Sauer R, Weinknecht S, Köhrmann K-U, Bamberg M. Radiotherapy for Stages IIA/B Testicular Seminoma: Final Report of a Prospective Multi-center Clinical Trial, 1101
- Clavell LA, *see* Dalton VK
- Clavère P, *see* Fumoleau P
- Clegg LX, *see* Harlan LC
- Clemons M, *see* Tchen N
- Clift S, *see* Salgia R
see Soiffer R
- Cloughesy T, *see* Jaeckle KA
- Coates AS, *see* Goldhirsch A
see Wallgren A
- Coates ASS, *see* Crivellari D
- Cobb J, *see* Strauss SJ
- Cobleigh M, Frame D. Is Trastuzumab Every 3 Weeks Ready for Prime Time? (editorial), 3900
- Cobleigh MA, *see* Winer EP
- Coggi G, *see* Buttitta F
- Cognetti F, *see* Alimonti A
see Pace A
- Cohen D, *see* Formenti SC
- Cohen EEW, *see* Rudin CM
- Cohen EEW, Rosen F, Stadler WM, Recant W, Stenson K, Huo D, Vokes EE. Phase II Trial of ZD1839 in Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck, 1980
- Cohen HJ, *see* Goldberg JM
see Kemeny MM
- Cohen IJ, *see* Ohali A
- Cohen JS, *see* Mardor Y
- Cohen LE, *see* Dalton VK
- Cohen PA, *see* Bedrosian I
- Cohen R, *see* Esteva FJ
- Cohen SJ, Ho L, Ranganathan S, Abbruzzese JL, Alpaugh RK, Beard M, Lewis NL, McLaughlin S, Rogatko A, Perez-Ruixo JJ, Thistle AM, Verhaeghe T, Wang H, Weiner LM, Wright JJ, Hudes GR, Meropol NJ. Phase II and Pharmacodynamic Study of the Farnesyltransferase Inhibitor R115777 as Initial Therapy in Patients With Metastatic Pancreatic Adenocarcinoma, 1301
- Coiffier B. Increasing Chemotherapy Intensity in Aggressive Lymphomas: A Renewal? (editorial), 2457
- Coiffier B, Mounier N, Bologna S, Fermé C, Tilly H, Sonet A, Christian B, Casanovas O, Jourdan E, Belhadj K, Herbrecht R. Efficacy and Safety of Rasburicase (Recombinant Urate Oxidase) in the Prevention and Treatment of Hyperuricemia During Induction Chemotherapy of Aggressive Non-Hodgkin's Lymphoma: Results of the GRAALI (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) Study, 4402
- Coit D, *see* Ilson DH
- Coit DG, *see* Weitz J
- Colan SD, *see* Lipshultz SE
- Colangelo L, *see* Dignam JJ
- Colangelo LH, *see* Allegra CJ
- Colantoni A, *see* Villa E
- Colbert N, *see* André T
- Cole D, *see* Blaney SM
- Colecchia M, *see* Gronchi A
- Coleman M, *see* Leonard JP
- Coleman N, *see* Gonzalez MA
- Colin P, *see* André T
- Colla S, *see* Giuliani N
- Collette L, *see* Fosså SD
- Collins J, *see* Crivellari D
see Wallgren A
- Collins JM. Functional Imaging in Phase I Studies: Decorations or Decision Making? (editorial), 2807
- Collins K, *see* Rayson D
- Colombat P, *see* Federico M
- Colombi M, *see* Baldini L
- Colombo N, *see* Buyse M
- Colombo R, Da Pozzo LF, Salonia A, Leib Z, Rigatti P, Baniel J, Calderara E, Pavone-Macaluso M. Multicentric Study Comparing Intravesical Chemotherapy Alone and With Local Microwave Hyperthermia for Prophylaxis of Recurrence of Superficial Transitional Cell Carcinoma, 4270
- Colomer D, *see* Roman-Gomez J
- Coltman CA Jr, *see* Unger JM
- Colwell B, *see* Moore MJ
- Comandone A, *see* Ferrari S
- Combaret V, *see* Ambros IM
- Comis RL, Miller JD, Aldigé CR, Krebs L, Stoval E. Public Attitudes Toward Participation in Cancer Clinical Trials, 830
- Compagno M, *see* Ladetto M
- Conconi A, *see* Ferreri AJM
see Zucca E

AUTHOR INDEX

- Connell PP, Weichselbaum RR. Gene Therapy: The Challenges of Translating Laboratory Research Into Clinical Practice. (editorial), 2230
- Connors JM, *see* Armitage JO
- see* Duggan DB
- see* Kouroukis CT
- Connors JM. Hodgkin's Lymphoma: The Hazards of Success (editorial), 3388
- Conradt S, *see* Razavi D
- Conte D, *see* Sozzi G
- Conte M, *see* De Bernardi B
- Conte P, *see* Buyse M
- Conter V, *see* Aricò M
- Conti F, *see* Papaldo P
- Cook EF, *see* Gill S
- Cook EH, *see* Kishi S
- Cook P, *see* Fossà SD
- Cooke E, *see* Tepper JE
- Cooper HA, *see* Hutchinson RJ
- Cooper K, *see* Davis MP
- Cooper MR, *see* Henderson IC
- see* Parnes HL
- Copeland LJ, *see* Markman M
- Coquard R, *see* Gérard J-P
- Corbett S, *see* Meropol NJ
- Cordon-Cardo C, *see* Gonen M
- see* Segal NH
- Corless CL, *see* Heinrich MC
- Cornelissen JJ, *see* Lokhorst HM
- Cornelius V, *see* Last KW
- Corradini P, *see* Ladetto M
- Correa DD, *see* Abrey LE
- Correa P, *see* Wong JEL
- Correa P. Chemoprevention of Gastric Cancer: Has the Time Come?, 270s
- Cortelazzo S, *see* Zucca E
- Cortes J, *see* Kantarjian HM
- Cortes JE, *see* Giles FJ
- Cortesi E, *see* Papaldo P
- Cosio S, *see* Buttitta F
- Cossu A, *see* Palmieri G
- Costagliola D, *see* Herida M
- Costa J, *see* Garcia-Rostan G
- Cote RJ, *see* Lugo TG
- Cottler-Fox M, *see* Lee C-K
- Cottu P, *see* Tourani J-M
- Couanet D, *see* Laithier V
- Coudert B, *see* Culine S
- Couillault G, *see* Pellegrino B
- Courneya KS, Mackey JR, Bell GJ, Jones LW, Field CJ, Fairey AS. Randomized Controlled Trial of Exercise Training in Postmenopausal Breast Cancer Survivors: Cardiopulmonary and Quality of Life Outcomes, 1660
- Courneya KS, *see* Segal RJ
- Couturier J, *see* Ambros IM
- Couvreux M-L, *see* Köhne C-H
- Coward D, *see* Huddart RA
- Cox H, *see* Graham PH
- Cox J, *see* Chakravarti A
- Cox JD, *see* Seymour JF
- Coxon FY, *see* Kolomainen DF
- Coyne CA, Xu R, Raich P, Plomer K, Dignan M, Wenzel LB, Fairclough D, Habermann T, Schnell L, Quella S, Cella D. Randomized, Controlled Trial of an Easy-to-Read Informed Consent Statement for Clinical Trial Participation: A Study of the Eastern Cooperative Oncology Group, 836
- Coyne PJ, *see* Smith TJ
- Crane CH, Thames HD, Hamilton SR. Will Identifying or Targeting Altered Marker Expression in Response to Cytotoxic Therapy Be of Prognostic or Therapeutic Value? (editorial), 3381
- Craviotto L, *see* Giuliani N
- Crawford ED, *see* Messing EM
- Crawford J, *see* Lawrence GA
- see* Lyman GH
- Crawford M, *see* Wright EP
- Creech CM, *see* Ayanian JZ
- Creech S, *see* Clark JI
- Crepin E, *see* Meijers-Heijboer H
- Cress RD, *see* Ayanian JZ
- Cress RD, O'Malley CD, Leiserowitz GS, Campleman SL. Patterns of Chemotherapy Use for Women With Ovarian Cancer: A Population-Based Study, 1530
- Crinò L, *see* Cappuzzo F
- Crist WM, *see* Breneman JC
- see* Pappo AS
- Crivellari D, Price K, Gelber RD, Castiglione-Gertsch M, Rudenstam C-M, Lindtner J, Fey MF, Senn H-J, Coates ASS, Collins J, Goldhirsch A. Adjuvant Endocrine Therapy Compared With No Systemic Therapy for Elderly Women With Early Breast Cancer: 21-Year Results of International Breast Cancer Study Group Trial IV, 4517
- Croghan IT, *see* Hurt RD
- Crowley J, *see* Gandara DR
- see* Unger JM
- Cruciani M, Malena M, Bosco O, Nardi S, Serpelloni G, Mengoli C. Reappraisal With Meta-Analysis of the Addition of Gram-Positive Prophylaxis to Fluoroquinolone in Neutropenic Patients, 4127
- Crum CP, Abbott DW, Quade BJ. Cervical Cancer Screening: From the Papanicolaou Smear to the Vaccine Era, 224s
- Crum CP, *see* Cannistra SA
- Crump M, Tu D, Shepherd L, Levine M, Bramwell V, Pritchard K. Risk of Acute Leukemia Following Epirubicin-Based Adjuvant Chemotherapy: A Report From the National Cancer Institute of Canada Clinical Trials Group, 3066
- Crump M, *see* Abrey LE
- see* Kouroukis CT
- see* Tchen N
- see* Tsang RW
- see* Vose JM
- Cufer T, *see* Therasse P
- Culine S, Lortholary A, Voigt J-J, Bugat R, Théodore C, Priou F, Kaminsky M-C, Lesimple T, Pivot X, Coudert B, Douillard J-Y, Merrouche Y, Allouache J, Goupil A, Négrier S, Viala J, Petrow P, Bouzy J, Laplanche A, Fizazi K. Cisplatin in Combination With Either Gemcitabine or Irinotecan in Carcinomas of Unknown Primary Site: Results of a Randomized Phase II Study—Trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01), 3479
- Cull A, *see* Wright EP
- Culliford AT, *see* Nash GM
- Cunningham D, *see* Chau I
- Curley SA, *see* Patt YZ
- Curran W, *see* Mehta MP
- see* Shaw E
- Curran WJ, *see* Brown PD
- Cutter G, *see* Kerlikowske K
- Cuvelier CA, *see* Van de Wiele C
- Cuzick J, *see* Duggan C
- Czerniecki BJ, *see* Bedrosian I

D

- Dagenais M, *see* Moore MJ
- Daghofer F, *see* Augustin H

AUTHOR INDEX

- Dagis A, *see* Stein AS
Dahl AA, *see* Fosså SD
Dahl O, *see* Sørbye H
Dähler W, *see* Mengis C
Dahut W, *see* Takimoto CH
Dakhil SR, *see* Velasquez WS
Dale DC, *see* Lyman GH
Daliani DD, *see* Carducci MA
Daling JR, *see* Li CI
Dalle JH, *see* Aladjidi N
Dallorso S, *see* De Bernardi B
Dalton VK, *see* Goldberg JM
Dalton VK, Rue M, Silverman LB, Gelber RD, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin M, Tarbell NJ, Sallan SE, Cohen LE. Height and Weight in Children Treated for Acute Lymphoblastic Leukemia: Relationship to CNS Treatment, 2953
Daly PA, *see* Bird BR
D'Amico AV, *see* Talcott JA
D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen M-H. Cancer-Specific Mortality After Surgery or Radiation for Patients With Clinically Localized Prostate Cancer Managed During the Prostate-Specific Antigen Era, 2163
Damle B, *see* Abraham J
Damokosh A, *see* Pustai L
Dancey J, *see* Moore MJ
Dan Costa S, *see* Kaufmann M
D'Angelica M, *see* Weitz J
D'Angelo MES, *see* Segal RJ
D'Angelo P, *see* De Bernardi B
D'Angio GJ, *see* Green DM
Daniel C, *see* Fizazi K
Daniell HW. Androgen Augmentation of Epoetin (correspondence), 2224
Daniel M-T, *see* Raffoux E
Daniel PT, *see* Rau B
Danishefsky S, *see* Slovin SF
Dananberg P, *see* Formenti SC
Dank M, *see* Mouridsen H
Dannenber AJ, *see* Altorki NK
Danson S, Lorigan P, Arance A, Clamp A, Ranson M, Hodgetts J, Lomax L, Ashcroft L, Thatcher N, Middleton MR. Randomized Phase II Study of Temozolomide Given Every 8 Hours or Daily With Either Interferon Alfa-2b or Thalidomide in Metastatic Malignant Melanoma, 2551
Danuser H, *see* Madersbacher S
Daponte A, *see* Palmieri G
Da Pozzo LF, *see* Colombo R
Dar AR, *see* Videtic GMM
Darcy KM, *see* Bookman MA
see Havrilesky L
D'Arminio Monforte A, *see* Nasti G
Darnfors C, *see* Ambros IM
Darnton SJ, Archer VR, Stocken DD, Mulholland PJ, Casson AG, Ferry DR. Preoperative Mitomycin, Ifosfamide, and Cisplatin Followed by Esophagectomy in Squamous Cell Carcinoma of the Esophagus: Pathologic Complete Response Induced by Chemotherapy Leads to Long-Term Survival, 4009
Das S, *see* Kishi S
Datchary J, *see* Fumoleau P
Daugaard G, *see* Powles T
Daugherty CK, *see* Helft PR
Daugherty CK, Steensma DP. Overcoming Obstacles to Hospice Care: An Ethical Examination of Inertia and Interaction, 42s
Daum S, Ullrich R, Heise W, Dederke B, Foss H-D, Stein H, Thiel E, Zeitz M, Riecken E-O. Intestinal Non-Hodgkin's Lymphoma: A Multicenter Prospective Clinical Study From the German Study Group on Intestinal Non-Hodgkin's Lymphoma, 2740
Davi F, *see* Vasconcelos Y
Davidson NE, *see* Citron ML
Davies AJ, *see* Taussig DC
Davies AL, *see* Panasuk DB
Davis DD, *see* Davis MP
Davis L, *see* Abraham J
Davis M, *see* Naughton M
Davis MP, Davis DD, Smith ML, Cooper K. Just Whose Autonomy Is It?, 67s
Davis MP, Walsh D, Lagman R, LeGrand SB. Randomized Clinical Trial of an Implantable Drug Delivery System (correspondence), 2801
Davis RB, *see* McCarthy EP
Davis T, *see* Chester JD
Dawson NA, *see* Halabi S
Day J, *see* El-Rayes BF
Deacon DH, *see* Slingluff CL Jr
DeAngelis LM, *see* Abrey LE
DeAngelis LM. Primary Central Nervous System Lymphoma: A Curable Brain Tumor (editorial), 4471
Deapen D, *see* Penson DF
Dearnaley DP, *see* Christian JA
see Huddart RA
De Berardis G, *see* Sacco M
De Bernardi B, *see* Ambros IM
see Indolfi P
De Bernardi B, Nicolas B, Boni L, Indolfi P, Carli M, di Montezemolo LC, Donfrancesco A, Pession A, Provenzi M, di Cataldo A, Rizzo A, Tonini GP, Dallorso S, Conte M, Gambini C, Garaventa A, Bonetti F, Zanazzo A, D'Angelo P, Bruzzi P. Disseminated Neuroblastoma in Children Older Than 1 Year at Diagnosis: Comparable Results With Three Consecutive High-Dose Protocols Adopted by the Italian Co-Operative Group for Neuroblastoma, 1592
De Beule N, *see* Hoang-Xuan K
DeBiase DA, *see* Thomas CT
de Bono J, *see* Propper DJ
see Tolcher AW
de Bree E, *see* Verwaal VJ
de Bruijn H, *see* Diamandis EP
Debruyne C, *see* Smit EF
DeCillis A, *see* Smith RE
Deckert M, *see* Pels H
Declerck L, *see* Masters GA
Dederke B, *see* Daum S
DeFor TE, *see* Baker KS
DeGeest K, *see* Ozols RF
Degner LF, *see* Hack TF
Degos L, *see* Raffoux E
de Graeff A, *see* Bottomley A
de Gramont A, *see* André T
de Haes H, Olschewski M, Kaufmann M, Schumacher M, Jonat W, Sauerbrei W. Quality of Life in Goserelin-Treated Versus Cyclophosphamide + Fluorouracil-Treated Premenopausal and Perimenopausal Patients With Node-Positive, Early Breast Cancer: The Zoladex Early Breast Cancer Research Association Trialists Group, 4510
Deiningner MWN, O'Brien SG, Ford JM, Drucker BJ. Practical Management of Patients With Chronic Myeloid Leukemia Receiving Imatinib, 1637
de Jong D, *see* Haas RLM
de Jong PC, *see* Pronk WG
De Koning HJ, *see* Kriege M
DeLaat C, *see* Bhatia S
Delanian S, Porcher R, Balla-Mekias S, Lefaix J-L. Randomized, Placebo-Controlled Trial of Combined Pentoxifylline and Tocopherol for Regression of Superficial Radiation-Induced Fibrosis, 2545
Delarue R, *see* Raffoux E

AUTHOR INDEX

- Delasalle K, *see* Weber D
- de las Peñas R, *see* Alberola V
- Delattre JY, *see* Hoang-Xuan K
- Delattre O, *see* Ambros IM
see Schleiermacher G
- De Lena M, *see* Volpi A
- Delling G, *see* Ozaki T
- Dell'Oro S, *see* Ferreri AJM
- Delmer A, *see* Bouabdallah R
- Del Monte G, *see* Pace A
- Delmore JE, *see* Omura GA
- Delozier T, *see* Freyer G
- Del Prever AB, *see* Ferrari S
- Del Principe MI, *see* Abruzzese E
- Delsol G, *see* Pellegrino B
- Delvaux N, *see* Razavi D
- Delves T, *see* Last KW
- Demakos E, *see* Weiss RB
- DeMarco T, *see* Schwartz MD
- Demaret C, *see* Marec-Berard P
- Demeocq F, *see* Pellegrino B
- Demers L, *see* Lipton A
- Demetri GD, *see* Esteva FJ
see Heinrich MC
see Henderson IC
- DeMets DL, *see* Love RR
- DeMichele A, *see* Esteva FJ
- De Micheli C, Fornengo P, Bosio A, Epifani G, Pascale C. Severe Radiation-Induced Proctitis Treated With Botulinum Anatoxin Type A (correspondence), 2627
- Demierre M-F, Nathanson L. Chemoprevention of Melanoma: An Unexplored Strategy, 158
- de Montezemolo LC, *see* De Bernardi B
- de Mulder PHM, *see* Fossà SD
- Den Boer ML, Harms DO, Pieters R, Kazemier KM, Göbel U, Körholz D, Graubner U, Haas RJ, Jorch N, Spaar HJ, Kaspers GJL, Kamps WA, Van der Does-Van den Berg A, Van Wering ER, Veerman AJP, Janka-Schaub GE. Patient Stratification Based on Prednisolone-Vincristine-Asparaginase Resistance Profiles in Children With Acute Lymphoblastic Leukemia, 3262
- Denham C, *see* Vogelzang NJ
- Denis L, *see* Rowinsky EK
- De Paola F, *see* Volpi A
- De Paolis M, *see* Bacci G
- Depisch D, *see* Scheithauer W
- DePriest PD, *see* Cannistra SA
- DePriest PD, DeSimone CP. Ultrasound Screening for the Early Detection of Ovarian Cancer, 194s
- de Prijck L, *see* Fossà SD
- De Renzo A, *see* Martelli M
- de Riese W, *see* Albers P
- De Rosa M, *see* Cappuzzo F
- De Ruyter A, *see* Powles T
- DeSantis D, *see* Segal NH
- DeSilvio M, *see* Roach M III
- DeSimone CP, *see* DePriest PD
- de Souza P, *see* Rosen LS
- de Thé H, *see* Raffoux E
- Detournignies L, *see* Beaumont M
- Dettmar P, *see* Zemzoum I
- de Vathaire F, *see* Le Deley M-C
- Devidas M, *see* Goorin AM
- De Vivo A, *see* Martelli M
- Devizzi L, *see* Ferreri AJM
- DeVore R, *see* Masters GA
- de Vries DE, *see* Autier P
- de Vries EGE, *see* Berends MJW
- de Widt-Levert LM, *see* Hoogerbrugge N
- Dewit LGH, *see* Haas RLM
- de Wit M, *see* Engert A
- de Wit R, Herrstedt J, Rapoport B, Carides AD, Carides G, Elmer M, Schmidt C, Evans JK, Horgan KJ. Addition of the Oral NK₁ Antagonist Aprepitant to Standard Antiemetics Provides Protection Against Nausea and Vomiting During Multiple Cycles of Cisplatin-Based Chemotherapy, 4105
- de Wit R, *see* Fossà SD
see Hesketh PJ
- DeWitte M, *see* Tolcher AW
- De Wolf-Peeters C, *see* Verburgh E
- D'haese S, *see* Efficace F
- Dhaini HR, Thomas DG, Giordano TJ, Johnson TD, Biermann JS, Leu K, Hollenberg PF, Baker LH. Cytochrome P450 CYP3A4/5 Expression as a Biomarker of Outcome in Osteosarcoma, 2481
- Dhillon B, *see* Cackett P
- Diamandis E, *see* Nam RK
- Diamandis EP, Scorilas A, Fracchioli S, van Gramberen M, de Bruijn H, Henrik A, Soosaipillai A, Grass L, Yousef GM, Stenman U-H, Massobrio M, van der Zee AGJ, Vergote I, Katsaros D. Human Kallikrein 6 (hK6): A New Potential Serum Biomarker for Diagnosis and Prognosis of Ovarian Carcinoma, 1035
- Diamandis EP, *see* Yousef GM
- Dias R, *see* Leyland-Jones B
- Díaz P, *see* Maillo A
- di Cataldo A, *see* De Bernardi B
- Dick SJ, *see* Kozelsky TF
- Dickler M, *see* Esteva FJ
- Di Cosimo S, *see* Alimonti A
see Papaldo P
- Diefenbach M, *see* Meropol NJ
- Diehl V. Advanced Hodgkin's Disease: ABVD Is Better, Yet Is Not Good Enough! (editorial), 583
- Diehl V, *see* Engert A
see Josting A
see Pels H
see Sieber M
- Diep CB, Thorstensen L, Meling GI, Skovlund E, Rognum TO, Lothe RA. Genetic Tumor Markers With Prognostic Impact in Dukes' Stages B and C Colorectal Cancer Patients, 820
- Diepenhorst FW, *see* Baak JPA
- Dierck RA, *see* Van de Wiele C
- Dietze O, *see* Pohl G
- Dighiero G, *see* Vasconcelos Y
- Dignam JJ, Ye Y, Colangelo L, Smith R, Mamounas EP, Wieand HS, Wolmark N. Prognosis After Rectal Cancer in Blacks and Whites Participating in Adjuvant Therapy Randomized Trials, 413
- Dignan M, *see* Coyne CA
- Di Lauro L, *see* Papaldo P
- Di Leo A, Bleiberg H, Buyse M. Overall Survival Is Not a Realistic End Point for Clinical Trials of New Drugs in Advanced Solid Tumors: A Critical Assessment Based on Recently Reported Phase III Trials in Colorectal and Breast Cancer, 2045
- Diller L, *see* Bhatia S
see Nichols KE
see Recklitis C
- Di Maria MV, *see* Hirsch FR
- Diment J, *see* Rosenthal G
- Dimitrijevic S, *see* Heinrich MC
- Dimopoulos MA, Anagnostopoulos A, Weber D. Treatment of Plasma Cell Dyscrasias With Thalidomide and Its Derivatives, 4444
- Dinapoli RP, *see* Brown PD

AUTHOR INDEX

- Dineen S, *see* Chao C
- Ding K, *see* Ernst DS
- Dinney CP, *see* Pagliaro LC
- DiPaola RS, *see* Strair RK
- Di Perri G, *see* Nasti G
- DiPersio JF, *see* Cashen A
- Di Renzo N, *see* Federico M
see Tartarone A
- Dittler H-J, *see* Ott K
- Di Tullio MT, *see* Indolfi P
- Dixon PF, *see* Groome PA
- Diz P, *see* Alberola V
- Djulgovic B, *see* Glasmacher A
- Dmitrovsky E. Combining Cytotoxic Chemotherapy With Cyclooxygenase-2 Inhibition (editorial), 2631
- Dobrez DG, *see* Hahn EA
- Dobrzynski D, *see* Mazumdar M
- Doehner H, *see* Cheson BD
- Döhner H, *see* Krauter J
- Doll DC, *see* Shahab N
- Doll R, *see* Bordeleau L
- Dols A, *see* Smith JW II
- Dombret H, *see* Beaumont M
see Boissel N
see Raffoux E
- Domchek SM, Eisen A, Calzone K, Stopfer J, Blackwood A, Weber BL. Application of Breast Cancer Risk Prediction Models in Clinical Practice, 593
- Donadio A, *see* Mazumdar M
- Donadio AC, Motzer RJ, Bajorin DF, Kantoff PW, Sheinfeld J, Houldsworth J, Chaganti RSK, Bosl GJ. Chemotherapy for Teratoma With Malignant Transformation, 4285
- Donahue D, *see* Salgia R
- Donahue T, *see* Carter CA
- Donaldson SS, *see* Breneman JC
see Green DM
see Packer RJ
see Pappo AS
see Smith RS
- Donfrancesco A, *see* De Bernardi B
- Dong R-P, *see* Fukuoka M
- Donna E, *see* Rosado MF
- Donnelly J, *see* Moore DH
- Dono K, *see* Yamamoto S
- Dooley M, *see* Stefanou A
- Doorduijn JK, van der Holt B, van Imhoff GW, van der Hem KG, Kramer MHH, van Oers MHJ, Ossenkoppele GJ, Schaafsma MR, Verdonck LF, Verhoef GEG, Steijaert MMC, Buijt I, Uyl-de Groot CA, van Agthoven M, Mulder AH, Sonneveld P. CHOP Compared With CHOP Plus Granulocyte Colony-Stimulating Factor in Elderly Patients With Aggressive Non-Hodgkin's Lymphoma, 3041
- Doorduijn JK, *see* Schouten HC
- Doran T, *see* Smith JW II
- Dörffel Y, *see* Faiss S
- Dörken B, *see* Kretschmar A
see Rau B
- Dornbusch HJ, *see* Kerbl R
- Doroshov J, *see* Takimoto CH
- Doubre H, *see* Fizazi K
- Douer D, *see* Giles FJ
- Douglass EC, *see* Sawyer MB
- Douillard J-Y, *see* Culine S
see Fukuoka M
- Downey RJ, Akhurst T, Ilson D, Ginsberg R, Bains MS, Gonen M, Koong H, Gollub M, Minsky BD, Zakowski M, Turnbull A, Larson SM, Rusch V. Whole Body ¹⁸F-FDG-PET and the Response of Esophageal Cancer to Induction Therapy: Results of a Prospective Trial, 428
- Downie FP, *see* Tchen N
- Dowsett M, *see* Johnston SRD
- Doz F, *see* Laithier V
see Vassal G
- Drandi D, *see* Ladetto M
- Dranoff G, *see* Salgia R
see Soiffer R
- Dresen A, *see* Thomas JP
- Dreves J, *see* Morgan B
- Driver D, *see* Strauss SJ
- Driver L, *see* Bruera E
- Droz J-P, *see* Extermann M
- Drucker BJ, *see* Deininger MWN
- Druker BJ. Imatinib As a Paradigm of Targeted Therapies, 239s
- Druker BJ, *see* Hahn EA
see Heinrich MC
- Du M, *see* Kantarjian HM
- Dubagunta S, *see* Bucaloiu ID
- Dubreuil-Lemaire M-L, *see* Alimi D
- Dubsky P, *see* Stift A
- Duc NB, *see* Love RR
- Duda R, *see* Soiffer R
- Dudek L, *see* Strair RK
- Dugan M, *see* Morgan B
- Duggan C, Marriott K, Edwards R, Cuzick J. Inherited and Acquired Risk Factors for Venous Thromboembolic Disease Among Women Taking Tamoxifen to Prevent Breast Cancer, 3588
- Duggan DB, Petroni GR, Johnson JL, Glick JH, Fisher RI, Connors JM, Canellos GP, Peterson BA. Randomized Comparison of ABVD and MOPP/ABV Hybrid for the Treatment of Advanced Hodgkin's Disease: Report of an Intergroup Trial, 607
- Duggan DB, *see* Henderson IC
see Parnes HL
- Dühmke E, *see* Engert A
- Duivenvoorden HJ, *see* van Oostrom I
- Dulmen AMv, *see* Mellink WAM
- Dummer R, *see* Hauschild A
- Dunkel IJ, *see* Wolden SL
- Dunn SM, *see* Boyle FM
- Dunst J, *see* Burdach S
- Dusenbery K, *see* Wells RJ
- Dutcher JP. The Prognostic Role of Detection of Circulating Melanoma Cells in the Blood (editorial), 757
- Dutcher JP, *see* Clark JI
- Dutta M, *see* Zenzoum I
- Duvillard P, *see* Morice P
- Dyer MJS. Bioweapons of Tumor Mass Destruction? (editorial), 3011

E

- Eapen LJ, *see* Groome PA
- Eapen M, *see* Serna DS
- Earle CC, Burstein HJ, Winer EP, Weeks JC. Quality of Non-Breast Cancer Health Maintenance Among Elderly Breast Cancer Survivors, 1447
- Earle CC, Emanuel EJ. Patterns of Care Studies: Creating "An Environment of Watchful Concern" (editorial), 4479
- Earle CC. Influenza Vaccination in Elderly Patients With Advanced Colorectal Cancer, 1161
- Earle CC, Park ER, Lai B, Weeks JC, Ayanian JZ, Block S. Identifying Potential Indicators of the Quality of End-of-Life Cancer Care From Administrative Data, 1133
- Earle CC, *see* Krzyzanowska MK

AUTHOR INDEX

- Eastham S, *see* Slingluff CL Jr
- Ebbert JO, Yang P, Vachon CM, Vierkant RA, Cerhan JR, Folsom AR, Sellers TA. Lung Cancer Risk Reduction After Smoking Cessation: Observations From a Prospective Cohort of Women, 921
- Ebbs S, *see* Ring A
- Ebert B, Shaffer K, Rennke H. Some Unusual Paraneoplastic Syndromes: Paraneoplastic Nephrotic Syndrome in a Patient With Lung Cancer, 2620
- Ebert MPA, Yu J, Hoffmann J, Rocco A, Röcken C, Kahmann S, Müller O, Korc M, Sung JJ, Malfertheiner P. Loss of Beta-Catenin Expression in Metastatic Gastric Cancer, 1708
- Eckert R, *see* Kretzschmar A
- Economou JS, *see* Ribas A
- Edan C, *see* Pellegrino B
- Edeline V, *see* Matthay KK
- Eder M, *see* Simon C
- Edge SB, *see* Mandelblatt JS
see Winer EP
- Edgerly M, *see* Abraham J
- Edick MJ, Gajjar A, Mahmoud HH, van de Poll MEC, Harrison PL, Panetta JC, Rivera GK, Ribeiro RC, Sandlund JT, Boyett JM, Pui C-H, Relling MV. Pharmacokinetics and Pharmacodynamics of Oral Etoposide in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia, 1340
- Edwards R, *see* Duggan C
- Edwards T, *see* Tolcher AW
- Eek R, *see* Fukuoka M
- Efficace F, Bottomley A, Osoba D, Gotay C, Flechtner H, D'haese S, Zurlo A. Beyond the Development of Health-Related Quality-of-Life (HRQOL) Measures: A Checklist for Evaluating HRQOL Outcomes in Cancer Clinical Trials—Does HRQOL Evaluation in Prostate Cancer Research Inform Clinical Decision Making?, 3502
- Efficace F, *see* Bottomley A
- Egerer G, *see* Pels H
- Eggermont AMM, *see* Autier P
see Mellink WAM
- Egli F, *see* Betticher DC
- Egorin M, *see* Takimoto CH
- Egorin MJ. Horseshoes, Hand Grenades, and Body-Surface Area-Based Dosing: Aiming for a Target (editorial), 182
- Egorin MJ. In Reply (correspondence), 2806
- Egorin MJ, *see* Beer TM
see Laufer M
- Ehninger G, *see* Schetelig J
- Ehrlich LD, *see* Padmanabhan H
- Eich H, *see* Sieber M
- Eiermann W, *see* Kaufmann M
- Eijkemans MJC, *see* Vergouwe Y
- Eilers KM, *see* Beer TM
- Eimermacher H, *see* Haferlach T
- Einhorn LH, *see* Fisch MJ
see George DW
see Vaena DA
- Eisen A, *see* Domchek SM
- Eisenberg B, *see* Heinrich MC
- Eisenberger MA, *see* Laufer M
- Eisenberg PD, *see* Moore MJ
see Schapira L
- Eisenhauer E, *see* Kouroukis CT
- Ek WB, *see* Berends MJW
- Ekert H, Ashley D. In Reply (correspondence), 1192
- Elashoff RM, *see* Wascher RA
- Elias D, *see* Mohamed F
- Ellard S, *see* Propper DJ
- Elledge RM, *see* Bardou V-J
- Elliott C, *see* Ernst DS
- Ellis LM. Antiangiogenic Therapy at a Crossroads: Clinical Trial Results and Future Directions, 281s
- Ellis LM. Antiangiogenic Therapy: More Promise and, Yet Again, More Questions (editorial), 3897
- Ellis LM, *see* Patt YZ
- Ellis MJ, *see* Burstein HJ
- Ellis P, *see* Johnston SRD
- Ellisen LM, *see* Burstein HJ
- Ellison D, *see* Taylor RE
- Ellwanger U, *see* Garbe C
- Elmer M, *see* de Wit R;
see Hesketh PJ
- El-Naggar AK, *see* Rudin CM
- El-Rayes BF, Zalupski MM, Shields AF, Vaishampayan U, Heilbrun LK, Jain V, Adsay V, Day J, Philip PA. Phase II Study of Gemcitabine, Cisplatin, and Infusional Fluorouracil in Advanced Pancreatic Cancer, 2920
- El-Serafi M, *see* Köhne C-H
- Elson P, *see* Majhail NS
- Elterman RD, *see* Bowers DC
- Ely S, *see* Leonard JP
- Emami M, *see* Nam RK
- Emanuel EJ, Schnipper LE, Kamin DY, Levinson J, Lichter AS. The Costs of Conducting Clinical Research, 4145
- Emanuel EJ, *see* Earle CC
- Emmanouilides C, *see* Vose JM
see Witzig TE
- Emmerich B, *see* Jung CP
- Emmons KM, Butterfield RM, Puleo E, Park ER, Mertens A, Gritz ER, Lahti M, Li FP. Smoking Among Participants in the Childhood Cancer Survivors Cohort: The Partnership for Health Study, 189
- Emoto M, Fujimitsu R, Iwasaki H, Kawarabayashi T. Diagnostic Challenges in Patients With Tumors: Normal-Sized Ovarian Cancer Detected by Color Doppler Ultrasound Using a Microbubble Contrast Agent, 3700
- Emri S, *see* Vogelzang NJ
- Engeler GP, *see* Kozelsky TF
- Engelhard VH, *see* Slingluff CL Jr
- Engelhart S, *see* Glasmacher A
- Engelmann K, *see* Leung TWT
- Engert A, Schiller P, Josting A, Herrmann R, Koch P, Sieber M, Boissevain F, de Wit M, Mezger J, Dühmke E, Willich N, Müller R-P, Schmidt BF, Renner H, Müller-Hermelink HK, Pfistner B, Wolf J, Hasenclever D, Löffler M, Diehl V. Involved-Field Radiotherapy Is Equally Effective and Less Toxic Compared With Extended-Field Radiotherapy After Four Cycles of Chemotherapy in Patients With Early-Stage Unfavorable Hodgkin's Lymphoma: Results of the HD8 Trial of the German Hodgkin's Lymphoma Study Group, 3601
- Engert A, *see* Josting A
see Pels H
see Sieber M
- Engstrom PF, *see* Schnoll RA
- Ennis M, *see* Bordeleau L
see Goodwin PJ
- Ensley JF, *see* Adelstein DJ
- Epifani G, *see* De Micheli C
- Erasmus JJ, Gladish GW, Broemeling L, Sabloff BS, Truong MT, Herbst RS, Munden RF. Interobserver and Intraobserver Variability in Measurement of Non-Small-Cell Carcinoma Lung Lesions: Implications for Assessment of Tumor Response, 2574
- Erba HP, *see* Ganz PA
- Erbersdobler A, *see* Augustin H
- Erdamar S, *see* Shariat SF
- Erickson BJ, *see* Buckner JC

- Erikstein B, *see* Brandberg Y
 Erlich R, *see* Olnes M
 Erlichman C, *see* Adjei AA
 see Goetz MP
 Ernst DS, Tannock IF, Winquist EW, Venner PM, Reyno L, Moore MJ, Chi K, Ding K, Elliott C, Parulekar W. Randomized, Double-Blind, Controlled Trial of Mitoxantrone/Prednisone and Clodronate Versus Mitoxantrone/Prednisone and Placebo in Patients With Hormone-Refractory Prostate Cancer and Pain, 3335
 Ernst DS, *see* Townsley CA
 Escalante C, *see* Bruera E
 Escalon J, *see* Hochster H
 Escarce JJ, *see* Lewis JH
 Eschenberg M, *see* Leonard JP
 Escudero P, *see* Andrés R
 Essner R, *see* Bleicher RJ
 see Chung MH
 Esteva FJ, Gaspy J, Baidas S, Laufman L, Hutchins L, Dickler M, Tripathy D, Cohen R, DeMichele A, Yocum RC, Osborne CK, Hayes DF, Hortobagyi GN, Winer E, Demetri GD. Multicenter Phase II Study of Oral Bexarotene for Patients With Metastatic Breast Cancer, 999
 Esteva FJ, *see* Pusztai L
 Esteve J, *see* Beaumont M
 Estey EH, *see* Cheson BD
 see Giles FJ
 Etienne A-M, *see* Razavi D
 Eton DT, Fairclough DL, Cella D, Yount SE, Bonomi P, Johnson DH. Early Change in Patient-Reported Health During Lung Cancer Chemotherapy Predicts Clinical Outcomes Beyond Those Predicted by Baseline Report: Results From Eastern Cooperative Oncology Group Study 5592, 1536
 Ettinger D, *see* Movsas B
 Evans A, *see* Nam RK
 Evans B, *see* Quinn JA
 Evans JK, *see* de Wit R
 see Hesketh PJ
 Ewerbeck V, *see* Ozaki T
 Exner GU, *see* Ozaki T
 Extermann M, Albrand G, Chen H, Zanetta S, Schonwetter R, Zulian GB, Cantor A, Droz J-P. Are Older French Patients As Willing As Older American Patients to Undertake Chemotherapy?, 3214
 Extermann M, *see* Sparreboom A
 Ezziddin S, *see* Palmedo H
- F**
- Fabbiano F, *see* Federico M
 Fabi A, *see* Papaldo P
 Facchini T, *see* Fumoleau P
 Faderl S, *see* Giles FJ
 see Kantarjian HM
 Fagioli F, *see* Ferrari S
 Fairclough D, *see* Coyne CA
 Fairclough DL, *see* Eton DT
 Fairey AS, *see* Courneya KS
 Faiss S, Pape U-F, Böhmig M, Dörfel Y, Mansmann U, Golder W, Riecken EO, Wiedenmann B. Prospective, Randomized, Multicenter Trial on the Antiproliferative Effect of Lanreotide, Interferon Alfa, and Their Combination for Therapy of Metastatic Neuroendocrine Gastroenteropancreatic Tumors—The International Lanreotide and Interferon Alfa Study Group, 2689
 Falcone A, *see* Musto P
 Falco P, *see* Ladetto M
 Falini B, *see* Martelli M
 Falkson C, *see* Nabholz J-M
 Falkson G, *see* Weiss RB
 Fallini M, *see* Masci G
 Fandi A, *see* Fizazi K
 Fargeot P, *see* Fumoleau P
 Faries M, *see* Bedrosian I
 Farrell S, *see* Charles CA
 Fassas A, *see* Lee C-K
 Fata F, *see* Bucaloiu ID
 Fauser AA, *see* Schetelig J
 Fava M, *see* Cilloni D
 Fava S, *see* Gridelli C
 Fayad L, *see* Khouri IF
 Fears T, *see* Oeffinger KC
 Featherstone C, Scolyer R, Hruby G, Tin M, Wills EJ, Hendel PN. Challenging and Unusual Cases: Malignant Mesothelioma Presenting as an Anterior Mediastinal Mass, 1416
 Federico M, Bellei M, Brice P, Brugiattelli M, Nagler A, Gisselbrecht C, Moretti L, Colombat P, Luminari S, Fabbiano F, Di Renzo N, Goldstone A, Carella AM. High-Dose Therapy and Autologous Stem-Cell Transplantation Versus Conventional Therapy for Patients With Advanced Hodgkin's Lymphoma Responding to Front-Line Therapy, 2320
 Federico M, *see* Baldini L
 Fegueur N, *see* Boissel N
 Fehrenbacher L, *see* Kabbinar F
 Feig BW, *see* Pisters PWT
 Feldman AL, Libutti SK, Pinkpank JF, Bartlett DL, Beresnev TH, Mavroukakis SM, Steinberg SM, Liewehr DJ, Kleiner DE, Alexander HR. Analysis of Factors Associated With Outcome in Patients With Malignant Peritoneal Mesothelioma Undergoing Surgical Debulking and Intraperitoneal Chemotherapy, 4560
 Felicioni L, *see* Buttitta F
 Felipe E, *see* Alberola V
 Fenaux P, *see* Beaumont M
 Feng Z, *see* Penson DF
 Fenstermacher MJ, *see* Pisters PWT
 Fermand-Brulé S, *see* Alimi D
 Fermand J-P, *see* Raffoux E
 Fermé C, *see* Coiffier B
 Fernandes AS Jr, *see* Lima VS
 Fernández LE, *see* Carr A
 Ferrajoli A, *see* Giles FJ
 Ferrara CA, *see* Altorki NK
 Ferrara D, *see* Marshall GM
 Ferrari A, *see* Indolfi P
 see Okcu MF
 Ferrari B, *see* Monti M
 Ferrari S, Briccoli A, Mercuri M, Bertoni F, Picci P, Tienghi A, Del Prever AB, Fagioli F, Comandone A, Bacci G. Postrelapse Survival in Osteosarcoma of the Extremities: Prognostic Factors for Long-Term Survival, 710
 Ferrari S, *see* Bacci G
 see Serra M
 Ferrelli I, *see* Villa E
 Ferremi P, *see* Re A
 Ferreri AJM, Abrey LE, Blay J-Y, Borisch B, Hochman J, Neuwelt EA, Yahalom J, Zucca E, Cavalli F, Armitage J, Batchelor T. Summary Statement on Primary Central Nervous System Lymphomas From the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002, 2407
 Ferreri AJM, Batchelor T, Zucca E, Cavalli F, Armitage J. International Collaborative Group Against Primary CNS Lymphomas (correspondence), 1649

AUTHOR INDEX

- Ferreri AJM, Blay J-Y, Reni M, Pasini F, Spina M, Ambrosetti A, Calderoni A, Rossi A, Vavassori V, Conconi A, Devizzi L, Berger F, Ponzoni M, Borisch B, Tinguely M, Cerati M, Milani M, Orvieto E, Sanchez J, Chevreau C, Dell'Oro S, Zucca E, Cavalli F. Prognostic Scoring System for Primary CNS Lymphomas: The International Extranodal Lymphoma Study Group Experience, 266
- Ferreri AJM, *see* Zucca E
- Ferrero D, *see* Cilloni D
- Ferrero J-M, *see* Tourani J-M
- Ferretti G, *see* Alimonti A
see Papaldo P
- Ferry DR, *see* Darnton SJ
- Fetting J, *see* Mehta P
- Fey M, *see* Wallgren A
- Fey MF, *see* Crivellari D
see Mengis C
- Feyereislova A, *see* Fukuoka M
- Fickers M, *see* Poortmans PMP
- Fidias P, *see* Fossella F
see Salgia R
- Field CJ, *see* Courneya KS
- Fields A, *see* Moore MJ
- Fière D, *see* Boissel N
- Figg WD, *see* Fine HA
see Hussain MM
- Figlin RA, *see* Clark JI
- Filipits M, *see* Pohl G
- Fimmers R, *see* Albers P
see Palmedo H
see Pels H
- Finch C, *see* Peshkin BN
see Schwartz MD
- Finch DE, *see* George DW
- Findlay B, *see* Gridelli C
- Fine H, *see* Jaeckle KA
- Fine HA, Wen PY, Maher EA, Viscosi E, Batchelor T, Lakhani N, Figg WD, Purow BW, Borkowf CB. Phase II Trial of Thalidomide and Carmustine for Patients With Recurrent High-Grade Gliomas, 2299
- Fingert H, *see* Varterasian M
- Fink K, *see* Jaeckle KA
- Fink U, *see* Ott K
- Finke J, Schmoor C, Lang H, Potthoff K, Bertz H. Matched and Mismatched Allogeneic Stem-Cell Transplantation From Unrelated Donors Using Combined Graft-Versus-Host Disease Prophylaxis Including Rabbit Anti-T Lymphocyte Globulin, 506
- Finke J, *see* Bertz H
- Finke R, *see* Burdach S
- Finlay J, *see* Quinn JA
- Fiore M, *see* Gronchi A
- Fioretta G, *see* Bouchardy C
- Fisch M, *see* Strasser F
- Fisch MJ, Loehrer PJ, Kristeller J, Passik S, Jung S-H, Shen J, Arquette MA, Brames MJ, Einhorn LH. Fluoxetine Versus Placebo in Advanced Cancer Outpatients: A Double-Blinded Trial of the Hoosier Oncology Group, 1937
- Fisch MJ, Titzer ML, Kristeller JL, Shen J, Loehrer PJ, Jung S-H, Passik SD, Einhorn LH. Assessment of Quality of Life in Outpatients With Advanced Cancer: The Accuracy of Clinician Estimations and the Relevance of Spiritual Well-Being—A Hoosier Oncology Group Study, 2754
- Fisher B, *see* Bear HD
see Bryant J
see Smith JW II
- Fisher C, *see* Kolomainen DF
- Fisher J, *see* Olivi A
- Fisher M, *see* Powles T
- Fisher RI, *see* Blayney DW
see Duggan DB
see Ganz PA
see Velasquez WS
- Fitzgerald J, *see* Mertens WC
- Fitzgibbon J, *see* Last KW
- Fizazi K, Doubre H, Le Chevalier T, Riviere A, Viala J, Daniel C, Robert L, Barthélemy P, Fandi A, Ruffié P. Combination of Raltitrexed and Oxaliplatin Is an Active Regimen in Malignant Mesothelioma: Results of a Phase II Study, 349
- Fizazi K, *see* Culine S
- Flaherty L, *see* Clark JI
- Flanagan E, *see* Propper DJ
- Flanigan RC, *see* Unger JM
- Flechtner H, *see* Bottomley A
see Efficace F
- Fledge S, *see* Ozaki T
- Flège S, *see* Kager L
- Fleischmann J, *see* Messing EM
- Fleming G, *see* Henderson IC
see Kemeny MM
- Fleming GF, *see* Sawyer MB
- Flesch M, *see* André T
- Fletcher CDM, *see* Heinrich MC
- Fletcher JA, *see* Heinrich MC
- Flieder DB, *see* Altorki NK
- Flinn I, *see* Bannerji R
see Vose JM
- Florena AM, *see* Quintini G
- Florentine B, *see* Formenti SC
- Flynn C, *see* Panasuk DB
- Flynn PJ, *see* Morrow GR
- Flynn PM, Willis B, Gaur AH, Shenep JL. Catheter Design Influences Recurrence of Catheter-Related Bloodstream Infection in Children With Cancer, 3520
- Fogler W, *see* Thomas JP
- Fojo T, *see* Abraham J
see Padmanabhan H
- Foley J, *see* Carter CA
- Folkes LK, *see* Rustin GJS
- Folloder J, *see* Vadhan-Raj S
- Folsom AR, *see* Ebbert JO
- Fonatsch C, *see* Büchner T
see Haferlach T
- Fong KW, *see* Leong SS
- Fong Y, *see* Gonen M
see Kemeny N
- Fonseca RP, *see* Lima VS
- Fontaine O, *see* Razavi D
- Fontanesi J, *see* Chakravarti A
- Foo KF, *see* Leong SS
- Forastiere AA, *see* Adelstein DJ
- Forbes JF, *see* Wallgren A
- Ford JM, *see* Deininger MWN
- Forman SJ, *see* Stein AS
- Formenti SC, Volm M, Skinner KA, Spicer D, Cohen D, Perez E, Bettini AC, Groshen S, Gee C, Florentine B, Press M, Danenberg P, Muggia F. Preoperative Twice-Weekly Paclitaxel With Concurrent Radiation Therapy Followed by Surgery and Postoperative Doxorubicin-Based Chemotherapy in Locally Advanced Breast Cancer: A Phase I/II Trial, 864
- Fornander T, *see* Nystedt M
- Fornengo P, *see* De Micheli C
- Forni C, *see* Bacci G
- Forouzesh B, *see* Rowinsky EK

- Forsyth P, *see* Abrey LE
 Foshag LJ, *see* Bleicher RJ
 Foss H-D, *see* Daum S
 Fossa S, *see* Christian JA
 Fosså SD, Dahl AA, Loge JH. Fatigue, Anxiety, and Depression in Long-Term Survivors of Testicular Cancer, 1249
 Fosså SD, de Wit R, Roberts JT, Wilkinson PM, de Mulder PHM, Mead GM, Cook P, de Prijck L, Stenning S, Aaronson NK, Bottomley A, Collette L. Quality of Life in Good Prognosis Patients With Metastatic Germ Cell Cancer: A Prospective Study of the European Organization for Research and Treatment of Cancer Genitourinary Group/Medical Research Council Testicular Cancer Study Group (30941/TE20), 1107
 Fosså SD, *see* Oldenburg J
 Fossati-Bellani F, *see* Bhatia S
 Fossella F, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E, Mattson KV, Ramlau R, Szczęsna A, Fidiás P, Millward M, Belani CP. Randomized, Multinational, Phase III Study of Docetaxel Plus Platinum Combinations Versus Vinorelbine Plus Cisplatin for Advanced Non-Small-Cell Lung Cancer: The TAX 326 Study Group, 3016
 Foster RS, *see* George DW
 Foster T, *see* Hwu W-J
 Fowler JM, *see* Ozols RF
 Fox BA, *see* Smith JW II
 Fracasso PM, Blessing JA, Morgan MA, Sood AK, Hoffman JS. Phase II Study of Oxaliplatin in Platinum-Resistant and Refractory Ovarian Cancer: A Gynecologic Group Study, 2856
 Fracchioli S, *see* Diamandis EP
 see Yousef GM
 Frame D, *see* Cobleigh M
 Franciosi M, *see* Sacco M
 Franco V, *see* Quintini G
 Francois Y, *see* Glehen O
 Frank AR, *see* Kozelsky TF
 Frankel S, *see* Vose JM
 Frankel SR, *see* Weiss MA
 Franklin J, *see* Josting A
 see Sieber M
 Franklin WA, *see* Hirsch FR
 Frappaz D, *see* Laithier V
 see Vassal G
 Fraser R, *see* Poirier M
 Frati L, *see* Gradilone A
 Freedman A, *see* Olnes M
 Freeman-Edward J, *see* Ambros IM
 Freeman NJ, Holik D. Uncommon Syndromes and Treatment Manifestations of Malignancy: Richter's Syndrome Heralded by Refractory Hypercalcemia, 170
 Frei E III, *see* Henderson IC
 Frelick RW. Partnering Between Cancer Centers: The American College of Surgeons, National Cancer Institute, American Cancer Society, Centers of Disease Control, American Society of Clinical Oncology, Society of Surgical Oncology, American Society of Therapeutic Radiation and Oncology, and Association of Community Cancer Centers Are Needed to Stimulate Improved Clinical Cancer Care (correspondence), 1895
 Frenay M, *see* Hoang-Xuan K
 see van den Bent MJ
 Freyer G, Delozier T, Lichinister M, Gedouin D, Bougnoux P, His P, Imadalou K, Trillet-Lenoir V. Phase II Study of Oral Vinorelbine in First-Line Advanced Breast Cancer Chemotherapy, 35
 Freyer G, *see* Gérard J-P
 see Glehen O
 Frickhofen N, *see* Büchner T
 Fridrik M, *see* Schmid M
 Friebert S, Kodish E. The Right to Decide, 70s
 Friedl A, *see* Thomas JP
 Friedl J, *see* Stift A
 Friedlander RJ Jr, *see* Burstein HJ
 Friedman A, *see* Gururangan S
 Friedman AH, *see* Quinn JA
 Friedman D, *see* Nichols KE
 Friedman HS, *see* Gururangan S
 see Quinn JA
 Frizzera G, *see* Peterson BA
 Frontini L, *see* Gridelli C
 Fryer-Edwards KA, *see* Back AL
 Fu KK, *see* Pollack A
 Fu P, *see* Gupta S
 Fuchs CS, Moore MR, Harker G, Villa L, Rinaldi D, Hecht JR. Phase III Comparison of Two Irinotecan Dosing Regimens in Second-Line Therapy of Metastatic Colorectal Cancer, 807
 Fuchs CS, *see* Ayanian JZ
 see Meyerhardt JA
 Fuchs H, *see* Gururangan S
 Fujimitsu R, *see* Emoto M
 Fujiwara Y, *see* Yamamoto S
 Fuks Z, *see* Kattan MW
 see Katz MS
 Fukuda H, *see* Ando N
 see Ohtsu A
 Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard J-Y, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A, Dong R-P, Baselga J. Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer, 2237
 Fuller GN, *see* Lang FF
 Fuller LM, *see* Seymour JF
 Fumoleau P, Bonnetterre J, Luporsi E. Adjuvant Chemotherapy for Node-Positive Breast Cancer Patients: Which is the Reference Today? (correspondence), 1190
 Fumoleau P, Kerbrat P, Romestaing P, Fargeot P, Brémond A, Namer M, Schraub S, Goudier M-J, Mihura J, Monnier A, Clavère P, Serin D, Seffert P, Pourny C, Facchini T, Jacquin J-P, Sztermer J-F, Datchary J, Ramos R, Luporsi E. Randomized Trial Comparing Six Versus Three Cycles of Epirubicin-Based Adjuvant Chemotherapy in Premenopausal, Node-Positive Breast Cancer Patients: 10-Year Follow-Up Results of the French Adjuvant Study Group 01 Trial, 298
 Fung BB, *see* Vokes EE
 Fung HC, *see* Stein AS
 Fung K, *see* Allison PJ
 Furman RR, *see* Leonard JP
 Furrer M, *see* Betticher DC
 Furukawa H, *see* Nashimoto A
 Fuxius S, *see* Morgan B
- ## G
- Gaafar R, *see* Smit EF
 Gabert J, *see* Boissel N
 Gabri M, *see* Carr A
 Gadd MA, *see* Burstein HJ
 Gaddipat JC, *see* Agrawal RS
 Gadducci A, *see* Buttitta F
 Gardner H, *see* Burdach S
 see Calaminus G
 see Kager L
 see Kerbl R
 Gaffney DK, Tsodikov A, Wiggins CL. Diminished Survival in Patients With Inner Versus Outer Quadrant Breast Cancers, 467

AUTHOR INDEX

- Gafni A, *see* Charles CA
- Gagné M-A, *see* Sigal JJ
- Gagnon DD, *see* Cella D
- Gajewski TF, *see* Peterson AC
- Gajjar A, *see* Edick MJ
- Gajra A, Newman N, Gamble GP, Kohman LJ, Graziano SL. Effect of Number of Lymph Nodes Sampled on Outcome in Patients With Stage I Non-Small-Cell Lung Cancer, 1029
- Gajra A, Graziano S. In Reply (correspondence), 4661
- Galanis E, *see* Goetz MP
see Hamid O
- Galavotti H, *see* Slingluff CL Jr
- Galbraith SM, Maxwell RJ, Lodge MA, Tozer GM, Wilson J, Taylor NJ, Stirling JJ, Sena L, Padhani AR, Rustin GJS. Combretastatin A4 Phosphate Has Tumor Antivascular Activity in Rat and Man as Demonstrated by Dynamic Magnetic Resonance Imaging, 2831
- Galbraith SM, *see* Rustin GJS
- Gallagher M, *see* Stevenson JP
- Gallagy G, *see* Gonzalez MA
- Gallamini A, *see* Cillonì D
- Gallardo H, *see* Segal NH
- Gallion HH, Brunetto VL, Cibull M, Lentz SS, Reid G, Soper JT, Burger RA, Andersen W. Randomized Phase III Trial of Standard Timed Doxorubicin Plus Cisplatin Versus Circadian Timed Doxorubicin Plus Cisplatin in Stage III and IV or Recurrent Endometrial Carcinoma: A Gynecologic Oncology Group Study, 3808
- Gallo C, *see* Gridelli C
see Palmieri G
- Gambini C, *see* Ambros IM
see De Bernardi B
- Gamble GP, *see* Gajra A
- Gamelin E, *see* André T
- Gamis A, *see* Wells RJ
- Gamis AS, Woods WG, Alonzo TA, Buxton A, Lange B, Barnard DR, Gold S, Smith FO. Increased Age at Diagnosis Has Significantly Negative Effect on Outcome in Children With Down Syndrome and Acute Myeloid Leukemia: A Report From the Children's Cancer Group Study 2891, 3415
- Gandara DR, Chansky K, Albain KS, Leigh BR, Gaspar LE, Lara PN Jr, Burris H, Gumerlock P, Kuebler JP, Bearden JD III, Crowley J, Livingston R. Consolidation Docetaxel After Concurrent Chemoradiotherapy in Stage IIIB Non-Small-Cell Lung Cancer: Phase II Southwest Oncology Group Study S9504, 2004
- Gandemer V, *see* Aladjidi N
- Gandhi V, *see* Kantarjian HM
- Ganesan TS, *see* Propper DJ
- Ganguly A, *see* Nichols KE
- Ganjoo KN, *see* Shafqat A
- Ganly I, Singh B. Topical ONYX-015 in the Treatment of Premalignant Oral Dysplasia: Another Role for the Cold Virus? (editorial), 4476
- Ganser A, *see* Krauter J
- Ganti AK, Potti A, Mehdi S. Uncommon Syndromes and Treatment Manifestations of Malignancy: Metastatic Non-Small-Cell Lung Cancer Presenting With Leukocytosis, 168
- Ganz PA, Greendale GA, Petersen L, Kahn B, Bower JE. Breast Cancer in Younger Women: Reproductive and Late Health Effects of Treatment, 4184
- Ganz PA, Guadagnoli E, Landrum MB, Lash TL, Rakowski W, Silliman RA. Breast Cancer in Older Women: Quality of Life and Psychosocial Adjustment in the 15 Months After Diagnosis, 4027
- Ganz PA, Moinpour CM, Pauler DK, Kornblith AB, Gaynor ER, Balcerzak SP, Gatti GS, Erba HP, McCoy S, Press OW, Fisher RI. Health Status and Quality of Life in Patients With Early-Stage Hodgkin's Disease Treated on Southwest Oncology Group Study 9133, 3512
- Ganz PA, Levine MN. In Reply (correspondence), 1894
- Garaventa A, *see* De Bernardi B
- Garay CA, *see* Rothenberg ML
- Garbe C, Paul A, Kohler-Späth H, Ellwanger U, Stroebel W, Schwarz M, Schlagenhauß B, Meier F, Schittek B, Blaheta H-J, Blum A, Rassner G. Prospective Evaluation of a Follow-Up Schedule in Cutaneous Melanoma Patients: Recommendations for an Effective Follow-Up Strategy, 520
- Garbe C, Leiter U. In Reply (correspondence), 3706, 3708
- Garber JE, *see* Cannistra SA
- Garces YI, Hays JT. Tobacco Dependence: Why Should an Oncologist Care?, 1884
- Garcia-Manero G, *see* Giles FJ
- Garcia-Rostan G, Zhao H, Camp RL, Pollan M, Herrero A, Pardo J, Wu R, Carcangiu ML, Costa J, Tallini G. *ras* Mutations Are Associated With Aggressive Tumor Phenotypes and Poor Prognosis in Thyroid Cancer, 3226
- Gargan L, *see* Bowers DC
- Gargiulo J, *see* Burstein HJ
- Garnett RF Jr, *see* Agrawal BL
see Agrawal RS
- Garzotto M, *see* Beer TM
- Gascoyne RD, *see* Kouroukis CT
- Gaskin D, *see* Meropol NJ
- Gaspar L, *see* Shaw E
- Gaspar LE, *see* Gandara DR
- Gasparini G, *see* Gridelli C
see Longo R
- Gassmann W, *see* Haferlach T
- Gatti GS, *see* Ganz PA
- Gattuso J, *see* Tyc VL
- Gatzemeier U, *see* Scagliotti GV
see Vogelzang NJ
- Gaulard P, *see* Bouabdallah R
- Gaur AH, *see* Flynn PM
- Gavino M, *see* Weber D
- Gayko U, *see* Leonard JP
- Gaynon P, *see* Clarke M
- Gaynon PS, *see* Hutchinson RJ
- Gaynor ER, *see* Ganz PA
- Gazelle G. A Good Death: Not Just an Abstract Concept, 95
- Gazzaniga P, *see* Gradilone A
- Gazzard B, *see* Powles T
- Geata A, *see* Giuliani N
- Gebbia V, *see* Gridelli C
- Gebhardt MC, *see* Goorin AM
- Gedouin D, *see* Freyer G
- Gee C, *see* Formenti SC
- Geiger P, *see* Thomas JP
- Gelber R, *see* Winer EP
- Gelber RD, *see* Crivellari D
see Dalton VK
see Goldberg JM
see Goldhirsch A
see Lipschultz SE
see Wallgren A
- Gelernter I, *see* Ohali A
- Gelman R, *see* Burstein HJ
- Gelmini R, *see* Villa E
- Gelmon K, *see* Leyland-Jones B
- George DW, Foster RS, Hromas RA, Robertson KA, Vance GH, Ulbright TM, Gobbett TA, Heiber DJ, Heerema NA, Ramsey HC, Thurston VC, Jung S-H, Shen J, Finch DE, Kelley MR, Einhorn LH. Update on Late Relapse of Germ Cell Tumor: A Clinical and Molecular Analysis, 113
- George T, *see* Gururangan S
- Gerami M, *see* Wascher RA

- Gérard J-P, Chapet O, Nemoz C, Romestaing P, Mornex F, Coquard R, Barbet N, Atlan D, Adeleine P, Freyer G. Preoperative Concurrent Chemoradiotherapy in Locally Advanced Rectal Cancer With High-Dose Radiation and Oxaliplatin-Containing Regimen: The Lyon R0–04 Phase II Trial, 1119
- Gerber M, *see* Shaw E
- Germa C, *see* Vassal G
- Gershanovich M, *see* Mouridsen H
- Gershenson DM, *see* Bodurka DC
- Gertz MA, Bauer BA. Caring (Really) for Patients Who Use Alternative Therapies for Cancer, 125s
- Geschwind J, *see* Leung TWT
- Geschwind J-F, *see* Yoo HY
- Gesme D Jr, *see* Buckner JC
- Geyer S, *see* Adjei AA
- Geyer SM, *see* Schild SE
- Ghahramani P, *see* Leyland-Jones B
- Gherlinzoni F, *see* Martelli M
- Giaccone G, *see* Fukuoka M
see Smit EF
- Giannarelli D, *see* Papaldo P
- Gianni L, *see* Kaufmann M
see Volpi A
- Gianni MA, *see* Zucca E
- Gianni W, *see* Repetto L
- Giano J, *see* Bodurka DC
- Giantonio B, *see* Stevenson JP
- Giarola M, *see* Bertario L
- Gibbs A, *see* Pusztaï L
- Gibbs JF, *see* Rajput A
see Varma GN
- Gibson J, *see* Slingluff CL Jr
- Giese A, Bjerkvig R, Berens ME, Westphal M. Cost of Migration: Invasion of Malignant Gliomas and Implications for Treatment, 1624
- Gietema HA, *see* Vuylsteke RJCLM
- Gilain L, *see* Allison PJ
- Gilbert M, *see* Grossman SA
- Gilbertson R, *see* Taylor RE
- Giles F, *see* Kantarjian HM
- Giles FJ, Faderl S, Thomas DA, Cortes JE, Garcia-Manero G, Douer D, Levine AM, Koller CA, Jeha SS, O'Brien SM, Estey EH, Kantarjian HM. Randomized Phase I/II Study of Troxacitabine Combined With Cytarabine, Idarubicin, or Topotecan in Patients With Refractory Myeloid Leukemias, 1050
- Giles FJ, Kantarjian HM, Cortes JE, Garcia-Manero G, Verstovsek S, Faderl S, Thomas DA, Ferrajoli A, O'Brien S, Wathen JK, Xiao L-C, Berry DA, Estey EH. Adaptive Randomized Study of Idarubicin and Cytarabine Versus Troxacitabine and Cytarabine Versus Troxacitabine and Idarubicin in Untreated Patients 50 Years or Older With Adverse Karyotype Acute Myeloid Leukemia, 1722
- Gill S, Shah A, Le N, Cook EF, Yoshida EM. Asian Ethnicity-Related Differences in Gastric Cancer Presentation and Outcome Among Patients Treated at a Canadian Cancer Center, 2070
- Gill S. In Reply (correspondence), 4253
- Gillespie A, *see* Blaney SM
- Gillessen S, *see* Soiffer R
- Gillibrand A, *see* Wright EP
- Gilliland F, *see* McTiernan A
see Penson DF
- Gilly FN, *see* Glehen O
- Gimbel M, *see* Nash GM
- Ginsberg R, *see* Downey RJ
- Giordano TJ, *see* Dhaini HR
- Giovannini M, *see* Leung TWT
- Giroto M, *see* Cilloni D
- Gisselbrecht C, *see* Bouabdallah R
see Federico M
- Giuliani N, Caramatti C, Roti G, Geata A, Colla S, Bonomini S, Hojden M, La Monica S, Sammarelli G, Lazzaretti M, Craviotto L, Mangoni L, Rizzoli V. Hematologic Malignancies With Extramedullary Spread of Disease: Multiple Myeloma With Extramedullary Involvement of the Pleura and Testes, 1887
- Giuliano M, *see* Indolfi P
- Gladish GW, *see* Erasmus JJ
- Glasmacher A, Prentice A, Gorschlüter M, Engelhart S, Hahn C, Djulbegovic B, Schmidt-Wolf IG. Itraconazole Prevents Invasive Fungal Infections in Neutropenic Patients Treated for Hematologic Malignancies: Evidence From a Meta-Analysis of 3,597 Patients, 4615
- Glasmacher A, *see* Pels H
- Glaspay J, *see* Esteva FJ
- Glaspay JA, *see* Ribas A
- Glatz-Krieger K, *see* Jantschke P
- Glehen O, Mithieux F, Osinsky D, Beaujard AC, Freyer G, Guertsch P, Francois Y, Peyrat P, Panteix G, Vignal J, Gilly FN. Surgery Combined With Peritonectomy Procedures and Intraperitoneal Chemohyperthermia in Abdominal Cancers With Peritoneal Carcinomatosis: A Phase II Study, 799
- Glendenning GA, *see* Hahn EA
- Glick HA, *see* Polsky D
- Glick JH, *see* Duggan DB
- Glicksman A, *see* Mardor Y
- Gloghini A, *see* Simonelli C
- Glomstein A, *see* Schmiegelow K
- Glover DA, Byrne J, Mills JL, Robison LL, Nicholson HS, Meadows A, Zeltzer LK. Impact of CNS Treatment on Mood in Adult Survivors of Childhood Leukemia: A Report From the Children's Cancer Group, 4395
- Glynn TP Jr, *see* Agrawal BL
- Gnant M, *see* Schmid M
see Stift A
- Gobbett TA, *see* George DW
- Gobbi P, *see* Baldini L
- Göbel U, *see* Burdach S
see Calaminus G
see Den Boer ML
see Schneider DT
- Gococo KO, *see* Ramanathan RK
- Gödény M, *see* Láng I
- Godzinski J, *see* Stewart RJ
- Goebel F-D, *see* Jung CP
- Goel R, *see* Townsley CA
- Goel S. Alternatives to Cystectomy in Muscle-Invasive Bladder Cancer (correspondence), 3003
- Goetz A, *see* Rowinsky EK
see Takimoto CH
- Goetz MP, Erlichman C, Windebank AJ, Reid JM, Sloan JA, Atherton P, Adjei AA, Rubin J, Pitot H, Galanis E, Ames MM, Goldberg RM. Phase I and Pharmacokinetic Study of Two Different Schedules of Oxaliplatin, Irinotecan, Fluorouracil, and Leucovorin in Patients With Solid Tumors, 3761
- Goffman J, *see* Stemmer SM
- Gold KF, *see* Hu JC
- Gold S, *see* Gamis AS
- Goldaniga M, *see* Baldini L
- Goldberg G, *see* Wadler S
- Goldberg JM, Silverman LB, Levy DE, Dalton VK, Gelber RD, Lehmann L, Cohen HJ, Sallan SE, Asselin BL. Childhood T-Cell Acute Lymphoblastic Leukemia: The Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Experience, 3616
- Goldberg M, *see* Movsas B

AUTHOR INDEX

- Goldberg R, *see* Hobday T
- Goldberg RM, *see* Goetz MP
- Goldenberg DM, *see* Leonard JP
- Goldenberg N, Kahn SR, Solymoss S. Markers of Coagulation and Angiogenesis in Cancer-Associated Venous Thromboembolism, 4194
- Golder W, *see* Faiss S
- Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn H-J. Meeting Highlights: Updated International Expert Consensus on the Primary Therapy of Early Breast Cancer, 3357
- Goldhirsch A, *see* Crivellari D
see Wallgren A
- Goldman DP, *see* Lewis JH
- Goldstein LJ, *see* Henderson IC
see Winer EP
- Goldstone A, *see* Bierman PJ
see Federico M
- Gollob JA, Veenstra KG, Parker RA, Mier JW, McDermott DF, Clancy D, Tutin L, Koon H, Atkins MB. Phase I Trial of Concurrent Twice-Weekly Recombinant Human Interleukin-12 Plus Low-Dose IL-2 in Patients With Melanoma or Renal Cell Carcinoma, 2564
- Gollub M, *see* Downey RJ
- Gomez Moreno H, *see* Zucca E
- Gómez-Moreta JA, *see* Malillo A
- Gomori JM, *see* Rosenthal G
- Gonen M, Banerjee D, Bertino J, Kemeny N. In Reply (correspondence), 3544
- Gonen M, Hummer A, Zervoudakis A, Sullivan D, Fong Y, Banerjee D, Klimstra D, Cordon-Cardo C, Bertino J, Kemeny N. Thymidylate Synthase Expression in Hepatic Tumors Is a Predictor of Survival and Progression in Patients With Resectable Metastatic Colorectal Cancer, 406
- Gonen M, *see* Downey RJ
see Ilson DH
see Kemeny N
see Weitz J
- González-Larriba JL, *see* Alberola V
- Gonzalez MA, Pinder SE, Gallagy G, Vowler SL, Morris LS, Bird K, Bell JA, Laskey RA, Coleman N. Minichromosome Maintenance Protein 2 Is a Strong Independent Prognostic Marker in Breast Cancer, 4306
- Goodman GR, Burian C, Koziol JA, Saven A. Extended Follow-Up of Patients With Hairy Cell Leukemia After Treatment With Cladribine, 891
- Goodwin PJ. Reversible Ovarian Ablation or Chemotherapy: Are We Ready for Quality of Life to Guide Adjuvant Treatment Decisions in Breast Cancer? (editorial), 4474
- Goodwin PJ, Ennis M, Pritchard KI, Koo J, Trudeau ME, Hood N. Diet and Breast Cancer: Evidence That Extremes in Diet Are Associated With Poor Survival, 2500
- Goodwin PJ, *see* Bordeleau L
- Goor O, Goor Y, Konikoff F, Trejo L, Naparstak E. Common Malignancies With Uncommon Sites of Presentation: Epigastric Distress Caused by a Duodenal Polyp: A Rare Presentation of Acute Leukemia, 4455
- Goor Y, *see* Goor O
- Goorin AM, Schwartzentruber DJ, Devidas M, Gebhardt MC, Ayala AG, Harris MB, Helman LJ, Grier HE, Link MP. Presurgical Chemotherapy Compared With Immediate Surgery and Adjuvant Chemotherapy for Nonmetastatic Osteosarcoma: Pediatric Oncology Group Study POG-8651, 1574
- Gorbounova V, *see* Fossella F
- Gordon D, *see* Rosen LS
- Gordon LI, *see* Witzig TE
- Gordon MS, *see* Clark JI
- Gore M. Carboplatin Equals Cisplatin: But How Do I Prescribe It? (editorial), 3183
- Gore ME, *see* Kolomainen DF
- Gores GJ, *see* Leung TWT
- Gorlia T, *see* van den Bent MJ
- Görlich K, *see* Krauter J
- Gorlick R, *see* Aung LL
see Kolb EA
- Gorschlüter M, *see* Glasmacher A
- Goshen Y, *see* Ohali A
- Gospodarowicz MK, *see* Tsang RW
see Zucca E
- Goss PE, *see* Tchen N
- Gotay C, *see* Efficace F
- Gottardi E, *see* Cilloni D
- Gottlieb AJ, *see* Peterson BA
- Goudier M-J, *see* Fumoleau P
- Gould A, *see* Wright EP
- Goupil A, *see* Culine S
- Grabenbauer GG, *see* Rödel C
- Gradilone A, Gazzaniga P, Ribuffo D, Scarpa S, Cigna E, Vasaturo F, Bottoni U, Innocenzi D, Calvieri S, Scuderi N, Frati L, Aglianò AM. *Survivin, bcl2, bax, and bcl-X* Gene Expression in Sentinel Lymph Nodes From Melanoma Patients, 306
- Gradishar WJ, *see* Citron ML
- Graefen M, *see* Augustin H
- Graham J, *see* Graham PH
- Graham M, *see* Movsas B
see Takimoto CH
- Graham PH, Browne L, Cox H, Graham J. Inhalation Aromatherapy During Radiotherapy: Results of a Placebo-Controlled Double-Blind Randomized Trial, 2372
- Gralla RJ, *see* Hesketh PJ
- Gralow J, *see* Hillner BE
see Winer EP
- Granato AM, *see* Volpi A
- Grandi C, *see* Licitra L
- Grañena A, *see* Roman-Gomez J
- Grass L, *see* Diamandis EP
- Gratecos N, *see* Beaumont M
- Graubner U, *see* Den Boer ML
- Gray S, Olopade OI. Direct-to-Consumer Marketing of Genetic Tests for Cancer: Buyer Beware (editorial), 3191
- Graziano F, *see* Kilickap S
- Graziano S, *see* Gajra A
- Greco FA, *see* Hainsworth JD
- Green DM, Grigoriev YA, Nan B, Takashima JR, Norkool PA, D'Angio GJ, Breslow NE. Correction to "Congestive Heart Failure After Treatment for Wilms' Tumor" (correspondence), 2447
- Green DM, Whitton JA, Stovall M, Mertens AC, Donaldson SS, Ruymann FB, Pendergrass TW, Robison LL. Pregnancy Outcome of Partners of Male Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study, 716
- Green DM, *see* Breslow NE
- Greenberg B, *see* Moore MJ
- Greenberg DB, *see* Sekeres MA
- Greenberg H, *see* Jaeckle KA
- Greendale GA, *see* Ganz PA
- Greenslade D, *see* Takimoto CH
- Greer BE, *see* Ozols RF
- Gregorc V, *see* Cappuzzo F
- Grem JL, *see* Takimoto CH
- Grey L, *see* Mandelblatt JS
- Gridelli C, Gallo C, Shepherd FA, Illiano A, Piantedosi F, Robbiati SF, Manzione L, Barbera S, Frontini L, Veltri E, Findlay B, Cigolari S, Myers R, Ianniello GP, Gebbia V, Gasparini G, Fava S, Hirsh V, Bezjak A, Seymour L, Perrone F. Gemcitabine Plus Vinorelbine Compared With Cisplatin Plus Vinorelbine or Cisplatin Plus Gemcitabine for Advanced Non-Small-Cell Lung Cancer: A Phase III Trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group, 3025

- Gridelli C, Maione P, Rossi A. Corticosteroids Underemployment in Delayed Chemotherapy-Induced Nausea and Emesis With Poor Adherence to American Society of Clinical Oncology Guidelines: Is This a Reasonable Clinical Choice for the Elderly? (correspondence), 4066
- Griener J, *see* Kishi S
- Grier HE, *see* Goorin AM
- Griffing S, *see* Kabbinavar F
- Grignon D, *see* Hanks GE
- Grignon DJ, *see* Pollack A
- Grigoriev YA, *see* Green DM
- Grill J, *see* Laithier V
- Grisanti S, *see* Zucca E
- Gritz ER, *see* Emmons KM
- Grogan T, *see* Blayney DW
- Grogan TM, *see* Velasquez WS
- Gronchi A, Casali PG, Mariani L, Lo Vullo S, Colecchia M, Lozza L, Bertulli R, Fiore M, Olmi P, Santinami M, Rosai J. Quality of Surgery and Outcome in Extra-Abdominal Aggressive Fibromatosis: A Series of Patients Surgically Treated at a Single Institution, 1390
- Groome PA, O'Sullivan B, Irish JC, Rothwell DM, Schulze K, Warde PR, Schneider KM, Mackenzie RG, Hodson DI, Hammond JA, Gulavita SPP, Eapen LJ, Dixon PF, Bissett RJ, Mackillop WJ. Management and Outcome Differences in Supraglottic Cancer Between Ontario, Canada, and the Surveillance, Epidemiology, and End Results Areas of the United States, 496
- Grosh WW, *see* Slingluff CL Jr
- Groshe S, *see* Formenti SC
- Gross N, *see* Ambros IM
- Grossman D, *see* Alexander A
- Grossman HB, *see* Pagliaro LC
see Unger JM
- Grossman SA, *see* Batchelor T
see Olivi A
- Grossman SA, O'Neill A, Grunnet M, Mehta M, Pearlman JL, Wagner H, Gilbert M, Newton HB, Hellman R. Phase III Study Comparing Three Cycles of Infusional Carmustine and Cisplatin Followed by Radiation Therapy With Radiation Therapy and Concurrent Carmustine in Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme: Eastern Cooperative Oncology Group Trial 2394, 1485
- Grottola A, *see* Villa E
- Grunberg SM, *see* Hesketh PJ
- Grüneisen A, *see* Büchner T
see Haferlach T
- Grunert F, *see* Jantschke P
- Grunnet M, *see* Grossman SA
- Guadagnoli E, *see* Ayanian JZ
see Ganz PA
see Keating NL
- Guardigni L, *see* Martelli M
- Guerci A, *see* Beaumont M
- Guerrero PC, *see* Belda-Iniesta C
- Guertsch P, *see* Glehen O
- Guettier C, *see* Bouabdallah R
- Gugger M, *see* Ratschiller D
- Guhlke S, *see* Palmedo H
- Gui G, *see* Ring A
- Guichard C, *see* Allison PJ
- Guilhot F, *see* Hahn EA
- Guilhot J, *see* Tourani J-M
- Guinebretière J-M, *see* Khanfir K
see Zelek L
- Gulavita SPP, *see* Groome PA
- Gumbrell L, *see* Rustin GJS
- Gumerlock P, *see* Gandara DR
- Günther T, *see* Schneider-Stock R
- Gupta RK, *see* Chung MH
- Gupta S, *see* Rothenberg ML
- Gupta S, Hussain T, MacLennan GT, Fu P, Patel J, Mukhtar H. Differential Expression of S100A2 and S100A4 During Progression of Human Prostate Adenocarcinoma, 106
- Gurney JG, *see* Packer RJ
- Gururangan S, *see* Quinn JA
- Gururangan S, McLaughlin C, Quinn J, Rich J, Reardon D, Halperin EC, Herndon J II, Fuchs H, George T, Provenzale J, Watral M, McLendon RE, Friedman A, Friedman HS, Kurtzberg J, Vredenbergh J, Martin PL. High-Dose Chemotherapy With Autologous Stem-Cell Rescue in Children and Adults With Newly Diagnosed Pineoblastomas, 2187
- Gustafsson G, *see* Schmiegelow K
- Gutheil J, *see* Meropol NJ
- Guzzo M, *see* Licitra L

H

- Ha CS, *see* Seymour JF
- Haas RJ, *see* Den Boer ML
- Haas RLM, Poortmans Ph, de Jong D, Aleman BMP, Dewit LGH, Verheij M, Hart AAM, van Oers MHJ, van der Hulst M, Baars JW, Bartelink H. High Response Rates and Lasting Remissions After Low-Dose Involved Field Radiotherapy in Indolent Lymphomas, 2474
- Haase D, *see* Haferlach T
- Haase R, *see* Burdach S
- Haaxma-Reiche H, *see* Poortmans PMP
- Habbema JDF, *see* Vergouwe Y
- Haber M, *see* Marshall G
see Marshall GM
- Habermann T, *see* Coyne CA
- Habicht J, *see* Betticher DC
- Hack TF, Pickles T, Bultz BD, Ruether JD, Weir LM, Degner LF, Mackey JR. Impact of Providing Audiotapes of Primary Adjuvant Treatment Consultations to Women With Breast Cancer: A Multisite, Randomized, Controlled Trial, 4138
- Hackett J, *see* Vose JM
- Hackman J, *see* Shaw E
- Hackman RC, *see* Hamid O
- Hadley J, *see* Polsky D
- Hadley T, *see* Chao C
- Haerting J, *see* Burdach S
- Haferlach T, *see* Büchner T
- Haferlach T, Kern W, Schoch C, Hiddemann W, Sauerland MC. In Reply (correspondence), 3004
- Haferlach T, Schoch C, Löffler H, Gassmann W, Kern W, Schnittger S, Fonatsch C, Ludwig W-D, Wuchter C, Schlegelberger B, Staib P, Reichle A, Kubica U, Eimermacher H, Balleisen L, Grüneisen A, Haase D, Aul C, Karow J, Lengfelder E, Wörmann B, Heinecke A, Sauerland MC, Büchner T, Hiddemann W. Morphologic Dysplasia in De Novo Acute Myeloid Leukemia (AML) Is Related to Unfavorable Cytogenetics but Has No Independent Prognostic Relevance Under the Conditions of Intensive Induction Therapy: Results of a Multiparameter Analysis From the German AML Cooperative Group Studies, 256
- Hagan K, *see* Moore MJ
- Hagberg H, *see* Schouten HC
- Hagemeyer A, *see* Verburgh E
- Hagemeyer FB, *see* Seymour JF
- Hahn C, *see* Glasmacher A
- Hahn EA, Glendenning GA, Sorensen MV, Hudgens SA, Druker BJ, Guilhot F, Larson RA, O'Brien SG, Dobrez DG, Hensley ML, Cella D. Quality of Life in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia on Imatinib Versus Interferon Alfa Plus Low-Dose Cytarabine: Results From the IRIS Study, 2138

- Hahn R, *see* Messing EM
- Hahn WC. Role of Telomeres and Telomerase in the Pathogenesis of Human Cancer, 2034
- Haider K, *see* Schmid M
- Haik BG, *see* Rodriguez-Galindo C
- Hainsworth J, *see* Tempero M
- Hainsworth JD, Litchy S, Barton JH, Houston GA, Hermann RC, Bradof JE, Greco FA. Single-Agent Rituximab as First-Line and Maintenance Treatment for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: A Phase II Trial of the Minnie Pearl Cancer Research Network, 1746
- Haisfield-Wolf ME, *see* Laufer M
- Halabi S, *see* Taplin M-E
- Halabi S, Small EJ, Hayes DF, Vogelzang NJ, Kantoff PW. Prognostic Significance of Reverse Transcriptase Polymerase Chain Reaction for Prostate-Specific Antigen in Metastatic Prostate Cancer: A Nested Study Within CALGB 9583, 490
- Halabi S, Small EJ, Kantoff PW, Kattan MW, Kaplan EB, Dawson NA, Levine EG, Blumenstein BA, Vogelzang NJ. Prognostic Model for Predicting Survival in Men With Hormone-Refractory Metastatic Prostate Cancer, 1232
- Haley D, *see* Smith JW II
- Hall GD, *see* Chester JD
- Hall-Craggs M, *see* Strauss SJ
- Haller DG, *see* Le Voyer TE
- see* Meyerhardt JA
- see* Ramanathan RK
- see* Rothenberg ML
- see* Stevenson JP
- Hallor M, *see* Burstein HJ
- Halperin EC, *see* Gururangan S
- Halpern S, *see* Heath JA
- Haluska F, *see* Soiffer R
- Haluska P, Luetmer PH, Inwards CY, Afessa B, Shives TC, Ingle JN. Complications of Therapy and a Diagnostic Dilemma Case: Diagnostic Dilemma: Sarcoidosis Simulating Metastatic Malignancy, 4650
- Hamdan H, *see* Havrilesky L
- Hamid O, Varterasian ML, Wadler S, Hecht JR, Benson A III, Galanis E, Uprichard M, Omer C, Bycott P, Hackman RC, Shields AF. Phase II Trial of Intravenous CI-1042 in Patients With Metastatic Colorectal Cancer, 1498
- Hamilton A, *see* Takimoto CH
- see* Therasse P
- Hamilton C, *see* Poulsen M
- Hamilton SR, *see* Crane CH
- Hamm J, *see* Moore MJ
- Hammack JE, *see* Buckner JC
- Hammerer PG, *see* Augustin H
- Hammond E, *see* Chakravarti A
- Hammond EH, *see* Pollack A
- Hammond JA, *see* Groome PA
- Hammond LA, *see* Rowinsky EK
- see* Tolcher AW
- Han S, *see* Roach M III
- Han WS, *see* Lee Y-H
- Hankey BF, *see* Harlan LC
- Hanks GE, Pajak TF, Porter A, Grignon D, Brereton H, Venkatesan V, Horwitz EM, Lawton C, Rosenthal SA, Sandler HM, Shipley WU. Phase III Trial of Long-Term Adjuvant Androgen Deprivation After Neoadjuvant Hormonal Cytoreduction and Radiotherapy in Locally Advanced Carcinoma of the Prostate: The Radiation Therapy Oncology Group Protocol 92-02, 3972
- Hanlon AL, *see* Le Voyer TE
- Hann I, *see* Clarke M
- Hannigan EV, *see* Rothenberg ML
- Hannigan JE. Direct Drug Advertising to Consumers: When Pharma Plays Doctor (correspondence), 3375
- Hansen E, *see* Betticher DC
- Hansen HJ, *see* Leonard JP
- Hansen M, *see* Poortmans PMP
- Hanson LJ, *see* Adjei AA
- Happersett L, *see* Wolden SL
- Haraf DJ, *see* Vokes EE
- Harbeck N, *see* Zinzow I
- Harbitz T, *see* Wiedswang G
- Hardan I, *see* Stemmer SM
- Hardy S, *see* Salgia R
- see* Soiffer R
- Harker G, *see* Fuchs CS
- Harlan LC, Clegg LX, Trimble EL. Trends in Surgery and Chemotherapy for Women Diagnosed With Ovarian Cancer in the United States, 3488
- Harlan LC, Hankey BF. The Surveillance, Epidemiology, and End-Results Program Database as a Resource for Conducting Descriptive Epidemiologic and Clinical Studies. (editorial), 2232
- Harlin H, *see* Peterson AC
- Harms D, *see* Calaminus G
- see* Krams M
- see* Schneider DT
- Harms DO, *see* Den Boer ML
- Harnett PR, Moynihan TJ. "But Doctor, What Have I Got to Lose . . . ?", 27s
- Harper P, Plunkett T, Khayat D. Quality Trials and Quality of Life in Non-Small-Cell Lung Cancer (editorial), 3007
- Harris AL, *see* Propper DJ
- see* Swinson DEB
- Harris D, *see* Phipps E
- Harris LN, *see* Burstein HJ
- Harris MB, *see* Goorin AM
- Harris RM, *see* Alexander A
- Harrison G, *see* Clarke M
- Harrison PL, *see* Edick MJ
- Hart AAM, *see* Haas RLM
- Hart LL, *see* Rothenberg ML
- Hartenbach EM, *see* Ozols RF
- Hartmann JT, *see* Schmoll H-J
- Hartmann M, *see* Albers P
- Hartmann O, *see* Laithier V
- see* Matthyas KK
- Harvey HA, *see* Lipton A
- Harvey J, *see* Poulsen M
- Hasenclever D, *see* Engert A
- Hassan MM, *see* Patt YZ
- Hassoun H, *see* Oo TH
- Hattinger CM, *see* Ambros IM
- Hauptmann S, *see* Rau B
- Hauschild A, Weichenthal M, Balda B-R, Becker JC, Wolff HH, Tilgen W, Schulte K-W, Ring J, Schadendorf D, Lischner S, Burg G, Dummer R. Prospective Randomized Trial of Interferon Alpha-2b and Interleukin-2 as Adjuvant Treatment for Resected Intermediate- and High-Risk Primary Melanoma Without Clinically Detectable Node Metastasis, 2883
- Hausmaninger H, *see* Pohl G
- see* Schmid M
- Havighurst TC, *see* Love RR
- Havlin K, *see* Burstein HJ
- Havrilesky L, Darcy KM, Hamdan H, Priore RL, Leon J, Bell J, Berchuck A. Prognostic Significance of p53 Mutation and p53 Overexpression in Advanced Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study, 3814
- Hawkins NJ, *see* Ward RL
- Hawkins R, *see* Buckner JC

- Hayden A, *see* Roychowdhury DF
- Hayes D, *see* Loprinzi CL
- Hayes DF, *see* Esteva FJ
see Halabi S
see Henderson IC
see Taplin M-E
- Hays JT, *see* Garces YI
- Head DR, *see* Cheson BD
- Healey D, *see* Varterasian M
- Healey JH, *see* Aung LL
see Kolb EA
- Heard R, *see* Meropol NJ
- Heath JA, Steinherz PG, Altman A, Sather H, Jhanwar S, Halpern S, Pieters R, Shah N, Steinherz L, Tannous R, Terry W, Trigg ME. Human Granulocyte Colony-Stimulating Factor in Children With High-Risk Acute Lymphoblastic Leukemia: A Children's Cancer Group Study, 1612
- Heath JA, *see* Nichols KE
- Hecht JR, *see* Fuchs CS
see Hamid O
- Heelan RT, *see* Miller VA
- Heerema NA, *see* George DW
see Hutchinson R
- Hegde U, *see* Leonard GD
- Heiber DJ, *see* George DW
- Heidebrecht H-J, *see* Krams M
- Heideman R, *see* Blaney SM
- Heidenreich A, *see* Albers P
- Heighway J, *see* Ratschiller D
- Heil G, *see* Krauter J
- Heilbrun LK, *see* El-Rayes BF
- Heimans JJ, *see* Vos MJ
- Heinecke A, *see* Büchner T
see Haferlach T
- Heiniger A, *see* Roman-Gomez J
- Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen C-J, Van den Abbeele AD, Druker BJ, Kiese B, Eisenberg B, Roberts PJ, Singer S, Fletcher CDM, Silberman S, Dimitrijevic S, Fletcher JA. Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor, 4342
- Heinrich MC, Corless CL. In Reply (correspondence), 3886
- Heinrich P, *see* Boyle FM
- Heise W, *see* Daum S
- Heit W, *see* Krauter J
- Held TK, *see* Schetelig J
- Helft PR, Hlubocky F, Daugherty CK. American Oncologists' Views of Internet Use by Cancer Patients: A Mail Survey of American Society of Clinical Oncology Members, 942
- Hellman R, *see* Grossman SA
- Helman LJ, *see* Goorin AM
- Helmstaedter C, *see* Pels H
- Hendel PN, *see* Featherstone C
- Henderson ES, *see* Peterson BA
- Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, Ingle JN, Cooper MR, Hayes DF, Tkaczuk KH, Fleming G, Holland JF, Duggan DB, Carpenter JT, Frei E III, Schilsky RL, Wood WC, Muss HB, Norton L. Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast Cancer, 976
- Henderson IC, Norton L, Berry DA. In Reply (correspondence), 4465
- Henderson IC, *see* Parnes HL
see Weiss RB
- Heneghan M, *see* Leung TWT
- Henner WD, *see* Beer TM
- Hennessy BT, Horgan A, Hogan M, Barry J, O'Reilly S, Breathnach O. Challenging Problems in Advanced Malignancy: Use of Positron Emission Tomography to Solve a Diagnostic Dilemma in a Patient With Non-Hodgkin's Lymphoma, 3168
- Hennig J, *see* Morgan B
- Henrichs C, *see* Zemzoum I
- Henrik A, *see* Diamandis EP
- Henry A, *see* Morgan B
- Hensel M, *see* Schetelig J
- Hensley ML, *see* Hahn EA
- Herbrecht R, *see* Coiffier B
- Herbst RS, *see* Erasmus JJ
- Herida M, Mary-Krause M, Kaphan R, Cadranel J, Poizot-Martin I, Rabaud C, Plaisance N, Tissot-Dupont H, Boue F, Lang J-M, Costagliola D. Incidence of Non-AIDS-Defining Cancers Before and During the Highly Active Antiretroviral Therapy Era in a Cohort of Human Immunodeficiency Virus-Infected Patients, 3447
- Hermann RC, *see* Hainsworth JD
- Hermine O, *see* Raffoux E
- Hermosin L, *see* Roman-Gomez J
- Hernberg M, Virkkunen P, Bono P, Ahtinen H, Mäenpää H, Joensuu H. Interferon Alfa-2b Three Times Daily and Thalidomide in the Treatment of Metastatic Renal Cell Carcinoma, 3770
- Herndon J II, *see* Gururangan S
- Herndon JE II, *see* Quinn JA
- Hero B, *see* Krams M
- Herrero M, *see* Garcia-Rostan G
- Herrmann R, *see* Engert A
see Hess V
see Jantschkeff P
- Herrstedt J, *see* de Wit R
- Herzog TJ, *see* Moore DH
- Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ. The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High-Dose Cisplatin—The Aprepitant Protocol 052 Study Group, 4112
- Hesketh PJ, *see* Oo TH
- Hess K, *see* Pusztai L
- Hess KR, *see* Jaeckle KA
- Hess M, *see* Seymour JF
- Hess V, Salzberg M, Borner M, Morant R, Roth AD, Ludwig C, Herrmann R. Combining Capecitabine and Gemcitabine in Patients With Advanced Pancreatic Carcinoma: A Phase I/II Trial, 66
- Heydon K, *see* Chakravarti A
- Heydon KH, *see* Pollack A
- Hibbitts S, *see* Slingluff CL Jr
- Hickish T, *see* Johnston SRD
- Hickok JT, *see* Morrow GR
- Hicks RJ, *see* Mac Manus MP
- Hiddemann W, *see* Büchner T
see Cheson BD
see Haferlach T
- Hietanen P, *see* Brandberg Y
- Higby DJ, *see* Mertens WC
- Hildebrand J, *see* Hoang-Xuan K
- Hilden JM, Watterson J, Chrastek J. Tell the Children, 37s
- Hill C, *see* Alimi D
see Le Deley M-C
- Hill HC, *see* Varma GN
- Hillman S, *see* Adjei AA
- Hillner BE. Trends in Clinical Trials Reports in Common Cancers Between 1989 and 2000, 1850
- Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee GC, Janjan NA, Cauley JA, Blumenstein BA, Albain KS, Lipton A, Brown S. American Society of

AUTHOR INDEX

- Clinical Oncology 2003 Update on the Role of Bisphosphonates and Bone Health Issues in Women With Breast Cancer, 4042
- Hillner BE, Kyle RA. In Reply (correspondence), 3178
- Hilt D, *see* Olivi A
- Himmelstein BP, Jackson NL, Pegram L. The Power of Silence, 41s
- Hirata K, *see* Tominaga T
- Hirohashi S, *see* Shimamura T
- Hironaka S, *see* Ishikura S
- Hirschfeld S, Ho PTC, Smith M, Pazdur R. Regulatory Approvals of Pediatric Oncology Drugs: Previous Experience and New Initiatives, 1066
- Hirsch FR, Varella-Garcia M, Bunn PA Jr, Di Maria MV, Veve R, Bremnes RM, Barón AE, Zeng C, Franklin WA. Epidermal Growth Factor Receptor in Non-Small-Cell Lung Carcinomas: Correlation Between Gene Copy Number and Protein Expression and Impact on Prognosis, 3798
- Hirsh V, *see* Gridelli C
see Rosen LS
- His P, *see* Freyer G
- Hitre E, *see* Láng I
- Hlubocky F, *see* Helft PR
- Ho AD, *see* Schetelig J
- Ho L, *see* Cohen SJ
- Ho M, *see* Nam RK
- Ho PTC, *see* Hirschfeld S
- Hoang-Xuan K, Taillandier L, Chinot O, Soubeyran P, Bogdhan U, Hildebrand J, Frenay M, De Beule N, Delattre JY, Baron B. Chemotherapy Alone as Initial Treatment for Primary CNS Lymphoma in Patients Older Than 60 Years: A Multicenter Phase II Study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group, 2726
- Hobday T, Sloan J, Goldberg R. In Reply (correspondence), 3179
- Hochberg F, *see* Batchelor T
- Hochman J, *see* Ferreri AJM
- Hochreiter W, *see* Madersbacher S
- Hochster H, Chachoua A, Speyer J, Escalon J, Zeleniuch-Jacquette A, Muggia F. Oxaliplatin With Weekly Bolus Fluorouracil and Low-Dose Leucovorin as First-Line Therapy for Patients With Colorectal Cancer, 2703
- Hochster H, *see* Tempero M
- Hodgetts J, *see* Danson S
- Hodgson DC, *see* Tsang RW
- Hodi FS, *see* Salgia R
see Soiffer R
- Hodson DI, *see* Groome PA
- Hoekman K, *see* Kuenen BC
- Hoekstra OS, *see* Vos MJ
- Hoelzer K, *see* Rivera E
- Höffken K, *see* Schetelig J
- Hoffman JS, *see* Fracasso PM
- Hoffman R, *see* Penson DF
- Hoffmann J, *see* Ebert MPA
- Höfler H, *see* Zemzoum I
- Hofstra RMW, *see* Berends MJW
- Hogan M, *see* Hennessy BT
- Hohenberger W, *see* Rödel C
- Hojden M, *see* Giuliani N
- Hokanson PJ, *see* Kobrinsky NL
- Holik D, *see* Freeman NJ
- Holland JC. Psychological Care of Patients: Psycho-Oncology's Contribution, 253s
- Holland JF, *see* Citron ML
see Henderson IC
see Peterson BA
see Weiss RB
- Holland R, *see* Kriege M
- Hollema H, *see* Berends MJW
- Hollenberg PF, *see* Dhaini HR
- Hollis D, *see* Tepper JE
- Holmberg SB, *see* Wallgren A
- Hon C, Kwok AKH, Shek TWH, Au WY. Unusual Locations of Involvement by Malignancies: Bilateral Hypopyon Heraldng CNS Relapse of Cutaneous Natural Killer Cell Lymphoma, 3368
- Honegger H, *see* Betticher DC
- Hong J-H, *see* Yen T-C
- Hong WK, *see* Rudin CM
- Hood N, *see* Goodwin PJ
- Hoogerbrugge N, Bult P, de Widt-Levert LM, Beex LV, Kiemeny LA, Ligtenberg MJL, Massuger LF, Boetes C, Manders P, Brunner HG. High Prevalence of Premalignant Lesions in Prophylactically Removed Breasts From Women at Hereditary Risk for Breast Cancer, 41
- Hoon DSB, *see* Kuo CT
see Wascher RA
- Horai T, *see* Fukuoka M
- Horgan A, *see* Hennessy BT
- Horgan D, *see* Weiss MA
- Horgan KJ, *see* de Wit R
see Hesketh PJ
- Horning SJ. Something Old, Something Few, Something Subjective, Something Déjà Vu (editorial), 1
- Horowitz IR, *see* Bookman MA
- Horowitz M, *see* Bierman PJ
- Horowitz MM, *see* Serna DS
- Horsfield MA, *see* Morgan B
- Horster S, *see* Jung CP
- Hortobagyi GN, *see* Esteva FJ
see Pusztai L
see Rivera E
see Valero V
see Woodward WA
- Horváth Z, *see* Láng I
- Horwich A, *see* Christian JA
see Huddart RA
- Horwitz EM, *see* Hanks GE
- Hoshida Y, *see* Yamamoto S
- Hoskins PJ, Swenerton KD, Pike JA, Lim P, Aquino-Parsons C, Wong F, Lee N. Small-Cell Carcinoma of the Cervix: 14 Years of Experience at a Single Institution Using a Combined-Modality Regimen of Involved-Field Irradiation and Platinum-Based Combination Chemotherapy, 3495
- Hossfeld D, *see* Schmoll H-J
- Hou N, *see* Kaklamani VG
- Houghton AN, *see* Hwu W-J
see Segal NH
- Houldsworth J, *see* Donadio AC
- Housman MG, *see* Lewis JH
- Houston GA, *see* Hainsworth JD
- Houston S, *see* Johnston SRD
- Howell A, *see* Kaufmann M
- Howes A, *see* Johnston SRD
- Hromas RA, *see* George DW
- Hruby G, *see* Featherstone C
- Hsu C-Y, *see* Lin J-C
- Hsueh E, *see* Chung MH
- Hsueh S, *see* Yen T-C
- Hu H, *see* Tchen N
- Hu H-M, *see* Smith JW II
- Hu JC, Gold KF, Pashos CL, Mehta SS, Litwin MS. Role of Surgeon Volume in Radical Prostatectomy Outcomes, 401
- Huang J, Barbera L, Brouwers M, Browman G, Mackillop WJ. Does Delay

- in Starting Treatment Affect the Outcomes of Radiotherapy? A Systematic Review, 555
- Huang K-G, *see* Yen T-C
- Huddart RA, *see* Christian JA
- Huddart RA, Norman A, Shahidi M, Horwich A, Coward D, Nicholls J, Dearnaley DP. Cardiovascular Disease as a Long-Term Complication of Treatment for Testicular Cancer, 1513
- Huddart RA, Norman A. In Reply (correspondence), 3888
- Hudes GR. In Reply (correspondence), 177
- Hudes GR, *see* Cohen SJ
- Hudgens SA, *see* Hahn EA
- Hudis C, *see* Buzdar A
see Citron ML
see Winer EP
- Hudson M, *see* Kishi S
- Hudson MM, *see* Smith RS
- Hughes C, *see* Schwartz MD
- Huguet F, *see* Beaumont M
- Huguet-Rigal F, *see* Boissel N
- Hui W-M, *see* Chan AO-O
- Huland H, *see* Augustin H
- Humerickhouse RA, *see* Carducci MA
- Hummer A, *see* Gonen M
see Katz MS
see Kemeny N
- Humphrey R, *see* Moore MJ
- Hung KN, *see* Au WY
- Hunt KK, *see* Pisters PWT
see Woodward WA
- Huo D, *see* Cohen EEW
- Hurd D, *see* Citron ML
- Hurd DD, *see* Peterson BA
- Hurt RD, Krook JE, Croghan IT, Loprinzi CL, Sloan JA, Novotny PJ, Kardinal CG, Knost JA, Tirona MT, Addo F, Morton RF, Michalak JC, Schaefer PL, Porter PA, Stella PJ. Nicotine Patch Therapy Based on Smoking Rate Followed by Bupropion for Prevention of Relapse to Smoking, 914
- Hurteau J, *see* Young RC
- Hurtz H-J, *see* Cella D
- Hurwitz CA, *see* Dalton VK
- Hurwitz HI, *see* Kabbinavar F
- Hussain MM, Kotz H, Minasian L, Premkumar A, Sarosy G, Reed E, Zhai S, Steinberg SM, Raggio M, Oliver VK, Figg WD, Kohn EC. Phase II Trial of Carboxyamidotriazole in Patients With Relapsed Epithelial Ovarian Cancer, 4356
- Hussain T, *see* Gupta S
- Hussey DH, *see* Thomas CT
- Huszti HC, *see* Nitschke R
- Hutchins L, *see* Esteva FJ
see Kohli M
- Hutchinson RJ, Gaynon PS, Sather H, Bertolone SJ, Cooper HA, Tannous R, Wells LM, Heerema NA, Sailer S, Trigg ME. Intensification of Therapy for Children With Lower-Risk Acute Lymphoblastic Leukemia: Long-Term Follow-Up of Patients Treated on Children's Cancer Group Trial 1881, 1790
- Hutton C, *see* Pritchard-Jones K
- Huvos AG, *see* Aung LL
see Kolb EA
- Hwang W-T, *see* Kazak AE
- Hwang Y-T, *see* Mandelblatt JS
see Polsky D
- Hwu P, *see* Yang JC
- Hwu W-J, Krown SE, Menell JH, Panageas KS, Merrell J, Lamb LA, Williams LJ, Quinn CJ, Foster T, Chapman PB, Livingston PO, Wolchok JD, Houghton AN. Phase II Study of Temozolomide Plus Thalidomide for the Treatment of Metastatic Melanoma, 3351
- Hynes HE, *see* Morrow GR
- Hyodo I, *see* Ohtsu A

I

- Ianniello GP, *see* Gridelli C
- Ianus J, *see* Hesketh PJ
- Ibrahim N, *see* Kantarjian HM
- Ide H, *see* Ando N
- Iizuka T, *see* Ando N
- Ikeda N, *see* Ohtsu A
- Ikeda T, *see* Tominaga T
- Ikeuchi S, *see* Ando N
- Illiano A, *see* Gridelli C
- Ilson D, *see* Downey RJ
- Ilson DH, Bains M, Kelsen DP, O'Reilly E, Karpeh M, Coit D, Rusch V, Gonen M, Wilson K, Minsky BD. Phase I Trial of Escalating-Dose Irinotecan Given Weekly With Cisplatin and Concurrent Radiotherapy in Locally Advanced Esophageal Cancer, 2926
- Im S-A, *see* Lee Y-H
- Imadalou K, *see* Freyer G
see Vassal G
- Imeson J, *see* Pritchard-Jones K
see Taylor RE
- Incaprera M, *see* Serra M
- Indelicato RA, Portenoy RK. Opioid Rotation in the Management of Refractory Cancer Pain, 87s
- Indelicato RA, Portenoy RK. In Reply (correspondence), 3005
- Indolfi P, Terenziani M, Casale F, Carli M, Bisogno G, Schiavetti A, Mancini A, Rondelli R, Pession A, Jenkner A, Pierani P, Tamaro P, De Bernardi B, Ferrari A, Santoro N, Giuliano M, Cecchetto G, Piva L, Surico G, Di Tullio MT. Renal Cell Carcinoma in Children: A Clinicopathologic Study, 530
- Indolfi P, *see* De Bernardi B
- Ingle JN, *see* Citron ML
see Haluska P
see Henderson IC
see Hillner BE
see Sledge GW
see Winer EP
- Innocenzi D, *see* Gradilone A
- Ino Y, *see* Shimamura T
- Inskip PD, *see* Oeffinger KC
see Packer RJ
- Inui TS, *see* Clark JA
- Inwards CY, *see* Haluska P
- Iodice G, *see* Tartarone A
- Irie HY, Jaklitsch MT, Shaffer K, Weinstein M, Salgia R. Unusual Problems in Breast Cancer and a Rare Lung Cancer Case: Primary Lymphoepithelioma-like Carcinoma of the Lung, 2215
- Irish JC, *see* Groome PA
- Ironside J, *see* Taylor RE
- Irwin M, *see* McTiernan A
- Isaacs C, *see* Peshkin BN
see Schwartz MD
- Ishida K, *see* Ando N
- Ishikura S, Nihei K, Ohtsu A, Boku N, Hironaka S, Mera K, Muto M, Ogino T, Yoshida S. Long-Term Toxicity After Definitive Chemoradiotherapy for Squamous Cell Carcinoma of the Thoracic Esophagus, 2697
- Iskander L, *see* Yousef GM
- Isla D, *see* Alberola V
see Andrés R

Isono K, *see* Ando N
 Issakov J, *see* Ohali A
 Ito Y, *see* Wong JEL
 Iturria NL, *see* Brown PD
 Ivy P, *see* Takimoto CH
 Iwasaki H, *see* Emoto M
 Iwashyna TJ, *see* Lamont EB
 Izzi I, *see* Re A

J

Jacchetti G, *see* Nasti G
 Jack W, *see* Kunkler I
 Jackman S, *see* Carter CA
 Jackson NL, *see* Himmelstein BP
 Jacobs IJ, *see* Skates SJ
 Jacobson J, *see* Lee C-K
 Jacquin J-P, *see* Fumoleau P
 Jaeckle K, *see* Blaney SM
 Jaeckle KA, Hess KR, Yung WKA, Greenberg H, Fine H, Schiff D, Pollack IF, Kuhn J, Fink K, Mehta M, Cloughesy T, Nicholas MK, Chang S, Prados M. Phase II Evaluation of Temozolomide and 13-*cis* Retinoic Acid for the Treatment of Recurrent and Progressive Malignant Glioma: A North American Brain Tumor Consortium Study, 2305
 Jaenicke F, *see* Mouridsen H
 Jaffe ES, *see* Leonard GD
 Jain V, *see* El-Rayes BF
 Jakesz R. In Reply (correspondence), 2446
 Jakesz R, *see* Pohl G
 see Schmid M
 see Stift A
 Jaklitsch M, *see* Irie HY
 see Salgia R
 see Soiffer R
 Jan J-S, *see* Lin J-C
 Janbu J, *see* Wiedswang G
 Jandolo B, *see* Pace A
 Janjan NA, *see* Hillner BE
 Janka-Schaub GE, *see* Den Boer ML
 Janne P, *see* Razavi D
 Jantschke P, Terracciano L, Lowy A, Glatz-Krieger K, Grunert F, Micheel B, Brümmer J, Laffer U, Metzger U, Herrmann R, Rochlitz C. Expression of CEACAM6 in Resectable Colorectal Cancer: A Factor of Independent Prognostic Significance, 3638
 Jarnagin W, *see* Kemeny N
 Järvinen HJ, *see* Renkonen E
 Jatoi A, Kumar S, Sloan JA, Nguyen PL. On Appetite and Its Loss, 79s
 Jatoi A, Nguyen PL, Kumar S, Sloan J, Loprinzi CL. In Reply (correspondence), 83s
 Jatoi A, *see* Schild SE
 Javle MM, *see* Varma GN
 Jean-François B, *see* Autier P
 Jeffrey F, *see* Randall ME
 Jaha S, *see* Kantarjian HM
 Jaha SS, *see* Giles FJ
 Jenkins R, *see* Buckner JC
 Jenkinson A, *see* Strair RK
 Jenkner A, *see* Indolfi P
 Jensen MM, *see* Kazak AE
 Jett JR, *see* Schild SE
 Jewett MAS, *see* Nam RK
 Jhanwar S, *see* Heath JA
 Jiang C, *see* Markman M
 see Rothenberg ML
 Jiang G, *see* Chang AE
 Jiang R-S, *see* Lin J-C
 Jimenez A, *see* Roman-Gomez J
 Jiménez U, *see* Alberola V
 Jivan A, *see* Morgan B
 Jöbsis AC, *see* van Rhijn BWG
 Joe A, *see* Palmedo H
 Joel SP, *see* Chester JD
 Joensuu H, *see* Heinrich MC
 see Hernberg M
 Johnsen HE, *see* Schouten HC
 Johnson D, *see* Masters GA
 Johnson DH, Arteaga CL. Gefitinib in Recurrent Non-Small-Cell Lung Cancer: An IDEAL Trial? (editorial), 2227
 Johnson DH, *see* Eton DT
 see Miller VA
 Johnson JL, *see* Duggan DB
 see Peterson BA
 Johnson JR, Williams G, Pazdur R. End Points and United States Food and Drug Administration Approval of Oncology Drugs, 1404
 Johnson M, *see* Powles T
 Johnson ME, *see* Loprinzi CL
 Johnson PJ, *see* Leung TWT
 Johnson R, *see* Tolcher AW
 Johnson RD, *see* Chaudhary UB
 Johnson TD, *see* Dhaini HR
 Johnston C, *see* Wright EP
 Johnston PG, Benson AB III, Catalano P, Rao MS, O'Dwyer PJ, Allegra CJ. Thymidylate Synthase Protein Expression in Primary Colorectal Cancer: Lack of Correlation With Outcome and Response to Fluorouracil in Metastatic Disease Sites, 815
 Johnston PG, *see* Allegra CJ
 Johnston SRD, Hickish T, Ellis P, Houston S, Kelland L, Dowsett M, Salter J, Michiels B, Perez-Ruixo JJ, Palmer P, Howes A. Phase II Study of the Efficacy and Tolerability of Two Dosing Regimens of the Farnesyl Transferase Inhibitor, R115777, in Advanced Breast Cancer, 2492
 Johnstone D, *see* Movsas B
 Jolivet J, *see* Townsley CA
 Jonak ZL, *see* Tolcher AW
 Jonat W. In Reply (correspondence), 2446
 Jonat W, *see* de Haes H
 Jones C, *see* Roach M III
 Jones D, *see* Millikan R
 Jones JL, *see* Swinson DEB
 Jones LW, *see* Courneya KS
 see Segal RJ
 Jones SE, *see* Buzdar A
 Jones T, *see* Anderson HL
 Jorch N, *see* Den Boer ML
 Jordan VC. The Ups and Downs of the Estrogen Receptor (editorial), 3
 Joss C, *see* Betticher DC
 Josting A, Wiedenmann S, Franklin J, May M, Sieber M, Wolf J, Engert A, Diehl V. Secondary Myeloid Leukemia and Myelodysplastic Syndromes in Patients Treated for Hodgkin's Disease: A Report From the German Hodgkin's Lymphoma Study Group, 3440
 Josting A, *see* Engert A
 see Sieber M
 Jourdan E, *see* Coiffier B
 Judy K, *see* Olivi A
 Juergens H, *see* Burdach S
 Juffs HG, *see* Tchen N
 Jun G, *see* Khouri IF
 Junck LR, *see* Lang FF
 Jundt G, *see* Kager L

- Jung CP, Horster S, Lohse P, Bogner JR, Emmerich B, Goebel F-D. Uncommon Hematologic Malignancies: Plasmablastic Leukemia in HIV-Associated Multicenter Castleman's Disease, 4248
- Jung K, *see* Salgia R
see Soiffer R
- Jung S-H, *see* Fisch MJ
see George DW
- Jurcic JG, *see* Weiss MA
- Jürgens H, *see* Kager L
see Ozaki T
- Justice L, *see* Smith JW II
- K**
- Kaasa S, *see* Brandberg Y
- Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E. Phase II, Randomized Trial Comparing Bevacizumab Plus Fluorouracil (FU)/Leucovorin (LV) With FU/LV Alone in Patients With Metastatic Colorectal Cancer, 60
- Kabbinavar F. In Reply (correspondence), 3543
- Kabisch H, *see* Kager L
- Kabuto T, *see* Ando N
- Kadin ME, *see* Younes A
- Kadish S, *see* Shaw E
- Kaelin CM, *see* Burstein HJ
- Kager L, Zoubek A, Pötschger U, Kastner U, Flege S, Kempf-Bielack B, Branscheid D, Kotz R, Salzer-Kuntschik M, Winkelmann W, Jundt G, Kabisch H, Reichardt P, Jürgens H, Gadner H, Bielack SS. Primary Metastatic Osteosarcoma: Presentation and Outcome of Patients Treated on Nonadjuvant Cooperative Osteosarcoma Study Group Protocols, 2011
- Kahmann S, *see* Ebert MPA
- Kahn B, *see* Ganz PA
- Kahn MJ, Lazarus CJ, Owens DP. Allowing Patients to Die: Practical, Ethical, and Religious Concerns, 3000
- Kahn SR, *see* Goldenberg N
- Kaiser R, *see* Tremblay P-B
- Kakkar AK, *see* Kuenen BC
- Kaklamani VG, Hou N, Bian Y, Reich J, Offit K, Michel LS, Rubinstein WS, Rademaker A, Pasche B. *TGFBR1**6A and Cancer Risk: A Meta-Analysis of Seven Case-Control Studies, 3236
- Kalda AL, *see* McKenzie DC
- Kalemkerian GP. "But Doctor, What Have I Got to Lose . . . ?" (correspondence), 30s
- Kalemkerian GP, *see* Amir M
- Kalifa C, *see* Laithier V
- Kallioniemi A, *see* Skotheim RI
- Kallioniemi O-P, *see* Skotheim RI
- Kamal N, *see* Bucaloiu ID
- Kamin DY, *see* Emanuel EJ
- Kaminsky M-C, *see* Culine S
- Kampel LJ. Challenging Problems in Advanced Malignancy: Disseminated Intravascular Coagulation in Metastatic Hormone-Refractory Prostate Cancer, 3168
- Kamps WA, *see* Den Boer ML
- Kanazawa Y, *see* Tsuchiya H
- Kang T, *see* Breslow NE
- Kantarjian HM, Gandhi V, Kozuch P, Faderl S, Giles F, Cortes J, O'Brien S, Ibrahim N, Khuri F, Du M, Rios MB, Jeha S, McLaughlin P, Plunkett W, Keating M. Phase I Clinical and Pharmacology Study of Clofarabine in Patients With Solid and Hematologic Cancers, 1167
- Kantarjian HM, *see* Giles FJ
- Kantoff PW, *see* Donadio AC
see Halabi S
see Talcott JA
see Taplin M-E
- Kanvinde MH, *see* Majhail NS
- Kanz L, *see* Krauter J
see Schmoll H-J
- Kaphan R, *see* Herida M
- Kaplan EB, *see* Halabi S
- Kaplan I, *see* Talcott JA
- Kaplan R, *see* Lewis JH
- Kappeler A, *see* Ratschiller D
- Kapur P, *see* Bowers DC
- Kardinal CG, *see* Hurt RD
see Ramanathan RK
- Kåresen R, *see* Wiedswang G
- Karnad AB. House Calls by Oncologists: A Home-Visit Primer, 102s
- Karow J, *see* Haferlach T
- Karpeh M, *see* Ilson DH
see Kattan MW
- Karpeh MS, *see* Weitz J
- Kasendorf EI, *see* Sekeres MA
- Kaspers GJL, *see* Den Boer ML
- Kastner U, *see* Kager L
- Kates RE, *see* Zemzoum I
- Katsaros D, *see* Diamandis EP
see Yousef GM
- Kattan MW, Karpeh MS, Mazumdar M, Brennan MF. Postoperative Nomogram for Disease-Specific Survival After an R0 Resection for Gastric Carcinoma, 3647
- Kattan MW, Shariat SF, Andrews B, Zhu K, Canto E, Matsumoto K, Muramoto M, Scardino PT, Ohori M, Wheeler TM, Slawin KM. The Addition of Interleukin-6 Soluble Receptor and Transforming Growth Factor Beta, Improves a Preoperative Nomogram for Predicting Biochemical Progression in Patients With Clinically Localized Prostate Cancer, 3573
- Kattan MW, Zelefsky MJ, Kupelian PA, Cho D, Scardino PT, Fuks Z, Leibel SA. Pretreatment Nomogram That Predicts 5-Year Probability of Metastasis Following Three-Dimensional Conformal Radiation Therapy for Localized Prostate Cancer, 4568
- Kattan MW, *see* Halabi S
see Shariat SF
- Katz MS, Zelefsky MJ, Venkatraman ES, Fuks Z, Hummer A, Leibel SA. Predictors of Biochemical Outcome With Salvage Conformal Radiotherapy After Radical Prostatectomy for Prostate Cancer, 483
- Katz RL, *see* Khouri IF
- Kaufman E, *see* Schwartz MD
- Kaufmann M, von Minckwitz G, Smith R, Valero V, Gianni L, Eiermann W, Howell A, Dan Costa S, Beuzeboc P, Untch M, Blohmer J-U, Sinn H-P, Sittke R, Souchon R, Tulusan AH, Volm T, Senn H-J. International Expert Panel on the Use of Primary (Preoperative) Systemic Treatment of Operable Breast Cancer: Review and Recommendations, 2600
- Kaufmann M, *see* de Haes H
- Kaufmann SH, *see* Adjei AA
- Kaukel E, *see* Fossella F
see Vogelzang NJ
- Kavanagh JJ, *see* Bodurka DC
- Kawarabayashi T, *see* Emoto M
- Kaye SB, *see* Kolomainen DF
- Kazak AE, Cant MC, Jensen MM, McSherry M, Rourke MT, Hwang W-T, Alderfer MA, Beele D, Simms S, Lange BJ. Identifying Psychosocial Risk Indicative of Subsequent Resource Use in Families of Newly Diagnosed Pediatric Oncology Patients, 3220
- Kazemier KM, *see* Den Boer ML
- Keating M, *see* Kantarjian HM
- Keating NL, Landrum MB, Ayanian JZ, Winer EP, Guadagnoli E. Consultation With a Medical Oncologist Before Surgery and Type of Surgery Among Elderly Women With Early-Stage Breast Cancer, 4532
- Keiding N, *see* Schmiegelow K

AUTHOR INDEX

- Kelland L, *see* Johnston SRD
- Keller J, *see* Poulsen M
- Kelley MR, *see* George DW
- Kelly WK, Steineck G. Bisphosphonates for Men With Prostate Cancer: Sifting Through the Rubble (editorial), 4261
- Kelsen DP, *see* Ilson DH
- Kelsey A, *see* Pritchard-Jones K
- Kelsey S, *see* Taussig DC
- Kemeny MM, Peterson BL, Kornblith AB, Muss HB, Wheeler J, Levine E, Bartlett N, Fleming G, Cohen HJ. Barriers to Clinical Trial Participation by Older Women With Breast Cancer, 2268
- Kemeny N, Jarnagin W, Gonen M, Stockman J, Blumgart L, Sperber D, Hummer A, Fong Y. Phase I/II Study of Hepatic Arterial Therapy With Floxuridine and Dexametason in Combination With Intravenous Irinotecan As Adjuvant Treatment After Resection of Hepatic Metastases From Colorectal Cancer, 3303
- Kemeny N, *see* Gonen M
- Kemeny NE, *see* Ramanathan RK
- Kempf-Bielack B, *see* Kager L
- Kennecke H, *see* Bryce C
- Kennedy I, *see* Nabholz J-M
- Kennedy PR, *see* Burstein HJ
- Kent S, *see* Peshkin BN
- Keppler U, *see* Scagliotti GV
- Kerbl R, Urban CE, Ambros IM, Dornbusch HJ, Schwinger W, Lackner H, Ladenstein R, Strenger V, Gadner H, Ambros PF. Neuroblastoma Mass Screening in Late Infancy: Insights Into the Biology of Neuroblastic Tumors, 4228
- Kerbrat P, *see* Fumoleau P
- Keresztes RS, *see* Altorki NK
- Kerlikowske K, Miglioretti DL, Ballard-Barbash R, Weaver DL, Buist DSM, Barlow WE, Cutter G, Geller BM, Yankaskas B, Taplin SH, Carney PA. Prognostic Characteristics of Breast Cancer Among Postmenopausal Hormone Users in a Screened Population, 4314
- Kern W, *see* Büchner T
see Haferlach T
- Kerner J, *see* Mandelblatt JS
- Ketas JC, *see* Leonard JP
- Kevric M, *see* Ozaki T
- Keyhani A, *see* Pagliaro LC
- Khakoo Y, *see* Wolden SL
- Khanfir K, Guinebretière J-M, Vanel D, Barreau-Pouhaer L, Bonvalot S, Le Cesne A. Unusual Problems in Breast Cancer and a Rare Lung Cancer Case: Aggressive Fibromatosis of the Chest Wall Arising Near a Breast Prosthesis, 2215
- Khayat D, *see* Harper P
- Khoo US, *see* Au WY
- Khouri IF, Lee M-S, Saliba RM, Jun G, Fayad L, Younes A, Pro B, Acholonu S, McLaughlin P, Katz RL, Champlin RE. Nonablative Allogeneic Stem-Cell Transplantation for Advanced/Recurrent Mantle-Cell Lymphoma, 4407
- Khoury H, *see* Cashen A
- Khuri F, *see* Kantarjian HM
- Kiechle M, *see* Zenzoum I
- Kiehl M, *see* Schetelig J
- Kiemeny LA, *see* Hoogerbrugge N
- Kienast J, *see* Schetelig J
- Kies MS, *see* Vokes EE
- Kiese B, *see* Heinrich MC
- Kilby A, *see* Strauss SJ
- Kilgore ML, *see* Lewis JH
- Kilickap S, Abali H, Celik I, Graziano F, Cascinu S. Bevacizumab, Bleeding, Thrombosis, and Warfarin (correspondence), 3542
- Kim G, *see* Allegra CJ
- Kim J, *see* Ma BBY
- Kim Y, *see* Lee Y-H
- Kimijima I, *see* Tominaga T
- Kindler HL, *see* Scagliotti GV
- King C, *see* Kunkler I
- King DK, *see* Morrow GR
- King DM, *see* Kolomainen DF
- King L, *see* Cannistra SA
- Kinjo Y, *see* Ando N
- Kinoshita T, *see* Nashimoto A
- Kirkels WJ, *see* van Rhijn BWG
- Kirsch I, *see* Allegra CJ
- Kirshner JJ, *see* Morrow GR
- Kish JA, *see* Adelstein DJ
- Kishi S, Griener J, Cheng C, Das S, Cook EH, Pei D, Hudson M, Rubnitz J, Sandlund JT, Pui C-H, Relling MV. Homocysteine, Pharmacogenetics, and Neurotoxicity in Children With Leukemia, 3084
- Kissenger RL, *see* Shahab N
- Kitada S, *see* Bannerji R
- Kitamura M, *see* Nashimoto A
- Klasa R, *see* Zucca E
- Klasa RJ. In Reply (correspondence), 2627
- Klastersky J, *see* Razavi D
- Kleeberg U, *see* Köhne C-H
- Kleibeuker JH, *see* Berends MJW
- Klein JP, *see* Serna DS
- Klein P, *see* Allegra CJ
- Kleiner DE, *see* Feldman AL
- Kliesch S, *see* Albers P
- Klijn JGM, *see* Kriege M
see Meijers-Heijboer H
see van Oostrom I
- Klimstra D, *see* Gonen M
see Weitz J
- Klockgether T, *see* Pels H
- Klokman WJ, *see* Aleman BMP
- Klosky JL, *see* Tyc VL
- Klug MG, *see* Kobrinsky NL
- Kluin-Nelemans HC, *see* Poortmans PMP
- Knapp FF Jr, *see* Palmedo H
- Knapp RC, *see* Skates SJ
- Knight R, *see* Takimoto CH
- Knittig S, *see* Silvestri GA
- Knost JA, *see* Hurt RD
- Knox B, *see* Strair RK
- Ko S, *see* Chan AO-O
- Ko Y-J, *see* Balk SP
- Kobrinsky NL, Klug MG, Hokanson PJ, Sjolander DE, Burd L. Impact of Smoking on Cancer Stage at Diagnosis, 907
- Kocha WI, *see* Videtic GMM
- Koch P, *see* Engert A
see Sieber M
- Koch T, *see* Sieber M
- Koczwara B, Clark MM. A Couple With Cancer: Conflicting Wishes, Joint Decisions, 174
- Kodish E, *see* Friebert S
- Kodish ED, *see* Simon C
- Koelbl O, *see* Vordermark D
- Kogner P, *see* Ambros IM
- Koh W-J. Controversies in the Radiotherapeutic Management of Cervical Cancer, 218s
- Koh W-J, *see* Cannistra SA
- Kohler-Späth H, *see* Garbe C
- Kohli M, Ali Khan M, Mehta P, Hutchins L. Combined Endocrine Blockade in Premenopausal Breast Cancer: A Superior Therapeutic Option for Adjuvant Management? (correspondence), 2445

- Kohman LJ, *see* Gajra A
- Kohn EC, *see* Hussain MM
- Köhne C-H, Wils J, Lorenz M, Schöffski P, Voigtmann R, Bokemeyer C, Lutz M, Kleeberg U, Ridwelski K, Souchon R, El-Serafi M, Weiss U, Burkhard O, Rückle H, Lichinitser M, Langenbuch T, Scheithauer W, Baron B, Couvreur M-L, Schmoll H-J. Randomized Phase III Study of High-Dose Fluorouracil Given As a Weekly 24-Hour Infusion With or Without Leucovorin Versus Bolus Fluorouracil Plus Leucovorin in Advanced Colorectal Cancer: European Organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952, 3721
- Köhrmann K-U, *see* Classen J
- Kolb EA, Kushner BH, Gorlick R, Laverdiere C, Healey JH, LaQuaglia MP, Huvos AG, Qin J, Vu HT, Wexler L, Wolden S, Meyers PA. Long-Term Event-Free Survival After Intensive Chemotherapy for Ewing's Family of Tumors in Children and Young Adults, 3423
- Kollender Y, *see* Ohali A
- Koller CA, *see* Giles FJ
- Kollmannsberger C, *see* Schmoll H-J
- Kolomainen DF, A'Hern R, Coxon FY, Fisher C, King DM, Blake PR, Barton DPJ, Shepherd JH, Kaye SB, Gore ME. Can Patients With Relapsed, Previously Untreated, Stage I Epithelial Ovarian Cancer Be Successfully Treated With Salvage Therapy?, 3113
- Komaki R, *see* Mehta MP
see Movsas B
- Konikoff F, *see* Goor O
- Koo J, *see* Goodwin PJ
- Koon H, *see* Gollob JA
- Koong H, *see* Downey RJ
- Kopeccky KJ, *see* Cheson BD
- Korc M, *see* Ebert MPA
- Körholz D, *see* Den Boer ML
- Kornblith AB, *see* Ganz PA
see Kemeny MM
- Kornek GV, *see* Scheithauer W
- Korones DN. Taking Time, 3366
- Korst RJ, *see* Altorki NK
- Koski G, *see* Bedrosian I
- Kosmidis PA. In Reply (correspondence), 756
- Kossman SE, *see* Weiss MA
- Kosuge T, *see* Shimamura T
- Kotz H, *see* Abraham J
see Hussain MM
- Kotz R, *see* Kager L
see Ozaki T
- Kouroukis CT, Belch A, Crump M, Eisenhauer E, Gascoyne RD, Meyer R, Lohmann R, Lopez P, Powers J, Turner R, Connors JM. Flavopiridol in Untreated or Relapsed Mantle-Cell Lymphoma: Results of a Phase II Study of the National Cancer Institute of Canada Clinical Trials Group, 1740
- Kovats E, *see* Scheithauer W
- Kowalski MO, *see* Small EJ
- Koyama H, *see* Tominaga T
- Kozelsky TF, Meyers GE, Sloan JA, Shanahan TG, Dick SJ, Moore RL, Engeler GP, Frank AR, McKone TK, Urias RE, Pilepich MV, Novotny PJ, Martenson JA. Phase III Double-Blind Study of Glutamine Versus Placebo for the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy, 1669
- Koziol JA, *see* Goodman GR
- Kozuch P, *see* Kantarjian HM
- Kragt DR, *see* Vuylsteke RJCLM
- Krahn MD, *see* Alibhai SMH
- Kramer K, *see* Cheung IY
see Kushner BH
- Kramer MHH, *see* Doorduijn JK
- Krams M, Heidebrecht H-J, Hero B, Berthold F, Harms D, Parwaresch R, Rudolph P. repp86 Expression and Outcome in Patients With Neuroblastoma, 1810
- Krasne D, *see* Bilchik AJ
- Krasnow SH, *see* Clark JA
- Krauter J, Görlich K, Ottmann O, Lübbert M, Döhner H, Heit W, Kanz L, Ganser A, Heil G. Prognostic Value of Minimal Residual Disease Quantification by Real-Time Reverse Transcriptase Polymerase Chain Reaction in Patients With Core Binding Factor Leukemias, 4413
- Kraybill WG, *see* Rajput A
- Krebs L, *see* Comis RL
- Krege S, *see* Albers P
- Kremer LCM, *see* van Dalen EC
- Kretzschmar A, Pink D, Thuss-Patience P, Dörken B, Reichart P, Eckert R. Extravasations of Oxaliplatin (correspondence), 4068
- Kriege M, Brekelmans CTM, Boetes C, Rutgers EJT, Oosterwijk JC, Tollenaar RA, Manoliu RA, Holland R, De Koning HJ, Klijn JGM. MRI Screening for Breast Cancer in Women With High Familial and Genetic Risk: First Results of the Dutch MRI Screening Study (MRISC), 238s
- Kris MG. Why Do We Need Another Antiemetic? Just Ask (editorial), 4077
- Kris MG, *see* Miller VA
- Krishman A, *see* Stein AS
- Kristeller J, *see* Fisch MJ
- Kristinsson J, *see* Schmiegelow K
- Kröger N, *see* Schetelig J
- Kroll S, *see* Armitage JO
- Krook JE, *see* Hurt RD
see Schnoll RA
- Kros JM, *see* van den Bent MJ
- Kroschinsky F, *see* Pels H
- Krown SE, *see* Hwu W-J
- Krozely P, *see* Miller VA
- Krug LM, *see* Miller VA
- Krystio RJ, *see* Patchell R
- Krzakowski M, *see* Nabholz J-M
see Rosen LS
- Krzyzanowska MK, Weeks JC, Earle CC. Treatment of Locally Advanced Pancreatic Cancer in the Real World: Population-Based Practices and Effectiveness, 3409
- Ku S-L, *see* Ward RL
- Kubica U, *see* Haferlach T
- Kubista E, *see* Pohl G
see Schmid M
- Kudoh S, *see* Fukuoka M
- Kuduk SD, *see* Slovin SF
- Kuebler JP, *see* Gandara DR
see Millikan R
- Kuenen BC, Levi M, Meijers JCM, van Hinsbergh VWM, Berkhof J, Kakkar AK, Hoekman K, Pinedo HM. Potential Role of Platelets in Endothelial Damage Observed During Treatment With Cisplatin, Gemcitabine, and the Angiogenesis Inhibitor SU5416, 2192
- Kuhl CK, Schrading S, Leutner CC, Morakkabati N, Trog D, Schmutzler R, Schild HH. Surveillance of "High Risk" Women With Proven or Suspected Familial (Hereditary) Breast Cancer: First Midterm Results of a Multi-Modality Clinical Screening Trial, 238s
- Kühl J, *see* Bürger B
- Kuhn J, *see* Jaeckle KA
- Kulp B, *see* Markman M
- Kumar S, *see* Jatoi A
- Kun L, *see* Smith RS
- Kun LE, *see* Rodriguez-Galindo C
- Kunii Y, *see* Nashimoto A
- Kuniyuki A, *see* Penson DF
- Kunkler I, Jack W, Prescott R, Williams L, King C. Postoperative Breast Irradiation: New Trials Needed in Older Patients (correspondence), 1893

- Kuntz KM, *see* Punglia RS
 Kunwar SM, *see* Lang FF
 Kuo C, *see* Wascher RA
 Kuo CT, Hoon DSB, Takeuchi H, Turner R, Wang H-J, Morton DL, Taback B. Prediction of Disease Outcome in Melanoma Patients by Molecular Analysis of Paraffin-Embedded Sentinel Lymph Nodes, 3566
 Kupelian PA, *see* Kattan MW
 Kurie JM. Cyclin D1 Expression in the Field of Exposure: Another Piece in the Molecular Auerbach Puzzle (editorial), 2056
 Kuriyan M, *see* Strair RK
 Kurtz J, *see* Bouchardy C
 Kurtzberg J, *see* Gururangan S
 Kushner BH, Yeh SDJ, Kramer K, Larson SM, Cheung N-KV. Impact of Metaiodobenzylguanidine Scintigraphy on Assessing Response of High-Risk Neuroblastoma to Dose-Intensive Induction Chemotherapy, 1082
 Kushner BH, *see* Cheung IY
 see Kolb EA
 Kusuda L, *see* Carter CA
 Kuter I, *see* Burstein HJ
 Kuttesch N, *see* Blaney SM
 Kuzel TC, *see* Ladewski LA
 Kvalheim G, *see* Schouten HC
 see Wiedswang G
 Kvaloy S, *see* Schouten HC
 Kwaan HC, *see* Ladewski LA
 Kwan E, *see* Marshall GM
 Kwasny W, *see* Schmid M
 Kwiatek J, *see* Rowinsky EK
 Kwok AKH, *see* Hon C
 Kwok K-F, *see* Chan AO-O
 Kyle RA, *see* Hillner BE
- L**
- La Cesa A, *see* Tonini G
 Lackner H, *see* Kerbl R
 Lacour B, *see* Le Deley M-C
 Ladenstein R, *see* Ambros IM
 see Kerbl R
 Ladetto M, Drandi D, Compagno M, Astolfi M, Volpato F, Voena C, Novarino A, Pollio B, Addeo A, Ricca I, Falco P, Cavallo F, Vallet S, Corradini P, Pileri A, Tamponi G, Palumbo A, Bertetto O, Boccadoro M, Tarella C. PCR-Detectable Nonneoplastic *Bcl-2/IgH* Rearrangements Are Common in Normal Subjects and Cancer Patients at Diagnosis but Rare in Subjects Treated With Chemotherapy, 1398
 Ladewski LA, Belknap SM, Nebeker JR, Sartor O, Lyons EA, Kuzel TC, Tallman MS, Raisch DW, Auerbach AR, Schumock GT, Kwaan HC, Bennett CL. Dissemination of Information on Potentially Fatal Adverse Drug Reactions for Cancer Drugs From 2000 to 2002: First Results From the Research on Adverse Drug Events and Reports Project, 3859
 Laffer U, *see* Jantschkeff P
 Lage H, *see* Rau B
 Lagman R, *see* Davis MP
 Lahorte C, *see* Van de Wiele C
 Lahti M, *see* Emmons KM
 Lai B, *see* Earle CC
 Lai C-H, *see* Yen T-C
 Laissue P, *see* Bouchardy C
 Laithier V, Grill J, Le Deley M-C, Ruchoux M-M, Couanet D, Doz F, Pichon F, Rubie H, Frappaz D, Vannier J-P, Babin-Boilletot A, Sariban E, Chastagner P, Zerah M, Raquin M-A, Hartmann O, Kalifa C. Progression-Free Survival in Children With Optic Pathway Tumors: Dependence on Age and the Quality of the Response to Chemotherapy—Results of the First French Prospective Study for the French Society of Pediatric Oncology, 4572
 Lakhani N, *see* Fine HA
 Lam KC, Yeo W, Lee JFY, Chow J, Mok TSK. Unusual Abdominal Tumors: Multiple Lymphomatous Polyposis in Mantle Cell Lymphoma, 950
 Lam S-K, *see* Chan AO-O
 Lamanna N, *see* Weiss MA
 Lamb LA, *see* Hwu W-J
 Lambert-Falls R, *see* Burstein HJ
 Lambert JM, *see* Tolcher AW
 Lambilliotte C, *see* Pellegrino B
 Lamm DL. Intravesical Therapy for Superficial Bladder Cancer: Slow but Steady Progress (editorial), 4259
 La Monica S, *see* Giuliani N
 Lamont EB, Iwashyna TJ. In Reply (correspondence), 1892
 Lance R, *see* Carter CA
 Landman-Parker J, *see* Pellegrino B
 see Schleiermacher G
 Landrum MB, *see* Ganz PA
 see Keating NL
 Landuzzi L, *see* Scotlandi K
 Lanfranchi A, *see* Re A
 Lang F, *see* Scheithauer W
 Lang FF, Bruner JM, Fuller GN, Aldape K, Prados MD, Chang S, Berger MS, McDermott MW, Kunwar SM, Junck LR, Chandler W, Yung WKA. Phase I Trial of Adenovirus-Mediated *p53* Gene Therapy for Recurrent Glioma: Biological and Clinical Results, 2508
 Lang H, *see* Finke J
 Láng I, Hitre E, Horváth Z, Gődény M. Unusual Abdominal and Pelvic Tumors: Resection of Originally Inoperable Liver Metastases of Gastrointestinal Stromal Tumor After Imatinib Mesylate Therapy, 3535
 Lang J-M, *see* Herida M
 Lang R, *see* Mouridsen H
 Lange B, *see* Gamis AS
 Lange BJ, *see* Kazak AE
 Langenbuch T, *see* Köhne C-H
 Langer AS, *see* Winer EP
 Langer C, *see* Movsas B
 Langston J, *see* Rodriguez-Galindo C
 Lanier KS, *see* Velasquez WS
 Laplanche A, *see* Culine S
 LaQuaglia MP, *see* Kolb EA
 Lara PN Jr, *see* Gandara DR
 Lara R, *see* Andrés R
 La Rocca RV, *see* Belani CP
 Larson RA, *see* Cheson BD
 see Hahn EA
 Larson SM, *see* Downey RJ
 see Kushner BH
 Lash TL, *see* Ganz PA
 Lashford LS, *see* Taylor RE
 Laskey RA, *see* Gonzalez MA
 Lasota J, *see* Schneider-Stock R
 Lasser DH, *see* Sekeres MA
 Last KW, Cornelius V, Delves T, Sieniawska C, Fitzgibbon J, Norton A, Amess J, Wilson A, Rohatiner AZS, Lister TA. Presentation Serum Selenium Predicts for Overall Survival, Dose Delivery, and First Treatment Response in Aggressive Non-Hodgkin's Lymphoma, 2335
 Lattime EC, *see* Strair RK
 Laufer M, Ramalingam S, Schoenberg MP, Haisfield-Wolf ME, Zuhowski EG, Trueheart IN, Eisenberger MA, Nativ O, Egorin MJ. Intravesical Gemcitabine Therapy for Superficial Transitional Cell Carcinoma of the Bladder: A Phase I and Pharmacokinetic Study, 697
 Laufman L, *see* Esteva FJ
 Laurent D, *see* Morgan B

- Lauria F, *see* Martelli M
 Lauta VM, *see* Martelli M
 Lauterbach I, *see* Seidemann K
 la Vecchia C, *see* Apolone G
 Laveder F, *see* Zucca E
 Laverdiere C, *see* Kolb EA
 Law NM, *see* Tan CK
 Law S, *see* Chan AO-O
 Lawrence GA, Crawford J. Benefits of Locoregional Treatment (correspondence), 4660
 Lawrence TS, *see* Shewach DS
 Laws HJ, *see* Burdach S
 Lawton C, *see* Hanks GE
 see Roach M III
 Lawton CA, *see* Pollack A
 Lax S, *see* Pohl G
 Lazarus CJ, *see* Kahn MJ
 Lazarus H, *see* Vose JM
 Lazarus HM, *see* Bierman PJ
 Lazzaretti M, *see* Giuliani N
 Le N, *see* Gill S
 Leachman SA, *see* Alexander A
 Le Bail N, *see* Rothenberg ML
 Lebbé G, *see* Raffoux E
 LeBlanc M, *see* Blayney DW
 see Unger JM
 Leblanc T, *see* Aladjidi N
 see Boissel N
 see Le Deley M-C
 see Pellegrino B
 Lebwahl D, *see* Abraham J
 Le Cesne A, *see* Khanfir K
 see Zelek L
 Le Chevalier T. Results of the Randomized International Adjuvant Lung Cancer Trial (IALT): Cisplatin-Based Chemotherapy (CT) Versus No CT in 1867 Patients (pts) With Resected Non—Small Cell Lung Cancer (NSCLC), 238s
 Le Chevalier T, *see* Fizazi K
 Le Deley M-C, Leblanc T, Shamsaldin A, Raquin M-A, Lacour B, Sommet D, Chompret A, Cayuela J-M, Bayle C, Bernheim A, de Vathaire F, Vassal G, Hill C. Risk of Secondary Leukemia After a Solid Tumor in Childhood According to the Dose of Epipodophyllotoxins and Anthracyclines: A Case-Control Study by the Société Française d’Oncologie Pédiatrique, 1074
 Le Deley M-C, *see* Laithier V
 Lee C-K, Barlogie B, Munshi N, Zangari M, Fassas A, Jacobson J, van Rhee F, Cottler-Fox M, Muwalla F, Tricot G. DTPACE: An Effective, Novel Combination Chemotherapy With Thalidomide for Previously Treated Patients With Myeloma, 2732
 Lee F, *see* Thomas JP
 Lee JFY, *see* Lam KC
 Lee JH, *see* Punglia RS
 Lee KM, *see* Leong SS
 Lee L, *see* Morgan B
 Lee M-S, *see* Khouri IF
 Lee N, *see* Hoskins PJ
 Lee SJ, *see* Serna DS
 Lee S-J, *see* Millikan R
 Lee SN, *see* Lee Y-H
 Lee S-N, *see* Lee Y-H
 Lee SW, *see* Lee Y-H
 Lee Y-H, Im S-A, Lee S-N, Kim Y, Seong C-M, Han WS, Lee SW, Park S-H, Lee SN. Challenging Problems in Advanced Malignancy: Chylopericardium During the Treatment of Non-Hodgkin’s Lymphoma, 3168
 Lefaix J-L, *see* Delanian S
 Legrand C, *see* Smit EF
 LeGrand SB, *see* Davis MP
 Lehmann L, *see* Goldberg JM
 Leib Z, *see* Colombo R
 Leibel SA, *see* Kattan MW
 see Katz MS
 see Wolden SL
 Leibenhaut M, *see* Mehta MP
 Leigh BR, *see* Gandara DR
 Leiserowitz GS, *see* Cress RD
 Leite EB, *see* Lima VS
 Leiter U, *see* Garbe C
 Leitzel K, *see* Lipton A
 Lenauer A, *see* Scheithauer W
 Lengfelder E, *see* Büchner T
 see Haferlach T
 Lensing S, *see* Tyc VL
 Lentz SS, *see* Gallion HH
 see Young RC
 Lenz H-J, *see* Ramanathan RK
 Lenzi R, *see* Tempero M
 Leon A, *see* Roman-Gomez J
 Leon J, *see* Havrilesky L
 Leon M, *see* Sozzi G
 Leonard GD, Hegde U, Butman J, Jaffe ES, Wilson WH. Uncommon Presentations of Malignancies: Extraocular Muscle Palsies in Subcutaneous Panniculitis-Like T-Cell Lymphoma, 2993
 Leonard JP, Coleman M, Ketas JC, Chadburn A, Ely S, Furman RR, Wegener WA, Hansen HJ, Ziccardi H, Eschenberg M, Gayko U, Cesano A, Goldenberg DM. Phase I/II Trial of Epratuzumab (Humanized Anti-CD22 Antibody) in Indolent Non-Hodgkin’s Lymphoma, 3051
 Leonard R, *see* Nabholz J-M
 Leonetti C, *see* Pace A
 Leong SS, Tan EH, Fong KW, Wilder-Smith E, Ong YK, Tai BC, Chew L, Lim SH, Wee J, Lee KM, Foo KF, Ang P, Ang PT. Randomized Double-Blind Trial of Combined Modality Treatment With or Without Amifostine in Unresectable Stage III Non—Small-Cell Lung Cancer, 1767
 Le Pechoux C, *see* Zelek L
 Lepidini G, *see* Papaldo P
 Lerman C, *see* Schwartz MD
 Lerner BH. *First, You Cry*, 25 Years Later, 122s
 Lesimple T, *see* Culine S
 Lester SC, *see* Burstein HJ
 Leszcz M, *see* Bordeleau L
 Leu K, *see* Dhaini HR
 Leung EH, *see* Citron ML
 Leung TWT, Yu S, Johnson PJ, Geschwind J, Vogl TJ, Engelmann K, Gores GJ, Giovannini M, O’Grady J, Heneghan M, Stewart M, Orenberg EK, Thuluvath PJ. Phase II Study of the Efficacy and Safety of Cisplatin-Epinephrine Injectable Gel Administered to Patients With Unresectable Hepatocellular Carcinoma, 652
 Leutner CC, *see* Kuhl CK
 Levenback C, *see* Bodurka DC
 Leverger G, *see* Aladjidi N
 see Boissel N
 see Pellegrino B
 Levi M, *see* Kuenen BC
 Levine A, *see* Armitage JO; Giles FJ
 Levine DA, Argenta PA, Yee CJ, Marshall DS, Olvera N, Bogomolny F, Rahaman JA, Robson ME, Offit K, Barakat RR, Soslow RA, Boyd J. Fallopian Tube and Primary Peritoneal Carcinomas Associated With BRCA Mutations, 4222
 Levine E, *see* Kemeny MM
 Levine EG, *see* Halabi S
 Levine M, *see* Crump M

AUTHOR INDEX

- Levine MA, *see* Ganz PA
see Pritchard KI
see Wright JR
- Levinson J, *see* Emanuel EJ
- Levis A, *see* Cilloni D
- Levitt R, *see* Buckner JC
- Le Voyer TE, Sigurdson ER, Hanlon AL, Mayer RJ, Macdonald JS, Catalano PJ, Haller DG. Colon Cancer Survival Is Associated With Increasing Number of Lymph Nodes Analyzed: A Secondary Survey of Inter-group Trial INT-0089, 2912
- Levy DE, *see* Goldberg JM
see Wadler S
- Levy R, *see* Weng W-K
- Levy V, *see* Vasconcelos Y
- Lew D, *see* Velasquez WS
- Lewin DN, *see* Chaudhary UB
- Lewis JH, Kilgore ML, Goldman DP, Trimble EL, Kaplan R, Montello MJ, Housman MG, Escarce JJ. Participation of Patients 65 Years of Age or Older in Cancer Clinical Trials, 1383
- Lewis NL, *see* Cohen SJ
- Lewitton M, *see* Massarweh S
- Leyland-Jones B, Gelmon K, Ayoub J-P, Arnold A, Verma S, Dias R, Ghahramani P. Pharmacokinetics, Safety, and Efficacy of Trastuzumab Administered Every 3 Weeks in Combination With Paclitaxel, 3965
- Lhéritier V, *see* Boissel N
- Li CI, Daling JR, Malone KE. Incidence of Invasive Breast Cancer by Hormone Receptor Status From 1992 to 1998, 28
- Li FP, *see* Emmons KM
- Li Q, *see* Chang AE
- Li Y, *see* Adelstein DJ
see Meropol NJ
- Lianes P, *see* Smit EF
- Liang BC, *see* Vose JM
- Liang R, *see* Au WY
see Chim CS
- Liang S, *see* Shakespeare TP
- Liang W-M, *see* Lin J-C
- Libby DM, *see* Altorki NK
- Liberati M, *see* Baldini L
- Libert Y, *see* Razavi D
- Libutti SK, *see* Feldman AL
- Lichinister M, *see* Freyer G
see Köhne C-H
- Lichter AS, *see* Emanuel EJ
- Licitra L, Grandi C, Guzzo M, Mariani L, Vullo SL, Valvo F, Quattrone P, Valagussa P, Bonadonna G, Molinari R, Cantù G. Primary Chemotherapy in Resectable Oral Cavity Squamous Cell Cancer: A Randomized Controlled Trial, 327
- Lieberman G, *see* Kabbinnar F
- Lien HH, *see* Oldenburg J
- Liepa AM, *see* Roychowdhury DF
- Liewehr DJ, *see* Feldman AL
see Yang JC
- Ligtenberg MJL, *see* Berends MJW
see Hoogerbrugge N
- Lillywhite L, *see* Nanduri VR
- Lim P, *see* Hoskins PJ
- Lim SH, *see* Leong SS
- Lima VS, Leite EB, Fonseca RP, Fernandes AS Jr. Patients Presenting With CNS Lesions: Primary Low-Grade Mucosa-Associated B-Cell Lymphoma of the Dura, 4058
- Lin J-C, Jan J-S, Hsu C-Y, Liang W-M, Jiang R-S, Wang W-Y. Phase III Study of Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Advanced Nasopharyngeal Carcinoma: Positive Effect on Overall and Progression-Free Survival, 631
- Lin JT, *see* Raja V
- Lin W-J, *see* Yen T-C
- Lincoln ST, *see* Wadler S
- Lindblom A, *see* Renkonen E
- Lindenauer PK, *see* Mertens WC
- Linder J, *see* Meyers FJ
- Linder N, *see* Ozaki T
- Lindtner J, *see* Crivellari D
see Wallgren A
- Link MP, *see* Breneman JC
see Goorin AM
see Smith RS
- Link T, *see* Weber WA
- Lippman SM, *see* Rudin CM
- Lipshultz SE, Lipsitz SR, Sallan SE, Gelber RD, Colan SD. In Reply (correspondence), 3377
- Lipsitz SR, *see* Lipshultz SE
- Lipson M, *see* Rodriguez-Galindo C
- Lipton A, *see* Hillner BE
- Lipton A, Ali SM, Leitzel K, Demers L, Harvey HA, Chaudri-Ross HA, Brady C, Wyld P, Carney W. Serum *HER-2/neu* and Response to the Aromatase Inhibitor Letrozole Versus Tamoxifen, 1967
- Lipton A, Leitzel K, Demers L, Harvey HA, Ali SM, Chaudri-Ross HA, Wyld P, Brady C, Carney W. In Reply (correspondence), 4657
- Lischner S, *see* Hauschild A
- List AF, *see* Unger JM
- List MA, *see* Vokes EE
- Lister J, *see* Witzig TE
- Lister TA. High-Dose Therapy for Follicular Lymphoma Revisited: Not If, but When? (editorial), 3894
- Lister TA, *see* Cheson BD
see Last KW
see Taussig DC
- Litchy S, *see* Hainsworth JD
- Litwin MS, *see* Hu JC
see Spencer BA
- Liu B, *see* Pagliaro LC
- Liu ET. Molecular Oncodiagnosics: Where We Are and We Need to Go (editorial), 2052
- Liu PY, *see* Markman M
see Rothenberg ML
- Livingston PO, *see* Hwu W-J
see Slovin SF
- Livingston R, *see* Citron ML
see Gandara DR
- Llewellyn-Thomas HA, *see* Bordeleau L
- Llombart-Cussac A, *see* Zelek L
- Lloyd RV, *see* Oliveira AM
- Loberiza FR Jr, *see* Bierman PJ
see Serna DS
- Lockwood GF, *see* Takimoto CH
- Lo-Coco F, *see* Cheson BD
- Lodder LN, *see* van Oostrom I
- Lodge MA, *see* Galbraith SM
- Loehrer PJ, *see* Fisch MJ
- Löffler H, *see* Büchner T
see Haferlach T
- Löffler M, *see* Engert A
- Logan TF, *see* Clark JI
- Loge JH, *see* Fosså SD
- Logothetis CJ, *see* Millikan R
- Lohi H, *see* Renkonen E
- Lohmann R, *see* Kouroukis CT
- Lohse P, *see* Jung CP

AUTHOR INDEX

- Lokhorst HM, Segeren CM, Verdonck LF, van der Holt B, Raymakers R, van Oers MHJ, Barge RMY, Schouten HC, Westveer PHM, Steijaert MMC, Cornelissen JJ, Sonneveld P. Partially T-Cell–Depleted Allogeneic Stem-Cell Transplantation for First-Line Treatment of Multiple Myeloma: A Prospective Evaluation of Patients Treated in the Phase III Study HOVON 24 MM, 1728
- Lollini P-L, *see* Scotlandi K
- Lomax L, *see* Danson S
- Lombardo L, *see* Cappuzzo F
- Lombardo M, *see* Baldini L
- Long HJ, *see* Omura GA
see Varia MA
see Young RC
- Longhi A, *see* Bacci G
- Longo R, Amici S, Carillio G, Gasparini G. Diagnostic Challenges in Patients With Tumors: Staphylococcal Scalded-Skin Syndrome in a Patient With Extended Small-Cell lung Cancer, 3700
- Löning L, *see* Bürger B
- Look KY, *see* Omura GA
- Loong F, *see* Au WY
see Chim CS
- Loose D, *see* Van de Wiele C
- Lopez M, *see* Papaldo P
- Lopez P, *see* Kouroukis CT
- López-Vivanco G, *see* Alberola V
- Lo Piccolo MS, *see* Cheung IY
- Loprinzi CL. The Art of Oncology: When the Tumor Is Not the Target, 1s
- Loprinzi CL, Canellos GP. A New Addition to the *Journal of Clinical Oncology*: The Art of Oncology—When the Tumor Is Not the Target, 2s
- Loprinzi CL, Hayes D, Smith T. Doc, Shouldn't We Be Getting Some Tests?, 108s
- Loprinzi CL, Johnson ME, Steer G. Doc, How Much Time Do I Have?, 5s
- Loprinzi CL, Martenson JA. Keratinocyte Growth Factor: Not Yet Ready for Prime Time (editorial), 1429
- Loprinzi CL, Rajkumar SV. Why Not Start With Thalidomide?, 2211
- Loprinzi CL. Editor's Note, 16s, 86s
- Loprinzi CL, In Reply (correspondence), 4463
- Loprinzi CL, *see* Hurt RD
see Jatoi A
see Schapira L
- Lordick F, *see* Ott K
- Lorenz D, *see* Chao C
- Lorenz M, *see* Köhne C-H
- Lorigan P, *see* Danson S
- Lortholary A, *see* Culine S
- Lothe RA, *see* Diep CB
see Skotheim RI
- Loud PA, *see* Rajput A
- Louie A, *see* Padmanabhan H
- Louvet C, *see* André T
- Lovelace W, *see* Vose JM
- Love RR, Duc NB, Havighurst TC, Mohsin SK, Zhang Q, DeMets DL, Allred DC. *HER-2/neu* Overexpression and Response to Oophorectomy Plus Tamoxifen Adjuvant Therapy in Estrogen Receptor-Positive Premenopausal Women With Operable Breast Cancer, 453
- Lo Vullo S, *see* Gronchi A
- Lowe BA, *see* Beer TM
- Löwenberg B, *see* Cheson BD
- Lowy A, *see* Jantschkeff P
- Loy V, *see* Albers P
- Lozano RD, *see* Patt YZ
- Lozza L, *see* Gronchi A
- Lu JJ, *see* Shakespeare TP
- Lübbert M, *see* Krauter J
- Lubeck D, *see* D'Amico AV
- Lucas V, *see* Tourani J-M
- Lucca J, *see* Salgia R
- Lucioni M, *see* Rossi G
- Lucraft H, *see* Taylor RE
- Ludwig C, *see* Hess V
- Ludwig W-D, *see* Büchner T
see Haferlach T
- Luegmayr A, *see* Ambros IM
- Luetmer PH, *see* Haluska P
- Lugo TG, Braun S, Cote RJ, Pantel K, Rusch V. Detection and Measurement of Occult Disease for the Prognosis of Solid Tumors, 2609
- Lui K-W, *see* Yen T-C
- Lukanich J, *see* Salgia R
- Lumbroso J, *see* Matthay KK
- Luminari S, *see* Baldini L
see Federico M
- Lunec J, *see* Ambros IM
- Luporsi E, *see* Fumoleau P
- Lutz M, *see* Köhne C-H
- Lyckholm L, *see* Neff P
- Lyden D, *see* Wolden SL
- Lyden E, *see* Breneman JC
- Lyman GH, Dale DC, Crawford J. Incidence and Predictors of Low Dose-Intensity in Adjuvant Breast Cancer Chemotherapy: A Nationwide Study of Community Practices, 4524
- Lynch C, *see* Salgia R
- Lynch GR, *see* Massarweh S
- Lynch HT, Snyder CL, Lynch JF, Riley BD, Rubinstein WS. Hereditary Breast-Ovarian Cancer at the Bedside: Role of the Medical Oncologist, 740
- Lynch HT. In Reply (correspondence), 4660
- Lynch JF, *see* Lynch HT
- Lynch T, *see* Salgia R
- Lynch TJ, *see* Sequist LV
- Lynch TJ Jr, *see* Roberts TG Jr
see Sekeres MA
- Lyons EA, *see* Ladewski LA

M

- Ma BBY, Bristow RG, Kim J, Siu LL. Combined-Modality Treatment of Solid Tumors Using Radiotherapy and Molecular Targeted Agents, 2760
- Ma MH, *see* Yang HH
- Ma SK, *see* Au WY
- Ma S-Y, *see* Yen T-C
- Maas R, *see* Ozaki T
- Macdonald DR. Regarding "Sweet Time Unafflicted" (correspondence), 958
- Macdonald JS. Chemotherapy in the Management of Gastric Cancer, 276s
- Macdonald JS, *see* Le Voyer TE
see Meyerhardt JA
see Unger JM
see Wong JEL
- MacDonald N, *see* Bruera E
see Schapira L
see Skates SJ
- Machin D, *see* Tan CK
- Machtay M, *see* Roach M III
- Mackenzie RG, *see* Groome PA
- Mackey JR, *see* Courneya KS
see Hack TF
- Mackillop WJ, *see* Groome PA
see Huang J
- Mackintosh J, *see* Poulsen M

AUTHOR INDEX

- MacLennan GT, *see* Gupta S
- Macleod A, *see* Fukuoka M
- Mac Manus MP, Hicks RJ, Matthews JP, McKenzie A, Rischin D, Salminen EK, Ball DL. Positron Emission Tomography Is Superior to Computed Tomography Scanning for Response-Assessment After Radical Radiotherapy or Chemoradiotherapy in Patients With Non–Small-Cell Lung Cancer, 1285
- Madelenat P, *see* Morice P
- Madersbacher S, Hochreiter W, Burkhard F, Thalmann GN, Danuser H, Markwalder R, Studer UE. Radical Cystectomy for Bladder Cancer Today—A Homogeneous Series Without Neoadjuvant Therapy, 690
- Maecker H, *see* Smith JW II
- Mäenpää H, *see* Hernberg M
- Maes B, *see* Verburgh E
- Maes K, *see* Tolcher AW
- Magagnoli M, *see* Masci G
- Magnac C, *see* Vasconcelos Y
- Magrini E, *see* Cappuzzo F
- Maher EA, *see* Fine HA
- Mahmound HH, *see* Edick MJ
- Maier SE, *see* Mardor Y
- Mailliard JA, *see* Schild SE
- Maillo A, Orfao A, Sayagués JM, Díaz P, Gómez-Moreta JA, Caballero M, Santamarta D, Santos-Briz A, Morales F, Taberner MD. New Classification Scheme for the Prognostic Stratification of Meningioma on the Basis of Chromosome 14 Abnormalities, Patient Age, and Tumor Histopathology, 3285
- Maione P, *see* Gridelli C
- Majhail NS, Urbain J-L, Albani JM, Kanvinde MH, Rice TW, Novick AC, Mekhail TM, Olencki TE, Elson P, Bukowski RM. F-18 Fluorodeoxyglucose Positron Emission Tomography in the Evaluation of Distant Metastases From Renal Cell Carcinoma, 3995
- Mäkiperna A, *see* Schmiegelow K
- Makuuchi H, *see* Ando N
- Malayeri R. Can Endocrine Treatment for Hormone-Positive Premenopausal Women With Early Breast Cancer Replace Adjuvant Chemotherapy? (correspondence), 2444
- Malena M, *see* Cruciani M
- Malet M, *see* Tourani J-M
- Malfertheiner P, *see* Ebert MPA
- Malhotra V, *see* Shahab N
- Malik AA, Moazzam N, Potti A. Unusual Abdominal Tumors: Small Bowel Carcinoid Presenting as an Acute Abdomen, 950
- Malin J, *see* Spencer BA
- Maloisel F, *see* Beaumont M
- Malone KE, *see* Li CI
- Malone SC, *see* Segal RJ
- Maloum K, *see* Vasconcelos Y
- Mamounas EP, *see* Bear HD
see Winer EP
- Manago J, *see* Strair RK
- Manara MC, *see* Scotlandi K
see Serra M
- Mancini A, *see* Indolfi P
- Mancini LL, *see* Monti M
- Mandahl N, *see* Skotheim RI
- Mandalia S, *see* Powles T
- Mandelblatt JS, Edge SB, Meropol NJ, Senie R, Tsangaris T, Grey L, Peterson BM Jr, Hwang Y-T, Kerner J, Weeks J. Predictors of Long-Term Outcomes in Older Breast Cancer Survivors: Perceptions Versus Patterns of Care, 855
- Mandelblatt JS, *see* Polsky D
- Mandelli F, *see* Martelli M
- Manders P, *see* Hoogerbrugge N
- Manegold C, *see* Scagliotti GV
see Smit EF
see Vogelzang NJ
- Manenti F, *see* Villa E
- Mangia A, *see* Volpi A
- Mangoni L, *see* Giuliani N
- Mani S, *see* Takimoto CH
- Manka-Waluch A, *see* Palmedo H
- Mann G, *see* Bürger B
see Seidemann K
- Mann H. Publication of Full Reports of Clinical Trials (correspondence), 4254
- Manne S, *see* Meropol NJ
- Mannel RS, *see* Ozols RF
see Randall ME
- Manning JT, *see* Seymour JF
- Manola J, *see* Messing EM
see Talcott JA
- Manoliu RA, *see* Kriege M
- Manounas EP, *see* Dignam JJ
- Mansmann U, *see* Faiss S
- Manzione L, *see* Gridelli C
- Marchal S, *see* Razavi D
- Marchetti A, *see* Buttitta F
- Marcom PK, *see* Burstein HJ
- Marcus AC, *see* Schnoll RA
- Marcus KJ, *see* Smith RS
- Mardor Y, Pfeffer R, Spiegelmann R, Roth Y, Maier SE, Nissim O, Berger R, Glicksman A, Baram J, Orenstein A, Cohen JS, Tichler T. Early Detection of Response to Radiation Therapy in Patients With Brain Malignancies Using Conventional and High b-Value Diffusion-Weighted Magnetic Resonance Imaging, 1094
- Marec-Berard P, Blay JY, Schell M, Buclon M, Demaret C, Ray-Coquard I. Risk Model Predictive of Severe Anemia Requiring RBC Transfusion After Chemotherapy in Pediatric Solid Tumor Patients, 4235
- Maresca V, *see* Pace A
- Margolese R, *see* Bear HD
- Margolin KA, *see* Clark JI
- Margraf LR, *see* Bowers DC
- Mariani G, *see* Quintini G
- Mariani L, *see* Gronchi A
see Licitra L
- Marinone C, *see* Cilloni D
- Markis E, *see* Pohl G
- Markman M. Role of Intraperitoneal Chemotherapy in the Front-Line Setting, 145s
- Markman M. The Myth of Measurable Disease in Ovarian Cancer (editorial), 3013
- Markman M, Liu PY, Wilczynski S, Monk B, Copeland LJ, Alvarez RD, Jiang C, Alberts D. Phase III Randomized Trial of 12 Versus 3 Months of Maintenance Paclitaxel in Patients With Advanced Ovarian Cancer After Complete Response to Platinum and Paclitaxel-Based Chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group Trial, 2460
- Markman M, Zanotti K, Peterson G, Kulp B, Webster K, Belinson J. Expanded Experience With an Intradermal Skin Test to Predict for the Presence or Absence of Carboplatin Hypersensitivity, 4611
- Markman M, *see* Cannistra SA
see Rothenberg ML
- Marks RS, *see* Adjei AA
- Markwalder R, *see* Madersbacher S
- Marmé D, *see* Morgan B
- Marnocha R, *see* Thomas JP
- Marolla P, *see* Papaldo P
- Marriott K, *see* Duggan C

AUTHOR INDEX

- Marshall DS, *see* Levine DA
- Marshall G, Norris M, Haber M. In Reply (correspondence), 4464
- Marshall GM, Haber M, Kwan E, Zhu L, Ferrara D, Xue C, Brisco MJ, Sykes PJ, Morley A, Webster B, Pozza LD, Waters K, Norris MD. Importance of Minimal Residual Disease Testing During the Second Year of Therapy for Children With Acute Lymphoblastic Leukemia, 704
- Marshall J, *see* Meropol NJ
- Marshall JL, *see* Rothenberg ML
- Martella C, *see* Buttitta F
- Martelli H, *see* Stewart RJ
- Martelli M, Gherlinzoni F, De Renzo A, Zinzani PL, De Vivo A, Cantonetti M, Falini B, Storti S, Meloni G, Rizzo M, Molinari AL, Lauria F, Moretti L, Lauta VM, Mazza P, Guardigni L, Pescarmona GE, Pileri SA, Mandelli F, Tura S. Early Autologous Stem-Cell Transplantation Versus Conventional Chemotherapy as Front-Line Therapy in High-Risk, Aggressive Non-Hodgkin's Lymphoma: An Italian Multicenter Randomized Trial, 1255
- Martelli M, *see* Zucca E
- Martellotta F, *see* Nasti G
- Martenson JA, *see* Kozelsky TF
see Loprinzi CL
- Martin M, *see* Nabholz J-M
- Martin PL, *see* Gururangan S
- Martinelli G, *see* Zucca E
- Martini A, *see* Rossi G
- Martino H, *see* Tolcher AW
- Martino S, *see* Citron ML
see Henderson IC
see Sledge GW
- Martinsson T, *see* Ambros IM
- Marubini E, *see* Moliterni A
- Mary-Krause M, *see* Herida M
- Maschmeyer G, *see* Büchner T
- Masci G, Magagnoli M, Zucali PA, Castagna L, Carnaghi C, Sarina B, Pedicini V, Fallini M, Santoro A. Minidose Warfarin Prophylaxis for Catheter-Associated Thrombosis in Cancer Patients: Can It Be Safely Associated With Fluorouracil-Based Chemotherapy?, 736
- Masera G, *see* Aricò M
see Clarke M
- Masi M, *see* Abruzzese E
- Maslak PG, *see* Weiss MA
- Mason M, *see* Christian JA
- Mason WP, *see* Abrey LE
- Massarweh S, Lewitton M, Popat U, Lynch GR. Small-Cell Cancers, and an Unusual Reaction to Chemotherapy: Synchronous Renal Cell Carcinoma and Limited-Stage Small-Cell Lung Cancer, 2439
- Massobrio M, *see* Diamandis EP
see Yousef GM
- Massuger LF, *see* Hoogerbrugge N
- Masters GA, Declerck L, Blanke C, Sandler A, DeVore R, Miller K, Johnson D. Phase II Trial of Gemcitabine in Refractory or Relapsed Small-Cell Lung Cancer: Eastern Cooperative Oncology Group Trial 1597, 1550
- Masterson M, *see* Wells RJ
- Mathieu C, *see* Autier P
- Mathisen D, *see* Salgia R
- Matsubara T, Yamada K, Nakagawa A. Risk of Second Primary Malignancy After Esophagectomy for Squamous Cell Carcinoma of the Thoracic Esophagus, 4336
- Matsumoto K, *see* Kattan MW
- Matthay K, *see* Blaney SM
- Matthay KK, Edeline V, Lumbroso J, Tanguy ML, Asselain B, Zucker JM, Valteau-Couanet D, Hartmann O, Michon J. Correlation of Early Metastatic Response by ¹²³I-Metaiodobenzylguanidine Scintigraphy With Overall Response and Event-Free Survival in Stage IV Neuroblastoma, 2486
- Matthews JP, *see* Mac Manus MP
- Matcke A, *see* Okcu MF
- Mattson KV, *see* Fossella F
- Mauch P, *see* Nichols KE
- Mauer A, *see* Adjei AA
- Maurer HM, *see* Breneman JC
see Pappo AS
- Mauriac L, *see* Therasse P
- Mavromatis B, Cheson BD. Monoclonal Antibody Therapy of Chronic Lymphocytic Leukemia, 1874
- Mavroukakis SM, *see* Feldman AL
- Maxwell RJ, *see* Galbraith SM
- May M, *see* Josting A
- Mayer AR, *see* Young RC
- Mayer M. From Access to Evidence: An Advocate's Journey, 3881
- Mayer RJ, *see* Le Voyer TE
see Meyerhardt JA
see Tepper JE
- Mayer-Steinacker R, *see* Ozaki T
- Mayeur D, *see* Tourani J-M
- Mayordomo JI, *see* Andrés R
- Mays T, *see* Tolcher AW
- Mazumdar M, Bacik J, Tickoo SK, Dobrzynski D, Donadio A, Bajorin D, Motzer R, Reuter V, Bosl GJ. Cluster Analysis of p53 and Ki67 Expression, Apoptosis, Alpha-Fetoprotein, and Human Chorionic Gonadotropin Indicates a Favorable Prognostic Subgroup Within the Embryonal Carcinoma Germ Cell Tumor, 2679
- Mazumdar M, *see* Kattan MW
- Mazza P, *see* Martelli M
- Mazzocco K, *see* Ambros IM
- Mazzucato M, *see* Re A
- McCarthy EP, Burns RB, Davis RB, Phillips RS. Barriers to Hospice Care Among Older Patients Dying With Lung and Colorectal Cancer, 728
- McClerran D, *see* Penson DF
- McCoy S, *see* Ganz PA
- McDermott D, *see* Clark JI
- McDermott DF, *see* Gollob JA
- McDermott MW, *see* Lang FF
- McGinnis WL, *see* Schild SE
- McGrath BE, *see* Varma GN
- McGreevey LS, *see* Heinrich MC
- McGuire J, *see* Rowinsky EK
- McGuire WP, *see* Moore DH
- McGuire WP III. Current Status of Taxane and Platinum-Based Chemotherapy in Ovarian Cancer, 133s
- McGuire WP III, *see* Cannistra SA
- McIntosh L, *see* Townsley CA
- McKenzie A, *see* Mac Manus MP
- McKenzie DC, Kalda AL. Effect of Upper Extremity Exercise on Secondary Lymphedema in Breast Cancer Patients: A Pilot Study, 463
- McKone TK, *see* Kozelsky TF
- McLaughlin C, *see* Gururangan S
- McLaughlin P, *see* Kantarjian HM
see Khouri IF
see Seymour JF
see Thomas CT
- McLaughlin S, *see* Cohen SJ
- McLendon RE, *see* Gururangan S
see Quinn JA
- McLeod DG, *see* Carter CA
- McMasters KM, *see* Chao C
- McNeese MD, *see* Woodward WA
- McSherry M, *see* Kazak AE

AUTHOR INDEX

- McTiernan A, Rajan KB, Tworoger SS, Irwin M, Bernstein L, Baumgartner R, Gilliland F, Stanczyk FZ, Yasui Y, Ballard-Barbash R. Adiposity and Sex Hormones in Postmenopausal Breast Cancer Survivors, 1961
- McTiernan A, *see* Strauss SJ
- Mead GM, *see* Fosså SD
see Zucca E
- Meadows A, *see* Glover DA
- Meadows AT, *see* Bhatia S
- Meagher A, *see* Ward RL
- Mechinaud F, *see* Schleiermacher G
- Mecklin J-P, *see* Renkonen E
- Medina D, *see* Strair RK
- Mehdi S, *see* Ganti AK
- Mehdi SA, *see* Pervez H
see Ramar K
- Mehta M, *see* Grossman SA
see Jaeckle KA
see Shaw E
- Mehta MP, Rodrigus P, Terhaard CHJ, Rao A, Suh J, Roa W, Souhami L, Bezjak A, Leibenhaut M, Komaki R, Schultz C, Timmerman R, Curran W, Smith J, Phan S-C, Miller RA, Renschler MF. Survival and Neurologic Outcomes in a Randomized Trial of Motexafin Gadolinium and Whole-Brain Radiation Therapy in Brain Metastases, 2529
- Mehta P, Fetting J. Can You Cure Him, for the Baby's Sake?, 4064
- Mehta P, *see* Kohli M
- Mehta SS, *see* Hu JC
- Meier F, *see* Garbe C
- Meijer S, *see* Smith JW II
see Vuylsteke RJCLM
- Meijers-Heijboer H, Brekelmans CTM, Menke-Pluymers M, Seynaeve C, Baalbergen A, Burger C, Crepin E, van den Ouweland AWM, van Geel B, Klijn JGM. Use of Genetic Testing and Prophylactic Mastectomy and Oophorectomy in Women With Breast or Ovarian Cancer From Families With a *BRCA1* or *BRCA2* Mutation, 1675
- Meijers-Heijboer H, *see* van Oostrom I
- Meijers JCM, *see* Kuenen BC
- Meisner C, *see* Classen J
- Mekhail TM, *see* Majhail NS
- Melemed AS, *see* Buzdar A
- Meling GI, *see* Diep CB
- Meller I, *see* Ohali A
- Mellink WAM, Dulmen AMv, Wiggers Th, Spreeuwenberg PMM, Eggermont AMM, Bensing JM. Cancer Patients Seeking a Second Surgical Opinion: Results of a Study on Motives, Needs, and Expectations, 1492
- Melnick W, *see* Townsley CA
- Melnychuk D, *see* Panasci L
- Meloni G, *see* Martelli M
- Melucci MT, *see* Palmieri G
- Mena M, *see* Nasti G
- Menard S, Biganzoli E, Valagussa P, Boracchi P, Moliterni A. In Reply (correspondence), 3180
- Ménard S, *see* Moliterni A
- Mendelsohn J, Baselga J. Status of Epidermal Growth Factor Receptor Antagonists in the Biology and Treatment of Cancer, 2787
- Mendez V, *see* Chenal M
- Menell JH, *see* Hwu W-J
- Mengis C, Aebi S, Tobler A, Dähler W, Fey MF. Assessment of Differences in Patient Populations Selected For or Excluded From Participation in Clinical Phase III Acute Myelogenous Leukemia Trials, 3933
- Mengoli C, *see* Cruciani M
- Menke-Pluymers M, *see* Meijers-Heijboer H
- Menon U, *see* Skates SJ
- Menten J, *see* van den Bent MJ
- Mentzer S, *see* Salgia R
see Soiffer R
- Menzel C, *see* Schmid M
- Mera K, *see* Ishikura S
- Merchant TE, *see* Rodriguez-Galindo C
- Merckaert I, *see* Razavi D
- Mercuri M, *see* Ferrari S
see Serra M
- Merino MJ, *see* Yang JC
- Merle-Béral H, *see* Vasconcelos Y
- Merli F, *see* Baldini L
- Meropol NJ, Somer RA, Gutheil J, Pelley RJ, Modiano MR, Rowinsky EK, Rothenberg ML, Redding SW, Serdar CM, Yao B, Heard R, Rosen LS. Randomized Phase I Trial of Recombinant Human Keratinocyte Growth Factor Plus Chemotherapy: Potential Role as Mucosal Protectant, 1452
- Meropol NJ, Weinfurt KP, Burnett CB, Balslem A, Benson AB III, Castel L, Corbett S, Diefenbach M, Gaskin D, Li Y, Manne S, Marshall J, Rowland JH, Slater E, Sulmasy DP, Van Echo D, Washington S, Schulman KA. Perceptions of Patients and Physicians Regarding Phase I Cancer Clinical Trials: Implications for Physician-Patient Communication, 2589
- Meropol NJ, Weinfurt KP, Schulman KA. In Reply (correspondence), 4659
- Meropol NJ, *see* Cohen SJ
see Kabbinar F
see Mandelblatt JS
- Merrell J, *see* Hwu W-J
- Merrill P, *see* Slingluff CL Jr
- Merritt JA, *see* Pagliaro LC
- Merrouche Y, *see* Culine S
- Mertens A, *see* Emmons KM
- Mertens AC, *see* Green DM
see Oeffinger KC
see Packer RJ
- Mertens F, *see* Skotheim RI
- Mertens WC, Higby DJ, Brown D, Parisi R, Fitzgerald J, Benjamin EM, Lindenauer PK. Improving the Care of Patients With Regard to Chemotherapy-Induced Nausea and Emesis: The Effect of Feedback to Clinicians on Adherence to Antiemetic Prescribing Guidelines, 1373
- Mertens WC, Higby DJ, Brown D, Parisi R, Fitzgerald J, Benjamin EM, Lindenauer PK. In Reply (correspondence), 4067
- Mervillie K, *see* Van de Wiele C
- Mesic JB, *see* Pollack A
- Messa F, *see* Cilloni D
- Messing EM, Manola J, Wilding G, Propert K, Fleischmann J, Crawford ED, Pontes JE, Hahn R, Trump D. Phase III Study of Interferon Alfa-NL as Adjuvant Treatment for Resectable Renal Cell Carcinoma: An Eastern Cooperative Oncology Group/Intergroup Trial, 1214
- Mesters RM, *see* Büchner T
- Meterissian S, *see* Poirier M
- Metzger U, *see* Jantschkeff P
- Metzner B, *see* Burdach S
see Schmol H-J
- Meyer-Bahlburg A, *see* Burdach S
- Meyerhardt JA, Catalano PJ, Haller DG, Mayer RJ, Macdonald JS, Benson AB III, Fuchs CS. Impact of Diabetes Mellitus on Outcomes in Patients With Colon Cancer, 433
- Meyer M, *see* Rödel C
see Varterasian M
- Meyer R, *see* Kouroukis CT
- Meyers CA, Wefel JS. The Use of the Mini-Mental State Examination to Assess Cognitive Functioning in Cancer Trials: No Ifs, Ands, Buts, or Sensitivity (editorial), 3557
- Meyers FJ, Linder J. Simultaneous Care: Disease Treatment and Palliative Care Throughout Illness, 1412
- Meyers GE, *see* Kozelsky TF

- Meyers PA, *see* Aung LL
see Kolb EA
- Meyer WH, *see* Breneman JC
see Nitschke R
- Meyskens FL, *see* Shanafelt T
- Meza JL, *see* Pappo AS
- Mezger J, *see* Engert A
- Michalak JC, *see* Hurt RD
- Micheel B, *see* Jantschke P
- Michel A, *see* Vasconcelos Y
- Michelagnoli M, *see* Strauss SJ
- Michel G, *see* Boissel N
- Michel LS, *see* Kaklamani VG
- Michelson H, *see* Brandberg Y
- Michieli M, *see* Re A
- Michiels B, *see* Johnston SRD
- Michon J, *see* Ambros IM
see Matthay KK
see Schleiermacher G
- Mick R, *see* Bedrosian I
- Middleton MR, *see* Danson S
- Mier JW, *see* Gollob JA
- Mietlowski W, *see* Morgan B
- Miettinen M, *see* Schneider-Stock R
- Migliorati CA. Bisphosphonates and Oral Cavity Avascular Bone Necrosis (correspondence), 4253
- Miglioretti DL, *see* Kerlikowske K
- Mignard D, *see* Vassal G
- Mihm M, *see* Salgia R
see Soiffer R
- Mihura J, *see* Fumoleau P
- Mikami I, *see* Uchitomi Y
- Milan I, *see* Bernardi D
- Milani M, *see* Ferreri AJM
- Miller JD, *see* Comis RL
- Miller K, *see* Masters GA
- Miller MP, *see* Anderson HL
- Miller RA, *see* Mehta MP
- Miller TP, *see* Blayney DW
see Velasquez WS
- Miller VA, Johnson DH, Krug LM, Pizzo B, Tyson L, Perez W, Krozely P, Sandler A, Carbone D, Heelan RT, Kris MG, Smith R, Ochs J. Pilot Trial of the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Gefitinib Plus Carboplatin and Paclitaxel in Patients With Stage IIIB or IV Non-Small-Cell Lung Cancer, 2094
- Miller WH Jr, *see* Panasci L
- Millikan R, Thall PF, Lee S-J, Jones D, Cannon MW, Kuebler JP, Wade J III, Logothetis CJ. Randomized, Multicenter, Phase II Trial of Two Multi-component Regimens in Androgen-Independent Prostate Cancer, 878
- Mills GM, *see* Belani CP
- Mills JL, *see* Glover DA
- Millward M, *see* Fossella F
- Minasian L, *see* Hussain MM
- Minsky BD, *see* Downey RJ
see Ilson DH
- Mitchell C, *see* Pritchard-Jones K
- Mitchell EP. Prognosis after Rectal Cancer Treatment in Blacks and Whites: Advanced Stage at Diagnosis or Other Factors? (editorial), 397
- Mitchell EP, *see* Ramanathan RK
- Mitchell SP, *see* Talcott JA
- Mithieux F, *see* Glehen O
- Mittal BB, *see* Vokes EE
- Miura S, *see* Tominaga T
- Miyata Y, *see* Ohtsu A
- Mlineritsch B, *see* Schmid M
- Moazzam N, *see* Malik AA
- Modiano MR, *see* Meropol NJ
- Moghrabi A, *see* Dalton VK
- Mohamed F, Sethna K, Elias D, Sugarbaker PH. Challenging and Unusual Cases: Peritoneal Cystic Mesothelioma, 1416
- Mohsin SK, *see* Love RR
- Moinpour CM, *see* Ganz PA
- Mok TSK, *see* Lam KC
- Molina A, *see* Stein AS
- Molina H, *see* Chenal M
- Molina T, *see* Bouabdallah R
- Molinari AL, *see* Martelli M
- Molinari R, *see* Licitra L
- Moliterni A, Ménard S, Valagussa P, Biganzoli E, Boracchi P, Balsari A, Casalini P, Tomasic G, Marubini E, Pilotti S, Bonadonna G. HER2 Overexpression and Doxorubicin in Adjuvant Chemotherapy for Resectable Breast Cancer, 458
- Moliterni A, *see* Menard S
- Monahan BP, *see* Takimoto CH
- Monden M, *see* Yamamoto S
- Monden Y, *see* Tominaga T
- Mondini P, *see* Bertario L
- Monk B, *see* Markman M
- Monni O, *see* Skotheim RI
- Monnier A, *see* Fumoleau P
see Mouridsen H
- Montello MJ, *see* Lewis JH
- Monti F, *see* Volpi A
- Monti M, Mancini LL, Ferrari B, Rahal D, Santoro A. Complications of Therapy and a Diagnostic Dilemma Case: Cutaneous Toxicity Induced by Cetuximab, 4650
- Monti M, *see* Volpi A
- Montie JE, *see* Thomas CT
- Moore DH, Donnelly J, McGuire WP, Almadrones L, Cella DF, Herzog TJ, Waggoner SE. Limited Access Trial Using Amifostine for Protection Against Cisplatin and 3-Hour Paclitaxel-Induced Neurotoxicity: A Phase II Study of the Gynecologic Oncology Group, 4207
- Moore J, *see* Vose JM
- Moore MJ, Hamm J, Dancy J, Eisenberg PD, Dagenais M, Fields A, Hagan K, Greenberg B, Colwell B, Zee B, Tu D, Ottaway J, Humphrey R, Seymour L. Comparison of Gemcitabine Versus the Matrix Metalloproteinase Inhibitor BAY 12-9566 in Patients With Advanced or Metastatic Adenocarcinoma of the Pancreas: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group, 3296
- Moore MJ, *see* Ernst DS
see Townsley CA
- Moore MR, *see* Fuchs CS
- Moore RL, *see* Kozelsky TF
- Morabito F, *see* Baldini L
- Morakkabati N, *see* Kuhl CK
- Morales F, *see* Maillou A
- Morales JA, *see* Bujanda DA
- Morales S, *see* Alberola V
- Morant R, *see* Hess V
- Moretti L, *see* Federico M
see Martelli M
- Morgan B, Thomas AL, Drevs J, Hennig J, Buchert M, Jivan A, Horsfield MA, Mross K, Ball HA, Lee L, Mietlowski W, Fuxius S, Unger C, O'Byrne K, Henry A, Cherryman GR, Laurent D, Dugan M, Marmé D, Steward WP. Dynamic Contrast-Enhanced Magnetic Resonance Imaging As a Biomarker for the Pharmacological Response of PTK787/ZK 222584, an Inhibitor of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, in Patients With Advanced Colorectal Cancer and Liver Metastases: Results From Two Phase I Studies, 3955
- Morgan E, *see* Bhatia S

AUTHOR INDEX

- Morgan MA, *see* Fracasso PM
- Morice P, Thoury A, Sabourin JC, Camatte S, Atallah D, Armand JP, Madelenat P, Duvillard P, Castaigne D. Unusual Abdominal and Pelvic Tumors: Spontaneous Regression of Peritoneal Implants in Borderline Ovarian Tumor After Salpingo-Oophorectomy, 3535
- Morimoto T, *see* Tominaga T
- Morino L, *see* Abruzzese E
- Morley A, *see* Marshall GM
- Mornex F, *see* Gérard J-P
- Morris LS, *see* Gonzalez MA
- Morrison VA. In Reply (correspondence), 3709
- Morrow GR, Hickok JT, Roscoe JA, Raubertas RF, Andrews PLR, Flynn PJ, Hynes HE, Banerjee TK, Kirshner JJ, King DK. Differential Effects of Paroxetine on Fatigue and Depression: A Randomized, Double-Blind Trial From the University of Rochester Cancer Center Community Clinical Oncology Program, 4635
- Morton DL, *see* Bilchik AJ
see Bleicher RJ
see Chung MH
see Kuo CT
see Wascher RA
- Morton KE, *see* Yang JC
- Morton RF, *see* Hurt RD
- Moskowitz CH, *see* Abrey LE
- Motohashi H, *see* Nashimoto A
- Motzer R, *see* Mazumdar M
- Motzer RJ. Renal Cell Carcinoma: A Priority Malignancy for Development and Study of Novel Therapies (editorial), 1193
- Motzer RJ, Sheinfeld J. Poor-Risk Testicular Cancer and High-Dose Chemotherapy (editorial), 4073
- Motzer RJ, *see* Donadio AC
- Moughan J, *see* Movsas B
- Moul JW, *see* Carter CA
see D'Amico AV
- Mounier N, *see* Bouabdallah R
see Coiffier B
- Mouridsen H, Gershanovich M, Sun Y, Pérez-Carrión R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Jaenicke F, Pluzanska A, Dank M, Becquart D, Bapsy PP, Salminen E, Snyder R, Chaudri-Ross H, Lang R, Wyld P, Bhatnagar A. Phase III Study of Letrozole Versus Tamoxifen as First-Line Therapy of Advanced Breast Cancer in Postmenopausal Women: Analysis of Survival and Update of Efficacy From the International Letrozole Breast Cancer Group, 2101
- Mourits MJE, *see* Berends MJW
- Mousses S, *see* Skotheim RI
- Movsas B, Moughan J, Komaki R, Choy H, Byhardt R, Langer C, Goldberg M, Graham M, Ettinger D, Johnstone D, Abrams R, Munden R, Starkschall G, Owen J. Radiotherapy Patterns of Care Study in Lung Carcinoma, 4553
- Moynihan TJ, *see* Harnett PR
- Mozzana R, *see* Zucca E
- Mozzillo N, *see* Palmieri G
- Mross K, *see* Morgan B
- Muggia F, *see* Formenti SC
see Hochster H
- Muggia FM. Boosting Bioavailability to Topotecan: What Do We Gain? (correspondence), 177
- Mughal TI, *see* Zucca E
- Mukherjee RK, *see* Shakespeare TP
- Mukhtar H, *see* Gupta S
- Mulder AH, *see* Doorduijn JK
- Mulholland PJ, *see* Darnton SJ
- Mulkerin D, *see* Takimoto CH
- Müller J, *see* Sønderkær S
- Müller O, *see* Ebert MPA
- Müller R-P, *see* Engert A
- Müller-Hermelink HK, *see* Engert A
see Sieber M
- Mulligan R, *see* Salgia R
see Soiffer R
- Mulne AF, *see* Bowers DC
- Multani PS, *see* Witzig TE
- Mumber M. Full-Impact Medicine (correspondence), 61s
- Mumber MP, *see* Schapira L
- Munck JN. Shorter is Not Better (correspondence), 1648
- Munden RF, *see* Erasmus JJ
see Movsas B
- Munsell M, *see* Okcu MF
- Munshi N, *see* Lee C-K
- Munster PN, *see* Buzdar A
- Muracciole X, *see* Tourani J-M
- Muramoto M, *see* Kattan MW
- Murawsky M, *see* Nabholz J-M
- Muriel AC, *see* Rauch PK
- Murray JL, *see* Puztai L
see Witzig TE
- Murray K, *see* Shaw E
- Murray PT, Ratain MJ. Estimation of the Glomerular Filtration Rate in Cancer Patients: A New Formula for New Drugs (editorial), 2633
- Muss H, *see* Randall ME
- Musselli C, *see* Slovin SF
- Muss H, *see* Randall ME
- Muss HB. Paris and New York: More in Common Than You Think! (editorial), 3189
- Muss HB, *see* Citron ML
see Henderson IC
see Kemeny MM
- Musto P, Falcone A, Sanpaolo G, Bodenizza C, Carella AM. Pamidronate for Early-Stage, Untreated Myeloma (correspondence), 3178
- Muto M, *see* Ishikura S
- Muwalla F, *see* Lee C-K
- Myers R, *see* Gridelli C

N

- Nabholtz J-M, Falkson C, Campos D, Szanto J, Martin M, Chan S, Pienkowski T, Zaluski J, Pinter T, Krzakowski M, Vorobiof D, Leonard R, Kennedy I, Azli N, Murawsky M, Riva A, Pouillart P. Docetaxel and Doxorubicin Compared With Doxorubicin and Cyclophosphamide as First-Line Chemotherapy for Metastatic Breast Cancer: Results of a Randomized, Multicenter, Phase III Trial, 968
- Nabholtz J-MA. In Reply (correspondence), 1190
- Nabulsi AA, *see* Carducci MA
- Nachman J. In Reply (correspondence), 1192
- Nademane AP, *see* Stein AS
- Nagai K, *see* Ando N
see Uchitomi Y
- Nagano H, *see* Yamamoto S
- Nagler A, *see* Federico M
- Naglie G, *see* Alibhai SMH
- Naidoo K, *see* Townsley CA
- Nakagawa A, *see* Matsubara T
- Nakagawa K, *see* Fukuoka M
- Nakajima T, *see* Nashimoto A
- Nakamori S, *see* Yamamoto S
- Nam R, *see* Alibhai SMH
- Nam RK, Zhang WW, Trachtenberg J, Diamandis E, Toi A, Emami M, Ho M, Sweet J, Evans A, Jewett MAS, Narod SA. Single Nucleotide Polymorphism of the Human Kallikrein-2 Gene Highly Correlates With Serum Human Kallikrein-2 Levels and in Combination Enhances Prostate Cancer Detection, 2312

AUTHOR INDEX

- Namer M, *see* Fumoleau P
- Nan B, *see* Green DM
- Nanduri VR, Lillywhite L, Chapman C, Parry L, Pritchard J, Vargha-Khadem F. Cognitive Outcome of Long-Term Survivors of Multisystem Langerhans Cell Histiocytosis: A Single-Institution, Cross-Sectional Study, 2961
- Nanni O, *see* Volpi A
- Nanni P, *see* Scotlandi K
- Naparstak E, *see* Goor O
- Napolitano M, *see* Palmieri G
- Nardi S, *see* Cruciani M
- Narod SA, *see* Nam RK
- Nascimento AG, *see* Oliveira AM
- Nash GM, Gimbel M, Shia J, Culliford AT, Nathanson DR, Ndubuisi M, Yamaguchi Y, Zeng ZS, Barany F, Paty PB. Automated, Multiplex Assay for High-Frequency Microsatellite Instability in Colorectal Cancer, 3105
- Nashimoto A, Nakajima T, Furukawa H, Kitamura M, Kinoshita T, Yamamura Y, Sasako M, Kunii Y, Motohashi H, Yamamoto S. Randomized Trial of Adjuvant Chemotherapy With Mitomycin, Fluorouracil, and Cytosine Arabinoside Followed by Oral Fluorouracil in Serosa-Negative Gastric Cancer: Japan Clinical Oncology Group 9206-1, 2282
- Nassif E, *see* Sigal JJ
- Nasti G, Talamini R, Antinori A, Martellotta F, Jacchetti G, Chiodo F, Ballardini G, Stoppini L, Di Perri G, Mena M, Tavio M, Vaccher E, D'Arminio Monforte A, Tirelli U. AIDS-Related Kaposi's Sarcoma: Evaluation of Potential New Prognostic Factors and Assessment of the AIDS Clinical Trial Group Staging System in the Haart Era—the Italian Cooperative Group on AIDS and Tumors and the Italian Cohort of Patients Naïve From Antiretrovirals, 2876
- Natale RB, *see* Unger JM
- Nathanson DR, *see* Nash GM
- Nathanson L, *see* Demierre M-F
- Nath AR, *see* Agrawal BL
see Agrawal RS
- Nativ O, *see* Laufer M
- Nattam SR, *see* Belani CP
- Naughton M, Davis M. Discussing Do-Not-Resuscitate Status: Furthering the Discourse (correspondence), 26s
- Naumann R, *see* Sieber M
- Naume B, *see* Wiedswang G
- Navarro M, *see* Bordeleau L
- Navarro S, *see* Ambros IM
- Ndubuisi M, *see* Nash GM
- Nealy KM, *see* Puzstai L
- Nebeker JR, *see* Ladewski LA
- Neese PY, *see* Slingluff CL Jr
- Neff P, Lyckholm L, Smith T. Truth or Consequences: What to Do When the Patient Doesn't Want to Know, 17s
- Neglia JP, *see* Baker KS
see Packer RJ
- Négrier S, *see* Culine S
- Nelson M, *see* Powles T
- Nemoz C, *see* Gérard J-P
- Nesland JM, *see* Skotheim RI
see Wiedswang G
- Neslon JB, *see* Carducci MA
- Neubauer A, *see* Schetelig J
- Neuberg D, *see* Salgia R
see Sledge GW
see Soiffer R
- Neumann A, *see* Stemmer SM
- Neuro-Oncology Working Group of the German Cancer Society. Neuro-Oncology Working Group 01 Trial of Nimustine Plus Teniposide Versus Nimustine Plus Cytarabine Chemotherapy in Addition to Involved-Field Radiotherapy in the First-Line Treatment of Malignant Glioma, 3276
- Neuwelt EA, *see* Ferreri AJM
- New P, *see* Batchelor T
- Newman N, *see* Gajra A
- Newton HB, *see* Grossman SA
- Neymark N, *see* Smit EF
- Neyroud-Caspar I, *see* Bouchardy C
- Ng HS, *see* Tan CK
- Ng K-K, *see* Yen T-C
- Ng T. Whether an Increase in Hemoglobin Above 12 g/dL Is of Clinical Benefit (correspondence), 2223
- Nguyen C, *see* Shariat SF
- Nguyen PL, *see* Jatoi A
- Nicholas MK, *see* Jaeckle KA
- Nicholl EJ, *see* Christian JA
- Nicholls J, *see* Huddart RA
- Nichols KE, *see* Breslow NE
- Nichols KE, Heath JA, Friedman D, Biegel JA, Ganguly A, Mauch P, Diller L. TP53, BRCA1, and BRCA2 Tumor Suppressor Genes Are Not Commonly Mutated in Survivors of Hodgkin's Disease With Second Primary Neoplasms, 4505
- Nicholson HS, *see* Glover DA
see Packer RJ
- Nicodemus CF, *see* Berek JS
- Nicolas B, *see* De Bernardi B
- Nicoletti G, *see* Scotlandi K
- Nicolucci A, *see* Sacco M
- Nieberg RK, *see* Young RC
- Niedzwiecki D, *see* Tepper JE
- Nielsen LB, *see* Sønderkær S
- Niemeyer C, *see* Seidemann K
- Nietert PJ, *see* Silvestri GA
- Nihei K, *see* Ishikura S
- Niland JC, *see* Stein AS
- Nilbert M, *see* Renkonen E
- Nilsson B, *see* Brandberg Y
- Nilsson J, *see* Brandberg Y
- Nimer SD, *see* Abrey LE
- Nisenbaum H, *see* Bedrosian I
- Nishimaki T, *see* Ando N
- Nishiwaki Y, *see* Fukuoka M
see Uchitomi Y
- Nissen NI, *see* Peterson BA
- Nissim O, *see* Mardor Y
- Nisticò C, *see* Papaldo P
- Nitschke R, Meyer WH, Huszti HC. When the Tumor Is Not the Target, Tell the Children (correspondence), 40s
- Niyikiza C, *see* Vogelzang NJ
- Noble WS, *see* Segal NH
- Noda K, *see* Fukuoka M
- Noguchi S, *see* Tominaga T
- Noguera R, *see* Ambros IM
- Nomura Y, *see* Tominaga T
- Nooter K, *see* Smorenburg CH
- Nora DT, *see* Bilchik AJ
- Norkool PA, *see* Breslow NE
see Green DM
- Norman A, *see* Christian JA
see Huddart RA
- Norris MD, *see* Marshall GM
- Norris R, *see* Breslow NE
- Nortier JWR, *see* Cella D
- Norton A, *see* Last KW

- Norton L, *see* Citron ML
see Henderson IC
see Parnes HL
see Weiss RB
- Nosari A, *see* Re A
- Novarino A, *see* Ladetto M
- Novick AC, *see* Majhail NS
- Novotny PJ, *see* Hurt RD
see Kozelsky TF
- Novotny WF, *see* Kabbinar F
- Noyes RD, *see* Alexander A
- Nunes RA, *see* Burstein HJ
- Nystedt M, Berglund G, Bolund C, Fornander T, Rutqvist LE. Side Effects of Adjuvant Endocrine Treatment in Premenopausal Breast Cancer Patients: A Prospective Randomized Study, 1836
- O**
- Oakervee H, *see* Taussig DC
- Oberlin O, *see* Bhatia S
see Pellegrino B
see Schleiermacher G
see Stewart RJ
- O'Brien S, *see* Giles FJ
see Kantarjian HM
- O'Brien SG, *see* Deining MWN
see Hahn EA
- O'Brien SM, *see* Giles FJ
- O'Byrne K, *see* Morgan B
see Swinson DEB
- Ochoa L, *see* Rowinsky EK
see Tolcher AW
- Ochs J, *see* Miller VA
- O'Connell M, *see* Tepper JE
- O'Connor LC, *see* Ayanian JZ
- O'Connor T, *see* Ward RL
- O'Donnell MR, *see* Stein AS
- Odrizola J, *see* Beaumont M
- O'Dwyer PJ, *see* Johnston PG
see Stevenson JP
- Oeffinger KC, Mertens AC, Sklar CA, Yasui Y, Fears T, Stovall M, Vik TA, Inskip PD, Robison LL. Obesity in Adult Survivors of Childhood Acute Lymphoblastic Leukemia: A Report from the Childhood Cancer Survivor Study, 1359
- O'Fallon JR, *see* Brown PD
see Buckner JC
- Offit K, *see* Kaklamani VG
see Levine DA
- Ogino T, *see* Ishikura S
- O'Grady J, *see* Leung TWT
- Ohali A, Avigad S, Cohen IJ, Meller I, Kollender Y, Issakov J, Gelernter I, Goshen Y, Yaniv I, Zaizov R. Association Between Telomerase Activity and Outcome in Patients With Nonmetastatic Ewing Family of Tumors, 3836
- Ohashi Y, *see* Tominaga T
- Ohno R, *see* Cheson BD
- Ohuri M, *see* Kattan MW
- Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H, Yamamichi N, Miyata Y, Ikeda N, Yamamoto S, Fukuda H, Yoshida S. Randomized Phase III Trial of Fluorouracil Alone Versus Fluorouracil Plus Cisplatin Versus Uracil and Tegafur Plus Mitomycin in Patients With Unresectable, Advanced Gastric Cancer: The Japan Clinical Oncology Group Study (JCOG9205), 54
- Ohtsu A, *see* Ishikura S
- Okamura H, *see* Uchitomi Y
- Okcu MF, Munsell M, Treuner J, Mattke A, Pappo A, Cain A, Ferrari A, Casanova M, Ozkan A, Raney B. Synovial Sarcoma of Childhood and Adolescence: A Multicenter, Multivariate Analysis of Outcome, 1602
- Okunieff P, *see* Chakravarti A
- Okuno SH, *see* Oliveira AM
- Oldenburg J, Alfsen GC, Lien HH, Aass N, Wæhre H, Fosså SD. Postchemotherapy Retroperitoneal Surgery Remains Necessary in Patients With Nonseminomatous Testicular Cancer and Minimal Residual Tumor Masses, 3310
- O'Leary MP, *see* Talcott JA
- O'Leary T, *see* Recklitis C
- Olencki TE, *see* Majhail NS
- Oliveira AM, Okuno SH, Nascimento AG, Lloyd RV. Skp2 Protein Expression in Soft Tissue Sarcomas, 722
- Oliver T, *see* Powles T
- Oliver VK, *see* Hussain MM
- Olivi A, Grossman SA, Tatter S, Barker F, Judy K, Olsen J, Bruce J, Hilt D, Fisher J, Piantadosi S. Dose Escalation of Carmustine in Surgically Implanted Polymers in Patients With Recurrent Malignant Glioma: A New Approaches to Brain Tumor Therapy CNS Consortium Trial, 1845
- Olivotto IA, Chua B, Allan SJ, Speers CH, Chia S, Ragaz J. Long-Term Survival of Patients With Supraclavicular Metastases at Diagnosis of Breast Cancer, 851
- Olivotto IA, Truong PT, Speers CH. Staging Reclassification Affects Breast Cancer Survival (correspondence), 4467
- Olkiewicz K, *see* Slovin SF
- Olmi P, *see* Gronchi A
- Olmes M, Alli P, Freedman A, Auster M, Erlich R. Hematologic Malignancies With Extramedullary Spread of Disease: Extra-Nodal Hodgkin's Disease Presenting as Rapidly Progressive Liver Failure, 1887
- Olopade OI, *see* Gray S
- Olschewski M, *see* de Haes H
- Olsen J, *see* Olivi A
- Olsen JH, *see* Skuladottir H
- Oltean G, *see* Zucca E
- Olvera N, *see* Levine DA
- O'Malley CD, *see* Cress RD
- Omer C, *see* Hamid O
- Omura G, *see* Buyse M
- Omura GA, Brady MF, Look KY, Averette HE, Delmore JE, Long HJ, Wadler S, Spiegel G, Arbuuck SG. Phase III Trial of Paclitaxel at Two Dose Levels, the Higher Dose Accompanied by Filgrastim at Two Dose Levels in Platinum-Pretreated Epithelial Ovarian Cancer: An Intergroup Study, 2843
- Omura GA. Modified Fibonacci Search (correspondence), 3177
- O'Neill A, *see* Batchelor T
see Grossman SA
- O'Neill BP, *see* Brown PD
- O'Neill S, *see* Ambros IM
- Ong YK, *see* Leong SS
- Ooi GC, *see* Chim CS
- Ooms ECM, *see* van Rhijn BWG
- Oosterwijk JC, *see* Kriege M
- Oo TH, Aish LS, Schneider D, Hassoun H. Uncommon Presentations of Malignancies: Carcinoid Tumor Presenting With Bone Marrow Metastases, 2993
- Oo TH, Aish LS, Schneider D, Hesketh PJ. Uncommon Hematologic Malignancies: Calcification in Untreated Primary Mediastinal Large B-Cell Lymphoma With Sclerosis, 4248
- Oppezzo P, *see* Vasconcelos Y
- O'Quigley J, *see* Vassal G
- Oram DH, *see* Skates SJ
- O'Reilly E, *see* Ilson DH
- O'Reilly S, *see* Hennessy BT

- Orenberg EK, *see* Leung TWT
 Orenstein A, *see* Mardor Y
 Orfao A, *see* Maíllo A
 Orlandi A, *see* Abruzzese E
 Orlandi G, *see* Abruzzese E
 Orvieto E, *see* Ferreri AJM
 Osborne CK, Arteaga CL. Role of Molecular and Genetic Markers in Breast Cancer Treatment Decisions, 285s
 Osborne CK, *see* Bardou V-J
 see Esteva FJ
 O'Shaughnessy JA, *see* Buzdar A
 Osinsky D, *see* Glehen O
 Osoba D, *see* Efficace F
 Osorio M, *see* Carr A
 Ossenkoppele GJ, *see* Doorduijn JK
 O'Sullivan B, *see* Groome PA
 Ota J, *see* Tominaga T
 Ott K, Fink U, Becker K, Stahl A, Dittler H-j, Busch R, Stein H, Lordfick F, Link T, Schwaiger M, Siewert J-R, Weber WA. Prediction of Response to Preoperative Chemotherapy in Gastric Carcinoma by Metabolic Imaging: Result of a Prospective Trial, 4604
 Ottaiano A, *see* Palmieri G
 Ottaway J, *see* Moore MJ
 Ottmann O, *see* Krauter J
 Oudard S, *see* Tourani J-M
 Ouldakci M, *see* Tourani J-M
 Overmoyer B. Combination Chemotherapy for Metastatic Breast Cancer: Reaching for the Cure (editorial), 580
 Overmoyer B, *see* Burstein HJ
 Owen J, *see* Movsas B
 Owens DP, *see* Kahn MJ
 Oza AM, *see* Rothenberg ML
 Ozaki T, Flege S, Kevric M, Linder N, Maas R, Delling G, Schwarz R, von Hochstetter AR, Salzer-Kuntschik M, Berdel WE, Jürgens H, Exner GU, Reichardt P, Mayer-Steinacker R, Ewerbeck V, Kotz R, Winkelmann W, Bielack SS. Osteosarcoma of the Pelvis: Experience of the Cooperative Osteosarcoma Study Group, 334
 Ozkan A, *see* Okcu MF
 Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R. Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study, 3194
 Ozols RF. Maintenance Therapy in Advanced Ovarian Cancer: Progression-Free Survival and Clinical Benefit (editorial), 2451
 Ozsahin M, *see* Zucca E
- P**
- Pacak K, *see* Padmanabhan H
 Pace A, Savarese A, Picardo M, Maresca V, Pacetti U, Del Monte G, Biroccio A, Leonetti C, Jandolo B, Cognetti F, Bove L. Neuroprotective Effect of Vitamin E Supplementation in Patients Treated With Cisplatin Chemotherapy, 927
 Pacetti U, *see* Pace A
 Pachipala KK, *see* Bucaloiu ID
 Packer R, *see* Blaney SM
 Packer RJ, Gurney JG, Punyko JA, Donaldson SS, Inskip PD, Stovall M, Yasui Y, Mertens AC, Sklar CA, Nicholson HS, Zeltzer LK, Neglia JP, Robison LL. Long-Term Neurologic and Neurosensory Sequelae in Adult Survivors of a Childhood Brain Tumor: Childhood Cancer Survivor Study, 3255
 Pacquement H, *see* Pellegrino B
 Padhani AR, *see* Galbraith SM
 Padley RJ, *see* Carducci MA
 Padmanabhan H, Ehrlich LD, Quazedo M, Fojo T, Louie A, Walther M, Pacak K. Unusual Locations of Involvement by Malignancies: Metastatic Pheochromocytoma to the Colon, 3368
 Pagliaro LC, Keyhani A, Williams D, Woods D, Liu B, Perrotte P, Slaton JW, Merritt JA, Grossman HB, Dinney CP. Repeated Intravesical Instillations of an Adenoviral Vector in Patients With Locally Advanced Bladder Cancer: A Phase I Study of p53 Gene Therapy, 2247
 Paidas CN, *see* Breneman JC
 Paik S, *see* Allegra CJ
 Pajak TF, *see* Hanks GE
 Paleologos N, *see* Abrey LE
 Palisaar J, *see* Augustin H
 Palmedo H, Manka-Waluch A, Albers P, Schmidt-Wolf IGH, Reinhardt M, Ezziddin S, Joe A, Roedel R, Fimmers R, Knapp FF Jr, Guhlke S, Biersack H-J. Repeated Bone-Targeted Therapy for Hormone-Refractory Prostate Carcinoma: Randomized Phase II Trial With the New, High-Energy Radiopharmaceutical Rhenium-188 Hydroxyethylidenediphosphonate, 2869
 Palmer JL, *see* Bruera E
 Palmer P, *see* Johnston SRD
 Palmieri G, Ascierto PA, Perrone F, Satriano SMR, Ottaiano A, Daponte A, Napolitano M, Caracò C, Mozzillo N, Melucci MT, Cossu A, Tanda F, Gallo C, Satriano RA, Castello G. Prognostic Value of Circulating Melanoma Cells Detected by Reverse Transcriptase-Polymerase Chain Reaction, 767
 Palumbo A, *see* Ladetto M
 Panageas KS, *see* Hwu W-J
 Panarello L, *see* Panasci L
 Panasci L, Stinson SF, Melnychuk D, Sandor V, Miller WH Jr, Batist G, Patenaude F, Bangash N, Panarello L, Alaoui-Jamali M, Sausville E. SarCNU, a Nitrosourea Analog on a Day 1, 5, and 9 Oral Schedule: A Phase I and Pharmacokinetic Study in Patients With Advanced Solid Tumors, 232
 Panasuk DB, Bauer TL, Davies AL, Schneider C, Flynn C. Common Malignancies With Uncommon Sites of Presentation: Anterior Mediastinal Rhabdomyosarcoma, 4455
 Panetta JC, *see* Edick MJ
 Panteix G, *see* Glehen O
 Pantel K, *see* Lugo TG
 Panzini I, *see* Tassinari D
 Paoletti P, *see* Vogelzang NJ
 Papadimitrakopoulou VA, *see* Rudin CM
 Papadopolous N, *see* Vadhan-Raj S
 Papadopoulos T, *see* Rödel C
 Papaldo P, Lopez M, Cortesi E, Cammilluzzi E, Antimi M, Terzoli E, Lepidini G, Vici P, Barone C, Ferretti G, Di Cosimo S, Nisticò C, Carlini P, Conti F, Di Lauro L, Botti C, Vitucci C, Fabi A, Giannarelli D, Marolla P. Addition of Either Lonidamine or Granulocyte Colony-Stimulating Factor Does Not Improve Survival in Early Breast Cancer Patients Treated With High-Dose Epirubicin and Cyclophosphamide, 3462
 Pape H, *see* Burdach S
 Pape U-F, *see* Faiss S
 Pappo AS, Meza JL, Donaldson SS, Wharam MD, Wiener ES, Qualman SJ, Maurer HM, Crist WM. Treatment of Localized Nonorbital, Nonparameningeal Head and Neck Rhabdomyosarcoma: Lessons Learned From Intergroup Rhabdomyosarcoma Studies III and IV, 638
 Pappo AS, *see* Breneman JC
 see Okcu MF
 Paradiso A, *see* Volpi A
 Pardo J, *see* Garcia-Rostan G
 Parellada C, *see* Chenal M
 Parham DM, *see* Breneman JC
 Parisi R, *see* Mertens WC

AUTHOR INDEX

- Park ER, *see* Earle CC
see Emmons KM
- Park S-H, *see* Lee Y-H
- Parker LM, *see* Burststein HJ
- Parker P, *see* Stein AS
- Parker RA, *see* Gollob JA
- Parliament MB, *see* Segal RJ
- Parmar M, *see* Buyse M
- Parnes HL, Cirrincione C, Aisner J, Berry DA, Allen SL, Abrams J, Chuang E, Cooper MR, Perry MC, Duggan DB, Sztatrowski TP, Henderson IC, Norton L. Phase III Study of Cyclophosphamide, Doxorubicin, and Fluorouracil (CAF) Plus Leucovorin Versus CAF for Metastatic Breast Cancer: Cancer and Leukemia Group B 9140, 1819
- Parr AL, *see* Allegra CJ
- Parry L, *see* Nanduri VR
- Partridge AH, Wang PS, Winer EP, Avorn J. Nonadherence to Adjuvant Tamoxifen Therapy in Women With Primary Breast Cancer, 602
- Parulekar W, *see* Ernst DS
- Parwaresch R, *see* Krams M
see Seidemann K
- Pascale C, *see* De Micheli C
- Pasche B, *see* Kaklamani VG
- Pashos CL, *see* Hu JC
- Pasini F, *see* Ferreri AJM
- Pasmantier MW, *see* Altorki NK
- Passik S, *see* Fisch MJ
- Pastorek J, *see* Swinson DEB
- Pastorino U, *see* Sozzi G
- Patchell R, Tibbs PA, Regine WF, Payne R, Saris S, Kryscio RJ, Young B. A Randomized Trial of Direct Decompressive Surgical Resection in the Treatment of Spinal Cord Compression Caused by Metastasis, 237s
- Patel J, *see* Gupta S
- Patel S, *see* Vadhan-Raj S
- Patel SR, *see* Pisters PWT
- Patenaude F, *see* Panasci L
- Pater JL, Pritchard KI. Optimal Chemotherapy for Women With Breast Cancer: The Plot Thickens (editorial), 963
- Pater JL, *see* Yee KWL
- Pathmanathan R, *see* Schneider DT
- Paties CT, *see* Cappuzzo F
- Patnaik A, *see* Rowinsky EK
see Tolcher AW
- Patt CH, *see* Yoo HY
- Patt YZ, Hassan MM, Lozano RD, Brown TD, Vauthey JN, Curley SA, Ellis LM. Phase II Trial of Systemic Continuous Fluorouracil and Subcutaneous Recombinant Interferon Alfa-2b for Treatment of Hepatocellular Carcinoma, 421
- Patterson BJ, *see* Tsang RW
- Patterson JW, *see* Slingluff CL Jr
- Paty PB, *see* Nash GM
- Paul A, *see* Garbe C
- Paul J, *see* Propper DJ
- Pauler DK, *see* Ganz PA
- Pauli M, *see* Rossi G
- Paulus U, *see* Sieber M
- Pautard B, *see* Aladjidi N
- Pautas C, *see* Boissel N
- Pavlidis P, *see* Segal NH
- Pavone-Macaluso M, *see* Colombo R
- Pawlicki M, *see* Rosen LS
- Payne R, *see* Patchell R
- Pazdur R, *see* Hirschfeld S
see Johnson JR
- Pearlman A, *see* Shaw E
- Pearlman JL, *see* Grossman SA
- Pearson ADJ, *see* Ambros IM
- Pearson M, *see* Bannerji R
- Pedicini V, *see* Masci G
- Peeters KCMJ, van de Velde CJH. Improving Treatment Outcome for Gastric Cancer: The Role of Surgery and Adjuvant Therapy, 272s
- Peeters KCMJ, *see* van de Velde CJH
see Wong JEL
- Pegram L, *see* Himelstein BP
- Pei D, *see* Kishi S
- Pein F, *see* Vassal G
- Pellegrini C, *see* Buttitta F
- Pellegrini F, *see* Sacco M
- Pellegrino B, Terrier-Lacombe MJ, Oberlin O, Leblanc T, Perel Y, Bertrand Y, Beard C, Edan C, Schmitt C, Plantaz D, Pacquement H, Vannier JP, Lambilliotte C, Couillault G, Babin-Boilletot A, Thuret I, Demeocq F, Leverger G, Delsol G, Landman-Parker J. Lymphocyte-Predominant Hodgkin's Lymphoma in Children: Therapeutic Abstention After Initial Lymph Node Resection—A Study of the French Society of Pediatric Oncology, 2948
- Pelley RJ, *see* Meropol NJ
- Pelosi G, *see* Sozzi G
- Pels H, Schmidt-Wolf IGH, Glasmacher A, Schulz H, Engert A, Diehl V, Zellner A, Schackert G, Reichmann H, Kroschinsky F, Vogt-Schaden M, Egerer G, Bode U, Schaller C, Deckert M, Fimmers R, Helmstaedter C, Atasoy A, Klockgether T, Schlegel U. Primary Central Nervous System Lymphoma: Results of a Pilot and Phase II Study of Systemic and Intraventricular Chemotherapy With Deferred Radiotherapy, 4489
- Peltomäki P. Role of DNA Mismatch Repair Defects in the Pathogenesis of Human Cancer, 1174
- Peltomäki P, *see* Renkonen E
- Pelzer H, *see* Vokes EE
- Pendergrass TW, *see* Green DM
- Penson DF, Feng Z, Kuniyuki A, McClerran D, Albertsen PC, Deapen D, Gilliland F, Hoffman R, Stephenson RA, Potosky AL, Stanford JL. General Quality of Life 2 Years Following Treatment for Prostate Cancer: What Influences Outcomes? Results From the Prostate Cancer Outcomes Study, 1147
- Penson DF, Stanford JL. In Reply (correspondence), 4655
- Perdichizzi S, *see* Scotlandi K
- Pereira JR, *see* Fossella F
- Perel Y, *see* Aladjidi N
see Boissel N
see Pellegrino B
- Perez E, *see* Formenti SC
- Perez EA, *see* Citron ML
- Pérez R, *see* Carr A
- Pérez-Carrión R, *see* Mouridsen H
- Perez-Ruixo JJ, *see* Johnston SRD
see Cohen SJ
- Perez W, *see* Miller VA
- Perkins GH, *see* Woodward WA
- Perkkio M, *see* Poutanen T
- Perlman EJ, *see* Breslow NE
- Perotti J, *see* Winer EP
- Perren TJ, *see* Wright EP
- Perrone F, *see* Gridelli C
see Palmieri G
- Perrotte P, *see* Pagliaro LC
- Perry J, *see* Chester JD
- Perry JC, *see* Sigal JJ
- Perry JR, Cairncross JG. Glioma Therapies: How to Tell Which Work? (editorial), 3547
- Perry MC, *see* Belani CP
see Parnes HL

AUTHOR INDEX

- Pervez H, Potti A, Mehdi SA. Challenging and Unusual Cases: Simultaneous Presentation of Acute Myelogenous Leukemia and Acute Myocardial Infarction, 1416
- Pervez H, Shaikh M, Potti A, Mehdi SA. Uncommon Presentations of Non-Hodgkin's Lymphoma: Primary Renal Lymphoma, 564
- Pescarmona GE, *see* Martelli M
- Peschel C, *see* Weber WA
- Peshkin BN, Isaacs C, Finch C, Kent S, Schwartz MD. Tamoxifen As Chemoprevention in BRCA1 and BRCA2 Mutation Carriers With Breast Cancer: A Pilot Survey of Physicians, 4322
- Peshkin BN, *see* Schwartz MD
- Pession A, *see* De Bernardi B
see Indolfi P
- Pestalozzi BC. Looking at the Dying Patient: The Ferdinand Hodler Paintings of Valentine Godé-Darel, 74s
- Peter M, *see* Schleiermacher G
- Peters B, *see* Schneider-Stock R
- Petersen L, *see* Ganz PA
- Petersen V, *see* Weber WA
- Peterson AC, Harlin H, Gajewski TF. Immunization With Melan-A Peptide-Pulsed Peripheral Blood Mononuclear Cells Plus Recombinant Human Interleukin-12 Induces Clinical Activity and T-Cell Responses in Advanced Melanoma, 2342
- Peterson BA, Petroni GR, Frizzera G, Barcos M, Bloomfield CD, Nissen NI, Hurd DD, Henderson ES, Sartiano GP, Johnson JL, Holland JF, Gottlieb AJ. Prolonged Single-Agent Versus Combination Chemotherapy in Indolent Follicular Lymphomas: A Study of the Cancer and Leukemia Group B, 5
- Peterson BA, *see* Duggan DB
- Peterson BL, *see* Kemeny MM
- Peterson BM Jr, *see* Mandelblatt JS
- Peterson G, *see* Markman M
- Peterson P, *see* Buzdar A
- Peters WA III, *see* Unger JM
- Peto R, *see* Clarke M
- Petrone S, *see* Small EJ
- Petroni GR, *see* Duggan DB
see Peterson BA
see Slingluff CL Jr
- Petros WP, *see* Stevenson JP
- Petrow P, *see* Culine S
- Peyrat P, *see* Glehen O
- Pezzullo JC, *see* Barbey JT
- Pfeffer MR, *see* Stemmer SM
- Pfeffer R, *see* Mardor Y
- Pfister C, *see* Tourani J-M
- Pfister DG, *see* Bennett CL
- Pfistner B, *see* Engert A
- Phan S-C, *see* Mehta MP
- Philip PA, *see* El-Rayes BF
- Philip T, *see* Schleiermacher G
- Phillips RS, *see* McCarthy EP
- Phipps E, True G, Harris D, Chong U, Tester W, Chavin SI, Braitman LE. Approaching the End of Life: Attitudes, Preferences, and Behaviors of African-American and White Patients and Their Family Caregivers, 549
- Pho L, *see* Yee KWL
- Piantadosi S, *see* Olivi A
- Piantadosi F, *see* Gridelli C
- Picardo M, *see* Pace A
- Piccart-Gebhart MJ. Mathematics and Oncology: A Match for Life? (editorial), 1425
- Piccart MJ, *see* Therasse P
- Picci P, *see* Ferrari S
see Scotlandi K
see Serra M
- Pichard-Léandri E, *see* Alimi D
- Pichon F, *see* Laithier V
- Pickles T, *see* Hack TF
- Picus J, *see* Taplin M-E
- Piedbois P, *see* André T
- Pienkowski T, *see* Nabholz J-M
- Pierani P, *see* Indolfi P
- Pierotti M, *see* Bertario L
see Sozzi G
- Pieters R, *see* Den Boer ML
see Heath JA
- Pietro Paolo M, *see* Repetto L
- Piguet C, *see* Aladjidi N
see Boissel N
- Pike JA, *see* Hoskins PJ
- Pilepich M, *see* Chakravarti A
- Pilepich MV, *see* Kozelsky TF
- Pileri A, *see* Ladetto M
- Pileri SA, *see* Martelli M
- Pilotti S, *see* Moliterni A
- Pinder SE, *see* Gonzalez MA
- Pinedo HM, *see* Kuenen BC
- Pingpank JF, *see* Feldman AL
- Pink D, *see* Kretzschmar A
- Pinotti G, *see* Zucca E
- Pinter T, *see* Nabholz J-M
- Pintilie M, *see* Tsang RW
- Pippen JE Jr, *see* Buzdar A
- Pirker R, *see* Pohl G
- Pirnia F, *see* Ratschiller D
- Pisters PWT, Ballo MT, Fenstermacher MJ, Feig BW, Hunt KK, Raymond KA, Burgess MA, Zagars GK, Pollock RE, Benjamin RS, Patel SR. Phase I Trial of Preoperative Concurrent Doxorubicin and Radiation Therapy, Surgical Resection, and Intraoperative Electron-Beam Radiation Therapy for Patients With Localized Retroperitoneal Sarcoma, 3092
- Pitot H, *see* Goetz MP
- Piva L, *see* Indolfi P
- Pivot X, *see* Culine S
see Zelek L
- Pizer BL, *see* Taylor RE
- Pizzo B, *see* Miller VA
- Plaisance N, *see* Herida M
- Plantaz D, *see* Pellegrino B
- Pless M, *see* Betticher DC
- Plomer K, *see* Coyne CA
- Pluda J, *see* Thomas JP
- Plunkett T, *see* Harper P
- Plunkett W, *see* Kantarjian HM
see Tempero M
- Pluzanska A, *see* Fossella F
see Mouridsen H
- Pohl G, Rudas M, Dietze O, Lax S, Markis E, Pirker R, Zielinski CC, Hausmaninger H, Kubista E, Samonigg H, Jakesz R, Filipits M. High p27^{Kip1} Expression Predicts Superior Relapse-Free and Overall Survival for Premenopausal Women With Early-Stage Breast Cancer Receiving Adjuvant Treatment With Tamoxifen Plus Goserelin, 3594
- Poirier M, Fraser R, Meterissian S. Unusual Abdominal and Pelvic Tumors: Aggressive Angiomyoma of the Pelvis: Response to Luteinizing Hormone-Releasing Hormone Agonist, 3535
- Poizot-Martin I, *see* Herida M
- Pollack A. A Call for More With a Desire for Less: Pelvic Radiotherapy With Androgen Deprivation in the Treatment of Prostate Cancer (editorial), 1899

AUTHOR INDEX

- Pollack A, Grignon DJ, Heydon KH, Hammond EH, Lawton CA, Mesic JB, Fu KK, Porter AT, Abrams RA, Shipley WU. Prostate Cancer DNA Ploidy and Response to Salvage Hormone Therapy After Radiotherapy With or Without Short-Term Total Androgen Blockade: An Analysis of RTOG 8610, 1238
- Pollack A, *see* Chakravarti A
- Pollack IF, *see* Jaeckle KA
- Pollan M, *see* Garcia-Rostan G
- Pollio B, *see* Ladetto M
- Pollock BH, *see* Thomas CT
- Pollock RE, *see* Pisters PWT
- Polo E, *see* Andrés R
- Polsky D, Mandelblatt JS, Weeks JC, Venditti L, Hwang Y-T, Glick HA, Hadley J, Schulman KA. Economic Evaluation of Breast Cancer Treatment: Considering the Value of Patient Choice, 1139
- Pond GR, *see* Townsley CA
- Pontes JE, *see* Messing EM
- Ponzoni M, *see* Ferreri AJM
- Poole J, *see* Chenal M
- Poortmans PH, *see* Haas RLM
- Poortmans PMP, Kluijn-Nelemans HC, Haaxma-Reiche H, Veer MV, Hansen M, Soubeyran P, Taphoorn M, Thomas J, Van den Bent M, Fickers M, Van Imhoff G, Rozewicz C, Teodorovic I, van Glabbeke M. High-Dose Methotrexate-Based Chemotherapy Followed by Consolidating Radiotherapy in Non-AIDS-Related Primary Central Nervous System Lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial, 20962
- Popat U, *see* Massarweh S
- Poplack DG, *see* Blaney SM
- Porcellini A, *see* Schouten HC
- Porcher R, *see* Delanian S
- Port JL, *see* Altorki NK
- Portenoy RK, *see* Indelicato RA
- Porter A, *see* Hanks GE
- Porter AT, *see* Pollack A
- Porter PA, *see* Hurt RD
- Portugal L, *see* Vokes EE
- Possinger K, *see* Tremblay P-B
- Postma TJ, *see* Vos MJ
- Potosky AL, *see* Penson DF
- Pötschger U, *see* Ambros IM
see Kager L
- Potthoff K, *see* Bertz H
see Finke J
- Potti A, *see* Ganti AK
see Malik AA
see Pervez H
see Ramar K
- Pouillart P, *see* Nabholz J-M
- Poulsen M, Rischin D, Walpole E, Harvey J, Mackintosh J, Ainslie J, Hamilton C, Keller J, Tripcony L. High-Risk Merkel Cell Carcinoma of the Skin Treated With Synchronous Carboplatin/Etoposide and Radiation: A Trans-Tasman Radiation Oncology Group Study—TROG 96: 07, 4371
- Poulson MJ. Not Just Tired, 1125
- Poupon J, *see* Raffoux E
- Pourny C, *see* Fumoleau P
- Poutanen T, Tikanoja T, Riikonen P, Silvast A, Perkkio M. Long-Term Prospective Follow-Up Study of Cardiac Function After Cardiotoxic Therapy for Malignancy in Children, 2349
- Powers J, *see* Kouroukis CT
- Powles T, Bower M, Daugaard G, Shamash J, De Ruiter A, Johnson M, Fisher M, Anderson J, Mandalia S, Stebbing J, Nelson M, Gazzard B, Oliver T. Multicenter Study of Human Immunodeficiency Virus-Related Germ Cell Tumors, 1922
- Powles TJ, *see* Winer EP
- Pozza LD, *see* Marshall GM
- Prados M, *see* Jaeckle KA
- Prados MD, *see* Lang FF
- Pratt CB, *see* Rodriguez-Galindo C
- Premkumar A, *see* Hussain MM
- Prentice A, *see* Glasmacher A
- Prescott R, *see* Kunkler I
- Press M, *see* Formenti SC
- Press OW, *see* Ganz PA
- Prevot G, *see* Tourani J-M
- Price K, *see* Crivellari D
see Wallgren A
- Price P, *see* Propper DJ
- Price PM, *see* Anderson HL
see Rustin GJS
- Priet R, *see* Batchelor T
- Pringle J, *see* Strauss SJ
- Priore RL, *see* Havrilesky L
- Priou F, *see* Culine S
- Pritchard J, *see* Nanduri VR
- Pritchard K, *see* Crump M
- Pritchard KI, Levine MN, Tu D. *neu/erB-2* Overexpression and Response to Hormonal Therapy in Premenopausal Women in the Adjuvant Breast Cancer Setting: Will It Play in Peoria? Part II (editorial), 399
- Pritchard KI. In Reply (correspondence), 2445
- Pritchard KI, *see* Bordeleau L
see Goodwin PJ
see Pater JL
see Therasse P
see Winer EP
- Pritchard-Jones K, Kelsey A, Vujanic G, Imeson J, Hutton C, Mitchell C. Older Age Is an Adverse Prognostic Factor in Stage I, Favorable Histology Wilms' Tumor Treated With Vincristine Monotherapy: A Study by the United Kingdom Children's Cancer Study Group, Wilms' Tumor Working Group, 3269
- Pritsch O, *see* Vasconcelos Y
- Pro B, *see* Khouri IF
see Seymour JF
- Pronk WG, Baars JP, de Jong PC, Westermann AM. Some Unusual Paraneoplastic Syndromes: Digital Ulceration as a Paraneoplastic Syndrome in Ovarian Cancer, 2620
- Proper K, *see* Messing EM
- Propper DJ, de Bono J, Saleem A, Ellard S, Flanagan E, Paul J, Ganesan TS, Talbot DC, Aboagye EO, Price P, Harris AL, Twelves C. Use of Positron Emission Tomography in Pharmacokinetic Studies to Investigate Therapeutic Advantage in a Phase I Study of 120-Hour Intravenous Infusion XR5000, 203
- Pross M, *see* Schneider-Stock R
- Proulx GM, *see* Varma GN
- Provencio M, *see* Alberola V
see Zucca E
- Provenzale J, *see* Gururangan S
- Provenzale JM, *see* Quinn JA
- Provenzi M, *see* De Bernardi B
- Pui C-H, *see* Edick MJ
see Kishi S
- Pui C-H. Toward Optimal Nervous System-Directed Treatment in Childhood Acute Lymphoblastic Leukemia (editorial), 179
- Puleo E, *see* Emmons KM
- Punglia RS, Kuntz KM, Lee JH, Recht A. Radiation Therapy Plus Tamoxifen Versus Tamoxifen Alone After Breast-Conserving Surgery in Postmenopausal Women With Stage I Breast Cancer: A Decision Analysis., 2260
- Punyko JA, *see* Packer RJ

- Puopolo M, *see* Yousef GM
 Purow BW, *see* Fine HA
 Puzstai L, Ayers M, Simmans FW, Damokosh A, Hess K, Valero V, Clark E, Ross J, Hortobagyi GN, Stec J. Emerging Science: Prospective Validation of Gene Expression Profiling-Based Prediction of Complete Pathologic Response to Neoadjuvant paclitaxel/FAC Chemotherapy in Breast Cancer, 237s
 Puzstai L, Zhen JH, Arun B, Rivera E, Whitehead C, Thompson WJ, Nealy KM, Gibbs A, Symmans WF, Esteva FJ, Booser D, Murray JL, Valero V, Smith TL, Hortobagyi GN. Phase I and II Study of Exisulind in Combination With Capecitabine in Patients With Metastatic Breast Cancer, 3454
 Puzstai L, *see* Rivera E
- Q**
- Qian W, *see* Schouten HC
 Qin J, *see* Kolb EA
 Quade BJ, *see* Crum CP
 Qualman SJ, *see* Breneman JC
 see Pappo AS
 Quattrone P, *see* Licitra L
 Quazedo M, *see* Padmanabhan H
 Quella S, *see* Coyne CA
 Quinn CJ, *see* Hwu W-J
 Quinn J, *see* Gururangan S
 Quinn JA, Reardon DA, Friedman AH, Rich JN, Sampson JH, Provenzale JM, McLendon RE, Gururangan S, Bigner DD, Herndon JE II, Avgeropoulos N, Finlay J, Tourt-Uhlig S, Affronti ML, Evans B, Stafford-Fox V, Zaknoen S, Friedman HS. Phase II Trial of Temozolomide in Patients With Progressive Low-Grade Glioma, 646
 Quinney HA, *see* Segal RJ
 Quintini G, Barbera V, Franco V, Florena AM, Spadola V, Mariani G. Uncommon Presentations of Non-Hodgkin's Lymphoma: Intravascular Large B-Cell Lymphoma Diagnosis on Prostate Biopsy, 564
 Qvist H, *see* Wiedswang G
- R**
- Rabaud C, *see* Herida M
 Radelbauer K, *see* Stift A
 Rademaker A, *see* Kaklamani VG
 Rademaker AW, *see* Vokes EE
 Raderer M, *see* Scheithauer W
 Radice P, *see* Bertario L
 Radlowski D, *see* Varterasian M
 Radvanyi F, *see* van Rhijn BWG
 Raffoux E, Rousselot P, Poupon J, Daniel M-T, Cassinat B, Delarue R, Taksin A-L, Réa D, Buzyn A, Tibi A, Lebbé G, Cimerman P, Chomienne C, Ferman J-P, de Thé H, Degos L, Hermine O, Dombret H. Combined Treatment With Arsenic Trioxide and All-*Trans*-Retinoic Acid in Patients With Relapsed Acute Promyelocytic Leukemia, 2326
 Ragaz J, *see* Bryce C
 see Olivotto IA
 Raggio M, *see* Hussain MM
 Raghavan D. New Prognostic Factors for Stage I Testicular Cancer: But Will They Make It to Broadway? (editorial), 4075
 Ragupathi G, *see* Slovin SF
 Rahal D, *see* Monti M
 Rahaman JA, *see* Levine DA
 Rai SN, *see* Tyc VL
 Raich P, *see* Coyne CA
 Raisch DW, *see* Ladewski LA
 Raiz P, *see* Simon C
 Rajan KB, *see* McTiernan A
 Raja V, Bessman D. Uncommon Presentations of Malignancies: Tumor Implantation After Pneumonectomy for Lung Cancer, 2993
 Raja V, Campbell GA. Unusual Cases Involving the CNS and Nasal Sinuses: Sinonasal Undifferentiated Carcinoma, 3875
 Raja V, Lin JT, Xiao S-Y. Unusual Abdominal Tumors: Intra-Abdominal Desmoplastic Small Round Cell Tumor, 950
 Rajeshkumar B, *see* Taplin M-E
 Rajkumar SV, *see* Loprinzi CL
 Rajput A, Loud PA, Gibbs JF, Kraybill WG. Diagnostic Challenges in Patients With Tumors: Gossypiboma (foreign body) Manifesting 30 Years After Laparotomy, 3700
 Rakowski W, *see* Ganz PA
 Ramalingam S, *see* Laufer M
 Ramanathan RK, *see* Rothenberg ML
 see Takimoto CH
 Ramanathan RK, Clark JW, Kemeny NE, Lenz H-J, Gococo KO, Haller DG, Mitchell EP, Kardinal CG. Safety and Toxicity Analysis of Oxaliplatin Combined With Fluorouracil or as a Single Agent in Patients With Previously Treated Advanced Colorectal Cancer, 2904
 Ramar K, Potti A, Mehdi SA. Uncommon Syndromes and Treatment Manifestations of Malignancy: Periorbital Edema and Imatinib Mesylate Therapy for Chronic Myelogenous Leukemia, 172
 Ramlau R, *see* Fossella F
 Ramondetta LM, Sills D. Spirituality and Religion in the "Art of Dying," 4460
 Ramos R, *see* Fumoleau P
 Ramsay NKC, *see* Baker KS
 Ramsey HC, *see* George DW
 Randall ME, Brunetto G, Muss H, Mannel RS, Spirtos N, Jeffrey F, Thigpen JT, Benda J. Whole Abdominal Radiotherapy Versus Combination Doxorubicin-Cisplatin Chemotherapy in Advanced Endometrial Carcinoma: A Randomized Phase III Trial of the Gynecologic Oncology Group, 237s
 Randall TC, Armstrong K. Differences in Treatment and Outcome Between African-American and White Women With Endometrial Cancer, 4200
 Raney B, *see* Okcu MF
 Ranganathan S, *see* Cohen SJ
 Rankin K, *see* Weber D
 Ranson M, *see* Danson S
 Rao A, *see* Mehta MP
 Rao MS, *see* Johnston PG
 Rapiti E, *see* Bouchardey C
 Rapoport B, *see* de Wit R
 Raquin M-A, *see* Laithier V
 see Le Deley M-C
 Rassner G, *see* Garbe C
 Ratain MJ, *see* Murray PT
 see Sawyer MB
 Ratcliffe C, *see* Sozzi G
 Ratschiller D, Heighway J, Gugger M, Kappeler A, Pirnia F, Schmid RA, Borner MM, Betticher DC. Cyclin D1 Overexpression in Bronchial Epithelia of Patients With Lung Cancer Is Associated With Smoking and Predicts Survival, 2085
 Rau B, Sturm I, Lage H, Berger S, Schneider U, Hauptmann S, Wust P, Riess H, Schlag PM, Dörken B, Daniel PT. Dynamic Expression Profile of *p21^{WAF1/CIP1}* and *Ki-67* Predicts Survival in Rectal Carcinoma Treated With Preoperative Radiochemotherapy, 3391
 Raubertas RF, *see* Morrow GR
 Rauch PK, Muriel AC, Cassem NH. Parents With Cancer: Who's Looking After the Children?, 117s
 Ravaioli A, *see* Tassinari D
 Ravelli A, *see* Rossi G

AUTHOR INDEX

- Ravindranath Y. Down Syndrome and Acute Myeloid Leukemia: The Paradox of Increased Risk for Leukemia and Heightened Sensitivity to Chemotherapy (editorial), 3385
- Ray-Coquard I, *see* Marec-Berard P
- Raymakers R, *see* Lokhorst HM
- Raymond KA, *see* Pisters PWT
- Rayon C, *see* Beaumont M
- Rayson D. Adjuvant Chemotherapy For Women With Young Children: Our Patients as Parents, 114s
- Rayson D. Sweet Time Unafflicted, 46s
- Rayson D, Reyno L. Exercise and Cancer: No Pain, Some Gain? (editorial), 1651
- Rayson D, Steele P, Collins K, Babineau T. Hereditary Breast Cancer: Shared Communication and Care (correspondence), 4660
- Razavi D, Merckaert I, Marchal S, Libert Y, Conradt S, Boniver J, Etienne A-M, Fontaine O, Janne P, Klastersky J, Reynaert C, Scalliet P, Slachmuylder J-L, Delvaux N. How to Optimize Physicians' Communication Skills in Cancer Care: Results of a Randomized Study Assessing the Usefulness of Posttraining Consolidation Workshops, 3141
- Re A, Cattanco C, Michieli M, Casari S, Spina M, Rupolo M, Allione B, Nosari A, Schiantarelli C, Viganò M, Izzi I, Ferremi P, Lanfranchi A, Mazzuccato M, Carosi G, Tirelli U, Rossi G. High-Dose Therapy and Autologous Peripheral-Blood Stem-Cell Transplantation As Salvage Treatment for HIV-Associated Lymphoma in Patients Receiving Highly Active Antiretroviral Therapy, 4423
- Réa D, *see* Raffoux E
- Reaman G, *see* Bhatia S
- Reardon D, *see* Gururangan S
- Reardon DA, *see* Quinn JA
- Recant W, *see* Cohen EEW
see Rudin CM
- Recht A, *see* Punglia RS
- Recklitis C, O'Leary T, Diller L. Utility of Routine Psychological Screening in the Childhood Cancer Survivor Clinic, 787
- Redding SW, *see* Meropol NJ
- Redman BG, *see* Chang AE
see Clark JI
- Reed E, *see* Hussain MM
- Reed JC, *see* Bannerji R
- Regine WF, *see* Patchell R
- Reich J, *see* Kaklamani VG
- Reichardt P, *see* Kager L
see Ozaki T
- Reichart P, *see* Kretzschmar A
- Reichle A, *see* Haferlach T
- Reichmann H, *see* Pels H
- Reid G, *see* Gallion HH
- Reid JM, *see* Goetz MP
- Reid RD, *see* Segal RJ
- Reineke T, *see* Sieber M
- Reines S, *see* Hesketh PJ
- Reinhardt M, *see* Palmedo H
- Reisch JS, *see* Bowers DC
- Reiter A, *see* Bürger B
see Seidemann K
- Reitsma D, *see* Rosen LS
- Relling MV, *see* Edick MJ
see Kishi S
- Remick SC, *see* Takimoto CH
- Reni M, *see* Ferreri AJM
- Renkonen E, Zhang Y, Lohi H, Salovaara R, Abdel-Rahman WM, Nilbert M, Aittomäki K, Järvinen HJ, Mecklin J-P, Lindblom A, Peltomäki P. Altered Expression of *MLH1*, *MSH2*, and *MSH6* in Predisposition to Hereditary Nonpolyposis Colorectal Cancer, 3629
- Renner H, *see* Engert A
- Rennke H, *see* Ebert B
- Renschler MF, *see* Mehta MP
- Repetto L, Gianni W, Pietropaolo M. In Reply (correspondence), 754
- Reuter V, *see* Mazumdar M
- Reverter-Branchat G, *see* Serra M
- Rey A, *see* Stewart RJ
- Reynaert C, *see* Razavi D
- Reyno L, *see* Ernst DS
see Rayson D
- Ribas A, Butterfield LH, Glaspy JA, Economou JS. Current Developments in Cancer Vaccines and Cellular Immunotherapy, 2415
- Ribeiro RC, *see* Edick MJ
- Ribrag V, *see* Bouabdallah R
- Ribuffo D, *see* Gradilone A
- Ricca I, *see* Ladetto M
- Rice TW, *see* Majhail NS
- Rich J, *see* Gururangan S
- Rich JN, *see* Quinn JA
- Richards S, *see* Clarke M
- Richardson D, *see* Swinson DEB
- Rick O, *see* Schmoll H-J
- Ridwelski K, *see* Köhne C-H
- Riecken E-O, *see* Daum S
- Riecken EO, *see* Faiss S
- Riehm H, *see* Bürger B
see Seidemann K
- Riess H, *see* Rau B
- Rigatti P, *see* Colombo R
- Rigault de la Longrais IA, *see* Yousef GM
- Riikonen P, *see* Poutanen T
- Riley BD, *see* Lynch HT
- Rinaldi D, *see* Belani CP
see Fuchs CS
- Ring A, Webb A, Ashley S, Allum WH, Ebbs S, Gui G, Sacks NP, Walsh G, Smith IE. Is Surgery Necessary After Complete Clinical Remission Following Neoadjuvant Chemotherapy for Early Breast Cancer, 4540
- Ring J, *see* Hauschild A
- Rini BI, Weinberg V, Bok R, Small EJ. Prostate-Specific Antigen Kinetics as a Measure of the Biologic Effect of Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Serologic Progression of Prostate Cancer, 99
- Rios MB, *see* Kantarjian HM
- Ripamonti C, Brunelli C. Randomized Clinical Trial of an Implantable Drug Delivery System Compared With Comprehensive Medical Management for Refractory Cancer Pain: Impact on Pain, Drug-Related Toxicity, and Survival (correspondence), 2802
- Ris H-B, *see* Betticher DC
- Rischin D, *see* Fukuoka M
see Mac Manus MP
see Poulsen M
- Risse M-L, *see* Vassal G
- Ritchey ML, *see* Breslow NE
- Riva A, *see* Nabholz J-M
- Rivera E, Valero V, Arun B, Royce M, Adinin R, Hoelzer K, Walters R, Wade JL III, Pusztai L, Hortobagyi GN. Phase II Study of Pegylated Liposomal Doxorubicin in Combination With Gemcitabine in Patients With Metastatic Breast Cancer, 3249
- Rivera E, *see* Pusztai L
- Rivera GK, *see* Edick MJ
- Riviere A, *see* Fizazi K
- Rixe O, *see* Tourani J-M
- Rizel S, *see* Stemmer SM
- Rizzo A, *see* De Bernardi B
- Rizzo J, *see* Rowinsky EK
- Rizzo JD, Cella D, Seidenfeld J. In Reply (correspondence), 2224

- Rizzo JD, *see* Bierman PJ
see Serna DS
- Rizzoli V, *see* Giuliani N
- Rizzo M, *see* Martelli M
- Roa W, *see* Mehta MP
- Roach M III, DeSilvio M, Lawton C, Uhl V, Machtay M, Seider MJ, Rotman M, Jones C, Asbell SO, Valicenti RK, Han S, Thomas CR Jr, Shipley WS. Phase III Trial Comparing Whole-Pelvic Versus Prostate-Only Radiotherapy and Neoadjuvant Versus Adjuvant Combined Androgen Suppression: Radiation Therapy Oncology Group 9413, 1904
- Roach M, *see* Chakravarti A
- Robbiati SF, *see* Gridelli C
- Robbins A, *see* Anderson HL
see Weiss RB
- Robbins JM, *see* Sigal JJ
- Robert L, *see* Fizazi K
- Roberts JT, *see* Fosså SD
- Robertson KA, *see* George DW
- Roberts PJ, *see* Heinrich MC
- Roberts TG Jr, Lynch TJ Jr, Chabner BA. The Phase III Trial in the Era of Targeted Therapy: Unraveling the “Go or No Go” Decision, 3683
- Robinson K, *see* Taylor RE
- Robinson RA, *see* Clark JA
- Robison LL, *see* Baker KS
see Bhatia S
see Glover DA
see Green DM
see Oeffinger KC
see Packer RJ
- Robson ME, *see* Levine DA
- Rocca M, *see* Briccoli A
- Rocco A, *see* Ebert MPA
- Rochard F, *see* Zelek L
- Rochlitz C, *see* Jantschke P
- Röcken C, *see* Ebert MPA
- Rödel C, Grabenbauer GG, Papadopoulos T, Hohenberger W, Schmoll H-J, Sauer R. Phase I/II Trial of Capecitabine, Oxaliplatin, and Radiation for Rectal Cancer, 3098
- Rödel C, Meyer M. In Reply (correspondence), 3003
- Rodríguez E, *see* Carr A
- Rodríguez-Galindo C, Wilson MW, Haik BG, Merchant TE, Billups CA, Shah N, Cain A, Langston J, Lipson M, Kun LE, Pratt CB. Treatment of Intraocular Retinoblastoma With Vincristine and Carboplatin, 2019
- Rodríguez MA, *see* Seymour JF
- Rodríguez R, *see* Stein AS
- Rodrigus P, *see* Mehta MP
- Roedel R, *see* Palmedo H
- Roessner A, *see* Schneider-Stock R
- Roetzer L, *see* Chao C
- Rogatko A, *see* Cohen SJ
- Rogers-Freezer L, *see* Yang JC
- Rognum TO, *see* Diep CB
- Rohatiner AZS, *see* Last KW
see Taussig DC
- Roila F, *see* Hesketh PJ
- Rollin B. Invited Commentary, 124s
- Romaguera J, *see* Seymour JF
- Roman-Gomez J, Castillejo JA, Jimenez A, Cervantes F, Boque C, Hermosin L, Leon A, Grañena A, Colomer D, Heiniger A, Torres A. Cadherin-13, a Mediator of Calcium-Dependent Cell-Cell Adhesion, Is Silenced by Methylation in Chronic Myeloid Leukemia and Correlates With Pretreatment Risk Profile and Cytogenetic Response to Interferon Alfa, 1472
- Romano G, *see* Tartarone A
- Romero P, *see* Smith JW II
- Romestaing P, *see* Fumoleau P
see Gérard J-P
- Rondelli R, *see* Indolfi P
- Roots I, *see* Tremblay P-B
- Rosado MF, Donna E, Ahn YS. Challenging Problems in Advanced Malignancy: Imatinib Mesylate-Induced Interstitial Pneumonitis, 3168
- Rosai J, *see* Gronchi A
- Roscoe JA, *see* Morrow GR
- Rosell R, *see* Alberola V
- Rosen F, *see* Cohen EEW
- Rosen FR, *see* Vokes EE
- Rosen LS, Gordon D, Tchekmedyan S, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, de Souza P, Zheng M, Urbanowitz G, Reitsma D, Seaman JJ. Zoledronic Acid Versus Placebo in the Treatment of Skeletal Metastases in Patients With Lung Cancer and Other Solid Tumors: A Phase III, Double-Blind, Randomized Trial—The Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group, 3150
- Rosen LS, *see* Meropol NJ
- Rosen M, *see* Stevenson JP
- Rosenberg SA, *see* Yang JC
- Rosenthal AN, *see* Skates SJ
- Rosenthal G, Gomori JM, Tobias S, Diment J, Shoshan Y. Unusual Cases Involving the CNS and Nasal Sinuses: Primary Leptomeningeal Melanoma, 3875
- Rosenthal SA, *see* Hanks GE
- Rose PG. Combined-Modality Therapy of Locally Advanced Cervical Cancer, 211s
- Rose PG, *see* Cannistra SA
- Rosetti P, *see* Volpi A
- Rösler N, *see* Tremblay P-B
- Ross J, *see* Pusztai L
- Ross JS, *see* Zemzoum I
- Ross M, *see* Slingluff CL Jr
- Rossi A, *see* Ferreri AJM
see Gridelli C
- Rossi E, *see* Cappuzzo F
- Rossi G, *see* Re A
- Rossi G, Lucioni M, Sammarchi L, Pauli M, Beluffi G, Martini A, Ravelli A. Uncommon Syndromes and Treatment Manifestations of Malignancy: Unusual Association of Lupus and Sarcoma, 166
- Rosthøj S, *see* Schmiegelow K
- Roth AD, *see* Betticher DC
see Hess V
- Rothenberg ML, Berlin JD. Therapeutic Strategies for Metastatic Colorectal Cancer: Simultaneous, Sequential, or Specific? (editorial), 3716
- Rothenberg ML, Liu PY, Braly PS, Wilczynski SP, Hannigan EV, Wadler S, Stuart G, Jiang C, Markman M, Alberts DS. Combined Intraperitoneal and Intravenous Chemotherapy for Women With Optimally Debulked Ovarian Cancer: Results From an Intergroup Phase II Trial, 1313
- Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK, Hart LL, Gupta S, Garay CA, Burger BG, Le Bail N, Haller DG. Superiority of Oxaliplatin and Fluorouracil-Leucovorin Compared With Either Therapy Alone in Patients With Progressive Colorectal Cancer After Irinotecan and Fluorouracil-Leucovorin: Interim Results of a Phase III Trial, 2059
- Rothenberg ML, *see* Meropol NJ
- Rothwell DM, *see* Groome PA
- Roth Y, *see* Mardor Y
- Roti G, *see* Giuliani N
- Rotman M, *see* Roach M III
- Rourke MT, *see* Kazak AE
- Rousseau P. Death Denial, 52s
- Rousseau P. Spirituality and the Dying Patient, 54s
- Rousselot P, *see* Boissel N
see Raffoux E

AUTHOR INDEX

- Rowinsky EK, Rizzo J, Ochoa L, Takimoto CH, Forouzes B, Schwartz G, Hammond LA, Patnaik A, Kwiatek J, Goetz A, Denis L, McGuire J, Tolcher AW. Phase I and Pharmacokinetic Study of Pegylated Camptothecin as a 1-Hour Infusion Every 3 Weeks in Patients With Advanced Solid Malignancies, 148
- Rowinsky EK. Challenges of Developing Therapeutics That Target Signal Transduction in Patients With Gynecologic and Other Malignancies, 175s
- Rowinsky EK, *see* Cannistra SA
see Meropol NJ
see Sledge GW
see Takimoto CH
see Tolcher AW
- Rowland JH, *see* Meropol NJ
- Roy P, *see* Zucca E
- Royce M, *see* Rivera E
- Roychowdhury D. Phase I Trials: Physician and Patient Perceptions (correspondence), 4658
- Roychowdhury DF, Hayden A, Liepa AM. Health-Related Quality-of-Life Parameters as Independent Prognostic Factors in Advanced or Metastatic Bladder Cancer, 673
- Roz E, *see* Sozzi G
- Roz L, *see* Sozzi G
- Rozewicz C, *see* Poortmans PMP
- Rubie H, *see* Laithier V
see Schleiermacher G
- Rubin A, *see* Strair RK
- Rubin J, *see* Goetz MP
- Rubino C, *see* Alimi D
- Rubinstein WS, *see* Kaklamani VG
see Lynch HT
- Rubnitz J, *see* Kishi S
- Ruchoux M-M, *see* Laithier V
- Rückle H, *see* Köhne C-H
- Rudas M, *see* Pohl G
- Rudenstam C-M, *see* Crivellari D
- Rudin CM, Cohen EEW, Papadimitrakopoulou VA, Silverman S Jr, Recant W, El-Naggar AK, Stenson K, Lippman SM, Hong WK, Vokes EE. An Attenuated Adenovirus, ONYX-015, As Mouthwash Therapy for Pre-malignant Oral Dysplasia, 4546
- Rudolph P, *see* Krams M
- Rue M, *see* Dalton VK
see Schnoll RA
- Ruedy S. Commentary, 116s
- Rueffer U, *see* Sieber M
- Ruether JD, *see* Hack TF
see Townsley CA
- Ruffie P, *see* Vogelzang NJ
- Ruffié P, *see* Fizazi K
- Ruggieri P, *see* Bacci G
- Ruiz-Casado A, *see* Alberola V
- Rumpler S, *see* Ambros IM
- Rupolo M, *see* Re A
- Rusch V, *see* Downey RJ
see Ilson DH
see Lugo TG
- Rusch VW. Pemetrexed and Cisplatin for Malignant Pleural Mesothelioma: A New Standard of Care? (editorial), 2629
- Rush R, *see* Wright EP
- Russo A, *see* Bertario L
- Rusthoven JJ, *see* Scagliotti GV
see Vogelzang NJ
- Rustin GJS. Use of CA-125 to Assess Response to New Agents in Ovarian Cancer Trials, 187s
- Rustin GJS, Galbraith SM, Anderson H, Stratford M, Folkes LK, Sena L, Gumbrell L, Price PM. Phase I Clinical Trial of Weekly Combretastatin A4 Phosphate: Clinical and Pharmacokinetic Results, 2815
- Rustin GJS, *see* Cannistra SA
see Galbraith SM
- Rutgers EJT, *see* Kriege M
- Rutqvist LE, *see* Nystedt M
- Rutt A, *see* Abraham J
- Ruyman FB, *see* Bhatia S
see Green DM
- Ryan CW, *see* Villano JL
- Ryan PD, *see* Burstein HJ

S

- Sabloff BS, *see* Erasmus JJ
- Sabourin JC, *see* Morice P
- Sacchi S, *see* Baldini L
- Sacco M, Valentini M, Belfiglio M, Pellegrini F, De Berardis G, Franciosi M, Nicolucci A. Randomized Trial of 2 Versus 5 Years of Adjuvant Tamoxifen for Women Aged 50 Years or Older With Early Breast Cancer: Italian Interdisciplinary Group for Cancer Evaluation Study of Adjuvant Treatment in Breast Cancer 01, 2276
- Sacks NP, *see* Ring A
- Saenz A, *see* Andrés R
- Saenz EC, *see* Belda-Iniesta C
- Saglio G, *see* Cilloni D
- Saiag P. Recommendations for an Effective Follow-Up Strategy in Melanoma Patients Should Be Tailored to the Investigations Performed During Initial Staging (correspondence), 3706
- Sailer S, *see* Hutchinson RJ
- Saito H, *see* Ohtsu A
- Sakamoto M, *see* Shimamura T
- Sakon M, *see* Yamamoto S
- Sala P, *see* Bertario L
- Saleem A, *see* Propper DJ
- Salgia R, Lynch T, Skarin A, Lucca J, Lynch C, Jung K, Hodi FS, Jaklitsch M, Mentzer S, Swanson S, Lukanich J, Bueno R, Wain J, Mathisen D, Wright C, Fidias P, Donahue D, Clift S, Hardy S, Neuberg D, Mulligan R, Webb I, Sugarbaker D, Mihm M, Dranoff G. Vaccination With Irradiated Autologous Tumor Cells Engineered to Secrete Granulocyte-Macrophage Colony-Stimulating Factor Augments Antitumor Immunity in Some Patients With Metastatic Non-Small-Cell Lung Carcinoma, 624
- Salgia R, *see* Brown JR
see Irie HY
- Saliba RM, *see* Khouri IF
- Sallan SE, *see* Dalton VK
see Goldberg JM
see Lipshultz SE
- Salminen E, *see* Mouridsen H
- Salminen EK, *see* Mac Manus MP
- Salonia A, *see* Colombo R
- Salovaara R, *see* Renkonen E
- Salter J, *see* Johnston SRD
- Saltz LB. Another Study of How to Give Fluorouracil? (editorial), 3711
- Salvatore S, *see* Buttitta F
- Salzberg M, *see* Hess V
- Salzer-Kuntschik M, *see* Kager L
see Ozaki T
- Sames D, *see* Slovin SF
- Samlowski WE, *see* Alexander A
- Sammarchi L, *see* Rossi G
- Sammarelli G, *see* Giuliani N
- Samonigg H, *see* Pohl G
see Schmid M

AUTHOR INDEX

- Sampson JH, *see* Quinn JA
 Samson Y, *see* Dalton VK
 Samur M, Bozcuk HS. Paradigm Shift in Adjuvant Treatment of Receptor Positive Premenopausal Breast Cancer Patients? Not Yet! (correspondence), 2444
 Sanchez AR, *see* Belda-Iniesta C
 Sanchez J, *see* Ferreri AJM
 Sánchez JJ, *see* Alberola V
 Sandison A, *see* Strauss SJ
 Sandler A, *see* Masters GA
 see Miller VA
 Sandler HM, *see* Hanks GE
 Sandlund JT, *see* Edick MJ
 see Kishi S
 Sandor V, *see* Panasci L
 San Miguel J, *see* Beaumont M
 Sanpaolo G, *see* Musto P
 Santamarta D, *see* Maíllo A
 Santinami M, *see* Gronchi A
 Santini D, *see* Tonini G
 Santoro A, *see* Bernardi D
 see Masci G
 see Monti M
 Santoro N, *see* Indolfi P
 Santos A, *see* Vassal G
 Santos-Briz A, *see* Maíllo A
 Sanz M, *see* Beaumont M
 Sanz MA, *see* Cheson BD
 Sappino A-P, *see* Bouchardy C
 Sargent D, *see* Allegra C
 Sariban E, *see* Laithier V
 Sarina B, *see* Masci G
 Saris S, *see* Patchell R
 Sarmiento UB, *see* Bujanda DA
 Sarosy G, *see* Hussain MM
 Sarris AH, *see* Zucca E
 Sartiano GP, *see* Peterson BA
 Sartor CI, *see* Citron ML
 Sartor O, *see* Ladewski LA
 Sartori S, *see* Tassinari D
 Sasako M. Principles of Surgical Treatment for Curable Gastric Cancer, 274s
 Sasako M, *see* Nashimoto A
 see Wong JEL
 Sæter G, *see* Skotheim RI
 Sather H, *see* Heath JA
 see Hutchinson RJ
 Sato Y, *see* Shimamura T
 Satriano RA, *see* Palmieri G
 Satriano SMR, *see* Palmieri G
 Sauerbrei W, *see* de Haes H
 Sauerland MC, *see* Büchner T
 see Haferlach T
 Sauer R, *see* Classen J
 see Rödel C
 Sauer T, *see* Wiedswang G
 Sausville E, *see* Panasci L
 Sautter-Bihl M-L, *see* Classen J
 Savarese A, *see* Pace A
 Saven A, *see* Goodman GR
 Sawka CA, *see* Bordeleau L
 Sawyer MB, Ratain MJ, Bertucci D, Smith RP, Schilsky RL, Vogelzang NJ, Shulman K, Douglass EC, Fleming GF. Phase I Study of an Oral Formulation of ZD9331 Administered Daily for 28 Days, 1859
 Sayagués JM, *see* Maíllo A
 Sayer HG, *see* Schetelig J
 Sayre DM, *see* Chang AE
 Scagliotti GV, Shin D-M, Kindler HL, Vasconcelles MJ, Keppler U, Manegold C, Burris H, Gatzemeier U, Blatter J, Symanowski JT, Rusthoven JJ. Phase II Study of Pemetrexed With and Without Folic Acid and Vitamin B₁₂ as Front-Line Therapy in Malignant Pleural Mesothelioma, 1556
 Scalliet P, *see* Razavi D
 Scaravaglio P, *see* Cilloni D
 Scardino PT, *see* Begg CB
 see Kattan MW
 see Shariat SF
 Scarpa S, *see* Gradilone A
 Scarpi E, *see* Volpi A
 Schaafsma MR, *see* Doorduijn JK
 Schaar D, *see* Strair RK
 Schackert G, *see* Pels H
 Schadendorf D, *see* Hauschild A
 Schaefer PL, *see* Hurt RD
 Schäfer P, *see* Bouchardy C
 Schaller C, *see* Pels H
 Schapira L. An Existential Oncologist, 77s
 Schapira L, Eisenberg PD, MacDonald N, Mumber MP, Loprinzi CL. A Revisitation of "Doc, How Much Time Do I Have?", 8s
 Schechter NR, *see* Woodward WA
 Scheffold C, *see* Schetelig J
 Scheinberg DA, *see* Weiss MA
 Scheithauer BW, *see* Brown PD
 see Buckner JC
 Scheithauer W, Kornek GV, Raderer M, Schüll B, Schmid K, Kovats E, Schneeweiss B, Lang F, Lenauer A, Depisch D. Randomized Multicenter Phase II Trial of Two Different Schedules of Capecitabine Plus Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer, 1307
 Scheithauer W, *see* Köhne C-H
 Schelenz C, *see* Tremblay P-B
 Schell M, *see* Marec-Berard P
 Schenkein D, *see* Vose JM
 Scher HI, *see* Slovin SF
 Schetelig J, Thiede C, Bornhäuser M, Schwerdtfeger R, Kiehl M, Beyer J, Sayer HG, Kröger N, Hensel M, Scheffold C, Held TK, Höffken K, Ho AD, Kienast J, Neubauer A, Zander AR, Fauser AA, Ehninger G, Siegert W. Evidence of a Graft-Versus-Leukemia Effect in Chronic Lymphocytic Leukemia After Reduced-Intensity Conditioning and Allogeneic Stem-Cell Transplantation: The Cooperative German Transplant Study Group, 2747
 Schiantarelli C, *see* Re A
 Schiavetti A, *see* Indolfi P
 Schiff D, *see* Jaeckle KA
 Schiffer CA. Differences in Outcome in Adolescents With Acute Lymphoblastic Leukemia: A Consequence of Better Regimens? Better Doctors? Both? (editorial), 760
 Schiffer CA, *see* Cheson BD
 Schild HH, *see* Kuhl CK
 Schild SE, Stella PJ, Geyer SM, Bonner JA, McGinnis WL, Mailliard JA, Brindle J, Jatoi A, Jett JR. The Outcome of Combined-Modality Therapy for Stage III Non-Small-Cell Lung Cancer in the Elderly, 3201
 Schiller JH. Platin or No Platin? That Is the Question (editorial), 3009
 Schiller JH, *see* Thomas JP
 Schiller P, *see* Engert A
 Schilsky RL. Hurry Up and Wait: Is Accelerated Approval of New Cancer Drugs in the Best Interests of Cancer Patients? (editorial), 3718
 Schilsky RL, *see* Citron ML
 see Henderson IC
 see Sawyer MB
 Schink JC, *see* Wadler S
 Schitteck B, *see* Garbe C

- Schittulli F, *see* Volpi A
 Schlag PM, *see* Rau B
 Schlagenhauff B, *see* Garbe C
 Schlegelberger B, *see* Haferlach T
 Schlegel U, *see* Pels H
 Schleicher J, *see* Schmoll H-J
 Schliermacher G, Peter M, Oberlin O, Philip T, Rubie H, Mechinaud F, Sommelet-Olive D, Landman-Parker J, Bours D, Michon J, Delattre O. Increased Risk of Systemic Relapses Associated With Bone Marrow Micrometastasis and Circulating Tumor Cells in Localized Ewing Tumor, 85
 Schleucher N, *see* Schmoll H-J
 Schlichting E, *see* Wiedswang G
 Schmid K, *see* Scheithauer W
 Schmid M, Jakesz R, Samonigg H, Kubista E, Gnant M, Menzel C, Seifert M, Haider K, Taucher S, Mlineritsch B, Steindorfer P, Kwasny W, Stierer M, Tausch C, Fridrik M, Wette V, Steger G, Hausmaninger H. Randomized Trial of Tamoxifen Versus Tamoxifen Plus Aminoglutethimide as Adjuvant Treatment in Postmenopausal Breast Cancer Patients With Hormone Receptor-Positive Disease: Austrian Breast and Colorectal Cancer Study Group Trial 6, 984
 Schmid RA, *see* Betticher DC
 see Ratschiller D
 Schmidberger H, *see* Classen J
 Schmidt B, *see* Weber WA
 Schmidt BF, *see* Engert A
 Schmidt C, *see* de Wit R
 Schmidt-Wolf IGH, *see* Glasmacher A
 see Palmedo H
 see Pels H
 Schmiegelow K, Björk O, Glomstein A, Gustafsson G, Keiding N, Kristinsson J, Mäkiperna A, Rosthøj S, Szumlanski C, Sørensen TM, Weinsilboum R. Intensification of Mercaptopurine/Methotrexate Maintenance Chemotherapy May Increase the Risk of Relapse for Some Children With Acute Lymphoblastic Leukemia, 1332
 Schmiegelow K, *see* Sønderkær S
 Schmiegelow M, *see* Sønderkær S
 Schmitt C, *see* Pellegrino B
 Schmitt JL, *see* Carducci MA
 Schmitt M, *see* Zenzoum I
 Schmitz N, *see* Bierman PJ
 Schmitz S-FH, *see* Betticher DC
 Schmoll H-J, Kollmannsberger C, Metzner B, Hartmann JT, Schleucher N, Schöffski P, Schleicher J, Rick O, Beyer J, Hossfeld D, Kanz L, Berdel WE, Andreessen R, Bokemeyer C. Long-Term Results of First-Line Sequential High-Dose Etoposide, Ifosfamide, and Cisplatin Chemotherapy Plus Autologous Stem Cell Support for Patients With Advanced Metastatic Germ Cell Cancer: An Extended Phase I/II Study of the German Testicular Cancer Study Group, 4083
 Schmoll H-J, *see* Köhne C-H
 see Rödel C
 Schmoor C, *see* Finke J
 Schmutzler R, *see* Kuhl CK
 Schnall M, *see* Stevenson JP
 Schneeweiss B, *see* Scheithauer W
 Schneider C, *see* Panasuk DB
 Schneider D, *see* Oo TH
 Schneider DT, Calaminus G, Wessalowski R, Pathmanathan R, Selle B, Sternschulte W, Harms D, Göbel U. Ovarian Sex Cord–Stromal Tumors in Children and Adolescents, 2357
 Schneider DT, *see* Calaminus G
 Schneider KM, *see* Groome PA
 Schneider-Stock R, Boltze C, Lasota J, Miettinen M, Peters B, Pross M, Roessner A, Günther T. High Prognostic Value of *p16^{INK4}* Alterations in Gastrointestinal Stromal Tumors, 1688
 Schneider U, *see* Rau B
 Schnell L, *see* Coyne CA
 Schnipper HH. Life After Breast Cancer, 104s
 Schnipper LE, *see* Emanuel EJ
 Schnittger S, *see* Haferlach T
 Schnoll RA, Zhang B, Rue M, Krook JE, Spears WT, Marcus AC, Engstrom PF. Brief Physician-Initiated Quit-Smoking Strategies for Clinical Oncology Settings: A Trial Coordinated by the Eastern Cooperative Oncology Group, 355
 Schoch C, *see* Büchner T
 see Haferlach T
 Schoenberg MP, *see* Laufer M
 Schöffski P, *see* Köhne C-H
 see Schmoll H-J
 Schonwetter R, *see* Extermann M
 Schorin M, *see* Dalton VK
 Schouten HC, Qian W, Kvaloy S, Porcellini A, Hagberg H, Johnsen HE, Doorduyn JK, Sydes MR, Kvalheim G. High-Dose Therapy Improves Progression-Free Survival and Survival in Relapsed Follicular Non-Hodgkin's Lymphoma: Results From the Randomized European CUP Trial, 3918
 Schouten HC, *see* Lokhorst HM
 Schrading S, *see* Kuhl CK
 Schramel F, *see* Smit EF
 Schrappe M, *see* Bürger B
 see Seidemann K
 Schraub S, *see* Fumoleau P
 Schueller G, *see* Stift A
 Schuler B, *see* Takimoto CH
 Schüll B, *see* Scheithauer W
 Schuller DE, *see* Adelstein DJ
 Schulman CC, *see* Carducci MA
 Schulman KA, *see* Meropol NJ
 see Polsky D
 Schulte K-W, *see* Hauschild A
 Schultes BC, *see* Berek JS
 Schultz C, *see* Mehta MP
 Schulze H, *see* Albers P
 Schulze K, *see* Groome PA
 Schulz H, *see* Pels H
 Schumacher M, *see* de Haes H
 Schumer ST, Cannistra SA. Granulosa Cell Tumor of the Ovary, 1180
 Schumock GT, *see* Ladewski LA
 Schupak K, *see* Wolden SL
 Schwaiger M, *see* Ott K
 see Weber WA
 Schwartz G, *see* Rowinsky EK
 see Tolcher AW
 Schwartz MD, Kaufman E, Peshkin BN, Isaacs C, Hughes C, DeMarco T, Finch C, Lerman C. Bilateral Prophylactic Oophorectomy and Ovarian Cancer Screening Following *BRCA1/BRCA2* Mutation Testing, 4034
 Schwartz MD, *see* Peshkin BN
 Schwartzentruber DJ, *see* Goorin AM
 see Yang JC
 Schwarz JB, *see* Slovin SF
 Schwarz M, *see* Garbe C
 Schwarz R, *see* Ozaki T
 Schwerdtfeger R, *see* Schetelig J
 Schwinger W, *see* Kerbl R
 Scolyer R, *see* Featherstone C
 Scorilas A, *see* Diamandis EP
 see Yousef GM
 Scotlandi K, Manara MC, Strammiello R, Landuzzi L, Benini S, Perdichizzi S, Serra M, Astolfi A, Nicoletti G, Lollini P-L, Bertoni F, Nanni P, Picci P. *c-kit* Receptor Expression in Ewing's Sarcoma: Lack of Prognostic Value but Therapeutic Targeting Opportunities in Appropriate Conditions, 1952

- Scotlandi K, *see* Serra M
- Scott C, *see* Shaw E
- Scott CG, *see* Segal RJ
- Scuderi N, *see* Gradilone A
- Seaman JJ, *see* Rosen LS
see Small EJ
- Seamans DP, Wong GY, Wilson JL. Interventional Pain Therapy for Intractable Abdominal Cancer Pain, 92s
- See L-C, *see* Yen T-C
- Seffert P, *see* Fumoleau P
- Segal NH, Pavlidis P, Noble WS, Antonescu CR, Viale A, Wesley UV, Busam K, Gallardo H, DeSantis D, Brennan MF, Cordon-Cardo C, Wolchok JD, Houghton AN. Classification of Clear-Cell Sarcoma as a Subtype of Melanoma by Genomic Profiling, 1775
- Segal RJ, Reid RD, Courneya KS, Malone SC, Parliament MB, Scott CG, Venner PM, Quinney HA, Jones LW, D'Angelo MES, Wells GA. Resistance Exercise in Men Receiving Androgen Deprivation Therapy for Prostate Cancer, 1653
- Segeren CM, *see* Lokhorst HM
- Seidemann K, Tiemann M, Lauterbach I, Mann G, Simonitsch I, Stanke-witz K, Schrappe M, Zimmermann M, Niemeyer C, Parwaresch R, Riehm H, Reiter A. Primary Mediastinal Large B-Cell Lymphoma With Sclerosis in Pediatric and Adolescent Patients: Treatment and Results From Three Therapeutic Studies of the Berlin-Frankfurt-Münster Group, 1782
- Seidenfeld J, *see* Rizzo JD
- Seider MJ, *see* Roach M III
- Seidman AD. Sequential Single-Agent Chemotherapy for Metastatic Breast Cancer: Therapeutic Nihilism or Realism? (editorial), 577
- Seifert M, *see* Schmid M
- Seipp CA, *see* Yang JC
- Sekeres MA, Chernoff M, Lynch TJ Jr, Kasendorf EI, Lasser DH, Greenberg DB. The Impact of a Physician Awareness Group and the First Year of Training on Hematology-Oncology Fellows, 3676
- Sekihara H, *see* Shimamura T
- Sela R, *see* Bordeleau L
- Selby PJ, *see* Wright EP
- Selle B, *see* Schneider DT
- Sellers TA, *see* Ebbert JO
- Sena L, *see* Galbraith SM
see Rustin GJS
- Senie R, *see* Mandelblatt JS
- Senn H-J, *see* Crivellari D
see Goldhirsch A
see Kaufmann M
- Senzon R, *see* Strair RK
- Seong C-M, *see* Lee Y-H
- Sequist LV, Lynch TJ. Aggressive Treatment for the Fit Elderly With Non-Small-Cell Lung Cancer? Yes! (editorial), 3186
- Serdar CM, *see* Meropol NJ
- Serin D, *see* Fumoleau P
- Serna DS, Lee SJ, Zhang M-j, Baker KS, Eapen M, Horowitz MM, Klein JP, Rizzo JD, Loberiza FR Jr. Trends in Survival Rates After Allogeneic Hematopoietic Stem-Cell Transplantation for Acute and Chronic Leukemia by Ethnicity in the United States and Canada, 3754
- Serpelloni G, *see* Cruciani M
- Serra M, Scotlandi K, Reverter-Branchat G, Ferrari S, Manara MC, Benini S, Incaprerà M, Bertoni F, Mercuri M, Briccoli A, Bacci G, Picci P. Value of P-Glycoprotein and Clinicopathologic Factors as the Basis for New Treatment Strategies in High-Grade Osteosarcoma of the Extremities, 536
- Serra M, *see* Scotlandi K
- Serve HL, *see* Büchner T
- Sethna K, *see* Mohamed F
- Setola E, *see* Bacci G
- Sexton W, *see* Carter CA
- Seymour JF, Pro B, Fuller LM, Manning JT, Hagemester FB, Romaguera J, Rodriguez MA, Ha CS, Smith TL, Ayala A, Hess M, Cox JD, Cabanillas F, McLaughlin P. Long-Term Follow-Up of a Prospective Study of Combined Modality Therapy for Stage I-II Indolent Non-Hodgkin's Lymphoma, 2115
- Seymour JF, *see* Zucca E
- Seymour L, *see* Gridelli C
see Moore MJ
see Townsley CA
- Seymour MT, *see* Chester JD
- Seynaeve C, *see* Meijers-Heijboer H
see van Oostrom I
- Sezer O, *see* Tremblay P-B
- Shaffer K, *see* Brown JR
see Ebert B
see Irie HY
- Shafqat A, Yum M-N, Abanour R, Ganjoo KN. Unusual Locations of Involvement by Malignancies: Testicular Plasmacytoma, 3368
- Shah A, *see* Gill S
- Shah N, *see* Heath JA
see Rodriguez-Galindo C
- Shahab N, Kissenger RL, Malhotra V, Doll DC. Hematologic Malignancies With Extramedullary Spread of Disease: Hepatosplenic T-Cell Lymphoma, 1887
- Shahidi M, *see* Huddart RA
- Shaikh M, *see* Pervez H
- Shakespeare TP, Lu JJ, Back MF, Liang S, Mukherjee RK, Wynne CJ. Patient Preference for Radiotherapy Fractionation Schedule in the Palliation of Painful Bone Metastases, 2156
- Shamash J, *see* Powles T
- Shamsaldin A, *see* Le Deley M-C
- Shanafelt T, Adjei A, Meyskens FL. When Your Favorite Patient Relapses: Physician Grief and Well-Being in the Practice of Oncology, 2616
- Shanahan TG, *see* Kozelsky TF
- Shannon C, Ashley S, Smith IE. Does Timing of Adjuvant Chemotherapy for Early Breast Cancer Influence Survival?, 3792
- Shapiro KN, *see* Bowers DC
- Shariat SF, Kattan MW, Erdamar S, Nguyen C, Scardino PT, Spencer DM, Wheeler TM, Slawin KM. Detection of Clinically Significant, Occult Prostate Cancer Metastases in Lymph Nodes Using a Splice Variant-Specific RT-PCR Assay for Human Glandular Kallikrein, 1223
- Shariat SF, *see* Kattan MW
- Sharma S, *see* Takimoto CH
- Shaw E, Scott C, Suh J, Kadish S, Stea B, Hackman J, Pearlman A, Murray K, Gaspar L, Mehta M, Curran W, Gerber M. RSR13 Plus Cranial Radiation Therapy in Patients With Brain Metastases: Comparison With the Radiation Therapy Oncology Group Recursive Partitioning Analysis Brain Metastases Database, 2364
- Shaw EG, *see* Brown PD
see Buckner JC
- Sheinfeld J, *see* Donadio AC
see Motzer RJ
- Shek TWH, *see* Chim CS
see Hon C
- Shenep JL, *see* Flynn PM
- Shen J, *see* Fisch MJ
see George DW
- Shen L, *see* Bruera E
- Shepherd FA, *see* Gridelli C
- Shepherd JH, *see* Kolomainen DF
- Shepherd L, *see* Crump M
- Sherry RM, *see* Yang JC
- Shewach DS, Lawrence TS. It's What's Inside That Counts (editorial), 3383
- Shi W, *see* Aung LL

AUTHOR INDEX

- Shia J, *see* Nash GM
- Shields AF, *see* El-Rayes BF
see Hamid O
- Shimada K, *see* Shimamura T
- Shimada Y, *see* Ando N
see Ohtsu A
- Shimamura T, Sakamoto M, Ino Y, Sato Y, Shimada K, Kosuge T, Sekihara H, Hirohashi S. Dysadherin Overexpression in Pancreatic Ductal Adenocarcinoma Reflects Tumor Aggressiveness: Relationship to E-Cadherin Expression, 659
- Shin D-M, *see* Scagliotti GV
- Shinoda M, *see* Ando N
- Shipley W, *see* Chakravarti A
- Shipley WS, *see* Roach M III
- Shipley WU, *see* Hanks GE
see Pollack A
- Shirao K, *see* Ohtsu A
- Shives TC, *see* Haluska P
- Shorter NA, *see* Aung LL
- Shoshan Y, *see* Rosenthal G
- Shulman K, *see* Sawyer MB
- Sicard E, *see* Vassal G
- Sieber M, Bredenfeld H, Josting A, Reineke T, Rueffer U, Koch T, Naumann R, Boissevain F, Koch P, Worst P, Soekler M, Eich H, Müller-Hermelink HK, Franklin J, Paulus U, Wolf J, Engert A, Diehl V. 14-Dday Variant of the Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine, and Prednisone Regimen in Advanced-Stage Hodgkin's Lymphoma: Results of a Pilot Study in the German Hodgkin's Lymphoma Study Group, 1734
- Sieber M, *see* Engert A
see Josting A
- Siegert W, *see* Schetelig J
- Siener R, *see* Albers P
- Sieniawska C, *see* Last KW
- Siewert J-R, *see* Ott K
- Sigal JJ, Perry JC, Robbins JM, Gagné M-A, Nassif E. Maternal Preoccupation and Parenting as Predictors of Emotional and Behavioral Problems in Children of Women With Breast Cancer, 1155
- Sigurdson ER. Lymph Node Dissection: Is It Diagnostic or Therapeutic? (editorial), 965
- Sigurdson ER, *see* Le Voyer TE
- Sijmons RH, *see* Berends MJW
- Silberman S, *see* Heinrich MC
- Silingardi V, *see* Baldini L
- Silliman RA. What Constitutes Optimal Care for Older Women With Breast Cancer? (editorial), 3554
- Silliman RA, *see* Clark JA
see Ganz PA
- Sills D, *see* Ramondetta LM
- Silvast A, *see* Poutanen T
- Silverman LB, *see* Dalton VK
see Goldberg JM
- Silverman S Jr, *see* Rudin CM
- Silvestri GA, Knittig S, Zoller JS, Nietert PJ. Importance of Faith on Medical Decisions Regarding Cancer Care, 1379
- Siminoff LA, *see* Simon C
- Simmans FW, *see* Puzstai L
- Simms S, *see* Kazak AE
- Simon C, Zyzanski SJ, Eder M, Raiz P, Kodish ED, Siminoff LA. Groups Potentially at Risk for Making Poorly Informed Decisions About Entry into Clinical Trials for Childhood Cancer, 2173
- Simone JV. In Reply (correspondence), 1895
- Simonelli C, Spina M, Cinelli R, Talamini R, Tedeschi R, Gloghini A, Vaccher E, Carbone A, Tirelli U. Clinical Features and Outcome of Primary Effusion Lymphoma in HIV-Infected Patients: A Single-Institution Study, 3948
- Simonitsch I, *see* Seidemann K
- Singer S, *see* Heinrich MC
see Soiffer R
- Singh B, *see* Ganly I
- Singletary SE, *see* Woodward WA
- Sinn H-P, *see* Kaufmann M
- Sittek R, *see* Kaufmann M
- Siu LL, *see* Ma BBY
see Townsley CA
see Yee KWL
- Sivesind D, *see* Strasser F
- Sjolander DE, *see* Kobrinsky NL
- Skarin A, *see* Salgia R
- Skates SJ, Menon U, MacDonald N, Rosenthal AN, Oram DH, Knapp RC, Jacobs IJ. Calculation of the Risk of Ovarian Cancer From Serial CA-125 Values for Preclinical Detection in Postmenopausal Women, 206s
- Skates SJ, *see* Cannistra SA
- Skinner KA, *see* Formenti SC
- Sklar CA, *see* Oeffinger KC
see Packer RJ
- Skotheim RI, Kallioniemi A, Bjerkhagen B, Mertens F, Brekke HR, Monni O, Mousseis S, Mandahl N, Sæter G, Nesland JM, Smeland S, Kallioniemi O-P, Lothe RA. Topoisomerase-II α Is Upregulated in Malignant Peripheral Nerve Sheath Tumors and Associated With Clinical Outcome, 4586
- Skovlund E, *see* Diep CB
- Skuladottir H, Olsen JH. Conditional Survival of Patients With the Four Major Histologic Subgroups of Lung Cancer in Denmark, 3035
- Schlammuylder J-L, *see* Razavi D
- Slater E, *see* Meropol NJ
- Slaton JW, *see* Pagliaro LC
- Slawin KM, *see* Kattan MW
see Shariat SF
- Sledge GW, Neuberger D, Bernardo P, Ingle JN, Martino S, Rowinsky EK, Wood WC. Phase III Trial of Doxorubicin, Paclitaxel, and the Combination of Doxorubicin and Paclitaxel as Front-Line Chemotherapy for Metastatic Breast Cancer: An Intergroup Trial (E1193), 588
- Sledge GW Jr. Preoperative Chemotherapy for Breast Cancer: Lessons Learned and Future Prospects (editorial), 4481
- Sleeboom HP, *see* Mouridsen H
- Slegers G, *see* Van de Wiele C
- Slingluff CL Jr, Petroni GR, Yamshchikov GV, Barnd DL, Eastham S, Galavotti H, Patterson JW, Deacon DH, Hibbitts S, Teates D, Neese PY, Grosh WW, Chianese-Bullock KA, Woodson EMH, Wiernasz CJ, Merrill P, Gibson J, Ross M, Engelhard VH. Clinical and Immunologic Results of a Randomized Phase II Trial of Vaccination Using Four Melanoma Peptides Either Administered in Granulocyte-Macrophage Colony-Stimulating Factor in Adjuvant or Pulsed on Dendritic Cells, 4016
- Sloan J, *see* Hobday T
see Jatoi A
- Sloan JA. Quality-of-Life Meta-Analysis: Why Treat It Differently? (correspondence), 1422
- Sloan JA, *see* Goetz MP
see Hurt RD
see Jatoi A
see Kozelsky TF
- Slotman BJ, *see* Vos MJ
- Slovak ML, *see* Stein AS
- Slovin SF, Ragupathi G, Musselli C, Olkiewicz K, Verbel D, Kuduk SD, Schwarz JB, Sames D, Danishefsky S, Livingston PO, Scher HI. Fully Synthetic Carbohydrate-Based Vaccines in Biochemically Relapsed

- Prostate Cancer: Clinical Trial Results With α -N-Acetylgalactosamine-O-Serine/Threonine Conjugate Vaccine, 4292
- Small EJ, Smith MR, Seaman JJ, Petrone S, Kowalski MO. Combined Analysis of Two Multicenter, Randomized, Placebo-Controlled Studies of Pamidronate Disodium for the Palliation of Bone Pain in Men With Metastatic Prostate Cancer, 4277
- Small EJ, *see* Halabi S
see Rini BI
see Taplin M-E
- Smeland S, *see* Skotheim RI
- Smit E, *see* Fukuoka M
- Smit EF, van Meerbeeck JPAM, Lianes P, Debruyne C, Legrand C, Schrammel F, Smit H, Gaafar R, Biesma B, Manegold C, Neymark N, Giaccone G. Three-Arm Randomized Study of Two Cisplatin-Based Regimens and Paclitaxel Plus Gemcitabine in Advanced Non-Small-Cell Lung Cancer: A Phase III Trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group—EORTC 08975, 3909
- Smit H, *see* Smit EF
- Smith A, *see* Wright EP
- Smith BL, *see* Burstein JH
see Citron ML
- Smith FO, *see* Gamis AS
- Smith IE, *see* Ring A
see Shannon C
- Smith J, *see* Mehta MP
- Smith JW, *see* Clark JI
- Smith JW II, Walker EB, Fox BA, Haley D, Wisner KP, Doran T, Fisher B, Justice L, Wood W, Vetto J, Maecker H, Dols A, Meijer S, Hu H-M, Romero P, Alvord WG, Urba WJ. Adjuvant Immunization of HLA-A2-Positive Melanoma Patients With a Modified gp100 Peptide Induces Peptide-Specific CD8⁺ T-Cell Responses, 1562
- Smith L, *see* Tolcher AW
- Smith M, *see* Hirschfeld S
- Smith ML, *see* Davis MP
- Smith MR, *see* Small EJ
- Smith R, *see* Bear HD
see Dignam JJ
see Kaufmann M
see Miller VA
see Mouridsen H
- Smith RE, Bryant J, DeCillis A, Anderson S. Acute Myeloid Leukemia and Myelodysplastic Syndrome After Doxorubicin-Cyclophosphamide Adjuvant Therapy for Operable Breast Cancer: The National Surgical Adjuvant Breast and Bowel Project Experience, 1195
- Smith RP, *see* Sawyer MB
- Smith RS, Chen Q, Hudson MM, Link MP, Kun L, Weinstein H, Billett A, Marcus KJ, Tarbell NJ, Donaldson SS. Prognostic Factors for Children With Hodgkin's Disease Treated With Combined-Modality Therapy, 2026
- Smith T, *see* Loprinzi CL
see Neff P
- Smith TJ, Staats P, Coyne PJ. In Reply (correspondence), 2803
- Smith TJ. Tell It Like It Is, 12s
- Smith TL, *see* Puztai L
see Seymour JF
- Smorenburg CH, Sparreboom A, Bontenbal M, Stoter G, Nooter K, Verweij J. Randomized Cross-Over Evaluation of Body-Surface Area-Based Dosing Versus Flat-Fixed Dosing of Paclitaxel, 197
- Snijders W, *see* Baak JPA
- Snyder CL, *see* Lynch HT
- Snyder DS, *see* Stein AS
- Snyder R, *see* Mouridsen H
- Sobin LH, *see* Bilchik AJ
- Soderdahl D, *see* Carter CA
- Soekler M, *see* Sieber M
- Soiffer R, Hodi FS, Haluska F, Jung K, Gillessen S, Singer S, Tanabe K, Duda R, Mentzer S, Jaklitsch M, Bueno R, Clift S, Hardy S, Neuberger D, Mulligan R, Webb I, Mihm M, Dranoff G. Vaccination With Irradiated, Autologous Melanoma Cells Engineered to Secrete Granulocyte-Macrophage Colony-Stimulating Factor by Adenoviral-Mediated Gene Transfer Augments Antitumor Immunity in Patients With Metastatic Melanoma, 3343
- Soignet SL, *see* Barbey JT
- Solymoss S, *see* Goldenberg N
- Somerfield M. Hazards of Quality-of-Life Data for Clinical Decision Making, 82s
- Somerfield MR, *see* Bennett CL
- Somer RA, *see* Meropol NJ
- Somlo G, *see* Stein AS
- Sommelet D, *see* Le Deley M-C
- Sommerlet-Olive D, *see* Schleiernmacher G
- Sonderker S, Schmiegelow M, Carstensen H, Nielsen LB, Müller J, Schmiegelow K. Long-Term Neurological Outcome of Childhood Brain Tumors Treated by Surgery Only, 1347
- Sonet A, *see* Bouabdallah R
see Coiffier B
- Sonneveld P, *see* Doorduijn JK
see Lokhorst HM
- Sonnichsen D, *see* Abraham J
- Sonoo H, *see* Tominaga T
- Sonpavde G. Communicating the Value of Adjuvant Chemotherapy, 948
- Sood AK, *see* Fracasso PM
- Soori GS, *see* Wadler S
- Soosaipillai A, *see* Diamandis EP
- Soper JT, *see* Gallion HH
- Soran A, *see* Bear HD
- Sorbye H, Dahl O. Carcinoembryonic Antigen Surge in Metastatic Colorectal Cancer Patients Responding to Oxaliplatin Combination Chemotherapy: Implications for Tumor Marker Monitoring and Guidelines (correspondence), 4466
- Sorensen MV, *see* Hahn EA
- Sørensen TM, *see* Schmiegelow K
- Soslow RA, *see* Levine DA
- Sosman JA, *see* Clark JI
- Soubeyran P, *see* Hoang-Xuan K
see Poortmans PMP
- Souchon R, *see* Classen J
see Kaufmann M
see Köhne C-H
- Souhami L, *see* Mehta MP
- Souweidane MM, *see* Wolden SL
- Sozzi G, Conte D, Leon M, Cirincione R, Roz L, Ratcliffe C, Roz E, Cirenei N, Bellomi M, Pelosi G, Pierotti MA, Pastorino U. Quantification of Free Circulating DNA As a Diagnostic Marker in Lung Cancer, 3902
- Spaar HJ, *see* Den Boer ML
- Spadola V, *see* Quintini G
- Sparreboom A, Verweij J, Extermann M. Paclitaxel Pharmacokinetics, Threshold Models, and Dosing Strategies (correspondence), 2804
- Sparreboom A, *see* Smorenburg CH
- Sparwasser C, *see* Albers P
- Spaulding M, *see* Clark JA
- Spears WT, *see* Schnoll RA
- Specia M, *see* Bordeleau L
- Speers CH, *see* Olivetto IA
- Speleman F, *see* Ambros IM
- Spencer BA, Steinberg M, Malin J, Adams J, Litwin MS. Quality-of-Care Indicators for Early-Stage Prostate Cancer, 1928
- Spencer DM, *see* Shariat SF
- Sperber D, *see* Kemeny N
- Speyer J, *see* Hochster H

AUTHOR INDEX

- Spicer D, *see* Formenti SC
 Spicer RD, *see* Stewart RJ
 Spiegel G, *see* Omura GA
 Spiegelmann R, *see* Mardor Y
 Spielberg RT, *see* Stein AS
 Spielmann M, *see* Zelek L
 Spiliopoulos A, *see* Betticher DC
 Spina M, *see* Bernardi D
 see Ferreri AJM
 see Re A
 see Simonelli C
 Spinelli P, *see* Bertario L
 Spiridonidis CH, *see* Blayney DW
 see Velasquez WS
 Spiritos N, *see* Randall ME
 Spreuwenberg PMM, *see* Mellink WAM
 Staats P, *see* Smith TJ
 Stadler W, *see* Cohen EEW
 see Taplin M-E
 Stafford S, *see* Buckner JC
 Stafford-Fox V, *see* Quinn JA
 Stahel R, *see* Betticher DC
 Stahl A, *see* Ott K
 Staib P, *see* Büchner T
 see Haferlach T
 Stamatoulas A, *see* Beaumont M
 Stanczyk FZ, *see* McTiernan A
 Stanford JL, *see* Penson DF
 Stankewitz K, *see* Seidemann K
 Starkschall G, *see* Movsas B
 Stadius Muller MG, *see* Vuylsteke RJCLM
 Staub E, *see* Blot E
 Stea B, *see* Shaw E
 Stebbing J, *see* Cackett P
 see Powles T
 Stec J, *see* Pusztai L
 Steele P, *see* Rayson D
 Steensma DP. Submitting to Autonomy, 62s
 Steensma DP. The Narrow Path, 57s
 Steensma DP. Why Me?, 64s
 Steensma DP, *see* Daugherty CK
 Steer G, *see* Loprinzi CL
 Stefanou A, Dooley M. Simple Method to Eliminate the Risk of Inadvertent Intrathecal Vincristine Administration (correspondence), 2044
 Steger G, *see* Schmid M
 Stegmaier C, *see* Arndt V
 Stehman FB, *see* Varia MA
 Steijaert MMC, *see* Doorduijn JK
 see Lokhorst HM
 Stein AS, O'Donnell MR, Slovak ML, Snyder DS, Nademanee AP, Parker P, Molina A, Somlo G, Fung HC, Krishnan A, Rodriguez R, Spielberger RT, Wang S, Dagsis A, Vora N, Arber DA, Niland JC, Forman SJ. Interleukin-2 After Autologous Stem-Cell Transplantation for Adult Patients With Acute Myeloid Leukemia in First Complete Remission, 615
 Stein H, *see* Daum S
 see Ott K
 Steinberg M, *see* Spencer BA
 Steinberg SM, *see* Feldman AL
 see Hussain MM
 see Yang JC
 Steindorfer P, *see* Schmid M
 Steineck G, *see* Kelly WK
 Steinherz L, *see* Heath JA
 Steinherz PG, *see* Heath JA
 Steinmetz ND, *see* Van de Wiele C
 Stelitano C, *see* Baldini L
 Stella PJ, *see* Hurt RD
 see Schild SE
 Stemmer SM, Rizel S, Hardan I, Adamo A, Neumann A, Goffman J, Brenner HJ, Pfeffer MR. The Role of Irradiation of the Internal Mammary Lymph Nodes in High-Risk Stage II to IIIA Breast Cancer Patients After High-Dose Chemotherapy: A Prospective Sequential Nonrandomized Study, 2713
 Stenman U-H, *see* Diamandis EP
 Stenning S, *see* Fosså SD
 Stenson K, *see* Cohen EEW
 see Rudin CM
 see Vokes EE
 Stephenson RA, *see* Penson DF
 Sternschulte W, *see* Schneider DT
 Stevens MCG, *see* Stewart RJ
 Stevenson JP, Rosen M, Sun W, Gallagher M, Haller DG, Vaughn D, Giantonio B, Zimmer R, Petros WP, Stratford M, Chaplin D, Young SL, Schnell M, O'Dwyer PJ. Phase I Trial of the Antivascular Agent Combretastatin A4 Phosphate on a 5-Day Schedule to Patients With Cancer: Magnetic Resonance Imaging Evidence for Altered Tumor Blood Flow, 4428
 Stewart WP, *see* Morgan B
 Stewart D, *see* Abrey LE
 see Townsley CA
 Stewart DB, *see* Tyc VL
 Stewart JA. Paul Peter Carbone, MD, 4071
 Stewart M, *see* Leung TWT
 Stewart RJ, Martelli H, Oberlin O, Rey A, Bouvet N, Spicer RD, Godzinski J, Stevens MCG. Treatment of Children With Nometastatic Paratesticular Rhabdomyosarcoma: Results of the Malignant Mesenchymal Tumors Studies (MMT 84 and MMT 89) of the International Society of Pediatric Oncology, 793
 Steyerberg EW, *see* Vergouwe Y
 Stierer M, *see* Schmid M
 Stift A, Friedl J, Dubsy P, Bachleitner-Hofmann T, Schueller G, Zontsich T, Benkoe T, Radelbauer K, Brostjan C, Jakesz R, Gnant M. Dendritic Cell-Based Vaccination in Solid Cancer, 135
 Stinson SF, *see* Panasci L
 Stirling JJ, *see* Galbraith SM
 Stitt LW, *see* Videtic GMM
 Stocken DD, *see* Darnton SJ
 Stockman J, *see* Kemeny N
 Stopfer J, *see* Domchek SM
 Stoppa AM, *see* Beaumont M
 Stoppini L, *see* Nasti G
 Storti S, *see* Martelli M
 Stoter G, *see* Smorenburg CH
 Stoval E, *see* Comis RL
 Stovall M, *see* Green DM
 see Oeffinger KC
 see Packer RJ
 Stratford M, *see* Stevenson JP
 Strair RK, Schaar D, Medina D, Todd MB, Aisner J, DiPaola RS, Manago J, Knox B, Jenkinson A, Senzon R, Baker C, Dudek L, Ciardella M, Kuriyan M, Rubin A, Lattime EC. Antineoplastic Effects of Partially HLA-Matched Irradiated Blood Mononuclear Cells in Patients With Renal Cell Carcinoma, 3785
 Strammiello R, *see* Scotlandi K
 Strasser F, Fisch M, Bodurka DC, Sivesind D, Bruera E. E-motions: Email for Written Emotional Expression, 98s
 Strasser F, *see* Bruera E
 Stratford M, *see* Rustin GJS
 Straus SE, *see* Townsley CA

- Strauss SJ, McTiernan A, Driver D, Hall-Craggs M, Sandison A, Cassoni AM, Kilby A, Michelagnoli M, Pringle J, Cobb J, Briggs T, Cannon S, Witt J, Whelan JS. Single Center Experience of a New Intensive Induction Therapy for Ewing's Family of Tumors: Feasibility, Toxicity, and Stem Cell Mobilization Properties, 2974
- Strenger R, *see* Burstein HJ
- Strenger V, *see* Kerbl R
- Stroebe W, *see* Garbe C
- Strom EA, *see* Woodward WA
- Stuart G, *see* Rothenberg ML
- Studer UE, *see* Madersbacher S
- Studs JL, *see* Chao C
- Stupp R, *see* Betticher DC
see van den Bent MJ
- Stürmer T, *see* Arndt V
- Sturm I, *see* Rau B
- Subbaramaiah K, *see* Altorki NK
- Sugarbaker D, *see* Salgia R
- Sugarbaker PH, *see* Mohamed F
- Sugarbaker PH. Carcinomatosis—Is Cure an Option? (editorial), 762
- Sugimachi K, *see* Tominaga T
- Suh J, *see* Mehta MP
see Shaw E
- Sullivan D, *see* Gonen M
- Sulmasy DP, *see* Meropol NJ
- Sun A, *see* Tsang RW
- Sun L, *see* Carter CA
see D'Amico AV
- Sun W, *see* Stevenson JP
- Sun X-S, *see* Tourani J-M
- Sun Y, *see* Mouridsen H
- Sung JJ, *see* Ebert MPA
- Surico G, *see* Indolfi P
- Swanson S, *see* Salgia R
- Sweet J, *see* Nam RK
- Sweet KM, Willis SK, Ashida WS, Westman JA. Use of Fear-Appeal Techniques in the Design of Tailored Cancer Risk Communication Messages: Implications for Healthcare Providers (correspondence), 3375
- Sweetenham JW, *see* Bierman PJ
- Swenerton KD, *see* Hoskins PJ
- Swinson DEB, Jones JL, Richardson D, Wykoff C, Turley H, Pastorek J, Taub N, Harris AL, O'Byrne KJ. Carbonic Anhydrase IX Expression, a Novel Surrogate Marker of Tumor Hypoxia, Is Associated With a Poor Prognosis in Non-Small-Cell Lung Cancer, 473
- Sydes MR, *see* Schouten HC
- Sykes PJ, *see* Marshall GM
- Symanowski J, *see* Vogelzang NJ
- Symanowski JT, *see* Scagliotti GV
- Symmans WF, *see* Puszta L
- Syndercombe-Court D, *see* Taussig DC
- Szalai JP, *see* Bordeleau L
- Szanto J, *see* Nabholz J-M
- Szatrowski TP, *see* Parnes HL
- Szczęśna A, *see* Fossella F
- Sztermer J-F, *see* Fumoleau P
- Szumanski C, *see* Schmiegelow K
- T
- Taback B, *see* Kuo CT
- Tabernero MD, *see* Maíllo A
- Taghipour G, *see* Bierman PJ
- Tai BC, *see* Leong SS
- Taillandier L, *see* Hoang-Xuan K
- Tait DM, *see* Taylor RE
- Takashima JR, *see* Green DM
- Takata I, *see* Fukuoka M
- Takeuchi H, *see* Kuo CT
- Takiguchi S, *see* Yamamoto S
- Takimoto C, *see* Tolcher AW
- Takimoto CH, Remick SC, Sharma S, Mani S, Ramanathan RK, Doroshow J, Hamilton A, Mulkerin D, Graham M, Lockwood GF, Ivy P, Egorin M, Schuler B, Greenslade D, Goetz A, Knight R, Thomas R, Monahan BP, Dahut W, Grem JL. Dose-Escalating and Pharmacological Study of Oxaliplatin in Adult Cancer Patients With Impaired Renal Function: A National Cancer Institute Organ Dysfunction Working Group Study, 2664
- Takimoto CH, Rowinsky EK. Dose-Intense Paclitaxel: Déjà Vu All Over Again? (editorial), 2810
- Takimoto CH, *see* Rowinsky EK
- Takiyama W, *see* Ando N
- Taksey JD, *see* Chaudhary UB
- Taksin A-L, *see* Raffoux E
- Talamini R, *see* Nasti G
see Simonelli C
- Talbot DC, *see* Propper DJ
- Talcott JA, Manola J, Clark JA, Kaplan I, Beard CJ, Mitchell SP, Chen RC, O'Leary MP, Kantoff PW, D'Amico AV. Time Course and Predictors of Symptoms After Primary Prostate Cancer Therapy, 3979
- Talcott JA. Quality of Care in Prostate Cancer: Important to Start and Too Important to Stop Here (editorial), 1902
- Talcott JA, *see* Clark JA
- Tallini G, *see* Garcia-Rostan G
- Tallman MS, *see* Cheson BD; Ladewski LA
- Tamaro P, *see* Indolfi P
- Tamboli CP. Long-Term Survivors of Testicular Cancer (correspondence), 3888
- Tamponi G, *see* Ladetto M
- Tamura T, *see* Fukuoka M
- Tan CK, Law NM, Ng HS, Machin D. Simple Clinical Prognostic Model for Hepatocellular Carcinoma in Developing Countries and its Validation, 2294
- Tan EH, *see* Leong SS
- Tanabe K, *see* Soiffer R
- Tanaka O, *see* Ando N
- Tanda F, *see* Palmieri G
- Tanguy ML, *see* Matthay KK
- Tannock I, *see* Townsley CA
- Tannock IF, *see* Ernst DS
see Tchen N
- Tannous R, *see* Heath JA
see Hutchinson RJ
- Taphoorn M, *see* Poortmans PMP
- Taphoorn MJB, *see* van den Bent MJ
- Taplin M-E, Kantoff PW. The Ingredients for Prostate Cancer Nomograms: The Addition of Biomarkers Sets the Table for Future Recipes (editorial), 3552
- Taplin M-E, Rajeshkumar B, Halabi S, Werner CP, Woda BA, Picus J, Stadler W, Hayes DF, Kantoff PW, Vogelzang NJ, Small EJ. Androgen Receptor Mutations in Androgen-Independent Prostate Cancer: Cancer and Leukemia Group B Study 9663, 2673
- Taplin SH, *see* Kerlikowske K
- Tarbell NJ, *see* Dalton VK
see Smith RS
- Tarella C, *see* Ladetto M
- Tartarone A, Romano G, Iodice G, Capobianco A, Di Renzo N. The Predictive Role of HER2 Overexpression in Early Breast Cancer (correspondence), 3180

AUTHOR INDEX

- Tassinari D, Panzini I, Sartori S, Ravaoli A. Surrogate Outcomes in Quality-of-Life Research: Where Will We End Up? (correspondence), 1894
- Tatter S, *see* Olivi A
- Taub N, *see* Swinson DEB
- Taucher S, *see* Schmid M
- Tausch C, *see* Schmid M
- Taussig DC, Davies AJ, Cavenagh JD, Oakervee H, Syndercombe-Court D, Kelsey S, Amess JAL, Rohatiner AZS, Lister TA, Barnett MJ. Durable Remissions of Myelodysplastic Syndrome and Acute Myeloid Leukemia After Reduced-Intensity Allografting, 3060
- Tavio M, *see* Nasti G
- Taylor JMG, *see* Thomas CT
- Taylor NJ, *see* Galbraith SM
- Taylor RE, Bailey CC, Robinson K, Weston CL, Ellison D, Ironside J, Lucraft H, Gilbertson R, Tait DM, Walker DA, Pizer BL, Imeson J, Lashford LS. Results of a Randomized Study of Preradiation Chemotherapy Versus Radiotherapy Alone for Nonmetastatic Medulloblastoma: The International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET-3 Study, 1581
- Taylor SA, *see* Blayney DW
- Tchekmedyan S, *see* Rosen LS
- Tchen N, Juffs HG, Downie FP, Yi Q-L, Hu H, Chemerynski I, Clemons M, Crump M, Goss PE, Warr D, Tweedale ME, Tannock IF. Cognitive Function, Fatigue, and Menopausal Symptoms in Women Receiving Adjuvant Chemotherapy for Breast Cancer, 4175
- Teates D, *see* Slingluff CL Jr
- Tedeschi R, *see* Simonelli C
- Tempero M, Plunkett W, van Haperen VR, Hainsworth J, Hochster H, Lenzi R, Abbruzzese J. Randomized Phase II Comparison of Dose-Intense Gemcitabine: 30-Minute Infusion and Fixed Dose Rate Infusion in Patients With Pancreatic Adenocarcinoma, 3402
- Tendas A, *see* Abbruzzese E
- ten Hoor KA, *see* Berends MJW
- Teodorovic I, *see* Poortmans PMP
- Tepper JE, O'Connell M, Hollis D, Niedzwiecki D, Cooke E, Mayer RJ. Analysis of Surgical Salvage After Failure of Primary Therapy in Rectal Cancer: Results From Intergroup Study 0114, 3623
- Terenziani M, *see* Indolfi P
- Terhaard CHJ, *see* Mehta MP
- Terracciano L, *see* Jantschke P
- Terrier-Lacombe MJ, *see* Pellegrino B
- Terrier P, *see* Zelek L
- Terry W, *see* Heath JA
- Tersak J, *see* Bhatia S
- Terzoli E, *see* Papaldo P
- Tester W, *see* Phipps E
- Thaler HT, *see* Aung LL
- Thall PF, *see* Millikan R
- Thalman GN, *see* Madersbacher S
- Thames HD, *see* Crane CH
see Thomas CT
- Thatcher N, *see* Danson S
- Théodore C, *see* Culine S
- Theoret H, *see* Bear HD
- Therasse P, Mauriac L, Welnicka-Jaskiewicz M, Bruning P, Cufer T, Bonnefoi H, Tomiak E, Pritchard KI, Hamilton A, Piccart MJ. Final Results of a Randomized Phase III Trial Comparing Cyclophosphamide, Epirubicin, and Fluorouracil With a Dose-Intensified Epirubicin and Cyclophosphamide + Filgrastim as Neoadjuvant Treatment in Locally Advanced Breast Cancer: An EORTC-NCIC-SAKK Multicenter Study, 843
- Theriault RL, *see* Woodward WA
- Theuer CP. Ethnicity-Related Gastric Cancer Survival (correspondence), 4253
- Thieblemont C, *see* Bouabdallah R
see Zucca E
- Thiede C, *see* Schetelig J
- Thiel E, *see* Daum S
- Thigpen JT, *see* Randall ME
- Thigpen T. Maybe More is Better (editorial), 2454
- Thistle AM, *see* Cohen SJ
- Thomas AL, *see* Morgan B
- Thomas CR Jr, *see* Roach M III
- Thomas CT, Bradshaw PT, Pollock BH, Montie JE, Taylor JMG, Thames HD, McLaughlin PW, DeBiose DA, Hussey DH, Wahl RL. Indium-111-Capromab Pendetide Radioimmunoscinigraphy and Prognosis for Durable Biochemical Response to Salvage Radiation Therapy in Men After Failed Prostatectomy, 1715
- Thomas DA, *see* Giles FJ
- Thomas DG, *see* Dhaini HR
- Thomas J, *see* Poortmans PMP
- Thomas JP, Arzooonian RZ, Alberti D, Marnocha R, Lee F, Friedl A, Tutsch K, Dresen A, Geiger P, Pluda J, Fogler W, Schiller JH, Wilding G. Phase I Pharmacokinetic and Pharmacodynamic Study of Recombinant Human Endostatin in Patients With Advanced Solid Tumors, 223
- Thomas R, *see* Bottomley A
see Takimoto CH
- Thomas X, *see* Beaumont M
see Boissel N
- Thompson IM, *see* Unger JM
- Thompson WJ, *see* Puztai L
- Thorstensen L, *see* Diep CB
- Thoury A, *see* Morice P
- Thuluvath PJ, *see* Leung TWT
see Yoo HY
- Thuret I, *see* Aladjidi N
see Pellegrino B
- Thürlimann B, *see* Goldhirsch A
see Wallgren A
- Thurston VC, *see* George DW
- Thuss-Patience P, *see* Kretschmar A
- Thuss-Patience PC, Peters U, Jurkat-Rott K, Pink D, Kretschmar A, Dörken B, Reichardt P. Acute Hypokalemic Tetraparesis Induced by Intravenous Methotrexate (correspondence), 1896
- Tibben A, *see* van Oostrom I
- Tibbs PA, *see* Patchell R
- Tibi A, *see* Raffoux E
- Tichler T, *see* Mardor Y
- Tickoo SK, *see* Mazumdar M
- Tiemann M, *see* Seidemann K
- Tienghi A, *see* Ferrari S
- Tikanoja T, *see* Poutanen T
- Tilgen W, *see* Hauschild A
- Tilly H, *see* Coiffier B
- Timmerman R, *see* Mehta MP
- Tin M, *see* Featherstone C
- Tinguely M, *see* Ferreri AJM
- Tirelli U, *see* Bernardi D
see Nasti G
see Re A
see Simonelli C
- Tirona MT, *see* Hurt RD
- Tissot-Dupont H, *see* Herida M
- Titzer ML, *see* Fisch MJ
- Tkaczuk KH, *see* Henderson IC
- Tobias S, *see* Rosenthal G
- Tobler A, *see* Mengis C
- Todd MB, *see* Strair RK
- Toge T, *see* Tominaga T
- Toi A, *see* Nam RK
- Toi M, *see* Tominaga T

AUTHOR INDEX

- Tolcher AW, Ochoa L, Hammond LA, Patnaik A, Edwards T, Takimoto C, Smith L, de Bono J, Schwartz G, Mays T, Jonak ZL, Johnson R, DeWitte M, Martino H, Audette C, Maes K, Chari RVJ, Lambert JM, Rowinsky EK. Cantuzumab Mertansine, a Maytansinoid Immunoconjugate Directed to the CanAg Antigen: A Phase I, Pharmacokinetic, and Biologic Correlative Study, 211
- Tolcher AW, *see* Rowinsky EK
- Tollenaar RA, *see* Kriege M
- Tomasic G, *see* Moliterni A
- Tomiak AT, *see* Videtic GMM
- Tomiak E, *see* Therasse P
- Tominaga T, Koyama H, Toge T, Miura S, Sugimachi K, Yamaguchi S, Hirata K, Monden Y, Nomura Y, Toi M, Kimijima I, Noguchi S, Sonoo H, Asaishi K, Ikeda T, Morimoto T, Ota J, Ohashi Y, Abe O. Randomized Controlled Trial Comparing Oral Doxifluridine Plus Oral Cyclophosphamide With Doxifluridine Alone in Women With Node-Positive Breast Cancer After Primary Surgery, 991
- Tomita K, *see* Tsuchiya H
- Tomita Y, *see* Yamamoto S
- Tomori C, *see* Bennett CL
- Tonini G, Vincenzi B, Santini D, Avvisati G, La Cesa A, Baldi A. Unusual Problems in Breast Cancer and a Rare Lung Cancer Case: Clinical Complete Response of Breast Cancer Metastases After Trastuzumab-Based Immunotherapy, 2215
- Tonini GP, *see* Ambros IM
see De Bernardi B
- Topalian SL, *see* Yang JC
- Torres A, *see* Roman-Gomez J
- Torri V, *see* Apolone G
see Buyse M
- Tötsch M, *see* Betticher DC
- Tourani J-M, Pfister C, Tubiana N, Ouldacaci M, Prevot G, Lucas V, Oudard S, Malet M, Cottu P, Ferrero J-M, Mayeur D, Rixe O, Sun X-S, Bernard O, Andre T, Tournigand C, Muracciole X, Guilhot J. Subcutaneous Interleukin-2 and Interferon Alfa Administration in Patients With Metastatic Renal Cell Carcinoma: Final Results of SCAPP III, a Large, Multicenter, Phase II, Nonrandomized Study With Sequential Analysis Design—The Subcutaneous Administration Propeukin Program Cooperative Group, 3987
- Tournigand C, *see* Tourani J-M
- Tourt-Uhlig S, *see* Quinn JA
- Townsley CA, Chi K, Ernst DS, Belanger K, Tannock I, Bjarnason GA, Stewart D, Goel R, Ruether JD, Siu LL, Jolivet J, McIntosh L, Seymour L, Moore MJ. Phase II Study of Troxacitabine (BCH-4556) in Patients With Advanced and/or Metastatic Renal Cell Carcinoma: A Trial of the National Cancer Institute of Canada-Clinical Trials Group, 1524
- Townsley CA, Naidoo K, Pond GR, Melnick W, Straus SE, Siu LL. Are Older Cancer Patients Being Referred to Oncologists? A Mail Questionnaire of Ontario Primary Care Practitioners to Evaluate Their Referral Patterns, 4627
- Tozer GM, *see* Galbraith SM
- Trachtenberg J, *see* Alibhai SMH
see Nam RK
- Trejo L, *see* Goor O
- Tremblay P-B, Kaiser R, Sezer O, Rösler N, Schelenz C, Possinger K, Roots I, Brockmüller J. Variations in the 5-Hydroxytryptamine Type 3B Receptor Gene as Predictors of the Efficacy of Antiemetic Treatment in Cancer Patients, 2147
- Tres A, *see* Andrés R
- Tretter CPG, *see* Clark JI
- Treuner J, *see* Okcu MF
- Tricot G, *see* Lee C-K
- Trigg ME, *see* Heath JA
see Hutchinson RJ
- Trillet-Lenoir V, *see* Freyer G
- Trimble EL, *see* Harlan LC
see Lewis JH
- Tripathy D, *see* Esteva FJ
- Tripcony L, *see* Poulsen M
- Trocha S, *see* Bilchik AJ
- Trog D, *see* Kuhl CK
- Trudeau ME, *see* Goodwin PJ
- True G, *see* Phipps E
- Trueheart IN, *see* Laufer M
- Trump D, *see* Messing EM
- Truong MT, *see* Erasmus JJ
- Truong PT, *see* Olivotto IA
see Videtic GMM
- Tsai C-S, *see* Yen T-C
- Tsang RW, Gospodarowicz MK, Pintilie M, Wells W, Hodgson DC, Sun A, Crump M, Patterson BJ. Localized Mucosa-Associated Lymphoid Tissue Lymphoma Treated With Radiation Therapy Has Excellent Clinical Outcome, 4157
- Tsangaris T, *see* Mandelblatt JS
- Tsodikov A, *see* Gaffney DK
- Tsuchiya H, Abdel-Wanis M, Kanazawa Y, Tomita K. In Reply (correspondence), 177
- Tu D, *see* Crump M
see Moore MJ
see Pritchard KI
- Tubiana N, *see* Tourani J-M
- Tubiana-Mathieu N, *see* André T
- Tucker SL, *see* Woodward WA
- Tulsky JA, *see* Back AL
- Tulusan AH, *see* Kaufmann M
- Tura S, *see* Martelli M
- Turley H, *see* Swinson DEB
- Turnbull A, *see* Downey RJ
- Turner R, *see* Kouroukis CT
see Kuo CT
- Turner RR, *see* Bilchik AJ
- Tursz T, *see* Zelek L
- Tutin L, *see* Gollob JA
- Tutsch K, *see* Thomas JP
- Tweeddale ME, *see* Tchen N
- Twelves C, *see* Propper DJ
- Tworoger SS, *see* McTiernan A
- Tyc VL, Rai SN, Lensing S, Klosky JL, Stewart DB, Gattuso J. Intervention to Reduce Intentions to Use Tobacco Among Pediatric Cancer Survivors, 1366
- Tyndale-Hines L, *see* Weber WA
- Tyson L, *see* Miller VA

U

- Uchitomi Y, Mikami I, Nagai K, Nishiwaki Y, Akechi T, Okamura H. Depression and Psychological Distress in Patients During the Year After Curative Resection of Non-Small-Cell Lung Cancer, 69
- Uhl V, *see* Roach M III
- Ulbright TM, *see* George DW
- Ullrich R, *see* Daum S
- Umeshita K, *see* Yamamoto S
- Unger C, *see* Morgan B
- Unger JM, LeBlanc M, Crowley JJ, Grossman HB, Natale RB, Wozniak AJ, Berenson JR, List AF, Peters WA III, Flanigan RC, Macdonald JS, Al-Sarraf M, Thompson IM, Coltman CA Jr. Estimating the Impact of New Clinical Trial Proven Cancer Therapy and Cancer Chemoprevention on Population Mortality: The Karnofsky Memorial Lecture, 2465
- Untch M, *see* Kaufmann M

- Uprichard M, *see* Hamid O
 Urbain J-L, *see* Majhail NS
 Urban CE, *see* Kerbl R
 Urbanowitz G, *see* Rosen LS
 Urba WJ, *see* Clark JI
 see Smith JW II
 Urias RE, *see* Kozelsky TF
 Uyl-de Groot CA, *see* Doorduijn JK
- V**
- Vaccher E, *see* Nasti G
 see Simonelli C
 Vachon CM, *see* Ebbert JO
 Vadell C, *see* Alberola V
 Vadhan-Raj S, Patel S, Bueso-Ramos C, Folloder J, Papadopoulos N, Burgess A, Broemeling LD, Broxmeyer HE, Benjamin RS. Importance of Predosing of Recombinant Human Thrombopoietin to Reduce Chemotherapy-Induced Early Thrombocytopenia, 3158
 Vaena DA, Abonour R, Einhorn LH. Long-Term Survival After High-Dose Salvage Chemotherapy for Germ Cell Malignancies With Adverse Prognostic Variables, 4100
 Vaishampayan U, *see* El-Rayes BF
 Valagussa P, *see* Licitra L
 see Menard S
 see Moliterni A
 Valdés Z, *see* Carr A
 Valent A, *see* Ambros IM
 Valentini M, *see* Sacco M
 Valero V, Hortobagyi GN. Are Anthracycline-Taxane Regimens the New Standard of Care in the Treatment of Metastatic Breast Cancer? (editorial), 959
 Valero V, *see* Kaufmann M
 see Pusztai L
 see Rivera E
 Valicenti RK, *see* Roach M III
 Vallet S, *see* Ladetto M
 Valsecchi MG, *see* Aricò M
 Valteau-Couanet D, *see* Matthay KK
 Valvo F, *see* Licitra L
 van Agthoven M, *see* Doorduijn JK
 van Besien K, *see* Bierman PJ
 Vance GH, *see* George DW
 van Dalen EC, van der Pal HJH, van den Bos C, Caron HN, Kremer LCM. Treatment for Asymptomatic Anthracycline-Induced Cardiac Dysfunction in Childhood Cancer Survivors: The Need For Evidence (correspondence), 3377
 Van den Abbeele AD, *see* Heinrich MC
 van den Belt-Dusebout AW, *see* Aleman BMP
 Van den Bent M, *see* Poortmans PMP
 van den Bent MJ, Taphoorn MJB, Brandes AA, Menten J, Stupp R, Frenay M, Chinot O, Kros JM, van der Rijt CCD, Vecht ChJ, Allgeier A, Gorlia T. Phase II Study of First-Line Chemotherapy With Temozolomide in Recurrent Oligodendroglial Tumors: The European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971, 2525
 van den Bos C, *see* van Dalen EC
 van den Ouweland AWM, *see* Meijers-Heijboer H
 van de Poll MEC, *see* Edick MJ
 Van der Does-Van den Berg A, *see* Den Boer ML
 van der Hem KG, *see* Doorduijn JK
 Vanderheyden J-L, *see* Van de Wiele C
 van der Holt B, *see* Doorduijn JK
 see Lokhorst HM
 van der Hulst M, *see* Haas RLM
 van der Kwast TH, *see* van Rhijn BWG
 van der Meer CA, *see* van Oostrom I
 van der Pal HJH, *see* van Dalen EC
 van der Rijt CCD, *see* van den Bent MJ
 van der Sluis T, *see* Berends MJW
 Vandertop WP, *see* Vos MJ
 van der Zee AGJ, *see* Berends MJW
 see Diamandis EP
 van de Velde CJH, *see* Peeters KCMJ
 see Wong JEL
 van de Velde CJH, Peeters KCMJ. The Gastric Cancer Treatment Controversy. (editorial), 2234
 Van de Wiele C, Lahorte C, Vermeersch H, Loose D, Mervillie K, Steinmetz ND, Vanderheyden J-L, Cuvelier CA, Slegers G, Dierck RA. Quantitative Tumor Apoptosis Imaging Using Technetium-99m-HYNIC Annexin V Single Photon Emission Computed Tomography, 3483
 van Diermen B, *see* Baak JPA
 van Diest PJ, *see* Baak JPA
 Vandroos C, *see* Cella D
 Van Echo D, *see* Meropol NJ
 Vanel D, *see* Khanfir K
 van Geel B, *see* Meijers-Heijboer H
 van Geel BN, *see* van Oostrom I
 van Glabbeke M, *see* Poortmans PMP
 van Gool AR, *see* van Oostrom I
 van Gramberen M, *see* Diamandis EP
 van Groeningen CJ, *see* Vos MJ
 van Haperen VR, *see* Tempero M
 van Hinsbergh VWM, *see* Kuenen BC
 Van Imhoff G, *see* Poortmans PMP
 van Imhoff GW, *see* Doorduijn JK
 van Kaik B, *see* Burdach S
 van Leeuwen FE, *see* Aleman BMP
 van Leeuwen PAM, *see* Vuylsteke RJCLM
 van Meerbeek JPAM, *see* Smit EF
 Vannier JP, *see* Pellegrino B
 Vannier J-P, *see* Laithier V
 van Oers MHJ, *see* Doorduijn JK
 see Haas RLM
 see Lokhorst HM
 van Oostrom I, Meijers-Heijboer H, Lodder LN, Duivenvoorden HJ, van Gool AR, Seynaeve C, van der Meer CA, Klijn JGM, van Geel BN, Burger CW, Wladimiroff JW, Tibben A. Long-Term Psychological Impact of Carrying a BRCA1/2 Mutation and Prophylactic Surgery: A 5-Year Follow-Up Study, 3867
 van Rhee F, *see* Lee C-K
 van Rhijn BWG, Vis AN, van der Kwast TH, Kirkels WJ, Radvanyi F, Ooms ECM, Chopin DK, Boevé ER, Jöbsis AC, Zwarthoff EC. Molecular Grading of Urothelial Cell Carcinoma With Fibroblast Growth Factor Receptor 3 and MIB-1 is Superior to Pathologic Grade for the Prediction of Clinical Outcome, 1912
 Van Roy N, *see* Ambros IM
 van Ruth, *see* Verwaal VJ
 van Slooten GW, *see* Verwaal VJ
 Van Steen K, *see* Bottomley A
 Vansteenkiste J, *see* Fukuoka M
 van Tinteren H, *see* Verwaal VJ
 van't Veer MB, *see* Aleman BMP
 Vanvoorden V, *see* Bottomley A
 Van Wering ER, *see* Den Boer ML
 Vara JAF, *see* Belda-Iniesta C
 Varella-Garcia M, *see* Hirsch FR
 Varesco L, *see* Bertario L
 Vargha-Khadem F, *see* Nanduri VR

- Varia MA, Stehman FB, Bundy BN, Benda JA, Clarke-Pearson DL, Alvarez RD, Long HJ. Intraperitoneal Radioactive Phosphorus (³²P) Versus Observation After Negative Second-Look Laparotomy for Stage III Ovarian Carcinoma: A Randomized Trial of the Gynecologic Oncology Group, 2849
- Varma GN, Winston JS, Hill HC, Gibbs JF, Proulx GM, McGrath BE, Javle MM. Unusual Locations of Involvement by Malignancies: Gastric Signet Ring Carcinoma Presenting As a Diffuse Thigh Mass, 3368
- Varterasian M, Meyer M, Fingert H, Radlowski D, Asbury P, Zhou X, Healey D. Baseline Heart Rate—Corrected QT and Eligibility for Clinical Trials in Oncology (correspondence), 3378
- Varterasian ML, *see* Hamid O
- Vasaturo F, *see* Gradilone A
- Vasconcelles MJ, *see* Scagliotti GV
- Vasconcelos Y, Davi F, Levy V, Oppezio P, Magnac C, Michel A, Yamamoto M, Pritsch O, Merle-Béral H, Maloum K, Ajchenbaum-Cymbalista F, Dighiero G. Binet's Staging System and *VH* Genes Are Independent but Complementary Prognostic Indicators in Chronic Lymphocytic Leukemia, 3928
- Vasey PA, *see* Cannistra SA
- Vasey PA. Role of Docetaxel in the Treatment of Newly Diagnosed Advanced Ovarian Cancer, 1365
- Vassal G, *see* Le Deley M-C
- Vassal G, Doz F, Frappaz D, Imadalou K, Sicard E, Santos A, O'Quigley J, Germa C, Risse M-L, Mignard D, Pein F. A Phase I Study of Irinotecan As a 3-Week Schedule in Children With Refractory or Recurrent Solid Tumors, 3844
- Vaughn D, *see* Stevenson JP
- Vauthey JN, *see* Patt YZ
- Vauthey J-N, Ajani JA. Liver Transplantation and Hepatocellular Carcinoma Biology: Begining of the End of the Era of Educated Guesses (editorial), 4265
- Vavassori V, *see* Ferreri AJM
- Vecchione A, *see* Alimonti A
- Vecht ChJ, *see* van den Bent MJ
- Veenstra KG, *see* Gollob JA
- Veer MV, *see* Poortmans PMP
- Veerman AJP, *see* Den Boer ML
- Vekhof A, *see* Beaumont M
- Velasquez WS, Lew D, Grogan TM, Spiridonidis CH, Balcerzak SP, Dakhil SR, Miller TP, Lanier KS, Chapman RA, Fisher RI. Combination of Fludarabine and Mitoxantrone in Untreated Stages III and IV Low-Grade Lymphoma: S9501, 1996
- Velazco D, *see* Agrawal BL
- Velikova G, *see* Wright EP
- Veltri E, *see* Gridelli C
- Venditti L, *see* Polsky D
- Venkatesan V, *see* Hanks GE
- Venkatraman ES, *see* Katz MS
- Venner PM, *see* Ernst DS
see Segal RJ
- Verbel D, *see* Slovin SF
- Verburgh E, Achten R, Maes B, Hagemeyer A, Boogaerts M, De Wolf-Peeters C, Verhoef G. Additional Prognostic Value of Bone Marrow Histology in Patients Subclassified According to the International Prognostic Scoring System for Myelodysplastic Syndromes, 273
- Verdonck LF, *see* Doorduijn JK
see Lokhorst HM
- Vergote I, *see* Diamandis EP
- Vergouwe Y, Steyerberg EW, Eijkemans MJC, Albers P, Habbema JDF. Predictors of Occult Metastasis in Clinical Stage I Nonseminoma: A Systematic Review, 4092
- Verhaeghe T, *see* Cohen SJ
- Verheij M, *see* Haas RLM
- Verhoef G, *see* Verburgh E
- Verhoef GEG, *see* Doorduijn JK
- Verma S, *see* Leyland-Jones B
- Vermeersch H, *see* Van de Wiele C
- Vermorken J, *see* Buyse M
- Verso M, Agnelli G. Venous Thromboembolism Associated With Long-Term Use of Central Venous Catheters in Cancer Patients, 3665
- Verstovsek S, *see* Giles FJ
- Verwaal VJ, van Ruth S, de Bree E, van Slooten GW, van Tinteren H, Boot H, Zoetmulder FAN. Randomized Trial of Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy and Palliative Surgery in Patients With Peritoneal Carcinomatosis of Colorectal Cancer, 3737
- Verweij J, *see* Smorenburg CH
see Sparreboom A
- Verweij J. Confusion Caused by Similarity in Manuscript Titles (correspondence), 1423
- Vescio RA, *see* Yang HH
- Vetto J, *see* Smith JW II
- Veve R, *see* Hirsch FR
- Viala J, *see* Culine S
see Fizazi K
- Viale A, *see* Segal NH
- Vici P, *see* Papaldo P
- Videtic GMM, Stitt LW, Dar AR, Kocha WI, Tomiak AT, Truong PT, Vincent MD, Yu EW. Continued Cigarette Smoking by Patients Receiving Concurrent Chemoradiotherapy for Limited-Stage Small-Cell Lung Cancer Is Associated With Decreased Survival, 1544
- Vierkant RA, *see* Ebbert JO
- Viganò M, *see* Re A
- Vignal J, *see* Glehen O
- Vik T, *see* Wells RJ
- Vik TA, *see* Oeffinger KC
- Villa E, Colantoni A, Cammà C, Grottola A, Buttafoco P, Gelmini R, Ferrelli I, Manenti F. Estrogen Receptor Classification for Hepatocellular Carcinoma: Comparison With Clinical Staging Systems, 441
- Villa E, *see* Cappuzzo F
- Villa L, *see* Fuchs CS
- Villano JL, Ryan CW. Patients Presenting With CNS Lesions: Subdural Presentation of Recurrent Breast Cancer, 4058
- Vincent MD, *see* Videtic GMM
- Vincenzi B, *see* Tonini G
- Virkkunen P, *see* Hernberg M
- Vis AN, *see* van Rhijn BWG
- Viscosi E, *see* Fine HA
- Vitolo U, *see* Zucca E
- Vitucci C, *see* Papaldo P
- Vlastos G, *see* Bouchardy C
- Voena C, *see* Ladetto M
- Vogel CL, *see* Burstein HJ
- Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P. Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma, 2636
- Vogelzang NJ, *see* Carducci MA
see Halabi S
see Sawyer MB
see Taplin M-E
- Vogl TJ, *see* Leung TWT
- Vogt-Schaden M, *see* Pels H
- Voigt J-J, *see* Culine S
- Voigtmann R, *see* Köhne C-H
- Vokes EE, Stenson K, Rosen FR, Kies MS, Rademaker AW, Witt ME, Brockstein BE, List MA, Fung BB, Portugal L, Mittal BB, Pelzer H, Weichselbaum RR, Haraf DJ. Weekly Carboplatin and Paclitaxel Followed by Concomitant Paclitaxel, Fluorouracil, and Hydroxyurea

AUTHOR INDEX

- Chemoradiotherapy: Curative and Organ-Preserving Therapy for Advanced Head and Neck Cancer, 320
- Vokes EE, *see* Adjei AA
see Cohen EEW
see Rudin CM
- Volm M, *see* Formenti SC
- Volm T, *see* Kaufmann M
- Volpato F, *see* Ladetto M
- Volpi A, Nanni O, De Paola F, Granato AM, Mangia A, Monti F, Schittulli F, De Lena M, Scarpi E, Rosetti P, Monti M, Gianni L, Amadori D, Paradiso A. *HER-2* Expression and Cell Proliferation: Prognostic Markers in Patients With Node-Negative Breast Cancer, 2708
- von Briel C, *see* Betticher DC
- von Gunten CF. Discussing Do-Not-Resuscitate Status, 20s
- von Gunten CF. Discussing Hospice Care, 31s
- von Gunten CF. Editorial Commentary, 60s
- von Gunten CF. In Reply (correspondence), 26s
- von Gunten CF, *see* Von Roenn JH
- von Hochstetter AR, *see* Ozaki T
- von Mehren M, *see* Heinrich MC
- von Minckwitz G, *see* Kaufmann M
- von Pawel J, *see* Fossella F
- Von Roenn JH, von Gunten CF. Setting Goals to Maintain Hope, 570
- Vora N, *see* Stein AS
- Vordermark D, Koelbl O. Quality of Life After Treatment for Prostate Cancer: No Difference Between Surgery and Radiotherapy? (correspondence), 465s
- Vorobiof D, *see* Nabholz J-M
- Vos MJ, Hoekstra OS, Barkhof F, Berkhof J, Heimans JJ, van Groenigen CJ, Vandertop WP, Slotman BJ, Postma TJ. Thallium-201 Single-Photon Emission Computed Tomography As an Early Predictor of Outcome in Recurrent Glioma, 3559
- Vose JM, Crump M, Lazarus H, Emmanouilides C, Schenkein D, Moore J, Frankel S, Flinn I, Lovelace W, Hackett J, Liang BC. Randomized, Multicenter, Open-Label Study of Pegfilgrastim Compared with Daily Filgrastim After Chemotherapy for Lymphoma, 514
- Vose JM, *see* Bierman PJ
- Voutsadakis IA, *see* Atallah D
- Vowler SL, *see* Gonzalez MA
- Vredenbergh J, *see* Gururangan S
- Vu HT, *see* Kolb EA
- Vujanic G, *see* Pritchard-Jones K
- Vullo SL, *see* Licitra L
- Vuytsteke RJCLM, van Leeuwen PAM, Stadius Muller MG, Gietema HA, Kragt DR, Meijer S. Clinical Outcome of Stage I/II Melanoma Patients After Selective Sentinel Lymph Node Dissection: Long-Term Follow-Up Results, 1057
- W**
- Wade J III, *see* Millikan R
- Wade JL III, *see* Rivera E
- Wadler S, Levy DE, Lincoln ST, Soori GS, Schink JC, Goldberg G. Topotecan Is an Active Agent in the First-Line Treatment of Metastatic or Recurrent Endometrial Carcinoma: Eastern Cooperative Oncology Group Study E3E93, 2110
- Wadler S, *see* Hamid O
see Omura GA
see Rothenberg ML
- Waggoner SE, *see* Moore DH
- Wagner H, *see* Grossman SA
- Wagner H Jr, *see* Adelstein DJ
- Wahl RL, *see* Thomas CT
- Währe H, *see* Oldenburg J
- Wain J, *see* Salgia R
- Walker DA, *see* Taylor RE
- Walker EB, *see* Smith JW II
- Wall L. Fish Oil Supplementation in Patients With Advanced Cancer (correspondence), 354s
- Wallgren A, Bonetti M, Gelber RD, Goldhirsch A, Castiglione-Gertsch M, Holmberg SB, Lindtner J, Thürlimann B, Fey M, Werner ID, Forbes JF, Price K, Coates AS, Collins J. Risk Factors for Locoregional Recurrence Among Breast Cancer Patients: Results From International Breast Cancer Study Group Trials I Through VII, 1205
- Walpole E, *see* Poulsen M
- Walsh D, *see* Davis MP
- Walsh G, *see* Ring A
- Walters R, *see* Rivera E
- Walther M, *see* Padmanabhan H
- Wanek LA, *see* Bleicher RJ
- Wang H, *see* Cohen SJ
- Wang H-J, *see* Kuo CT
see Wascher RA
- Wang PS, *see* Partridge AH
- Wang S, *see* Stein AS
- Wang W-Y, *see* Lin J-C
- Warde PR, *see* Groome PA
- Ward RL, Cheong K, Ku S-L, Meagher A, O'Connor T, Hawkins NJ. Adverse Prognostic Effect of Methylation in Colorectal Cancer Is Reversed by Microsatellite Instability, 3729
- Warkentin P, *see* Wells RJ
- Warr D, *see* Tchen N
- Warr DG, *see* Hesketh PJ
- Wascher RA, Morton DL, Kuo C, Elashoff RM, Wang H-J, Gerami M, Hoon DSB. Molecular Tumor Markers in the Blood: Early Prediction of Disease Outcome in Melanoma Patients Treated With a Melanoma Vaccine, 2558
- Washington S, *see* Meropol NJ
- Watanabe H, *see* Ando N
- Waters K, *see* Marshall GM
- Wathen JK, *see* Giles FJ
- Watral M, *see* Gururangan S
- Watson K, *see* Wright EP
- Watterson J, *see* Hilden JM
- Wawer A, *see* Burdach S
- Weaver DL, *see* Kerlikowske K
- Webb A, *see* Ring A
- Webb I, *see* Salgia R
see Soiffer R
- Weber BL, *see* Domchek SM
- Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide Alone or With Dexamethasone for Previously Untreated Multiple Myeloma, 16
- Weber D, *see* Dimopoulos MA
- Weber M. Opioid Switching (correspondence), 300s
- Weber WA, Petersen V, Schmidt B, Tyndale-Hines L, Link T, Peschel C, Schwaiger M. Positron Emission Tomography in Non-Small-Cell Lung Cancer: Prediction of Response to Chemotherapy by Quantitative Assessment of Glucose Use, 2651
- Weber WA, *see* Ott K
- Webster B, *see* Marshall GM
- Webster K, *see* Markman M
- Weder W, *see* Betticher DC
- Wee J, *see* Leong SS
- Weeks J, *see* Mandelblatt JS
- Weeks JC, *see* Earle CC
see Krzyzanowska MK
see Polsky D
- Wefel JS, *see* Meyers CA

- Wegener WA, *see* Leonard JP
- Weichenthal M, *see* Hauschild A
- Weichselbaum RR, *see* Connell PP
see Vokes EE
- Weinberg MA, *see* Carducci MA
- Weinberg V, *see* Rini BI
- Weiner LM, *see* Cohen SJ
- Weinfurt KP, *see* Meropol NJ
- Weinknecht S, *see* Classen J
- Weinshilboum R, *see* Schmiegelow K
- Weinstein H, *see* Smith RS
- Weinstein M, *see* Irie HY
- Weir LM, *see* Hack TF
- Weiss GR, *see* Clark JI
- Weiss MA, Maslak PG, Jurcic JG, Scheinberg DA, Aliff TB, Lamanna N, Frankel SR, Kossman SE, Horgan D. Pentostatin and Cyclophosphamide: An Effective New Regimen in Previously Treated Patients With Chronic Lymphocytic Leukemia, 1278
- Weiss RB, Woolf SH, Demakos E, Holland JF, Berry DA, Falkson G, Cirrincione CT, Robbins A, Bothun S, Henderson IC, Norton L. Natural History of More Than 20 Years of Node-Positive Primary Breast Carcinoma Treated With Cyclophosphamide, Methotrexate, and Fluorouracil-Based Adjuvant Chemotherapy: A Study by the Cancer and Leukemia Group B, 1825
- Weiss U, *see* Köhne C-H
- Weissbach L, *see* Albers P
- Weitz J, Antonescu CR, Brennan MF. Localized Extremity Soft Tissue Sarcoma: Improved Knowledge With Unchanged Survival Over Time, 2719
- Weitz J, D'Angelica M, Gonen M, Klimstra D, Coit DG, Brennan MF, Karpch MS. Interaction of Splenectomy and Perioperative Blood Transfusions on Prognosis of Patients With Proximal Gastric and Gastroesophageal Junction Cancer, 4597
- Wells GA, *see* Segal RJ
- Wells LM, *see* Hutchinson RJ
- Wells RJ, Adams MT, Alonzo TA, Arceci RJ, Buckley J, Buxton AB, Dusenbery K, Gamis A, Masterson M, Vik T, Warkentin P, Whitlock JA. Mitoxantrone and Cytarabine Induction, High-Dose Cytarabine, and Etoposide Intensification for Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia: Children's Cancer Group Study 2951, 2940
- Wells W, *see* Tsang RW
- Welnicka-Jaskiewicz M, *see* Therasse P
- Wen PY, *see* Fine HA
- Weng W-K, Levy R. Two Immunoglobulin G Fragment C Receptor Polymorphisms Independently Predict Response to Rituximab in Patients With Follicular Lymphoma, 3940
- Wenzel LB, *see* Coyne CA
- Werner CP, *see* Taplin M-E
- Werner ID, *see* Wallgren A
- Wernli M, *see* Betticher DC
- Wesley UV, *see* Segal NH
- Wessalowski R, *see* Schneider DT
- West DW, *see* Ayanian JZ
- Westermann AM, *see* Pronk WG
- Westman JA, *see* Sweet KM
- Weston CL, *see* Taylor RE
- Westphal M, *see* Giese A
- Westveer PHM, *see* Lokhorst HM
- Wette V, *see* Schmid M
- Wexler L, *see* Kolb EA
- Wharam MD, *see* Breneman JC
see Pappo AS
- Wharton JT, *see* Bodurka DC
- Wheeler J, *see* Kemeny MM
- Wheeler TM, *see* Kattan MW
see Shariat SF
- Whelan JS, *see* Strauss SJ
- Whelan T, *see* Charles CA
- Whelan TJ, *see* Winer EP
- White CA, *see* Witzig TE
- White DE, *see* Yang JC
- White R, *see* Clark JI
- Whitehead C, *see* Pusztai L
- Whitlock JA, *see* Wells RJ
- Whitton JA, *see* Green DM
- Wickerham DL, *see* Bear HD
- Widemann B, *see* Abraham J
- Wieand HS. Is Relative Risk Reduction a Useful Measure for Patients or Families Who Must Choose a Method of Treatment? (editorial), 4263
- Wiedand HS, *see* Allegra CJ
see Dignam JJ
- Wieczorek TJ, *see* Brown JR
- Wiedenmann B, *see* Faiss S
- Wiedenmann S, *see* Josting A
- Wiedswang G, Borgen E, Kåresen R, Kvalheim G, Nesland JM, Qvist H, Schlichting E, Sauer T, Janbu J, Harbitz T, Naume B. Detection of Isolated Tumor Cells in Bone Marrow Is an Independent Prognostic Factor in Breast Cancer, 3469
- Wiener ES, *see* Pappo AS
- Wiernasz CJ, *see* Slingluff CL Jr
- Wiggers Th, *see* Mellink WAM
- Wiggins CL, *see* Gaffney DK
- Wiklund T, *see* Brandberg Y
- Wilczynski S, *see* Markman M
- Wilczynski SP, Rothenberg ML
- Wilder-Smith E, *see* Leong SS
- Wilding G, *see* Messing EM
see Thomas JP
- Wilking N, *see* Brandberg Y
- Wilkinson PM, *see* Fosså SD
- Wilkinson S, Chodak GW. Critical Review of Complementary Therapies for Prostate Cancer, 2199
- Willan A, *see* Charles CA
- Willem J, *see* Autier P
- Willemze R, *see* Cheson BD
- Willers R, *see* Calaminus G
- Willey J, *see* Bruera E
- Williams C, *see* Buyse M
- Williams D, *see* Pagliaro LC
- Williams G, *see* Johnson JR
- Williams L, *see* Kunkler I
- Williams LJ, *see* Hwu W-J
- Willich N, *see* Engert A
- Willis B, *see* Flynn PM
- Willis SK, *see* Sweet KM
- Willman CL, *see* Cheson BD
- Wills EJ, *see* Featherstone C
- Wils J, *see* Köhne C-H
- Wilson A, *see* Last KW
- Wilson J, *see* Galbraith SM
- Wilson JL, *see* Seamans DP
- Wilson K, *see* Ilson DH
- Wilson MW, *see* Rodriguez-Galindo C
- Wilson WH, *see* Leonard GD
- Windebank AJ, *see* Goetz MP
- Winer E, *see* Buzdar A
see Esteva FJ
- Winer EP, Hudis C, Burstein HJ, Bryant J, Chlebowski RT, Ingle JN, Edge SB, Mamounas EP, Gelber R, Gralow J, Goldstein LJ, Pritchard KI,

AUTHOR INDEX

- Braun S, Cobleigh MA, Langer AS, Perotti J, Powles TJ, Whelan TJ, Browman GP. American Society of Clinical Oncology Technology Assessment Working Group Update: Use of Aromatase Inhibitors in the Adjuvant Setting, 2597
- Winer EP, *see* Burstein HJ
see Citron ML
see Earle CC
see Keating NL
see Partridge AH
- Winick NJ, *see* Bowers DC
- Winkelmann W, *see* Kager L
see Ozaki T
- Winqvist EW, *see* Ernst DS
- Winston JS, *see* Varma GN
- Wiseman GA, *see* Witzig TE
- Wisner KP, *see* Smith JW II
- Witt J, *see* Strauss SJ
- Witt ME, *see* Vokes EE
- Wittekind C, *see* Albers P
- Witzig TE, White CA, Gordon LI, Wiseman GA, Emmanouilides C, Murray JL, Lister J, Multani PS. Safety of Yttrium-90 Ibritumomab Tiuxetan Radioimmunotherapy for Relapsed Low-Grade, Follicular, or Transformed Non-Hodgkin's Lymphoma, 1263
- Wladimiroff JW, *see* van Oostrom I
- Woda BA, *see* Taplin M-E
- Wolchok JD, Chapman PB. How Can We Tell When Cancer Vaccines Vaccinate? (editorial), 586
- Wolchok JD, *see* Hwu W-J
see Segal NH
- Wolden S, *see* Kolb EA
- Wolden SL, Dunkel IJ, Souweidane MM, Happersett L, Khakoo Y, Schupak K, Lyden D, Leibel SA. Patterns of Failure Using a Conformal Radiation Therapy Tumor Bed Boost for Medulloblastoma, 3079
- Wolf J, *see* Engert A
see Josting A
see Sieber M
- Wolf JK, *see* Bodurka DC
- Wolf RE, *see* Ayanian JZ
- Wolff HH, *see* Hauschild A
- Wolkov H, *see* Chakravarti A
- Wolmark N, *see* Allegra CJ
see Bear HD
see Dignam JJ
- Womer RB, Bickert B. In Reply (correspondence), 2044
- Wong BC-Y, *see* Chan AO-O
- Wong F, *see* Hoskins PJ
- Wong GY, *see* Seamans DP
- Wong J, *see* Chan AO-O
- Wong JEL, Ito Y, Correa P, Peeters KCMJ, van de Velde CJH, Sasako M, Macdonald JS. Therapeutic Strategies in Gastric Cancer, 267s
- Wong WM, *see* Au WY
- Wood W, *see* Smith JW II
- Wood WC, *see* Goldhirsch A
see Henderson IC
see Sledge GW
- Woods D, *see* Pagliaro LC
- Woods WG, *see* Gamis AS
- Woodson EMH, *see* Slingluff CL Jr
- Woodward WA, Strom EA, Tucker SL, McNeese MD, Perkins GH, Schechter NR, Singletary SE, Theriault RL, Hortobagyi GN, Hunt KK, Buchholz TA. Changes in the 2003 American Joint Committee on Cancer Staging for Breast Cancer Dramatically Affect Stage-Specific Survival, 3244
- Woolf SH, *see* Weiss RB
- Wörmann B, *see* Büchner T
see Haferlach T
- Worst P, *see* Sieber M
- Wozniak AJ, *see* Unger JM
- Wright C, *see* Salgia R
- Wright EP, Selby PJ, Crawford M, Gillibrand A, Johnston C, Perren TJ, Rush R, Smith A, Velikova G, Watson K, Gould A, Cull A. Feasibility and Compliance of Automated Measurement of Quality of Life in Oncology Practice, 374
- Wright JJ, *see* Adjei AA
see Cohen SJ
- Wright JR, Levine MN. Researching the Cost of Research (editorial), 4081
- Wright WE, *see* Ayanian JZ
- Wu CL, *see* Chakravarti A
- Wu H, *see* Carter CA
- Wu R, *see* Garcia-Rostan G
- Wu Y, *see* Berends MJW
- Wuchter C, *see* Haferlach T
- Wust P, *see* Rau B
- Wykoff C, *see* Swinson DEB
- Wyld P, *see* Lipton A
see Mouridsen H
- Wynne CJ, *see* Shakespeare TP

X

- Xerri L, *see* Bouabdallah R
- Xiao L-C, *see* Giles FJ
- Xiao S-Y, *see* Raja V
- Xu R, *see* Coyne CA
- Xu S, *see* Bedrosian I
- Xue C, *see* Marshall GM

Y

- Yahalom J, *see* Ferreri AJM
- Yakren S, *see* Bennett CL
- Yamada K, *see* Matsubara T
- Yamaguchi S, *see* Tominaga T
- Yamaguchi Y, *see* Nash GM
- Yamamichi N, *see* Ohtsu A
- Yamamoto M, *see* Vasconcelos Y
- Yamamoto S, Tomita Y, Hoshida Y, Takiguchi S, Fujiwara Y, Yasuda T, Yano M, Nakamori S, Sakon M, Monden M, Aozasa K. Expression Level of Valosin-Containing Protein Is Strongly Associated With Progression and Prognosis of Gastric Carcinoma, 2537
- Yamamoto S, Tomita Y, Nakamori S, Hoshida Y, Nagano H, Dono K, Umeshita K, Sakon M, Monden M, Aozasa K. Elevated Expression of Valosin-Containing Protein (p⁹⁷) in Hepatocellular Carcinoma Is Correlated With Increased Incidence of Tumor Recurrence, 447
- Yamamoto S, *see* Nashimoto A
see Ohtsu A
- Yamamura Y, *see* Nashimoto A
- Yamana H, *see* Ando N
- Yamshchikov GV, *see* Slingluff CL Jr
- Yanagihara R, *see* Rosen LS
- Yang HH, Ma MH, Vescio RA, Berenson JR. Overcoming Drug Resistance in Multiple Myeloma: The Emergence of Therapeutic Approaches to Induce Apoptosis, 4239
- Yang JC, Sherry RM, Steinberg SM, Topalian SL, Schwartzentruber DJ, Hwu P, Seipp CA, Rogers-Freezer L, Morton KE, White DE, Liewehr DJ, Merino MJ, Rosenberg SA. Randomized Study of High-Dose and Low-Dose Interleukin-2 in Patients With Metastatic Renal Cancer, 3127
- Yang P, *see* Ebbert JO
- Yaniv I, *see* Ohali A

AUTHOR INDEX

Yankaskas B, *see* Kerlikowske K
 Yankelevitz DF, *see* Altorki NK
 Yano M, *see* Yamamoto S
 Yano S, *see* Fukuoka M
 Yao B, *see* Meropol NJ
 Yap JT, *see* Anderson HL
 Yasuda T, *see* Yamamoto S
 Yasui Y, *see* Bhatia S
 see McTiernan A
 see Oeffinger KC
 see Packer RJ
 Yau T, *see* Chim CS
 Ye W, *see* Chung MH
 Ye Y, *see* Dignam JJ
 Yee CJ, *see* Levine DA
 Yee GC, *see* Hillner BE
 Yee KWL, Pater JL, Pho L, Zee B, Siu LL. Enrollment of Older Patients in Cancer Treatment Trials in Canada: Why is Age a Barrier?, 1618
 Yee R, *see* Chung MH
 Yeh SDJ, *see* Kushner BH
 Yen T-C, Ng K-K, Ma S-Y, Chou H-H, Tsai C-S, Hsueh S, Chang T-C, Hong J-H, See L-C, Lin W-J, Chen J-T, Huang K-G, Lui K-W, Lai C-H. Value of Dual-Phase 2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography in Cervical Cancer, 3651
 Yeo W, *see* Lam KC
 Yi Q-L, *see* Tchen N
 Yocum RC, *see* Esteva FJ
 Yoo HY, Patt CH, Geschwind J-F, Thuluvath PJ. The Outcome of Liver Transplantation in Patients With Hepatocellular Carcinoma in the United States Between 1988 and 2001: 5-Year Survival Has Improved Significantly With Time, 4329
 Yorke R, Chirala M, Younes M. *c-Kit* Proto-Oncogene Product Is Rarely Detected in Colorectal Adenocarcinoma (correspondence), 3886
 Yoshida EM, *see* Gill S
 Yoshida S, *see* Ishikura S
 see Ohtsu A
 Younes A, Kadin ME. Emerging Applications of the Tumor Necrosis Factor Family of Ligands and Receptors in Cancer Therapy, 3526
 Younes A, *see* Khouri IF
 Younes M, *see* Yorke R
 Young B, *see* Patchell R
 Young D, *see* Bannerji R
 Young RC, Brady MF, Nieberg RK, Long HJ, Mayer AR, Lentz SS, Hurteau J, Alberts DS. Adjuvant Treatment for Early Ovarian Cancer: A Randomized Phase III Trial of Intraperitoneal ³²P or Intravenous Cyclophosphamide and Cisplatin—A Gynecologic Oncology Group Study, 4350
 Young SL, *see* Stevenson JP
 Younger J, *see* Burstein HJ
 Yount SE, *see* Eton DT
 Yousef GM, Scorilas A, Katsaros D, Fracchioli S, Iskander L, Borgono C, Rigault de la Longrais IA, Puopolo M, Massobrio M, Diamandis EP. Prognostic Value of the Human Kallikrein Gene 15 Expression in Ovarian Cancer, 3119
 Yousef GM, *see* Diamandis EP
 YoussefAgha A, *see* Chao C
 Yu EW, *see* Videtic GMM
 Yu J, *see* Ebert MPA
 Yu S, *see* Leung TWT
 Yueng Y-H, *see* Chan AO-O
 Yum M-N, *see* Shafqat A
 Yung WKA, *see* Jaeckle KA
 see Lang FF
 Yurdseven S, *see* Zemzoum I

Z

Zaballos P, *see* Andrés R
 Zagari MJ, *see* Cella D
 Zagars GK, *see* Pisters PWT
 Zaizov R, *see* Ohali A
 Zaknoen S, *see* Quinn JA
 Zakowski M, *see* Downey RJ
 Zalupski MM, *see* El-Rayes BF
 Zaluski J, *see* Nabholz J-M
 Zanazzo A, *see* De Bernardi B
 Zander AR, *see* Schetelig J
 Zanetta S, *see* Extermann M
 Zangari M, *see* Lee C-K
 Zanotti K, *see* Markman M
 Zaslavsky AM, *see* Ayanian JZ
 Zee B, *see* Moore MJ
 see Yee KWL
 Zeitz M, *see* Daum S
 Zelefsky MJ, *see* Kattan MW
 see Katz MS
 Zelek L, Llombart-Cussac A, Terrier P, Pivot X, Guinebrière JM, Le Pechoux C, Tursz T, Rochard F, Spielmann M, Le Cesne A. Prognostic Factors in Primary Breast Sarcomas: A Series of Patients With Long-Term Follow-Up, 2583
 Zelenetz A, *see* Abrey LE
 Zeleniuch-Jacquotte A, *see* Hochster H
 Zellner A, *see* Pels H
 Zeltzer LK, *see* Glover DA
 see Packer RJ
 Zemzoum I, Kates RE, Ross JS, Dettmar P, Dutta M, Henrichs C, Yurdseven S, Höfler H, Kiechle M, Schmitt M, Harbeck N. Invasion Factors uPA/PAI-1 and HER2 Status Provide Independent and Complementary Information on Patient Outcome in Node-Negative Breast Cancer, 1022
 Zeng C, *see* Hirsch FR
 Zeng ZS, *see* Nash GM
 Zerah M, *see* Laithier V
 Zerevoudakis A, *see* Gonen M
 Zhai S, *see* Hussain MM
 Zhang B, *see* Schnoll RA
 Zhang M-j, *see* Serna DS
 Zhang P, *see* Bedrosian I
 Zhang Q, *see* Love RR
 Zhang WW, *see* Nam RK
 Zhang Y, *see* Renkonen E
 Zhao H, *see* Garcia-Rostan G
 Zhen JH, *see* Pusztaí L
 Zheng M, *see* Rosen LS
 Zhou X, *see* Varterasian M
 Zhu K, *see* Kattan MW
 Zhu L, *see* Marshall GM
 Ziccardi H, *see* Leonard JP
 Ziegler H, *see* Arndt V
 Zielinski CC, *see* Pohl G
 Zimmer R, *see* Stevenson JP
 Zimmermann K, *see* Seidemann K
 Zimmermann M, *see* Bürger B
 Zinzani PL, *see* Martelli M
 Zoetmulder FAN, *see* Verwaal VJ
 Zoller JS, *see* Silvestri GA
 Zone JJ, *see* Alexander A
 Zonnenberg BA, *see* Carducci MA
 Zontsich T, *see* Stift A
 Zoubek A, *see* Kager L

AUTHOR INDEX

Zucali PA, *see* Masci G

Zucca E, Conconi A, Mughal TI, Sarris AH, Seymour JF, Vitolo U, Klasa R, Ozsahin M, Mead GM, Gianni MA, Cortelazzo S, Ferreri AJM, Ambrosetti A, Martelli M, Thiéblemont C, Gomez Moreno H, Pinotti G, Martinelli G, Mozzana R, Grisanti S, Provencio M, Balzarotti M, Laveder F, Oltean G, Callea V, Roy P, Cavalli F, Gospodarowicz MK. Patterns of Outcome and Prognostic Factors in Primary Large-Cell Lymphoma of the Testis in a Survey by the International Extranodal

Lymphoma Study Group, 20

Zucca E, *see* Ferreri AJM

Zucker JM, *see* Matthay KK

Zuhowski EG, *see* Laufer M

Zulian GB, *see* Extermann M

Zurlo A, *see* Efficace F

Zwarthoff EC, *see* van Rhijn BWG

Zyzanski SJ, *see* Simon C